WO2012117000A1 - 3-amino-pyridines as gpbar1 agonists - Google Patents

3-amino-pyridines as gpbar1 agonists Download PDF

Info

Publication number
WO2012117000A1
WO2012117000A1 PCT/EP2012/053386 EP2012053386W WO2012117000A1 WO 2012117000 A1 WO2012117000 A1 WO 2012117000A1 EP 2012053386 W EP2012053386 W EP 2012053386W WO 2012117000 A1 WO2012117000 A1 WO 2012117000A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
trifluoromethyl
methyl
phenyl
benzamide
Prior art date
Application number
PCT/EP2012/053386
Other languages
French (fr)
Other versions
WO2012117000A8 (en
Inventor
Caterina Bissantz
Henrietta Dehmlow
Shawn David Erickson
Prabha Saba Karnachi
Kyungjin Kim
Rainerm E. MARTIN
Patrizio Mattei
Ulrike Obst Sander
Sherrie Lynn Pietranico-Cole
Hans Richter
Christoph Ullmer
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2013142011/04A priority Critical patent/RU2594886C2/en
Priority to EP12706049.9A priority patent/EP2681194B1/en
Priority to CN201280010939.5A priority patent/CN103415507B/en
Priority to MX2013009356A priority patent/MX341565B/en
Priority to ES12706049.9T priority patent/ES2538655T3/en
Priority to KR1020137026117A priority patent/KR101573997B1/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to JP2013555853A priority patent/JP5702001B2/en
Priority to BR112013022110-0A priority patent/BR112013022110B1/en
Priority to CA2827718A priority patent/CA2827718C/en
Publication of WO2012117000A1 publication Critical patent/WO2012117000A1/en
Publication of WO2012117000A8 publication Critical patent/WO2012117000A8/en
Priority to HK14103757.1A priority patent/HK1190707A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

This invention relates to novel 3-aminopyridines of the formula (I) wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

Description

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS
FIELD OF THE INVENTION
The present invention relates to novel 3 -amino pyridines having pharmaceutical activity, their manufacture, pharmaceutical compositions containing them and their potential use as medicaments.
In particular, the present invention relates to compounds of the formula
Figure imgf000002_0001
wherein B1, B2 and R1 to R6 are as described below, or to pharmaceutically acceptable salts thereof.
The compounds are modulators or ligands of the GPBAR1 receptor. More particularly, the compounds are potent GPBAR1 agonists and may therefore be useful for the treatment and prevention of metabolic and inflammatory diseases, in particular type II diabetes.
Diabetes mellitus is an ever-increasing threat to human health. For example, in the United States current estimates maintain that about 16 million people suffer from diabetes mellitus. Type II diabetes also known as non-insulin-dependent diabetes mellitus accounts for
approximately 90-95% of diabetes cases, killing about 193Ό00 U.S. residents each year. Type II diabetes is the seventh leading cause of all deaths. In Western societies, type II diabetes currently affects 6% of the adult population with world-wide frequency expected to grow by 6% per annum. Although there are certain inheritable traits that may predispose particular individuals to developing type II diabetes, the driving force behind the current increase in incidence of the disease is the increased sedentary life- style, diet, and obesity now prevalent in developed countries. About 80% of diabetics with type II diabetes are significantly overweight. Also, an increasing number of young people are developing the disease. Type II diabetes is now internationally recognized as one of the major threats to human health in the 21st century. Type II diabetes manifests as inability to adequately regulate blood-glucose levels and may be characterized by a defect in insulin secretion or by insulin resistance. Namely, those who suffer from type II diabetes have too little insulin or cannot use insulin effectively. Insulin resistance refers to the inability of the body tissues to respond properly to endogenous insulin. Insulin resistance develops because of multiple factors, including genetics, obesity, increasing age, and having high blood sugar over long periods of time. Type II diabetes, sometimes called mature onset, can develop at any age, but most commonly becomes apparent during adulthood. However, the incidence of type II diabetes in children is rising. In diabetics glucose levels build up in the blood and urine causing excessive urination, thirst, hunger, and problems with fat and protein metabolism. If left untreated, diabetes mellitus may cause life-threatening complications, including blindness, kidney failure, and heart disease.
Type II diabetes is currently treated at several levels. A first level of therapy is through diet and/or exercise, either alone or in combination with therapeutic agents. Such agents may include insulin or pharmaceuticals that lower blood glucose levels. About 49% of individuals with Type II diabetes require oral medications, about 40% require insulin injections or a combination of insulin injections and oral medications, and 10% use diet and exercise alone.
Current therapies include: insulin secretagogues, such as sulphonylureas, which increase insulin production from pancreatic β-cells; glucose-lowering effectors, such as metformin which reduce glucose production from the liver; activators of the peroxisome proliferator-activated receptor γ (PPARy), such as the thiazolidinediones, which enhance insulin action; and oc- glucosidase inhibitors which interfere with gut glucose production. There are, however, deficiencies associated with currently available treatments. For example sulphonylureas and insulin injections can be associated with hypoglycemic episodes and weight gain. Furthermore, patients often lose responsiveness to sulphonylureas over time. Metformin and oc-glucosidase inhibitors often lead to gastrointestinal problems and PPARy agonists tend to cause increased weight gain and edema.
Bile acids (BA) are amphipathic molecules which are synthesized in the liver from cholesterol and stored in the gall bladder until secretion to the duodenum and intestine to play an important role in the solubilization and absorption of dietary fat and lipid-soluble vitamins. Approximately 99% of BA are absorbed again by passive diffusion and active transport in the terminal ileum and transported back to the liver via the portal vein (enterohepatic circulation). In the liver, BA decrease their own biosynthesis from cholesterol through the activation of the farnesoid X receptor alpha (FXRoc) and small heterodimer partner (SHP), leading to the transcriptional repression of cholesterol 7oc-hydroxylase, the rate-limiting step of BA
biosynthesis from cholesterol. GPBAR1, in the literature termed TGR5, M-BAR or BG37, was recently identified as a G- protein coupled receptor (GPCR) responsive to BA (Kawamata et al, J. Biol. Chem. 2003, 278, 9435-9440; Maruyama et al, Biochem. Biophys. Res. Commun. 2002, 298, 714-719). GPBAR1 is a G(alpha)s -coupled GPCR and stimulation by ligand binding causes activation of adenylyl cyclase which leads to the elevation of intracellular cAMP and subsequent activation of downstream signaling pathways. The human receptor shares 86, 90, 82, and 83% amino acid identity to bovine, rabbit, rat, and mouse receptor, respectively. GPBAR1 is abundantly expressed in the intestinal tract, monocytes and macrophages, lung, spleen, placenta, kidney, and stomach (Kawamata et al, J. Biol. Chem. 2003, 278, 9435-9440). BA induced receptor internalization, intracellular cAMP production and activation of extracellular signal-regulated kinase in GPBARl-expressing HEK293 and CHO cells.
GPBAR1 was found to be abundantly expressed in monocytes/macrophages from humans and rabbits (Kawamata et al, J. Biol. Chem. 2003, 278, 9435-9440), and BA treatment suppressed LPS-induced cytokine production in rabbit alveolar macrophages and human THP-1 cells expressing GPBAR1. These data suggest that bile acids can suppress the macrophage function via activation of GPBAR1. In the liver functional GPBAR1 was found in the plasma membranes of Kupffer cells, mediating inhibition of LPS-induced cytokine expression (Keitel, Biochem. Biophys. Res. Commun. 2008, 372, 78-84), and of sinusoidal endothelial cells, where bile salts led to an increase in intracellular cAMP and to the activation and enhanced expression of the endothelial nitric oxide (NO) synthase (Keitel, Hepatology 2007, 45, 695-704).
Furthermore, GPBAR1 has been detected in cholangiocytes of rat liver (Keitel, Biochem.
Biophys. Res. Commun. 2008, 372, 78-84). Hydrophobic bile acids, such as taurolithocholic acid, increase cAMP in cholangiocytes suggesting that GPBAR1 may modulate ductal secretion and bile flow. Indeed, GPBAR1 staining colocalized with the cyclic adenosine monophosphate regulated chloride channel cystic fibrosis transmembrane conductance regulator (CFTR) and the apical sodium-dependent bile salt uptake transporter (ASBT). A functional coupling of GPBAR1 to chloride secretion and bile flow has been shown using GPBAR1 agonists (Keitel et al, Hepatology 2009, 50, 861-870; Pellicciari et al, J. Med. Chem. 2009, 52, 7958-7961). In summary, GPBAR1 agonists may trigger a protective as well as medicative mechanism in cholestatic livers.
GPBAR1 is expressed in intestinal enteroendocrine cell lines from human (NCI-H716) and murine (STC-1, GLUTag) origin (Maruyama et al, Biochem. Biophys. Res. Commun. 2002, 298, 714-719). Stimulation of GPBAR1 by BA stimulated cAMP production in NCI -H716 cells. Intracellular increases in cAMP suggested that BA may induce the secretion of glucagon-like peptide-1 (GLP-1). Indeed, activation of GPBAR1 by BA promoted GLP-1 secretion in STC-1 cells (Katsuma et al, Biochem. Biophys. Res. Commun. 2005, 329, 386-390). Receptor- specificity has been demonstrated by RNA interference experiments which revealed that reduced expression of GPBAR1 resulted in diminished secretion of GLP-1. There is compelling evidence that GPBARl-mediated GLP-1 and PYY release from intestinal L-cells extends to in vivo. In the isolated vascularly perfused rat colon, BA have been shown to trigger GLP-1 secretion
(Plaisancie et al., J. Endocrin. 1995, 145, 521-526). Using a combination of pharmacological and genetic gain- and loss-of-function studies in vivo, GPBAR1 signaling was shown to induce GLP-1 release, leading to improved liver and pancreatic function and enhanced glucose tolerance in obese mice (Thomas et al., Cell Metabolism, 2009, 10, 167-177). In humans, intracolonic administration of deoxycholate showed marked increases in plasma levels of GLP-1 and the co- secreted PYY (Adrian et al., Gut 1993, 34, 1219-1224).
GLP-1 is a peptide secreted from enteroendocrine L cells has been shown to stimulate insulin release in glucose dependent manner in humans (Kreymann et al., Lancet 1987, 2, 1300- 1304) and studies in experimental animals demonstrated that this incretin hormone is necessary for normal glucose homeostasis. In addition, GLP-1 can exert several beneficial effects in diabetes and obesity, including 1) increased glucose disposal, 2) suppression in glucose production, 3) reduced gastric emptying, 4) reduction in food intake and 5) weight loss. More recently, much research has been focused on the use of GLP-1 in the treatment of conditions and disorders such as diabetes mellitus, stress, obesity, appetite control and satiety, Alzheimer's disease, inflammation, and diseases of the central nervous system (see, for example, Bojanowska et al, Med. Sci. Monit. 2005, 8, RA271-8; Perry et al, Current Alzheimer Res. 2005, 3, 377-385; and Meier et al., Diabetes Metab. Res. Rev. 2005, 2, 91-117). However, the use of a peptide in clinical treatment is limited due to difficult administration, and in vivo stability. Therefore, a small molecule that either mimics the effects of GLP-1 directly, or increases GLP-1 secretion, may be useful in treatment of the variety of conditions or disorders described above, namely diabetes mellitus. PYY is co-secreted with GLP-1 from intestinal L-cells following a meal. A dipeptidyl peptidase-IV (DPP4) cleavage product of PYY is PYY[3-36] (Eberlein et al., Peptides 1989, 10, 797-803; Grandt et al., Regul. Pept. 1994, 51, 151-159). This fragment constitutes approximately 40% of total PYY-like immunoreactivity in human and canine intestinal extracts and about 36% of total plasma PYY immunoreactivity in a fasting state to slightly over 50% following a meal. PYY[3-36] is reportedly a selective ligand at the Y2 and Y5 receptors. Peripheral administration of PYY reportedly reduces gastric acid secretion, gastric motility, exocrine pancreatic secretion (Yoshinaga et al., Am. J. Physiol. 1992, 263, G695-701), gallbladder contraction and intestinal motility (Savage et al., Gut 1987, 28, 166-170). It has been demonstrated that intra-arcuate (IC) or intra-peritoneal (IP) injection of PYY3-36 reduced feeding in rats and, as a chronic treatment, reduced body weight gain. Intra-venous (IV) infusion (0.8 pmol/kg/min) for 90 min of PYY3-36 reduced food intake in obese and normal human subjects by 33% over 24 hours. These findings suggest that the PYY system may be a therapeutic target for the treatment of obesity (Bloom et. al, Nature 2002, 418, 650-654).
Furthermore, activation of GPBAR1 might be beneficial for the treatment of obesity and metabolic syndrome. Mice fed on a high fat diet (HFD) containing 0.5% cholic acid gained less weight than control mice on HFD alone independent of food intake (Watanabe et al., Nature 2006, 439, 484-489). These effects were independent of FXR-alpha, and are likely to result from the binding of BA to GPBAR1. The proposed GPBARl-mediated mechanism is leading to the subsequent induction of the cAMP-dependent thyroid hormone activating enzyme type 2 (D2) which converts the inactive T3 into the active T4, resulting in the stimulation of the thyroid hormone receptor and promoting energy expenditure. Mice lacking the D2 gene were resistant to cholic acid-induced weight loss. In both rodents and humans, the most thermogenically important tissues (the brown adipose and skeletal muscle) are specifically targeted by this mechanism because they co-express D2 and GPBAR1. The BA-GPBARl-cAMP-D2 signalling pathway is therefore a crucial mechanism for fine-tuning energy homeostasis that can be targeted to improve metabolic control.
It is therefore an object of the present invention to provide selective, directly acting GPBAR1 agonists. Such agonists are useful as therapeutically active substances, particularly in the treatment and/or prevention of diseases which are associated with the activation of GPBAR1.
The novel compounds of the present invention exceed the compounds known in the art, inasmuch as they are small molecules and they bind to and selectively activate GPBAR1 very efficiently. They are expected to have an enhanced therapeutic potential compared to the compounds already known in the art and can be used for the treatment of diabetes, obesity, metabolic syndrome, hypercholesterolemia, dyslipidemia and a wide range of acute and chronic inflammatory diseases.
SUMMARY OF THE INVENTION
The present invention relates to 3-aminopyridines of the formula
Figure imgf000006_0001
wherein B1 is CR7 or N; B2 is CR8 or N;
R1 is selected from the group consisting of phenyl, said phenyl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, C1-7- alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl, hydroxy- Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7-alkoxy, C1-7- alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, phenyl-Ci_7- alkoxy,
heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl, heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, C1-7- alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl,
3,6-dihydro-2H-pyran-4-yl, and piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups; R is selected from the group consisting of hydrogen, Ci_7-alkyl,
halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cyano,
Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino,
aminocarbonyl, Ci_7-alkylaminocarbonyl, di-Ci_7-alkylaminocarbonyl,
hydroxy-Ci_7-alkyl-(Ci_7-alkyl)amino, Ci_7-alkoxy-Ci_7-alkyl-(Ci_7-alkyl)amino, and heteroaryl;
R2a is selected from the group consisting of hydrogen, methyl and halogen;
R is selected from the group consisting of Ci_7-alkyl,
halogen-Ci_7-alkyl, hydroxy-Ci_7-alkyl, Ci_7-alkoxy-Ci_7-alkyl, Ci_7-alkylcarbonyl-Ci_7- alkyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl-Ci_7-alkyl, cyano-Ci_7-alkyl,
aminocarbonyl-Ci_7-alkyl, Ci_7-alkylaminocarbonyl-Ci_7-alkyl,
di-Ci_7-alkylaminocarbonyl-Ci_7-alkyl, Ci_7-alkylsulfonyl-Ci_7-alkyl,
C3_7-cycloalkyl, C3_7-cycloalkyl-Ci_7-alkyl, unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, hydroxy and Ci_7-alkyl,
heterocyclyl-Ci_7-alkyl, wherein heterocyclyl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl,
heteroaryl-Ci_7-alkyl, wherein heteroaryl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl and
phenyl-Ci_7-alkoxycarbonylamino-Ci_7-alkyl; is selected from the group consisting of hydrogen, halogen, Ci_7-alkyl and Ci_7-alkoxy; and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, Ci_7-cycloalkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, carboxyl, Ci_7-alkoxycarbonyl,
Ci_7-alkoxycarbonyl-Ci_7-alkyl,
hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkoxy,
Ci_7-alkylsulfanyl, hydroxy-Ci_7-alkylsulfanyl, Ci_7-alkoxy-Ci_7-alkylsulfanyl,
Ci_7-alkylsulfonyl, hydroxy-Ci_7-alkylsulfonyl, Ci_7-alkoxy-Ci_7-alkylsulfonyl,
carboxyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkylsulfonyl,
Ci_7-alkoxycarbonyl-Ci_7-alkylsulfanyl, Ci_7-alkoxycarbonyl-Ci_7-alkylsulfonyl,
Ci_7-alkoxycarbonylamino-Ci_7-alkylsulfanyl,
carboxyl-Ci_7-alkyl-aminocarbonyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkyl-aminocarbonyl- Ci_7-alkylsulfonyl,
heterocyclylsulfanyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl,
heterocyclylsulfonyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl,
heterocyclyl-Ci_7-alkylsulfanyl, heterocyclyl-Ci_7-alkylsulfonyl,
aminosulfonyl, Ci_7-alkylaminosulfonyl, di-(Ci_7-alkyl)-aminosulfonyl,
Ci_7-alkylsulfonylamino-Ci_7-alkylsulfanyl, Ci_7-alkylsulfonylamino-Ci_7-alkylsulfonyl, aminosulfonylamino-Ci_7-alkylsulfanyl, aminosulfonylamino-Ci_7-alkylsulfonyl, amino-Ci_7-alkylsulfanyl, amino-Ci_7-alkylsulfonyl,
aminocarbonyl-Ci_7-alkyl, aminocarbonyl-Ci_7-alkylsulfonyl
amino, Ci_7-alkylamino, di-(Ci_7-alkyl)-amino, hydroxy-Ci_7-alkylamino, nitro, unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, Ci_7-alkyl and Ci_7-alkoxycarbonyl; is hydrogen or halogen; and R is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen,
halogen-Ci_7-alkyl and Ci_7-alkoxy; or pharmaceutically acceptable salts thereof.
The invention is also concerned with processes for the manufacture of compounds of formula I.
The invention also relates to pharmaceutical compositions comprising a compound as described above and a pharmaceutically acceptable carrier and/or adjuvant.
A further aspect of the invention is the use of compounds of formula I as therapeutically active substances for the treatment of diseases which are associated with the modulation of GPBAR1 activity. The invention thus potentially relates to a method for the treatment of a disease associated with the modulation of GPBAR1 activity such as for example diabetes, particularly type II diabetes or gestational diabetes.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention.
The term "halogen" refers to fluoro, chloro, bromo and iodo, with fluoro, chloro and bromo being of particular interest. More particularly, halogen refers to fluoro and chloro.
The term "alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, particularly one to sixteen carbon atoms, more particularly one to ten carbon atoms. The term "Ci_io-alkyl" refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to ten carbon atoms, such as e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, ie/t-butyl, pentyl, 1,1,3,3-tetramethyl-butyl and the like. Lower alkyl groups as described below are also preferred alkyl groups. The term "lower alkyl" or "Ci_7-alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 7 carbon atoms, in particular a straight or branched- chain alkyl group with 1 to 6 carbon atoms and more particularly a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched Ci_7 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls and the isomeric heptyls, in particular methyl and ethyl. The term "cycloalkyl" or "C3_7-cycloalkyl" denotes a saturated carbocyclic group containing from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, more particularly cyclopropyl.
The term "lower cycloalkylalkyl" or "C3_7-cycloalkyl-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a cycloalkyl group. Among the lower cycloalkylalkyl groups of particular interest resides cyclopropylmethyl.
The term "cycloalkyl-oxy" or "C3_7-cycloalkyl-oxy" refers to the group Rc-0-, wherein Rc is cycloalkyl and the term "cycloalkyl" has the previously given significance. Examples of lower cycloalkyl-oxy groups are cyclopropyloxy or cyclobutyloxy.
The term "lower alkoxy" or "Ci_7-alkoxy" refers to the group R'-O-, wherein R' is lower alkyl and the term "lower alkyl" has the previously given significance. Examples of lower alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, in particular methoxy. The term "lower cycloalkylalkoxy" or "C3_7-cycloalkyl-Ci_7-alkoxy" refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a cycloalkyl group. Among the lower cycloalkylalkyl groups of particular interest resides cyclopropylmethyl.
The term "lower alkoxyalkyl" or "Ci_7-alkoxy-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a lower alkoxy group. Among the lower alkoxyalkyl groups of particular interest are
methoxymethyl and 2-methoxyethyl.
The term "lower alkoxyalkoxy" or "Ci_7-alkoxy-Ci_7-alkoxy" refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a further lower alkoxy group. Among the lower alkoxyalkoxy groups of particular interest are 2-methoxyethoxy and 3-methoxypropoxy.
The term hydroxy means the group -OH.
The term "lower hydroxyalkyl" or "hydroxy-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a hydroxy group. Among the particular interesting lower hydroxyalkyl groups are
hydroxymethyl or hydroxyethyl. "Lower hydroxyalkoxy" or "hydroxy-Ci_7-alkoxy" refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a hydroxy group. Among the particular interesting lower hydroxyalkyl groups are
hydroxyethoxy or hydroxypropoxy. The term "lower halogenalkyl" or "halogen-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a halogen atom, particularly fluoro or chloro, most particularly fluoro. Among the lower halogenalkyl groups of particular interest are trifluoromethyl, difluoromethyl, trifluoroethyl, 2,2- difluoroethyl, fluoromethyl and chloromethyl, with trifluoromethyl or difluoromethyl being especially interesting.
The term "lower halogenalkoxy" or "halogen-Ci_7-alkoxy" refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a halogen atom, particularly fluoro or chloro, most particularly fluoro. Among the lower halogenalkoxy groups of particular interest are trifluoromethoxy, difluoromethoxy, fluoromethoxy and chloromethoxy, more particularly trifluoromethoxy.
The term "cyano" refers to the group -CN.
The term "lower cyanoalkyl" or "cyano-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a cyano group. A cyanoalkyl group of particular interest is cyanomethyl. The term "lower cyanoalkoxy" or "cyano-Ci_7-alkoxy" refers to a lower alkoxy group as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a cyano group.
The term "carboxyl" means the group -COOH.
The term "lower carboxylalkyl" or "carboxyl-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a carboxyl group. Among the lower carboxylalkyl groups of particular interest are
carboxylmethyl (-CH2-COOH) and carboxylethyl (-CH2-CH2-COOH).
"Lower carboxylalkoxy" or "carboxyl-Ci_7-alkoxy" refers to a lower alkoxy group as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a carboxyl group. Among the lower carboxylalkoxy groups of particular interest are carboxylmethoxy (-0-CH2-COOH) and carboxylethoxy (-0-CH2-CH2-COOH).
The term "lower alkoxycarbonyl" or "Ci_7-alkoxycarbonyl" refers to the group -COOR, wherein R is lower alkyl and the term "lower alkyl" has the previously given significance. Lower alkoxycarbonyl groups of particular interest are methoxycarbonyl or ethoxycarbonyl. The term "lower alkoxycarbonylalkyl" or "Ci_7-alkoxycarbonyl-Ci_7-alkyl" means a lower alkyl group as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by Ci_7-alkoxycarbonyl. A lower alkoxycarbonylalkyl group of particular interest is -CH2-COOCH3. The term "lower alkoxycarbonylalkoxy" or "Ci_7-alkoxycarbonyl-Ci_7-alkoxy" means a lower alkoxy group as defined above wherein one of the hydrogen atoms of the lower alkoxy group is replaced by Ci_7-alkoxycarbonyl. An example for a lower alkoxycarbonylalkoxy group is -O-CH2-COOCH3.
The term "lower alkylsulfanyl" or "Ci_7-alkylsulfanyl" means the group -S-R, wherein R is a lower alkyl group as defined above. A lower alkylsulfanyl group of particular interest is methylsulfanyl.
The term "lower hydroxyalkylsulfanyl" or "hydroxy- Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a hydroxy group. Among the particular interesting lower hydroxyalkylsulfanyl groups are hydroxyethylsulfanyl.
The term "lower alkoxyalkylsulfanyl" or "Ci_7-alkoxy-Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by an alkoxy group. Among the particular interesting lower alkoxyalkylsulfanyl groups are methoxyethylsulfanyl. The term "carboxylalkylsulfanyl" or "carboxyl-Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a carboxyl group. Among the particular interesting lower carboxyl-alkylsulfanyl groups are -S-(CH2)3-COOH or -S-(CH2)4-COOH.
The term "lower alkoxycarbonylalkylsulfanyl" or "Ci_7-alkoxycarbonyl-Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a lower alkoxycarbonyl group. Among the particular interesting lower alkoxycarbonyl-alkylsulfanyl groups is -S-(CH2)2-COOCH3.
The term "lower alkoxycarbonylaminoalkylsulfanyl" or "Ci_7-alkoxycarbonylamino-Ci_7- alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a lower alkoxycarbonylamino group. Among the particular interesting lower alkoxycarbonylamino-alkylsulfanyl groups is the group -S-(CH2)2-NH-COOC(CH3)3. The term "lower carboxylalkyl-aminocarbonyl-alkylsulfanyl" or "carboxyl-Ci_7-alkyl- aminocarbonyl-Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a lower carboxylalkyl-aminocarbonyl group. Among the particular interesting lower carboxylalkyl- aminocarbonyl-alkylsulfanyl groups is the group -S-(CH2)4-CO-NH-CH2-COOH.
The term "aminosulfanyl" refers to the group -S-NH2.
The term "lower aminoalkylsulfanyl" or "amino-Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by an amino group. Among the particular interesting lower aminoalkylsulfanyl groups is -S-(CH2)2-NH2.
The term "lower alkylsulfonylamino-alkylsulfanyl" or "Ci_7-alkyl-sulfonylamino-Ci_7- alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a lower alkylsulfonylamino group. Among the particular interesting lower alkylsulfonylamino-alkylsulfanyl groups is the group -S-(CH2)2-NH-S02-CH3.
The term "lower aminosulfonylamino-alkylsulfanyl" or "aminosulfonylamino-Ci_7- alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by an aminosulfonylamino group. Among the particular interesting lower aminosulfonylamino-alkylsulfanyl groups is the group -S-(CH2)2-NH-S02-NH2.
The term "lower heterocyclylalkylsulfanyl" or "heterocyclyl-Ci_7-alkylsulfanyl" refers to lower alkylsulfanyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfanyl group is replaced by a heterocyclyl group as defined below. Among the particular interesting lower heterocyclylalkylsulfanyl groups is azetidinyl-ethylsulfanyl. The term "lower alkylsulfonyl" or "Ci_7-alkylsulfonyl" means the group -S(0)2-R, wherein
R is a lower alkyl group as defined above. A lower alkylsulfonyl group of particular interest is methylsulfonyl.
The term "lower alkylsulfonylalkyl" or "Ci_7-alkylsulfonyl-Ci_7-alkyl" means a lower alkyl group as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by Ci_7-alkylsulfonyl. A preferred lower alkylsulfonylalkyl group is -(CH2)2-S(0)2-CH3.
The term "lower hydroxyalkylsulfonyl" or "hydroxy- Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by a hydroxy group. Among the particular interesting lower hydroxyalkylsulfonyl groups are hydroxyethylsulfonyl.
The term "lower alkoxyalkylsulfonyl" or "Ci_7-alkoxy-Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by an alkoxy group. Among the particular interesting lower alkoxyalkylsulfonyl groups is methoxyethylsulfonyl.
The term "carboxylalkylsulfonyl" or "carboxyl-Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by a carboxyl group. Among the particular interesting lower carboxyl-alkylsulfonyl groups are -S(0)2-(CH2)3-COOH or -S(0)2-(CH2)4-COOH.
The term "lower alkoxycarbonylalkylsulfonyl" or "Ci_7-alkoxycarbonyl-Ci_7-alkyl- sulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by a lower alkoxycarbonyl group. Among the particular interesting lower alkoxycarbonyl-alkylsulfonyl groups is -S(0)2-(CH2)2- COOCH3.
The term "lower aminocarbonyl-alkylsulfonyl" or "aminocarbonyl-Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by an aminocarbonyl group. Among the particular interesting lower aminocarbonyl-alkylsulfonyl groups is the group -S(0)2-(CH2)4-CO-NH2. The term "lower alkylsulfonylamino-alkylsulfonyl" or "Ci_7-alkyl-sulfonylamino-Ci_7- alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by a lower alkylsulfonylamino group. Among the particular interesting lower alkylsulfonylamino-alkylsulfonyl groups is the group -S02-(CH2)2-NH-S02-CH3. The term "lower aminosulfonylamino-alkylsulfonyl" or "aminosulfonylamino-Ci_7- alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by an aminosulfonylamino group. Among the particular interesting lower aminosulfonylamino-alkylsulfonyl groups is the group -S02-(CH2)2-NH-S02-NH2. The term "lower heterocyclylalkylsulfonyl" or "heterocyclyl-Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by a heterocyclyl group as defined below. Among the particular interesting lower heterocyclylalkylsulfonyl groups is azetidinyl-ethylsulfonyl. The term "lower carboxylalkyl-aminocarbonyl-alkylsulfonyl" or "carboxyl-Ci_7-alkyl- aminocarbonyl-Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by a lower carboxylalkyl-aminocarbonyl group. Among the particular interesting lower carboxylalkyl- aminocarbonyl-alkylsulfonyl groups is the group -S(0)2-(CH2)4-CO-NH-CH2-COOH.
The term "aminosulfonyl" means the group -S(0)2-NH2.
The term "lower alkylaminosulfonyl" or "Ci_7-alkylaminosulfonyl" defines the group -S(0)2-NH-R, wherein R is lower alkyl and the term "lower alkyl" has the previously given meaning. An example of a lower alkylaminosulfonyl group is methylaminosulfonyl. The term "di-lower alkylaminosulfonyl" or "di-Ci_7-alkylaminosulfonyl" defines the group
-S(0)2-NRR', wherein R and R' are lower alkyl groups as defined above. An example of a di- lower alkylaminosulfonyl group is dimethylaminosulfonyl.
The term "aminoalkylsulfonyl" or "amino-Ci_7-alkylsulfonyl" refers to lower alkylsulfonyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkylsulfonyl group is replaced by an amino group. Among the particular interesting lower aminoalkylsulfonyl groups is -S(0)2-(CH2)2-NH2.
"Amino" refers to the group -NH2. The term "Ci_7-alkylamino" means a group -NHR, wherein R is lower alkyl and the term "lower alkyl" has the previously given significance. The term "di-Ci_7-alkylamino" means a group -NRR', wherein R and R' are lower alkyl groups as defined above.
The term "Ci_7-alkoxy-Ci_7-alkyl-Ci_7-alkylamino" refers to a group -NRR", wherein R is a lower alkyl group as defined above and R" is a lower alkoxyalkyl group as defined herein.
The term "Ci_7-hydroxyalkyl-Ci_7-alkylamino" refers to a group -NRR", wherein R is a lower alkyl group as defined above and R" is a lower hydroxyalkyl group as defined herein. The term "lower alkylcarbonyl" or "Ci_7-alkylcarbonyl" defines the group
-CO-R, wherein R is lower alkyl and the term "lower alkyl" has the previously given meaning. A lower alkylcarbonyl group of particular interest is acetyl.
The term "lower alkylcarbonylalkyl" or "Ci_7-alkylcarbonyl-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a lower alkylcarbonyl group.
The term "aminocarbonyl" refers to the group -CO-NH2. The term "lower aminocarbonylalkyl" or "aminocarbonyl-Ci_7-alkyl" means lower alkyl groups as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by aminocarbonyl. A lower aminocarbonylalkyl group of particular interest is -CH2-CONH2.
The term "lower alkylaminocarbonyl" or "Ci_7-alkyl-aminocarbonyl" refers to a group -CONH-R14, wherein R14 is lower alkyl as defined herein before.
The term "lower alkylaminocarbonylalkyl" or "Ci_7-alkyl-aminocarbonyl-Ci_7-alkyl" means a lower alkyl group as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by lower alkylaminocarbonyl. A typical lower alkylaminocarbonylalkyl group has for example the formula -CH2-CONHR, wherein R is lower alkyl. The term "di-C1-7- alkyl-aminocarbonyl-Ci_7-alkyl" refers to a lower alkyl group as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by di-Ci_7-alkyl-aminocarbonyl group of the formula -CO-NRR' , wherein R and R' are lower alkyl groups.
The term "di-Ci_7-alkyl-aminocarbonyl" refers to a group -CONR14R15, wherein R14 and R15 are lower alkyl as defined herein before. The term "phenyloxy" refers to the group -O-Ph wherein Ph is phenyl.
The term "lower phenylalkyl" or "phenyl-Ci_7-alkyl" means lower alkyl groups as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by an optionally substituted phenyl group. An example is benzyl.
The term "lower phenylalkoxy" or "phenyl-Ci_7-alkoxy" means a lower alkoxy group as defined above wherein one of the hydrogen atoms of the lower alkoxy group is replaced by an optionally substituted phenyl group. An example for a "phenyl-Ci_7-alkoxy" group is benzyloxy.
The term "lower phenylalkoxy-carbonylamino" or "phenyl-Ci_7-alkoxy-carbonylamino" means a group -NH-CO-ORv, wherein Rv is a lower phenylalkyl group as defined above. The term "lower phenylalkoxy-carbonylaminoalkyl" or "phenyl-Ci_7-alkoxy-carbonylamino-Ci_7- alkyl" means a lower alkyl group as defined above wherein one of the hydrogen atoms of the lower alkyl group is replaced by the group -NH-CO-ORv.
The term "heterocyclyl" refers to a saturated or partly unsaturated 3-, 4-, 5-, 6- or 7- membered ring which can comprise one, two or three atoms selected from nitrogen, oxygen and/or sulphur. Examples of heterocyclyl rings include aziridinyl, azetidinyl, oxetanyl, piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, thiadiazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, thiomorpholinyl, 2-oxo-l,2- dihydropyridinyl and l,l-dioxo-l 6-thiomorpholinyl. The term "heterocyclyl" further refers to bicyclic groups comprising two 3- to 7-membered rings, in which one or both rings can contain one, two or three atoms selected from nitrogen, oxygen or sulphur and one of the carbon atoms is a member of both rings (a "spiro" group). An example for such a bicyclic heterocyclyl group is 2-oxa-6-aza-spiro[3.3]heptyl. The term "heterocyclyl-oxy" refers to the group -O-Het wherein Het is a heterocyclyl group as defined above.
The term "lower heterocyclylalkyl" or "heterocyclyl-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a heterocyclyl group as defined above. The term "lower heterocyclylalkoxy" or "heterocyclyl-Ci_7-alkoxy" means a lower alkoxy group as defined above wherein one of the hydrogen atoms of the lower alkoxy group is replaced by a heterocyclyl group as defined above.
The term "heterocyclylsulfanyl" means the group -S-Het, wherein Het is a heterocyclyl group as defined above. Lower heterocyclylsulfanyl groups of particular interest are oxetan-3-yl- sulfanyl or azetidinyl-sulfanyl.
The term "heterocyclylsulfonyl" means the group -S(0)2-Het, wherein Het is a
heterocyclyl group as defined above. Lower heterocyclylsulfonyl groups of particular interest are oxetan-3-yl-sulfonyl, azetidinyl-sulfonyl or morpholinyl-sulfonyl.
The term "heteroaryl" in general refers to an aromatic 5- or 6-membered ring which comprises one, two or three atoms selected from nitrogen, oxygen and/or sulphur, such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, imidazolyl, furyl, thiazolyl and thienyl. The term "heteroaryl" further refers to bicyclic aromatic groups comprising two 5- or 6-membered rings, in which one or both rings can contain one, two or three atoms selected from nitrogen, oxygen or sulphur, such as quinolinyl, isoquinolinyl, cinnolinyl, pyrazolo[l,5-a]pyridyl, imidazo[l,2-a]pyridyl, quinoxalinyl, benzothiazolyl, benzotriazolyl, indolyl and indazolyl. Most particularly, heteroaryl is pyridyl or pyrrolyl.
The term "lower heteroarylalkyl" or "heteroaryl-Ci_7-alkyl" refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a heteroaryl group as defined above.
The term "nitro" refers to the group -N02. The term "oxo" means that a C-atom of the heterocyclyl or heteroaryl ring is substituted by =0, thus meaning that the heterocyclyl or heteroaryl ring may contain one or more carbonyl (- CO-) groups.
Compounds of formula I can form pharmaceutically acceptable salts. The term
"pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are for example acid addition salts of compounds of formula I with physiologically compatible mineral acids, such as hydrochloric acid, sulfuric acid, sulfurous acid or phosphoric acid; or with organic acids, such as methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, lactic acid,
trifluoroacetic acid, citric acid, fumaric acid, maleic acid, malonic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, succinic acid or salicylic acid. In addition, pharmaceutically acceptable salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polymine resins and the like. The compound of formula I can also be present in the form of zwitterions.
Pharmaceutically acceptable salts of compounds of formula I of particular interest are the hydrochloride salts.
The compounds of formula I can also be solvated, e.g. , hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration). The term "pharmaceutically acceptable salts" also includes physiologically acceptable solvates.
"Isomers" are compounds that have identical molecular formulae but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers".
Stereoisomers that are not mirror images of one another are termed "diastereoisomers", and stereoisomers that are non-superimposable mirror images are termed "enantiomers", or sometimes optical isomers. A carbon atom bonded to four nonidentical substituents is termed a "chiral center". In detail, the present invention relates to compounds of the formula
Figure imgf000019_0001
wherein
B1 is CR7 or N; B2 is CR8 or N;
R1 is selected from the group consisting of phenyl, said phenyl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, C1-7- alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl, hydroxy- Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7-alkoxy, C1-7- alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, phenyl-Ci_7- alkoxy,
heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl, heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, C1-7- alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl,
3,6-dihydro-2H-pyran-4-yl, and piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups;
R is selected from the group consisting of hydrogen, Ci_7-alkyl,
halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cyano,
Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino,
aminocarbonyl, Ci_7-alkylaminocarbonyl, di-Ci_7-alkylaminocarbonyl, hydroxy-Ci_7-alkyl-(Ci_7-alkyl)amino, Ci_7-alkoxy-Ci_7-alkyl-(Ci_7-alkyl)amino, and heteroaryl; is selected from the group consisting of hydrogen, methyl and halogen; is selected from the group consisting of Ci_7-alkyl,
halogen-Ci_7-alkyl, hydroxy-Ci_7-alkyl, Ci_7-alkoxy-Ci_7-alkyl, Ci_7-alkylcarbonyl-Ci_7- alkyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl-Ci_7-alkyl, cyano-Ci_7-alkyl,
aminocarbonyl-Ci_7-alkyl, Ci_7-alkylaminocarbonyl-Ci_7-alkyl,
di-Ci_7-alkylaminocarbonyl-Ci_7-alkyl, Ci_7-alkylsulfonyl-Ci_7-alkyl,
C3_7-cycloalkyl, C3_7-cycloalkyl-Ci_7-alkyl,
unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, hydroxy and Ci_7-alkyl,
heterocyclyl-Ci_7-alkyl, wherein heterocyclyl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl,
heteroaryl-Ci_7-alkyl, wherein heteroaryl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl and
phenyl-Ci_7-alkoxycarbonylamino-Ci_7-alkyl; is selected from the group consisting of hydrogen, halogen, Ci_7-alkyl and Ci_7-alkoxy; and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, Ci_7-cycloalkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, carboxyl, Ci_7-alkoxycarbonyl,
Ci_7-alkoxycarbonyl-Ci_7-alkyl,
hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkoxy,
Ci_7-alkylsulfanyl, hydroxy-Ci_7-alkylsulfanyl, Ci_7-alkoxy-Ci_7-alkylsulfanyl,
Ci_7-alkylsulfonyl, hydroxy-Ci_7-alkylsulfonyl, Ci_7-alkoxy-Ci_7-alkylsulfonyl,
carboxyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkylsulfonyl,
Ci_7-alkoxycarbonyl-Ci_7-alkylsulfanyl, Ci_7-alkoxycarbonyl-Ci_7-alkylsulfonyl,
Ci_7-alkoxycarbonylamino-Ci_7-alkylsulfanyl,
carboxyl-Ci_7-alkyl-aminocarbonyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkyl-aminocarbonyl- Ci_7-alkylsulfonyl,
heterocyclylsulfanyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl,
heterocyclylsulfonyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl,
heterocyclyl-Ci_7-alkylsulfanyl, heterocyclyl-Ci_7-alkylsulfonyl,
aminosulfonyl, Ci_7-alkylaminosulfonyl, di-(Ci_7-alkyl)-aminosulfonyl, Ci_7-alkylsulfonylamino-Ci_7-alkylsulfanyl, Ci_7-alkylsulfonylamino-Ci_7-alkylsulfonyl, aminosulfonylamino-Ci_7-alkylsulfanyl, aminosulfonylamino-Ci_7-alkylsulfonyl, amino-Ci_7-alkylsulfanyl, amino-Ci_7-alkylsulfonyl,
aminocarbonyl-Ci_7-alkyl, aminocarbonyl-Ci_7-alkylsulfonyl
amino, Ci_7-alkylamino, di-(Ci_7-alkyl)-amino, hydroxy-Ci_7-alkylamino, nitro,
unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, Ci_7-alkyl and Ci_7-alkoxycarbonyl;
R is hydrogen or halogen; and
R is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen,
halogen-Ci_7-alkyl and Ci_7-alkoxy; or pharmaceutically acceptable salts thereof.
One group of compounds of formula I according to the invention are those, wherein R1 is phenyl, said phenyl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen- Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7- alkoxy, carboxyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl, hydroxy-Ci_7-alkyl, hydroxy-Ci_7- alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7-alkoxy, Ci_7-alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, phenyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7- alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl. In particular, R1 is phenyl, said phenyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano- Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl, hydroxy-Ci_7-alkyl, hydroxy-Ci_ 7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7-alkoxy, Ci_7-alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, phenyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7- alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl, more particularly being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7- alkoxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, C1-7- alkoxycarbonyl, hydroxy-Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7- alkoxy, Ci_7-alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino and phenyl-Ci_7-alkoxy. More particularly, the invention relates to compounds of formula I as shown above, wherein R1 is phenyl, said phenyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, halogen, and Ci_7-alkoxy.
Most particularly, the invention relates to compounds of formula I, wherein R1 is selected from the group consisting of phenyl, 2-methyl-phenyl, 2-ethyl-phenyl, 2-fluoro-phenyl, 2-chloro- phenyl, 2-trifluoromethyl-phenyl, 2-methoxy-phenyl, 2-isopropoxy-phenyl, 2-trifluoromethoxy- phenyl, 2-aminophenyl, 2-cyano-phenyl, 2-cyclopropyloxy-phenyl, 2-cyclobutyloxy-phenyl, 2- benzyloxy-phenyl, 2-oxetan-3-yl-phenyl, 2-oxetan-3-ylmethoxy-phenyl, 2,3-dimethyl-phenyl, 2,3-dimethoxy-phenyl, 2,4-difluoro-phenyl, 2-fluoro-3-methoxy-phenyl, 2-fluoro-5-methoxy- phenyl, 2-fluoro-6-methoxy-phenyl, 4-fluoro-2-methoxy-phenyl, 4-fluoro-2-methyl-phenyl, 2,4- dimethyl-phenyl, 4-methoxy-2-methyl-phenyl, 4-chloro-2-methyl-phenyl, 5-chloro-2-methyl- phenyl, 5-fluoro-2-methyl-phenyl, 3-fluoro-2-methoxy-phenyl, 3-fluoro-2-methyl-phenyl, 2- fluoro-5-methyl-phenyl, 2-benzyloxy-4-fluoro-phenyl, 4-fluoro-2-methoxy-phenyl, 4-fluoro-2- hydroxy-phenyl, 2-cyanomethoxy-4-fluoro-phenyl, 4-fluoro-2-(2-hydroxyethoxy)-phenyl, 2- (cyano-methyl-methoxy)-4-fluoro-phenyl, 5-fluoro-2-methoxy-phenyl, 2,5-difluoro-phenyl, 2,6- difluoro-phenyl, 2-chloro-3-fluoro-phenyl, 2-methyl-5-methoxycarbonyl-phenyl, 2-methyl-5- carboxyl-phenyl, 2-methoxycarbonylmethoxy-4-fluoro-phenyl, 5-chloro-4-fluoro-2-methoxy- phenyl, 3,5-difluoro-2-methoxy-phenyl, 2,6-difluoro-3-methoxyphenyl, 3,4-difluoro-2-methoxy- phenyl and 4,5-difluoro-2-methoxy-phenyl. Furthermore, the invention relates to compounds of formula I as shown above, wherein R1 is selected from the group consisting of
heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_ 7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7- alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl,
3,6-dihydro-2H-pyran-4-yl, and
piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups. In particular, the invention relates to compounds of formula I as shown above, wherein R1 is selected from the group consisting of
heteroaryl, said heteroaryl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen- Ci_7-alkyl, halogen-Ci_7-alkoxy and cycloalkyl-Ci_7-alkoxy,
3,6-dihydro-2H-pyran-4-yl, and
piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups. More particularly, compounds of the present invention are those, wherein R is pyridyl, said pyridyl being substituted with one, two or three groups selected from the group consisting of selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, heterocyclyl- oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl. More particularly, R1 is pyridyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7- alkoxy and cycloalkyl-Ci_7-alkoxy. Even more particularly, R1 is pyridyl substituted with C1-7- alkoxy. The invention also relates to compounds of formula I as shown above, wherein R1 is pyridazinyl, said pyridazinyl being substituted with one or two groups selected from the group consisting of Ci_7-alkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy and cycloalkyl-Ci_7-alkoxy. More particularly, R1 is pyridazinyl being substituted with one or two Ci_7-alkoxy groups. The invention further relates to compounds of formula I, wherein R1 is 3,6-dihydro-2H- pyran-4-yl or piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups.
Compounds of formula I according to the present invention are further those, wherein R selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl, halogen- Ci_7-alkoxy, cyano, Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, aminocarbonyl, Ci_7-alkylaminocarbonyl, di-Ci_7-alkylaminocarbonyl, hydroxy-Ci_7-alkyl-(Ci_7-alkyl)amino, Ci_ 7-alkoxy-Ci_7-alkyl-(Ci_7-alkyl)amino, and heteroaryl. More particularly, R is hydrogen or halogen and even more particularly, R is hydrogen. Most particularly, heteroaryl is pyrrolyl.
Compounds of formula I are further those, wherein R2a is selected from the group consisting of hydrogen, methyl and halogen. More particularly, R2a is hydrogen or halogen, and most particularly, R2a is hydrogen.
Compounds of formula I according to the invention are further those, wherein R is selected from the group consisting of
is selected from the group consisting of Ci_7-alkyl,
halogen-Ci_7-alkyl, hydroxy-Ci_7-alkyl, Ci_7-alkoxy-Ci_7-alkyl, Ci_7-alkylcarbonyl-Ci_7-alkyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl-Ci_7-alkyl, cyano-Ci_7-alkyl,
aminocarbonyl-Ci_7-alkyl, Ci_7-alkylaminocarbonyl-Ci_7-alkyl,
di-Ci_7-alkylaminocarbonyl-Ci_7-alkyl, Ci_7-alkylsulfonyl-Ci_7-alkyl,
C3_7-cycloalkyl, C3_7-cycloalkyl-Ci_7-alkyl, unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, hydroxy and Ci_7-alkyl,
heterocyclyl-Ci_7-alkyl, wherein heterocyclyl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl,
heteroaryl-Ci_7-alkyl, wherein heteroaryl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl and
phenyl-Ci_7-alkoxycarbonylamino-Ci_7-alkyl.
More particularly, R is selected from the group consisting of Ci_7-alkyl, halogen-Ci_7-alkyl, aminocarbonyl-Ci_7-alkyl and Ci_7-alkylsulfonyl-Ci_7-alkyl. In particular, R is methyl and even more particularly, R is selected from halogen-Ci_7-alkyl, aminocarbonyl-Ci_7-alkyl and C1-7- alkylsulfonyl-Ci_7-alkyl.
The present invention further relates to compounds of formula I, wherein R4 is selected from the group consisting of hydrogen, halogen, Ci_7-alkyl and Ci_7-alkoxy. In particular, R4 is hydrogen or halogen and more particularly, R4 is hydrogen. Compounds of formula I according to the invention are furthermore those, wherein R5 and
R6 are independently from each other from each other selected from the group consisting of hydrogen, Ci_7-alkyl, Ci_7-cycloalkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, carboxyl, Ci_7-alkoxycarbonyl, Ci_7-alkoxycarbonyl- Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkoxy, Ci_7-alkylsulfanyl, hydroxy-Ci_7- alkylsulfanyl, Ci_7-alkoxy-Ci_7-alkylsulfanyl, Ci_7-alkylsulfonyl, hydroxy-Ci_7-alkylsulfonyl, Ci_ 7-alkoxy-Ci_7-alkylsulfonyl, carboxyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkylsulfonyl, C1-7- alkoxycarbonyl-Ci_7-alkylsulfanyl, Ci_7-alkoxycarbonyl-Ci_7-alkylsulfonyl, C1-7- alkoxycarbonylamino-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkyl-aminocarbonyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkyl-aminocarbonyl-Ci_7-alkylsulfonyl, heterocyclylsulfanyl, wherein
heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl, heterocyclylsulfonyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl, heterocyclyl-Ci_7-alkylsulfanyl, heterocyclyl-Ci_7-alkylsulfonyl, aminosulfonyl, Ci_7-alkylaminosulfonyl, di-(Ci_7-alkyl)- aminosulfonyl, Ci_7-alkylsulfonylamino-Ci_7-alkylsulfanyl, Ci_7-alkylsulfonylamino-Ci_7- alkylsulfonyl, aminosulfonylamino-Ci_7-alkylsulfanyl, aminosulfonylamino-Ci_7-alkylsulfonyl, amino-Ci_7-alkylsulfanyl, amino-Ci_7-alkylsulfonyl, aminocarbonyl-Ci_7-alkyl, aminocarbonyl- Ci_7-alkylsulfonyl, amino, Ci_7-alkylamino, di-(Ci_7-alkyl)-amino, hydroxy-Ci_7-alkylamino, nitro, unsubstituted heterocyclyl and heterocyclyl substituted with one or two groups selected from halogen, oxo, Ci_7-alkyl and Ci_7-alkoxycarbonyl. In particular, R5 and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, Ci_7-cycloalkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7- alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, carboxyl, Ci_7-alkoxycarbonyl, C1-7- alkylsulfanyl, hydroxy-Ci_7-alkylsulfanyl, Ci_7-alkoxy-Ci_7-alkylsulfanyl, Ci_7-alkylsulfonyl, hydroxy-Ci_7-alkylsulfonyl, Ci_7-alkoxy-Ci_7-alkylsulfonyl, , aminosulfonyl, C1-7- alkylaminosulfonyl, di-(Ci_7-alkyl)-aminosulfonyl, amino, Ci_7-alkylamino, di-(Ci_7-alkyl)-amino, nitro, unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl.
More particularly, R5 and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, Ci_7-alkoxycarbonyl, Ci_7-alkylsulfonyl, di-(Ci_7-alkyl)- aminosulfonyl, amino, nitro and heterocyclyl selected from morpholinyl or 2-oxo-pyrrolidinyl. Even more particularly, R5 and R6 are independently from each other selected from the group consisting of halogen, halogen-Ci_7-alkyl, Ci_7-alkyl and Ci_7-alkylsulfonyl. Compounds of formula I according to the invention are further those, wherein B 1 is CR 7 and B 2 is CR 8 and wherein R 7 is hydrogen or halogen and R 8 is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl and Ci_7-alkoxy.
Compounds of formula I according to the invention are also those, wherein B 1 is N and B 2 is CR 8 and wherein R 7 is hydrogen or halogen and R 8 is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl and Ci_7-alkoxy.
In addition, compounds of formula I according to the invention are also those, wherein B1 is CR 7 and B 2 is N and wherein R 7 is hydrogen or halogen and R 8 is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl and Ci_7-alkoxy.
In particular, R 7 and R 8 are independently selected from hydrogen or halogen, more particularly R 7 and R 8 are hydrogen.
In a further aspect, the invention relates to compounds of formula I, wherein B1 is CR7 or N; B2 is CR8 or N;
R is selected from the group consisting of phenyl, said phenyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7- alkyl, halogen-Ci_7-alkoxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl, hydroxy-Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7-alkoxy, Ci_7-alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino and phenyl-Ci_7-alkoxy, heteroaryl, said heteroaryl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen- Ci_7-alkyl, halogen-Ci_7-alkoxy and cycloalkyl-Ci_7-alkoxy,
3,6-dihydro-2H-pyran-4-yl, and piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups;
2
R is selected from the group consisting of hydrogen, Ci_7-alkyl,
halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cyano,
Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino,
aminocarbonyl, Ci_7-alkylaminocarbonyl, di-Ci_7-alkylaminocarbonyl,
hydroxy-Ci_7-alkyl-(Ci_7-alkyl)amino, Ci_7-alkoxy-Ci_7-alkyl-(Ci_7-alkyl)amino, and heteroaryl;
R2a is selected from the group consisting of hydrogen, methyl and halogen;
R is selected from the group consisting of Ci_7-alkyl,
halogen-Ci_7-alkyl, hydroxy-Ci_7-alkyl, Ci_7-alkoxy-Ci_7-alkyl, Ci_7-alkylcarbonyl-Ci_7- alkyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl-Ci_7-alkyl, cyano-Ci_7-alkyl,
aminocarbonyl-Ci_7-alkyl, Ci_7-alkylaminocarbonyl-Ci_7-alkyl,
di-Ci_7-alkylaminocarbonyl-Ci_7-alkyl, Ci_7-alkylsulfonyl-Ci_7-alkyl,
C3_7-cycloalkyl, C3_7-cycloalkyl-Ci_7-alkyl,
unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, hydroxy and Ci_7-alkyl,
heterocyclyl-Ci_7-alkyl, wherein heterocyclyl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl,
heteroaryl-Ci_7-alkyl, and
phenyl-Ci_7-alkoxycarbonylamino-Ci_7-alkyl;
R4 is selected from the group consisting of hydrogen, halogen, Ci_7-alkyl and Ci_7-alkoxy; R5 and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, Ci_7-cycloalkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, carboxyl, Ci_7-alkoxycarbonyl,
Ci_7-alkylsulfonyl, hydroxy-Ci_7-alkylsulfonyl, Ci_7-alkoxy-Ci_7-alkylsulfonyl, aminosulfonyl, Ci_7-alkylaminosulfonyl, di-(Ci_7-alkyl)-aminosulfonyl,
amino, Ci_7-alkylamino, di-(Ci_7-alkyl)-amino, nitro,
unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl; R is hydrogen or halogen; and
R is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen,
halogen-Ci_7-alkyl and Ci_7-alkoxy; or pharmaceutically acceptable salts thereof.
Particular compounds of formula I are the following:
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3- chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
2-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
4- fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
2-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3,5-dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3,5-difluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3.4- dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3-chloro-4-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
3.5- dichloro-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-benzamide,
N-(6-methoxy-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(6-methylamino-4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide, N-(6-amino-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[6-(4-methanesulfonyl-piperazin-l-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-3,5-bz5- trifluoromethyl-benzamide,
N-{6-[(2-methoxy-ethyl)-methyl-amino]-4-o-tolyl-pyridin-3-yl}-N-methyl-3,5-bz5- trifluoromethyl-benzamide,
N-(6-cyano-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-3,5-bz'5-trifluoromethyl- benzamide,
3,5-dichloro-N-methyl-N-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-benzamide, hydrochloride salt, N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-oxazol-2-ylmethyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-m
3,5-dichloro-N-[4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-benzamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2,4-dimethyl-phenyl)-pyridin-3-yl]^
N-[4-(4-methoxy-2-methyl-phenyl)-pyridin-3-yl]^
N-methyl-3,5-bz5-trifluoromethyl-N-[4-(2-trifluoromethyl-phenyl)-pyridin-3-yl^
N-[4-(2-methoxy-phenyl)-pyridin-3-yl]-N-meth^^
N-[4-(4-chloro-2-methyl-phenyl)-pyridin-3-y^
N-methyl-N-[4-(2-trifluoromethoxy-phenyl)-^^
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-mem^
N-methyl-N-(2-methyl-[3,4']bipyridinyl-3'-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(3'-methyl-[4,4']bipyridinyl-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-isopropoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-cyano-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2,4-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-mem^
N- [4- (4 , 5 -difluoro-2-methoxy-phenyl) -pyridin- benzamide,
N-[4-(2,3-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(3-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzam N-[4-(2-fluoro-5-methyl-phenyl)-pyridin-3-yl]-N^
N-[4-(2-benzyloxy-4-fluoro-phenyl)-pyridin-3-yl]-N^
N-(5-fluoro-2-methoxy-[3,4']bipyridinyl-3'-yl)-N^^
N-(5-chloro-2-methoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benz
N-(2-isopropoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(2-methoxy-6-methyl-[3,4']bipyridinyl-3'-yl)-N^
N-[4-(4-fluoro-2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamid (2-{3-[(3,5-bz5-trifluoromethyl-benzoyl)-methyl-amino]-pyridin-4-yl}-5-fluoro-phenoxy)-acetic acid methyl ester,
N-(3'-cmoro-2'-methoxy-[4,4']bipyridinyl-3-yl^
N-[4-(2-cyanomethoxy-4-fluoro-phenyl)-pyridin-3-y^
benzamide,
N- { 4- [4-fluoro-2-(2-hydroxy-ethoxy)-phenyl] -pyridin-3 -yl } -N-methyl-3 ,5-bzs-trifluoromethyl- benzamide,
N- { 4- [2-(cyano-methyl-methoxy)-4-fluoro-phenyl] -pyridin-3 -yl } - V-methyl-3 ,5-bis- trifluoromethyl-benzamide, N-[4-(3,6-dimethoxy-pyridazin-4-yl)-pyridin-3-y^
N-(2-chloro-5-fluoro-[3,4']bipyridinyl-3'-yl)-N-m
N-(2'-chloro-3'-fluoro-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz'5-trifluoromethyl-benzam
N-methyl-N-(3-methyl-[2,4']bipyridinyl-3'-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzam N-[4-(3,5-difluoro-2-methoxy-phenyl)-pyridin^
benzamide,
N-[4-(3,4-difluoro-2-methoxy-phenyl)-pyridin-3-yl^^
benzamide,
N-[4-(2,5-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-fluoro-3-methoxy-phenyl)-pyridin-3-yl]-N-meth^
N-[4-(2-fluoro-5-methoxy-phenyl)-pyridin-3-yl]-N-meth^
N-[4-(2,6-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-chloro-3-fluoro-phenyl)-pyridin-3-yl]-N-meth^
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-N-meth^
N-[4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-N-meth^
N-(3-fluoro-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(3'-methoxy-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
N-(3'-fluoro-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(6-chloro-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl- benzamide,
N-(3,6'-dichloro-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
3- bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl-isophthalamic acid methyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-hydroxymethyl-N-methyl-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-(l-hydroxy-l-methyl-ethyl)-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-hydroxy-N-methyl-5-trifluoromethyl-benzamide,
4- bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methoxy-N-methyl-5-trifluoromethyl-benzamide, N-[4-(5-chloro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, 3 - { 3 - [(3 ,5-bz5-trifluoromethyl-benzoyl)-methyl-amino] -pyridin-4-yl } -4-methyl-benzoic acid methyl ester,
3-{3-[(3,5-bz5-trifluoromethyl-benzoyl)-methyl-amino]-pyridin-4-yl}-4-methyl-benzoic acid, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-cy
N-(6,5'-dichloro-2'-fluoro-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-be
{(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester,
N-[4-(2-cmoro-phenyl)-pyridin-3-yl]-N-(2-m
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide,
4,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
4-methoxy-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
N-{4-[2-(2-hydroxy-ethyl)-phenyl]-pyridin-3-yl}-N-m
3-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide,
4-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3,5,N-trimethyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide,
N-(6-methoxy-[2,4']bipyridinyl-3'-yl)-N-mem^
N-(6-methoxy-[3,4']bipyridinyl-3'-yl)-N-mem^
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethoxy-benzamide,
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3,4-bz5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methylcarbamoylmethyl-3,5-bz5-triflu
benzamide,
3-chloro-5-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3,4,5-trifluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
N-[4-(2,3-dimethyl-phenyl)-pyridin-3-yl]-N^
N-methyl-N-[2-(2,2,2-trifluoro-ethoxy)-[3,4']bipyridinyl-3'-yl]-3,5-bz5-trifluorometh
benzamide,
N-(2-cyclopropylmethoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide, 3,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-fluoro-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(3-chloro-2-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5-trifluoromethyl- benzamide,
N-methyl-N-[6-(lH-pyrrol-2-yl)-4-o-tolyl-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide, 3-methanesulfonyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-hydroxy-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2,2-difluoro-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-carbamoylmethyl-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-dimethylcarbamoylmethyl-3,5-bz5-trifluoromethyl- benzamide, 2- chloro-6,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-isonicotinamide,
2,6-dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-isonicotinamide,
4,6-dimethyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide,
4-chloro-6-methyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide,
4,6-dichloro-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-cyclopropyl-3,5-bz5-trifluoromethyl-benzamide, (2-{(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-ethyl)- carbamic acid benzyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-isopropyl-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(6-methyl-4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
3- dimethylsulfamoyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzam
3-fluoro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-fluoro-N-methyl-5-trifluoromethyl- benzamide,
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-fluoro-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-dimethylsulfamoyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-eth 5-trifluoromethyl-benzamide,
3-fluoro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-3,5-bz'5-trifluorometh benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-metha
benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-dimethylsulfamoyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide,
3-fluoro-N-(2-methoxy-[3,4]bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5-trifluoromethyl- benzamide,
3-methanesulfonyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide, 3-dimethylsulfamoyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-y^
isonicotinamide,
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-2,6-bz'5-trifluoromethyl- isonicotinamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-2,6-bz5-trifluoromethyl- isonicotinamide,
3-cyano-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-(4-o-tolyl-pyridin-3-yl)-N-(2,2,2-trifluoro-em^
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-methyl-3-morpholin-4-yl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-(2,2-difluoro-ethyl)-N-[4-(4-fluoro-2-methoxy-p
isonicotinamide,
N-(2,2-difluoro-ethyl)-N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5- trifluoromethyl-isonicotinamide,
N-(2,2-difluoro-ethyl)-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide^ N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2-methanesulfonyl-ethyl)-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-cyanomethyl-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-(2-methanesulfonyl-ethyl)-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide,
3-amino-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-(2-cyano-ethyl)-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(3,6-dihydro-2H-pyran-4-yl)-pyridin^
N-[4-(2,3-dimethoxy-phenyl)-pyridin-3-yl]-N-mem^
N-[4-(2-ethyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
2- chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-6-trifluoromethyl- isonicotinamide,
3- dimethylsulfamoyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
2-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-6-trifluoromethyl-isonicotinamide,
[[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl- benzoyl)-amino] -acetic acid methyl ester,
{ (2,6-bz5-trifluoromethyl-pyridine-4-carbonyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3- yl] -amino} -acetic acid methyl ester,
N-(2-amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- bzs(trifluoromethyl)isonicotinamide,
N-[4-(2-cyanomethyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, methyl 2-(N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- bzs(trifluoromethyl)isonicotinamido)acetate,
N-carbamoylmethyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2,6-bis-trifluoromethyl- isonicotinamide,
methyl 2-(3-(N,N-dimethylsulfamoyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-5- (trifluoromethyl)benzamido)acetate,
N-carbamoylmethyl-3-dimethylsulfamoyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-5- trifluoromethyl-benzamide,
[(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amino]- acetic acid methyl ester,
N-carbamoylmethyl-3-methanesulfonyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-5-trifluoromethyl- benzamide,
methyl 2-(N-(2-methoxy-3,4'-bipyridin-3'-yl)-2,6-bz5(trifluoromethyl)isonicotinamido)acetate,
N-(2-amino-2-oxoethyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-2,6- bz's(trifluoromethyl)isonicotinamide,
N-methyl-3-nitro-N-(4-o-tolylpyridin-3-yl)-5-(trifluoromethyl)benzamide,
N-methyl-3-(2-oxo-pyrrolidin-l-yl)-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
[[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- amino] -acetic acid methyl ester,
N-carbamoylmethyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
{ (3,5-bz5-trifluoromethyl-benzoyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid methyl ester, N-carbamoylmethyl-N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3,5-bz5- trifluoromethyl-benzamide,
4,6-bzs-trifluoromethyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide, N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5-trifluoromethyl- benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5- trifluoromethyl-benzamide,
N-(2-amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-3-(methylsulfonyl)- 5-(trifluoromethyl)benzamide,
2-methanesulfonyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-6-trifluoromethyl-isonicotm
methyl 2-(N-(4-(2-fluoro-6-methoxyphenyl)pyridin-3-yl)-2,6- bz5(trifluoromethyl)isonicotinamido)acetate,
methyl 2-(N-(4-(2-fluorophenyl)pyridin-3-yl)-2,6-bz5(trifluoromethyl)isonicotinamido)acetate, N-carbamoylmethyl-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
2-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-6-methoxy-N-methyl-isonicotinamide, N-carbamoylmethyl-N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-oxetan-3-yl-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[6-chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3 -yl]-N-(2-oxo-butyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3 -yl]-3-methanesulfonyl- V-(2-oxo-butyl)-5- trifluoromethyl-benzamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3 - yl] - 3 -methanesulf onyl-N- methyl- 5 -trifluoromethyl- benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3 -yl]-2-methoxy-N-methyl-6-trifluoromethyl- isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3 -yl]-N-(3-methyl-oxetan-3-ylmethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-methyl-3,5-bz5-trifluoromethyl-N-[4-(l,3,5-trimethyl-lH-pyrazol-4-yl)-pyridin-3-yl]- benzamide,
N-[4-(2,4-dimethyl-thiazol-5-yl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(3,5-dimethyl-isoxazol-4-yl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-methyl-N-[4-(4-methyl-2H-pyrazol-3-yl)-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide, and
N-[2-chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
or pharmaceutically acceptable salts thereof.
The invention further relates to
[[4-(2-fluoro-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]- acetic acid methyl ester,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-(2,2-difluoro-ethyl)-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy-ethylsulfanyl)-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methoxy-ethanesulfonyl)-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy-ethanesulfonyl)-N-methyl-5- trifluoromethyl-benzamide,
N-carbamoylmethyl-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5-trifluoromethyl- benzamide,
N-(6-ethyl-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bis-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2-methanesulfonyl-N-methyl-6-trifluoromethyl- isonicotinamide,
N-[4-(2-amino-phenyl)-pyridin-3-yl]-N-methyl-3,5-bis-trifluoromethyl -benzamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-propionic acid methyl ester,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-propionic acid methyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-hydroxy-N-methyl-5-trifluoromethyl- benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethoxy- benzamide,
N-cyanomethyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide, N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-methoxy-ethyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-2-methyl-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(5-methyl-isoxazol-3- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(R)- l-(tetrahydro-furan-
2- yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)- l-(tetrahydro-furan- 2-yl)methyl]-5-trifluoromethyl-benzamide,
[2-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-ethyl]-carbamic acid tert-butyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-oxetan-3-yl-5-trifluoromethyl- benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methoxy-ethoxy)-N-methyl-5- trifluoromethyl-benzamide,
3- (2-amino-ethylsulfanyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3-chloro-5-cyclopropyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-benzamide, 4-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-m
phenylsulfanyl)-butyric acid,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy-ethoxy)-N-methyl-5- trifluoromethyl-benzamide,
3-(2-amino-ethanesulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(2-cyclopropoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-pentanoic acid,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-hydroxy-ethyl)-3-methanesulfonyl-5-trifluoromethyl- benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenyl)-azetidine-l-carboxylic acid tert-butyl ester,
3- bromo-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethoxy- benzamide,
4- (3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-butyric acid, 5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-pentanoic acid,
3-(azetidine-l-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(l-methyl-lH-imidazol-
2- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(oxetan-3-ylsulfanyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethoxy-benzamide,
N-[6-chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3- (4-carbamoyl-butane-l-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(morpholine-4-sulfonyl)-5- trifluoromethyl-benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-5-methanesulfonyl-N-methyl- benzamide,
N-[4-(2-benzyloxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
3-(2-azetidin- l-yl-ethylsulfanyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3-cyclopropyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-5-methanesulfonyl-N-methyl- benzamide,
N-[4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl]-N-methyl-3-{ [2- (sulfamoylamino)ethyl] sulfanyl } -5-(trifluoromethyl)benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methanesulfonylamino-ethylsulfanyl)-N- methyl-5-trifluoromethyl -benzamide,
3-methanesulfonyl-N-[4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3-(2-azetidin- l-yl-ethanesulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenyl) -propionic acid ethyl ester, N-[4-(2-benzyloxy-4-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-azetidine- l-carboxylic acid tert-butyl ester,
N-[4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl]-N-methyl-3-{ [2- (sulfamoylamino)ethyl]sulfonyl}-5-(trifluoromethyl)benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2^
methyl-5-trifluoromethyl-benzamide,
3-(2-hydroxy-ethylamino)-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benza
3-methanesulfonyl-N-methyl-N-{4-[2-(oxetan-3-yloxy)-phenyl]-pyridin-3-yl}-5-trifluorometh benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(tetrahydro-furan-3- ylmethyl)-5-trifluoromethyl-benzamide,
3-methanesulfonyl-N-methyl-N-[4-(2-trifl^
benzamide,
3-(azetidin-3-ylsulfanyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluorometh benzamide,
N-[4-(2-cyclobutoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl-benzamide, 3-methanesulfonyl-N-methyl-N-[2-(2,2,2-trifluoro-ethoxy)-[3,4']bipyridinyl-3'-yl]-5- trifluoromethyl-benzamide,
3-(azetidine-3-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3-(2-carbamoyl-ethyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(l-methanesulfonyl-azetidine-3-sulfonyl)-N- methyl-5-trifluoromethyl -benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(5-methyl-oxazol-2- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(2,4-difluoro-5-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(2,6-difluoro-3-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-cyanomethyl-3-methanesulfonyl-5-trifluoromethyl- benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-5- trifluoromethyl-benzamide,
[[4-(2-chloro-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]- acetic acid methyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(R)- l-(tetrahydro-pyran-
2- yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)- l-(tetrahydro-pyran- 2-yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-mem^
5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(4-methyl-oxazol-2- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methan^
benz amide,
N-[4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
3- methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)- l-(tetrahydro-pyran- 3-yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-5-methanesulfonyl-N- methyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-3-(morpholine-4-sulfonyl)- 5-trifluoromethyl-benzamide,
3-bromo-N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-5-trifluoromethyl- benzamide,
3-(l, l-dioxo-thiomorpholine-4-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N- methyl-5-trifluoromethyl -benzamide,
N-[4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(2-oxa-6-aza-spiro[3.3]heptane-6- sulfonyl)-5-trifluoromethyl-benzamide N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-methanesulfonyl- ethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridm^
ethyl)-5-trifluoromethyl-benzamide,
3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3- yl]-5-trifluoromethyl-benzamide,
[[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- amino] -acetic acid methyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-3-(oxetan-3-ylsulfanyl)-5- trifluoromethyl-benzamide,
N-cyanomethyl-3-methanesulfonyl-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-5- trifluoromethyl-benzamide,
5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-phenylsulfanyl)-pentanoic acid,
N-(2-chloro-[3,4']bipyridinyl-3'-yl)-3-methanesulfonyl-N-methyl-5-trifluoromethyl-benzamide, N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide,
[5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-phenylsulfanyl)-pentanoylamino] -acetic acid,
5-(3-{ [4-(5-chloro-4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-benzenesulfonyl)-pentanoic acid,
[5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-benzenesulfonyl)-pentanoylamino] -acetic acid,
3-methanesulfonyl-N-methyl-N-{6-methyl-4-[2-(oxetan-3-yloxy)-phenyl]-pyridin-3-yl}-5- trifluoromethyl-benzamide,
N-carbamoylmethyl-3-methanesulfonyl-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-5- trifluoromethyl-benzamide,
3-{3'-[(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-methyl-amino]-[3,4']bipyridinyl-2- yloxy}-azetidine-l-carboxylic acid tert-butyl ester,
3-methanesulfonyl-N-methyl-N-{6-methyl-4-[2-(oxetan-3-ylmethoxy)-phenyl]-pyridin-3-yl}-5- trifluoromethyl-benzamide,
N-methyl-N-(4-phenyl-pyridin-3-yl)-3,5-bis-trifluoromethyl-benzamide, and
3-methanesulfonyl-N-methyl-N-(4-phenyl-pyridin-3-yl)-5-trifluoromethyl-benzamide, or pharmaceutically acceptable salts thereof. More particularly, compounds of formula I of the present invention are the following:
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methy
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-m
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-meth^
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluorometh
benzamide,
N-[4-(3-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-m
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-N-meth^
3-bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
4-bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3-trifluoromethyl-benzamide,
N-[4-(5-chloro-2-methyl-phenyl)-pyridin-3-yl]-N^
3-{3-[(3,5-bz5-trifluoromethyl-benzoyl)-methyl-amino]-pyridin-4-yl}-4-methyl-benzoic acid methyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2,2,^
{(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester,
N-(6-methoxy-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-fluoro-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide, N-methyl-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-2,6-bz5-trifluoromethyl- isonicotinamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2-amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- bz5(trifluoromethyl)isonicotinamide,
N-carbamoylmethyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide, N-(2-amino-2-oxoethyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-2,6- bzs(trifluoromethyl)isonicotinamide,
N-carbamoylmethyl-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-carbamoylmethyl-N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5-trifluorom isonicotinamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluorom benzamide, and
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2-methoxy-N-methyl-6-trifluoromem isonicotinamide,
N-[2-chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3-(2-amino-ethanesulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
4-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-butyric acid,
5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-pentanoic acid,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(morpholine-4-sulfonyl)-5- trifluoromethyl-benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-5-methanesulfonyl-N-methyl- benzamide,
3-methanesulfonyl-N-methyl-N-{4-[2-(oxetan-3-yloxy)-phenyl]-pyridin-3-yl}-5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide, and
3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3- yl]-5-trifluoromethyl-benzamide,
or pharmaceutically acceptable salts thereof.
Most particularly, compounds of formula I of the present invention are the following: N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-meth^
benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-2,6-bz5-trifluoromethyl- isonicotinamide,
N-carbamoylmethyl-N-[4-(4-fluoro-2-methoxy-phenyl^^
isonicotinamide,
N-carbamoylmethyl-N-[4-(2-fluoro-6-methoxy-pheny^
isonicotinamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
4-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-butyric acid,
or pharmaceutically acceptable salts thereof.
The pharmaceutically acceptable salts of the compounds of formula I also individually constitute advantageous compounds of the present invention.
Compounds of formula I can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography
(chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.
It will be appreciated, that the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.
A further aspect of the present invention is the process for the manufacture of compounds of formula I as defined above, which process comprises a) reacting a compound of the formula II
Figure imgf000044_0001
wherein G is -OH or -CI, B1, B2 and R4 to R6 are as defined above, with an amine formula III
Figure imgf000044_0002
wherein R 1 to R 3 are as defined above, in the presence of a coupling reagent under basic conditions to obtain a compound of the formula I
Figure imgf000044_0003
wherein B1, B2 and R1 to R6 are as defined above, and, if desired,
converting the compound obtained into a pharmaceutically acceptable salt, or, alternatively, b) reacting a compound of the formula IV
Figure imgf000044_0004
wherein B1, B2 and R2 to R6 are as defined above and X is selected from the group consisting of halogen, triflate and mesylate, with a boronic acid or ester of the formula V
R1-B(OR')2 V, wherein R1 is as defined above and R' is hydrogen or a pinacol or trimethylene glycol ester, in the presence of a palladium catalyst and a base to o bbtt;ain a compound of the formula I
Figure imgf000045_0001
wherein B 1, B2 and R1 to R6 are as defined above, and, if desired,
converting the compound obtained into a pharmaceutically acceptable salt, or, alternatively, c) reacting a compound of the formula VI
Figure imgf000045_0002
wherein B1, B2, R1 and R3 to R6 are as defined above and X' means a halogen atom, with a boronic acid or ester of the formula V
R2 -B(OR')2 V,
2'
wherein R is selected from Ci_7-alkyl, C3_7-cycloalkyl, halogen-Ci_7-alkyl and heteroaryl and R' is hydrogen or a pinacol or trimethylene glycol ester, in the presence of a palladium catalyst and a base to obtain a compound of the formula I*
Figure imgf000046_0001
wherein B 1, B2, R1 and R3 to R6 are as defined above and R2 is selected from Ci-7-alkyl, C3_7-cycloalkyl, halogen-Ci-7-alkyl and heteroaryl, and, if desired,
converting the compound obtained into a pharmaceutically acceptable salt. Appropriate coupling agents are for example N,N'-carbonyldiimidazole (CDI), Ν,Ν'- dicyclohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N' -ethyl-carbodiimide- hydrochloride (EDCI), 0-(benzotriazol-l-yl)-N,N,A^,A^-tetramethyluronium tetrafluoroborate (TBTU) , 1 - [bz's(dimethylamino)methylene] - 1 H- 1 ,2,3 -triazolo [4,5-b]pyridinium-3 -oxide hexafluorophosphate (HATU), l-hydroxy- l,2,3-benzotriazole (HOBT), 2-chloro- l- methylpyridinium iodide, 2-bromo- 1 -methylpyridinium iodide or benzotriazol- 1 - yloxytris(dimethylamino)phosphonium hexafluorophoshate (BOP). "Under basic conditions" means the presence of a base such as diisopropylethylamine, triethylamine, N-methylmorpholine or 4-(dimethylamino)-pyridine. The reaction is carried out in a suitable solvent such as for example N,N-dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, at temperatures between 0 °C and ambient temperature.
A palladium catalyst means a catalyst suitable for a Suzuki coupling reaction such as dichloro[ 1 , -bz5(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine. The coupling is preferably carried out in the presence of a base such as sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
The invention further relates to compounds of formula I as defined above obtainable according to a process as defined above. In more detail, compounds of formula I according to the present invention can be prepared by the methods and procedures given below.
If one of the starting materials or compounds of formula I contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described e.g. in "Protective Groups in Organic
Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.) can be introduced before the critical step applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.
A typical procedure for the preparation of compounds of formula I is illustrated in Scheme 1.
Compounds of general formula IA (R2 = R2a = H), IB (R2 = CI, R2a = H) and IC (R2 = H, R2a = CI) can be prepared for example as outlined in Scheme 1 by reacting commercially available pyridin-3-yl-carbamic acid tert-butyl esters 1 (R2 = R2a = H, R2 = H, R2a = CI, or R2 = CI, R2a = H) with a suitable base such as ie/ -butyllithium in an appropriate solvent, such as tetrahydrofuran or diethyl ether, at temperatures between 0 °C and -75 °C and treating the generated lithium species with an iodinating agent such as iodine to give intermediate 2 (step a). Alternatively, intermediates 2 in which R2 is chloro and R2a is hydrogen can be prepared by literature procedures (for example WO2008/127399 or J.-U. Peters et ah, Bioorg. Med. Chem. Lett. 2010, 20, 3405-3408). Intermediates 2 in which R2 is hydrogen and R2a is chloro are commercially available. Alkylation of intermediates 2 with R X, in which X is a suitable leaving group such as chlorine, bromine, iodine, OSOialkyl (e.g. mesylate (methanesulfonate),
OSOifluoroalkyl (e.g. triflate (trifluoromethanesulfonate) or OSOiaryl (e.g. tosylate (p- toluenesulfonate)), using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0 °C and the boiling temperature of the solvent, yields intermediates 3 (step b).
Removal of the Boc protective group applying methods known to those skilled in the art (e.g. using trifluoroacetic acid in dichloromethane at temperatures between 0 °C and room temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates 4 (step c). Scheme 1
Figure imgf000048_0001
10
Reaction of intermediates 4 with (substituted) boronic acids R^BiOH)! or boronic esters R^E^OR')! (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture yields intermediates 5 (step d). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev. 1995, 95, 2457-2483; A. Suzuki, J. Organomet. Chem. 1999, 576, 147- 168; V. Polshettiwar et ah, Chem. Sus. Chem. 2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R BFSK can be used in the cross -coupling reaction applying a palladium catalyst such as, e.g. ieirafo's(triphenylphosphine) palladium(O), palladium(II) acetate or dichloro[l, -bz5(diphenylphosphino)ferrocene]- palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium
carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
Intermediates 5 can be also synthesized by reacting intermediates 4 with (substituted) aryl- or heteroaryl tin reagents R^-Snl^ (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tetrakis- (triphenylphosphine)palladium(O), benzylbz's(triphenylphosphine)-palladium(II) chloride, bz5(triphenylphosphine)palladium(II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent such as THF, dioxane, DMF (N,N-dimethylformamide) or HMPA (hexamethylphosphoramide) or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. StiUe couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina et ah, J. Org. React. 1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art.
Alternatively, intermediates 5 can be synthesized from reaction of intermediates 4 with (substituted) aryl- or heteroaryl zinc halides R^-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g.
ieirafo's(triphenylphosphine)nickel(0)) or palladium catalyst (e.g. ieirafo's(triphenylphosphine) palladium(O)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross- coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99;
"Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art.
Acylation of intermediates 5 with aryl- or heteroaryl carboxylic acids II (either
commercially available or accessible by methods known in the art) furnishes target structures IA - IC (step e). Amide couplings of this type are widely described in the literature (e.g.,
Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be
accomplished by the usage of coupling reagents such as, e.g., N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l-[bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3- oxide hexafluorophosphate (HATU), l-hydroxy-l,2,3-benzotriazole (HOBT), Obenzotriazol-1- yl-N,N,N\N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l- methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N- dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with intermediates 5 in an appropriate solvent such as dichloromethane or DMF (N,N- dimethylformamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the boiling point of the solvent or solvent mixture to furnish compounds of the general formula IA - IC.
Compounds of the general formula IA - IC can also be prepared by converting
intermediates 4 into intermediates 10 (step f) by acylation with aryl- or heteroaryl carboxylic acids II (either commercially available or accessible by methods known in the art). Amide couplings of this type are widely described in the literature (e.g., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g., N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1- [bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3-oxide
hexafluorophosphate (HATU), l-hydroxy-l,2,3-benzotriazole (HOBT), Obenzotriazol-l-yl- N,N,N\N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l- methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N- dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with
intermediates 5 in an appropriate solvent such as dichloromethane or DMF (N,N- dimethylformamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture to furnish intermediates 10.
Reaction of intermediates 10 with (substituted) boronic acids 1^-13(011)2 or boronic esters R^-BiOR')! (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture yields compounds IA - IC (step g). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422; Chem. Rev. 1995, 95, 2457-2483; A. Suzuki, J. Organomet. Chem. 1999, 576, 147-168; V. Polshettiwar et ah, Chem. Sus. Chem. 2010, 3, 502-522) and are well known to those skilled in the art.
Alternatively, aryl- or heteroaryl-trifluoroborates R^FsK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g. ieirafo's(triphenylphosphine)palladium(0), palladium(II) acetate or dichloro[l, -bz5(diphenylphosphino)ferrocene]-palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
Compounds IA - IC can be also synthesized by reacting intermediates 10 with (substituted) aryl- or heteroaryl tin reagents R^SnRs (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g.
ieirafo's(triphenylphosphine)palladium(0), benzyl-bz's(triphenylphosphine)palladium(II) chloride, bz5(triphenylphosphine)palladium(II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina et al, J. Org. React. 1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art (step g).
Alternatively, compounds IA - IC can be synthesized from reaction of intermediates 10 with (substituted) aryl- or heteroaryl zinc halides R^-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel {e.g.
ieirafo's(triphenylphosphine)nickel(0)) or palladium catalyst {e.g. ieirafo's(triphenylphosphine)- palladium(O)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature {e.g. "Name Reactions for Homologations-Part I: Negishi cross- coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99;
"Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art (step g).
Intermediates 4 in which R2 is chlorine, R2a is hydrogen and R3 is methyl can be prepared from commercially available (or prepared according to WO2006/018725) 6-chloro-4-iodo- pyridin-3-amine (8, R2 = CI, R2a = H), e.g. by reaction with trimethyl orthoformate in the presence of catalytic amounts of acid such as trifluoroacetic acid at elevated temperatures and reducing the in situ formed iminium species with a suitable reducing agent such as, e.g. lithium aluminum hydride in tetrahydrofuran at temperatures preferably between 0 °C and room temperature (step h).
Intermediates 4 in which R is an R9CH2 or an R9R10CH substituent can be also synthesized from commercially available 3-amino-4-iodopyridine (8, R2 = R2a = H), for example via reductive alkylation (step h). Reductive alkylations (or sometimes called reductive aminations) are widely described in literature and are well known in the art. For example, the amine functionality in compound 8 can be reacted with (optionally substituted) aldehydes R9CHO or ketones R9C(0)R10 applying a reducing system such as, e.g. sodium borohydride, sodium triacetoxy-borohydride, sodium cyanoborohydride or di-n-butyltin dichloride with triphenyl- silane, in an appropriate solvent such as 1,2-dichloroethane or tetrahydrofuran to furnish intermediates 4 (R3 = R9CH2 and R9R10CH, respectively). Acetic acid may be used as catalyst for the reactions with ketones R9C(0)R10. Indium trichloride with triethylsilane in methanol might be used as well (step h). Intermediates 4 with R2 = R2a = H and R3 = Me have also been described in literature: E. K. Yum, Bull. Korean Chem. Soc. 2002, 23, 535-536.
Intermediates 5 are accessible from intermediates 7 by removal of the Boc protective group applying methods known to those skilled in the art {e.g. using trifluoroacetic acid in
dichloromethane at temperatures between 0 °C and room temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4 Ed., 2006, Wiley N.Y. (step k).
Intermediates 7 can be synthesized for example from intermediates 3 (step 1) for example by reaction with (substituted) boronic acids R^-B OH or boronic esters R^-B OR.'^ (e.g.
pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in
Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz5(diphenylphosphino)-ferrocene] palladium(II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture. Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev. 1995, 95, 2457-2483, A. Suzuki, J.
Organomet. Chem. 1999, 576, 147-168; V. Polshettiwar et al, Chem. Sus. Chem. 2010, 3, 502- 522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoro- borates R BFSK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g. ieirafe'5(triphenylphosphine)palladium (0), palladium (II) acetate or dichloro[l, - bz's(diphenylphosphino)ferrocene]-palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
Intermediates 7 can be also synthesized by reacting intermediates 3 with (substituted) aryl- or heteroaryl tin reagents R^-SnRs (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tetrakis- (triphenylphosphine)palladium(O), benzylbzs(triphenylphosphine)-palladium(II) chloride, bz5(triphenylphosphine)palladium(II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina, J. Org. React. 1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art (step 1). Alternatively, intermediates 7 can be synthesized from reaction of intermediates 3 with
(substituted) aryl- or heteroaryl zinc halides Rl-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g. tetrakis(tn- phenylphosphine)nickel (0)) or palladium catalyst (e.g. ieirafo's(triphenylphosphine)palladium(0)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross- Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem.2010, 4343) and well known to those skilled in the art (step 1). Intermediates 7 can also be synthesized from intermediates 6 through alkylation using compounds of the type R X, in which X is a suitable leaving group such as chlorine, bromine, iodine, OSOialkyl (e.g. mesylate (methanesulfonate), OSOifluoroalkyl (e.g. triflate
(trifluoromethanesulfonate) or OSOiaryl (e.g. tosylate (p-toluenesulfonate)), using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0 °C and the boiling temperature of the solvent (step j).
Intermediates 6 in turn can be synthesized from intermediates 2 for example by reaction with (substituted) boronic acids R^B OH or boronic esters R^BiOR')! (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz5(diphenylphosphino)-ferrocene]palladium(II) dichloro- methane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture (step i). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem.1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev.1979, 95, 2457-2483; A. Suzuki, J. Organomet. Chem.1999, 576, 147-168; V. Polshettiwar et al, Chem. Sus. Chem.2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R^FsK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g.
ieirafo's(triphenylphosphine)palladium (0), palladium(II) acetate or dichloro[l, -bz'5(diphenyl- phosphino)ferrocene]-palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture. Intermediates 6 can be also synthesized by reacting intermediates 2 with (substituted) aryl- or heteroaryl tin reagents R^-Snl^ (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tetrakis- (triphenylphosphine)palladium(O), benzylbz's(triphenylphosphine)-palladium(II) chloride, bz5(triphenylphosphine)palladium(II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl.1986, 25, 508-524; V. Farina, J. Org. React.1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art (step i).
Alternatively, intermediates 6 can be synthesized from reaction of intermediates 2 with (substituted) aryl- or heteroaryl zinc halides Rl-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g.
ieirafo's(triphenylphosphine)nickel(0)) or palladium catalyst (e.g.
ieirafo's(triphenylphosphine)palladium(0)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for
Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem.2010, 4343-4354) and well known to those skilled in the art (step i).
Intermediates 5 are also accessible from intermediates 9 (step n) using reductive alkylations (or sometimes called reductive aminations) that are widely described in literature and are well known in the art. For example, intermediates 5 in which R is a methyl group can be synthesized by reaction with trimethyl orthoformate in the presence of catalytic amounts of acid such as trifluoroacetic acid at elevated temperatures and reducing the in situ formed iminium species with a suitable reducing agent such as, e.g. lithium aluminum hydride in tetrahydrofuran at temperatures preferably between 0 °C and room temperature. Alternatively, for intermediates 5 wherein R is a -CH2-R9 or -CHR9R10 substituent, the amine functionality in compounds 9 can be reacted with (optionally substituted) aldehydes R9CHO or ketones R9C(0)R10 using a reducing system such as, e.g. sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride or di-n-butyltin dichloride with triphenylsilane, in an appropriate solvent such as 1,2-dichloroethane or tetrahydrofuran to furnish intermediates 5 (step n). Acetic acid may be used as catalyst for the reactions with ketones. Indium trichloride with triethylsilane in methanol might be used as well. Intermediates 5 may be also synthesized from intermediates 9 by protection of the amine functionality in 9 with a suitable protective group such as, e.g. a Boc protective group using methods described in literature and known in the art, alkylating the resulting tert-butyl carbamate with R X, in which X is a suitable leaving group such as chlorine, bromine, iodine, OS02alkyl (e.g. mesylate (methanesulfonate), OS02fluoroalkyl (e.g. triflate (trifluoromethanesulfonate) or OS02aryl (e.g. tosylate (p-toluenesulfonate)) using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0 °C and the boiling temperature of the solvent and removing the Boc protective group by methods known to those skilled in the art (e.g. using trifluoroacetic acid in dichloromethane at temperatures between 0 °C and room
temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.).
A number of intermediates 5 in which R2 is chlorine, R2a = hydrogen and R3 is a methyl group have also been described in literature (e.g. WO2006/013050 or WO2005/002577).
Intermediates 9 can be synthesized from commercially available 3-amino-4-iodopyridines 8 (R2 = R2a = H or R2 = CI, R2a = H) by reaction with (substituted) boronic acids R1-B(OH)2 or boronic esters R1-B(OR')2 (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, - bz's(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct,
ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture (step m). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem.1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev.1995, 95, 2457-2483; A. Suzuki, Organomet. Chem.1999, 576, 147-168; V. Polshettiwar et al, Chem. Sus. Chem.2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R^FsK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g.
ieirafe'5(triphenylphosphine)palladium(0), palladium(II) acetate or dichloro[l, - bzs(diphenylphosphino)ferrocene]-palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture. Alternatively, intermediates 9 can be reacted with (substituted) aryl- or heteroaryl tin reagents R^-Snl^ (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. ieirafo's-(triphenyrphosphine) palladium(O), benzylbz's(triphenylphosphine)-palladium(II) chloride, bz's(triphenylphosphine) palladium(II) dichloride or dichloro[ 1 , -bz5(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMTP or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride to furnish intermediates 5 (step n). Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina, J. Org. React. 1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art.
Intermediates 5 can be also synthesized from reaction of intermediates 9 with (substituted) aryl- or heteroaryl zinc halides R^-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g. tetrakis(trip enyl- phosphine)nickel(O)) or palladium catalyst (e.g. ieirafo's(triphenylphosphine)palladium(0)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley-VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art (step n).
Compounds of the general formula IA' in which R2 = R2a = H and R3 is a methyl group can also be prepared as outlined in Scheme 2. Commercially available 3-amino-4-bromopyridine 11 is converted into intermediate 12 through reductive alkylation, e.g. by reacting 11 with trimethyl orthoformate in the presence of catalytic amounts of acid such as trifluoroacetic acid at elevated temperatures and reducing the in situ formed iminium species with a suitable reducing agent such as, e.g. lithium aluminum hydride in tetrahydrofuran at temperatures preferably between 0 °C and room temperature (step a). Scheme 2
Figure imgf000058_0001
I V (R2 = IV ' = II. IV = Me)
Acylation of intermediate 12 with aryl- or heteroaryl carboxylic acids II (either commercially available or accessible by methods described in references or by methods known in the art) gives intermediates 13 (step b). Amide couplings of this type are widely described in the literature (e.g. , Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g. , N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l-[bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3- oxide hexafluorophosphate (HATU), l-hydroxy-l,2,3-benzotriazole (HOBT), Obenzotriazol- 1- yl-N,N,N\N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l- methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N-dimethyl- formamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g. , triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4- (dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane. Reaction of the acid chloride with amines 12 in an appropriate solvent such as dichloromethane or DMF (N,N-dimethylformamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture yields intermediates 13.
Reaction of intermediates 13 with (substituted) boronic acids 1^-13(011)2 or boronic esters RZ-E OR')! (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and
Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium (II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture yields compounds IA' (R2 = R2a = H, R3 = Me; step c). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem.1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev.1979, 95, 2457-2483; A. Suzuki, J. Organomet. Chem.1999, 576, 147-168; V. Polshettiwar et al, Chem. Sus. Chem.2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R^FsK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g. tetrakis- (triphenylphosphine)palladium(O), palladium(II) acetate or dichloro[l, -bz'5(diphenyl- phosphino)ferrocene]palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
Compounds IA' (R2 = R2a = H, R3 = Me) can be also synthesized by reacting intermediates 13 with (substituted) aryl- or heteroaryl tin reagents R^SnRs (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. ieirafo's(triphenylphosphine)palladium(0), benzylbz5(triphenyl- phosphine)palladium(II) chloride, bz's(triphenylphosphine)palladium(II) dichloride or
dichloro[l, -bz5(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl.1986, 25, 508-524; V. Farina, J. Org. React.1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art (step c). Alternatively, compounds IA' (R2 = R2a = H, R3 = Me) can be synthesized from reaction of intermediates 13 with (substituted) aryl- or heteroaryl zinc halides Rx-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g. ieirafo's(triphenylphosphine)nickel(0)) or palladium catalyst (e.g. tetrakis(trip enyl- phosphine)palladium(O)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross-coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik. Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art (step c).
Compounds of the general formula ID (R2 = RnO, R2a = H) may be prepared according to Scheme 3. For example, commercially available 2-chloro-5-nitropyridine 14 may be treated with sodium alkoxide (either commercially available or prepared by methods known in the art) in a manner described in the literature (R. H. Pager et al., Aust. J. Chem. 2003, 56, 913-916; Y.
Nishikawa et ah, J. Med. Chem. 1989, 32, 583-593) to give 2-alkoxy-5-nitropyridines 15 (step a). Intermediates 15 in which R11 is a phenyl group have been described in the literature (e.g. WO 1999/24404; WO 2008/025539).
The nitro group in intermediates 15 may then be reduced to the amino group by one of numerous known methods such as tin(II) chloride in a solvent such as ethanol or hydrogenation catalyzed by a transition metal such as palladium or platinum in a solvent such as ethyl acetate or ethanol to give intermediates 16 (step b). Carbamoylation of the aniline in intermediates 16 can be carried out by conventional methods described in the literature, for example, WO
2009/119700, to give intermediates 17 (step c). Reaction of intermediates 17 with a suitable base such as, e.g. ie/ -butyllithium in an appropriate solvent, such as tetrahydrofuran or diethyl ether, at temperatures between 0 °C and -75 °C and treating the generated lithium species with an iodinating agent such as iodine gives intermediates 18 (step d).
Scheme 3
Figure imgf000061_0001
14 15
Figure imgf000061_0002
24 (R2 = CI, R2a = H)
IB (R2 = CI, R2a = H)
Alkylation of intermediates 18 with R3X, in which X is a suitable leaving group such as chlorine, bromine, iodine, OS02alkyl (e.g. mesylate (methanesulfonate), OSOifluoroalkyl (e.g triflate (trifluoromethanesulfonate) or OS02aryl (e.g. tosylate (p-toluenesulfonate)), using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0 °C and the boiling temperature of the solvent, yields intermediates 19 (step e).
Reaction of intermediates 19 with (substituted) boronic acids 1^-13(011)2 or boronic esters RZ-E OR' )! (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and
Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium (II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium (II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture yields intermediates 20 (step f). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem.1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev.1979, 95, 2457; A. Suzuki, J. Organomet. Chem.1999, 576, 147-168; V. Polshettiwar, Chem. Sus. Chem.2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R^FsK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g. ieirafo's(triphenylphosphine)palladium(0), palladium(II) acetate or dichloro[l, -bz5(diphenylphosphino)ferrocene]-palladium(II)
dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
Intermediates 20 can be also synthesized by reacting intermediates 19 with (substituted) aryl- or heteroaryl tin reagents R^SnRs (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tetrakis- (triphenylphosphine)palladium(O), benzylbz's(triphenylphosphine)-palladium(II) chloride, bz5(triphenylphosphine)palladium(II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMTP or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl.1986, 25, 508-524; V. Farina et al., J. Org. React.1998, 50, 1-652; T. N. Mitchell,
Synthesis 1992, 9, 803-815) and well known to those skilled in the art.
Alternatively, intermediates 20 can be synthesized from reaction of intermediates 19 with (substituted) aryl- or heteroaryl zinc halides Rl-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g. tetrakis- (triphenylphosphine)nickel(O)) or palladium catalyst (e.g. tetrakis(tnphenyl- phosphine)palladium(O)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art.
Intermediates 20 may also be prepared by converting intermediates 18 into intermediates 22 by cross -coupling reactions (step i) and alkylation of intermediates 22 with compounds of the type R X (step j) using the conditions as outlined before.
Intermediates 20 are then converted into intermediates 21 by removal of the Boc protective group applying methods known to those skilled in the art (e.g. using trifluoroacetic acid in dichloromethane at temperatures between 0 °C and room temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y. (step g).
Acylation of intermediates 21 with aryl- or heteroaryl carboxylic acids II (either
commercially available or accessible by methods known in the art) furnishes target structures ID (step h). Amide couplings of this type are widely described in the literature (e.g., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g., N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexyl- carbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1- [bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluoro- phosphate (HATU), 1 -hydroxy- 1, 2,3 -benzotriazole (HOBT), <9-benzotriazol-l-yl-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l-methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N-dimethylformamide (DMF), dimethylacetamide (DM Ac), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with intermediates 5 in an appropriate solvent such as dichloromethane or DMF (N,N-dimethylformamide) and a base, e.g. triethylamine, N,N- diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture to furnish compounds of the general formula ID. Intermediates 21 may also be prepared from intermediates 23 by reductive alkylations (or sometimes called reductive aminations) which are widely described in literature and well known in the art. For example, intermediates 21 in which R is a methyl group may be prepared, e.g. by reaction of intermediates 23 with trimethyl orthoformate in the presence of catalytic amounts of acid such as trifluoro acetic acid at elevated temperatures and reducing the in situ formed iminium species with a suitable reducing agent such as, e.g. lithium aluminum hydride in tetrahydrofuran at temperatures preferably between 0 °C and room temperature (step k).
Intermediates 21 in which R is a R9CH2 or a R9R10CH substituent can be also synthesized from intermediates 23 by reaction with (optionally substituted) aldehydes R9CHO and ketones
R9C(0)R10, respectively, applying a reducing system such as, e.g. sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride or di-n-butyltin dichloride with triphenylsilane, in an appropriate solvent such as 1,2-dichloroethane or tetrahydrofuran (R 3 = R 9 CH2 and
R9R10CH, respectively; step k). Acetic acid may be used as catalyst for the reactions with ketones R9C(0)R10. Indium trichloride with triethylsilane in methanol might be used as well. Intermediates 23 can be synthesized from intermediates 22 by removal of the Boc protective group applying methods known to those skilled in the art (e.g. using trifluoroacetic acid in dichloromethane at temperatures between 0 °C and room temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y. (step n). Furthermore, intermediates 21 can be prepared from intermediates 24 (prepared as described for intermediate 5 under Scheme 1) by reaction of intermediates 24 with alcohols RnOH in the presence of an appropriate base such as sodium or potassium hydroxide, in a suitable solvent such as, e.g. DMF or DMSO (step 1). In order to enhance the rate of conversion heating might be applied, whereby conventional heating or microwave-assisted heating might be employed using a suitable microwave irradiation apparatus. Furthermore, the reaction can be conducted without a solvent using the alcohol RuOH as reactant and reagent.
Alternatively, compounds ID can be prepared by reacting compounds IB with an alcohol RnOH in the presence of an appropriate catalyst such as, e.g. in's(dibenzylideneacetone)- dipalladium(O) (optionally with a ligand such as, e.g. (R)-(+)-2,2'-bzs(di-p-tolylphosphino)-l,l'- binaphthyl) and a base such as, e.g. potassium ie/ -butoxide or sodium hydride in a suitable solvent such as, e.g. dioxane or toluene (step m). Scheme 4
Figure imgf000065_0001
ID' (R2 = OMe, R2a = H)
Figure imgf000065_0002
ID (R2 = R"0, R2a = H)
Compounds of the general formula ID in which R2 is RnO, R2a is H and R11 is an alkyl group can alternatively be prepared according to Scheme 4 from compounds ID' in which R is a methoxy group (prepared by the methods described under Scheme 3). The 6-methoxypyridine compounds can be converted into the 6-hydroxypyridine intermediates 25 for example by treating with a strong aqueous acid such as HCl or HBr with or without heating in a polar solvent such as methanol (step a). Alternatively, compounds ID' (R = OMe) can be treated with iodo- trimethyl-silane in a suitable solvent such as, e.g. dichloromethane at temperatures between room temperature and the boiling point of the solvent to give intermediates 25. The 6-hydroxypyridine intermediates 25 may then be alkylated selectively on oxygen by methods described in literature (T. Ross-Kelly, J. Am. Chem. Soc. 1988, 110, 6471-6480; WO2005/115977) to give compounds ID. For example, reaction of intermediates 25 with alkyl halides such as benzyl bromide or n- propyl bromide in a solvent such as benzene or chloroform in the presence of silver salts such as silver carbonate gives the corresponding 6-alkoxy derivatives ID (R2 = RnO, R2a = H, R11 = alkyl; step b). Scheme 5
Figure imgf000066_0001
IE' (R2 = NH2, R2a = H)
2 12 13 12
Compounds of general formula IE in which R is an amino substituent NR R (R = (substituted) alkyl or cycloalkyl, R2a is hydrogen and R13 = H, (substituted) alkyl or cycloalkyl,
12 13
or R and R together form a ring) may be prepared as described in Scheme 5. The 6-chloro substituent in intermediates 24 (prepared as described for intermediate 5 in
Scheme 1) may be directly converted to an amino group NR 12 R 13 by a reaction commonly referred to as the Hartwig-Buchwald aryl amination. This reaction (step a) couples an aryl moiety with variously substituted and functionalized amines. It can be carried out under a variety of conditions employing a transition metal catalyst, e.g. palladium acetate or in's(dibenzylidene- acetone)dipalladium(O), a ligand such as (9,9-dimethyl-9H-xanthene-4,5-diyl)bz5(diphenyl- phosphine) or triphenylphosphine, a base such as sodium ierz-butoxide and a solvent such as toluene or dioxane (Org. Synth., Coll. 2004, 10, 423; J. F. Hartwig et al, J. Am. Chem. Soc. 1994, 116, 5969-5970; WO 2009/158431) to give intermediates 26. In order to enhance the rate of conversion heating might be applied, whereby conventional heating or microwave-assisted heating might be employed using a suitable microwave irradiation apparatus.
Intermediates 26 in which R 12 and R 13≠ hydrogen then may be acylated directly with aryl and heteroaryl carboxylic acids II (step b) to give compounds of general formula IE (R 12≠ H,
R 13≠ H). Amide couplings of this type are widely described in the literature (e.g.,
Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be
accomplished by the usage of coupling reagents such as, e.g., N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexyl-carbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l-[bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3- oxide hexafluoro-phosphate (HATU), l-hydroxy-l,2,3-benzotriazole (HOBT), O-benzotriazol-l- yl-N,N,N\N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l- methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N- dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with
intermediates 26 in an appropriate solvent such as dichloromethane or DMF (N,N- dimethylformamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture to furnish compounds of the general formula IE.
For compounds in which R 12≠ H and R 13 = H, the secondary 6-amino group of
intermediates 26 may be protected with a suitable protecting group to give intermediates 27 (step c) using methods well known to those skilled in the art and as described in the chemical literature, e.g. "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y. The 3-amino group in intermediates 27 is then acylated with aryl- or heteroaryl carboxylic acids II using the conditions described above to give intermediates 28 (step d). Deprotection of the 6-amino group using methods well-known to those skilled in the art and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y. furnishes compounds IE (R 13 = H, step e). Compounds of general formula IE in which R 2 signifies an amino substituent NR 12 R 13 (R 12 = (substituted) alkyl or cycloalkyl and
R 13 = H, (substituted) alkyl or cycloalkyl or R 12 and R 13 together form a ring) may be also prepared from compounds IB and amines of the type HNR 12 R 13 (step f) by using for example a Hartwig-Buchwald amination reaction as described above under step a. In order to facilitate an aryl amination, intermediates 24 and compounds IB may be first converted to the corresponding 6-iodo or 6-bromo pyridines. These trans-halogenation reactions are widely described in literature and known in the art. For example, conversion of 6- chloropyridyl intermediates to 6-iodopyridyl intermediates may be carried out by heating 6- chloropyridyl intermediates with hydriodic acid and an excess of iodide from a source such as sodium iodide in a polar solvent such as acetonitrile (e.g. U. Luening et ah, Eur. J. Org. Chem. 2009, 14, 2328-2341). Alternatively, the 6-chloro intermediates may be reacted with sodium iodide and chloro-trimethyl-silane in a suitable solvent such as, e.g. propanenitrile (e.g. J.
Clayden et ah, J. Am. Chem. Soc. 2009, 131, 5331-5343) or with acetyl chloride or acetic anhydride and sodium iodide in, e.g. acetonitrile (e.g. M.G. Banwell, A. C. Bissember, . Org. Chem. 2009, 74, 4893-4895) to furnish the 6-iodo compounds.
The 6-bromo intermediates may be produced by analogous methods, for example by reacting the 6-chloro intermediates with bromo-trimethyl-silane in a suitable solvent such as, e.g. propanenitrile (e.g. M. V. Patel et al, J. Med. Chem. 2006, 49, 7450-7465). Alternatively, phosphorus(V) oxybromide (e.g. J. W. Streef et ah, J. Heterocycl. Chem. 1985, 22, 985-991) or hydrobromic acid in acetic acid (e.g. Md. K. Nazeeruddin et ah, Inorg. Chem. 2006, 45, 4642- 4653) may be used. The transformation can be carried out at temperatures ranging from room temperature up to the boiling point of the solvent. Microwave heating may also be applied.
Compounds of general formula IE' in which R signifies a primary amino substituent -N¾ may be prepared by converting the 6-chloro substituent in compounds IB to a benzhydrylidene amine ("imine") by treatment of compounds IB with commercially available benzophenone imine applying Hartwig-Buchwald amination conditions as described above under step a, to give intermediates 29 (step g). Cleavage of the imine group for example using an acid such as, e.g. aqueous HC1 or by catalytic hydrogenation, treatment with hydroxylamine hydrochloride or a catalytic amount of HC1 in wet THF provides compounds IE' in which R is a primary amino group (N¾, step h). Scheme 6
Figure imgf000069_0001
IH (R2 = Heteroaryl (Het), R2a = H)
Compounds of the general formulas IF to I-H can be prepared for example as outlined in Scheme 6 by the methods and procedures given below. Compounds of the general formula IF in which R2 is a cyano group and R2a is hydrogen can be prepared for example by reaction of compounds IB with a suitable source of cyanide such as zinc cyanide in a solvent such as, e.g. DMF or dioxane at elevated temperatures up to the boiling point of the solvent with or without using a substoichiometric amount of a transition metal catalyst such as e.g. ieirafo's(triphenylphosphine)palladium(0). Alternatively, cyanide may be introduced using superstoichiometric amounts of copper(I)cyanide in a polar solvent such as DMF or dioxane and a suitable catalyst such as in's(dibenzylideneacetone)dipalladium(0) and l,l '-bz5(diphenyl-phosphino)ferrocene as ligand (step a). The use of microwave irradiation may facilitate the reaction.
Compounds of the general formula IG in which R signifies an alkyl (e.g. a methyl, ethyl, propyl, isopropyl, isobutyl) or a cycloalkyl (e.g. a cyclopropyl) group and R2a is hydrogen can be prepared for example from compounds IB. For example, reaction of compounds IB with
(substituted) boronic acids R 2 -B(OH)2 or boronic esters R 2 -B(OR')2 (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and
Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz5(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium(II) acetate with
triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture yields compounds IG (step b). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev. 1995, 95, 2457-2483; A. Suzuki, J. Organomet. Chem. 1999, 576, 147-168; V. Polshettiwar, Chem. Sus. Chem. 2010, 3, 502) and are well known to those skilled in the art. Compounds IG can be also synthesized by reacting compounds IB with (substituted) alkyl tin reagents R -SnR3 (R = e.g. Me or ft-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tezra£z's-(triphenylphosphine)palladium(0),
benzylbz's(triphenylphosphine)-palladium(II) chloride, bz's(triphenylphosphine)palladium(II) dichloride or dichloro[l, -bz5(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina et ah, J. Org. React. 1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art (step b). Alternatively, compounds IF can be synthesized from reaction of compounds IB with (substituted) alkyl zinc halides R -ZnX (X = CI, Br or I) (either
commercially available or synthesized by methods described in literature) using a nickel (e.g. ieirafo's(triphenylphosphine)nickel(0)) or palladium catalyst (e.g.
ieirafo's(triphenylphosphine)palladium(0)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for
Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 23, 4343-4354) and well known to those skilled in the art (step b). Alternatively, Grignard reactions, treating compounds IB with organomagnesium
compounds of the type R -MgX (X = CI or Br) in an appropriate solvent such as, e.g.
tetrahydrofuran or NMP may be used to prepare compounds IG. Reactions of this type have also been described in literature (e.g. F. Lamaty et al., Synthetic Commun. 2009, 39, 1583-1591).
Furthermore, compounds IB can be reacted with commercially available aluminum compounds of the type (R 2 )3A1 (R 2 = Me, Et, z'so-butyl) using an appropriate catalyst such, as e.g. ieirafo's(triphenylphosphine)palladium(0), bz's(triphenylphosphine)palladium(II) dichloride or ins(dibenzylideneacetone)dipalladium(0) in the presence of triphenylphosphine, in a suitable solvent such as, e.g. dimethoxyethane, dioxane, toluene, hexane, DMF or mixtures thereof at temperatures ranging from room temperature to the boiling point of the solvent or solvent mixtures, to furnish compounds IG. Reactions of this type have also been described in literature (e.g. A. Cappelli et al, ChemMedChem 2010, 5, 739-748; M. J. Bamford et al, Bioorg. Med. Chem. Lett. 2005, 15, 3407-3411). In order to enhance the rate of conversion microwave-assisted heating might be applied.
Alternatively, compounds IG in which R signifies a trifluoromethyl group can be synthesized from compounds IB by reaction with sodium trifluoroacetate in the presence of copper(I)iodide in an appropriate solvent like l-methyl-2-pyrrolidone (e.g. R. D. Chambers et al, J. Chem. Soc, Perkin Trans. 1, 1988, 4, 921-926) or using (trifluoromethyl)trimethylsilane, copper(I)iodide with or without potassium fluoride in NMP as described in literature (e.g. R. C. Lemoine et al, Bioorg. Med. Chem. Lett. 2010, 20, 704-708, M. Schlosser et al, Eur. J. Org. Chem. 2003, 8, 1559-1568).
Furthermore, a cyclopropyl substituent can be introduced for example through palladium- catalyzed (e.g. ieirafo's(triphenylphosphine)palladium(0)) reaction of compounds IB with a preformed complex of 9-borabicyclo[3.3.1]nonane and propargylbromide in the presence of an appropriate base like, e.g. sodium hydroxide in an appropriate solvent like tetrahydrofuran in analogy to published procedures (J. A. Soderquist et al, Tetrahedron Lett. 2000, 41, 4251-4255). Furthermore, compounds IG in which R is a methyl or a trifluoromethyl group, respectively, may also be prepared from commercially available 4-chloro- or 4-bromo-6-methyl-pyridine-3- ylamine and 4-chloro- or 4-bromo-6-trifluoromethyl-pyridine-3-ylamine, respectively, as starting materials, applying the same synthetic methodology as described for compound 8 in Scheme 1. 2
Compounds of the general formula IH in which R signifies a heteroaryl (Het) substituent and R2a is hydrogen can be prepared for example from compounds IB by reaction with
(substituted) boronic acids Het-B(OH)2 or boronic esters Het-B(OR')2 (e.g. pinacol or
trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz5(diphenylphosphino)-ferrocene] palladium (II)
dichloromethane adduct, ieirafo's(triphenylphosphine)palladium (0) or palladium (II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture (step c).
Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev. 1995, 95, 2457-2483; A. Suzuki, J.
Organomet. Chem. 1999, 576, 147-168; V. Polshettiwar, Chem. Sus. Chem. 2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R^FsK can be used in the cross-coupling reaction applying a palladium catalyst such as, e.g. ieirafo's(triphenylphosphine)palladium (0), palladium(II) acetate or dichloro[l, - bz's(diphenylphosphino)ferrocene] -palladium (II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture.
Compounds IH can be also synthesized by reacting compounds IB with (substituted) heteroaryl tin reagents Het-SnR3 (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tetrakis-
(triphenylphosphine)palladium (0), benzylbz's(triphenylphosphine)-palladium (II) chloride, bzs(triphenylphosphine)palladium (II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium(II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride. Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina et al, J. Org. React. 1998, 50, 1-652; T. N. Mitchell,
Synthesis 1992, 9, 803-815) and well known to those skilled in the art.
Alternatively, compounds IH can be synthesized from reaction of compounds IB with (substituted) heteroaryl zinc halides Het-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g. tetrakis(trip enyl- phosphine)nickel(O)) or palladium catalyst (e.g. ieirafo's(triphenylphosphine)palladium(0)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent. Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art.
In some cases, the conversion of compounds IB into the corresponding 6-iodo or 6-bromo pyridines may facilitate an aryl alkylation. These trans-halogenation reactions are widely described in literature and known in the art. For example, conversion of compounds IB into their 6-iodopyridyl analogues may be carried out by heating compounds IB with hydriodic acid and an excess of iodide from a source such as sodium iodide in a polar solvent such as acetonitrile (e.g. F. Eggers, U. Luening, Eur. J. Org. Chem. 2009, 14, 2328-2341). Alternatively, compounds IB may be reacted with sodium iodide and chloro-trimethyl-silane in a suitable solvent such as, e.g. propanenitrile (e.g. J. Clayden et ah, J. Am. Chem. Soc. 2009, 131, 5331-5343) or with acetyl chloride or acetic anhydride and sodium iodide in, e.g. acetonitrile (e.g. A. C. Bissember, M. G. Banwell, J. Org. Chem. 2009, 74, 4893-4895) to furnish the 6-iodo compounds. The 6- bromo intermediates may be produced by analogous methods, for example by reacting compounds IB with bromotrimethylsilane in a suitable solvent such as, e.g. propanenitrile (e.g. M. V. Patel et al, J. Med. Chem. 2006, 49, 7450-7465). Alternatively, phosphorus(V) oxybromide (e.g. J. W. Streef et ah, J. Heterocycl. Chem. 1985, 22, 985-991) or hydrobromic acid in acetic acid (e.g. Md. K. Nazeeruddin, S. Fantacci, M. Graetzel et ah, Inorg. Chem. 2006, 45, 4642-4653) may be used. The transformation can be carried out at temperatures ranging from room temperature up to the boiling point of the solvent. Microwave heating may also be applied.
Scheme 7
Figure imgf000074_0001
I-I (R2 = C(0)NR14R1S, R2a = H)
Compounds of the general formula I-I (R2 = C(0)NR14R15 with R14 and R15 independently from each other being hydrogen or Ci-7-alkyl) can be prepared as outlined in Scheme 7. Intermediates 30 can be prepared for example by transition metal-catalyzed
alkoxycarbonylation, reacting compounds IB with carbon monoxide using a suitable transition metal catalyst, for example, [l,l'-bzs(diphenylphosphino)ferrocene] dichloropalladium(II) in a solvent such as methanol or ethanol, to give the alkyl ester intermediates 30 (step a). Supra- atmospheric pressures, e.g. 10 atm, of CO gas may facilitate the reaction. Under such pressures, the reaction is best run in a reaction vessel and using equipment designed to withstand high pressures. The reaction can be carried out in the presence of a base such as, e.g. tertiary amines, for example, triethylamine. Intermediates 31 are accessible by cleavage of the ester functionality in intermediates 30 under basic (e.g. methyl or ethyl esters with lithium or sodium hydroxide in polar solvents such as, e.g. methanol, water or tetrahydrofuran or mixtures of said solvents) or under acidic conditions (e.g. a tert-butyl ester using trifluoro acetic acid with or without a solvent (e.g. dichloromethane), concentrated hydrochloric acid in tetrahydrofuran or formic acid in an appropriate solvent such as alcohols like, e.g. isopropanol). Reaction of intermediates 31 with amines of the type HNR14R15 gives compounds I-I. Amide coupling of this type are widely described in the literature (e.g. , Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g., Ν,Ν'- carbonyldiimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), l-(3-dimethyl- aminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l-[bz5(dimethylamino)methylene]-lH- l,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU), l-hydroxy-1,2,3- benzotriazole (HOBT), 0-benzotriazol-l-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l-methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N-dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the acid functionality in
intermediates 31 can be converted into the acid chloride by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with amines of the type HNR14R15 in an appropriate solvent such as dichloromethane or DMF (N,N- dimethylformamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture furnishes compounds of the general formula I-I.
Compounds of the general formula I-I (R2 = C(0)NR14R15 with R14 and R15 independently from each other being hydrogen or Ci_7-alkyl, R2a = H) can also be prepared as outlined in
Scheme 8 from intermediate 32. Alkylation of (6-chloro-4-iodo-pyridin-3-yl)-carbamic acid ie/ -butyl ester 32 (prepared according to published procedures, e.g. J.-U. Peters et ah, Bioorg. Med. Chem. Lett. 2010, 20, 3405-3408; WO 2008/127399) with R3X, in which X is a suitable leaving group such as chlorine, bromine, iodine, OS02alkyl (e.g. mesylate (methanesulfonate), OS02fluoroalkyl (e.g. triflate (trifluoromethane-sulfonate) or OS02aryl (e.g. tosylate (p-toluenesulfonate)), using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0 °C and the boiling temperature of the solvent, yields intermediates 33 (step a).
Scheme 8
Figure imgf000076_0001
I-I (R2 = C(0)NR14R15, R2a = H)
Reaction of intermediates 33 with (substituted) boronic acids R^BiOH)! or boronic esters R^E^OR')! (e.g. pinacol or trimethylene glycol ester, either commercially available or prepared using literature procedures as described for example in "Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine" by Dennis G. Hall (ed.) 1st Ed., 2005, John Wiley & Sons, New York) using a suitable catalyst (e.g. dichloro[l, -bz'5(diphenylphosphino)- ferrocene] palladium (II) dichloromethane adduct, ieirafo's(triphenylphosphine)palladium(0) or palladium (II) acetate with triphenylphosphine) in an appropriate solvent (e.g. dioxane, dimethoxyethane, water, toluene, N,N-dimethylformamide or mixtures thereof) and a suitable base (e.g. sodium carbonate, sodium hydrogen carbonate, potassium fluoride, potassium carbonate or triethylamine) at temperatures between room temperature and the boiling point of the solvent or solvent mixture yields intermediates 34 (step b). Suzuki reactions of this type are broadly described in literature (e.g. A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422; A. Suzuki, N. Miyaura, Chem. Rev. 1995, 95, 2457-2483; A. Suzuki, J. Organomet. Chem. 1999, 576, 147- 168; V. Polshettiwar et ah, Chem. Sus. Chem. 2010, 3, 502-522) and are well known to those skilled in the art. Alternatively, aryl- or heteroaryl-trifluoroborates R BFSK can be used in the cross -coupling reaction applying a palladium catalyst such as, e.g. tetrakis(^p enyl- phosphine)palladium(O), palladium(II) acetate or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]-palladium(II) dichloromethane adduct in the presence of a suitable base such as cesium carbonate or potassium phosphate in solvents such as toluene, THF, dioxane, water or mixtures thereof, at temperatures between room temperature and the boiling point of the solvent or solvent mixture. Intermediates 34 can be also synthesized by reacting intermediates 33 with (substituted) aryl- or heteroaryl tin reagents R^-Snl^ (R = e.g. Me or n-Bu; either commercially available or prepared according to literature procedures) in the presence of a suitable catalyst (e.g. tetrakis- (triphenylphosphine)palladium (0), benzylbz's(triphenylphosphine)-palladium (II) chloride, bzs(triphenylphosphine)palladium (II) dichloride or dichloro[l, -bz'5(diphenylphosphino)- ferrocene]palladium (II) dichloromethane adduct) in an appropriate solvent (e.g. THF, dioxane, DMF or HMPA or mixtures thereof) at temperatures between room temperature and the boiling point of the solvent or solvent mixture, optionally in the presence of lithium chloride (step b). Stille couplings of this type are broadly described in literature (e.g. J. K. Stille, Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524; V. Farina et al, J. Org. React. 1998, 50, 1-652; T. N. Mitchell, Synthesis 1992, 9, 803-815) and well known to those skilled in the art.
Alternatively, intermediates 34 can be synthesized from reaction of intermediates 33 with (substituted) aryl- or heteroaryl zinc halides R^-ZnX (X = CI, Br or I) (either commercially available or synthesized by methods described in literature) using a nickel (e.g.
ieirafo's(triphenylphosphine)nickel(0)) or palladium catalyst (e.g. tetrakis(^p enyl- phosphine)palladium(O)) in an appropriate solvent such as, e.g. THF or DMA in a temperature range between room temperature and boiling point of the solvent (step b). Negishi couplings of this type are broadly described in literature (e.g. "Name Reactions for Homologations-Part I: Negishi cross -coupling reaction", Li, J. J., Corey, E. J., Eds.; Wiley & Sons, Hoboken, NJ, 2009, 70-99; "Metal-Catalyzed Cross-Coupling Reactions", Diederich, F.; Stang, P. J., Eds.; Wiley- VCH: Weinheim, Germany, 1998, 1-47; E. Erdik, Tetrahedron 1992, 48, 9577-9648; G. Organ, Eur. J. Org. Chem. 2010, 4343-4354) and well known to those skilled in the art. Transition metal-catalyzed alkoxycarbonylation of intermediates 34 (step c), using carbon monoxide and a suitable transition metal catalyst, for example, [l,r-bz's(diphenylphosphino) ferrocene] dichloropalladium (II) in a solvent such as methanol or ethanol, gives the alkyl ester intermediates 35. Supra- atmospheric pressures, e.g. 10 atm, of CO gas may facilitate the reaction. Under such pressures, the reaction is best run in a reaction vessel and using equipment designed to withstand high pressures. The reaction can be carried out in the presence of a base such as, e.g. tertiary amines, for example, triethylamine.
The ester functionality in intermediates 35 is cleaved under basic (e.g. methyl or ethyl esters with lithium or sodium hydroxide in polar solvents such as, e.g. methanol, water or tetrahydrofuran or mixtures of said solvents) or under acidic conditions (e.g. a ieri-butyl ester using trifluoroacetic acid with or without a solvent (e.g. dichloromethane), concentrated hydrochloric acid in tetrahydrofuran or formic acid in an appropriate solvent such as alcohols like, e.g. isopropanol) to furnish intermediates 36 (step d).
Reaction of intermediates 36 with amines of the type HNR14R15 gives intermediates 38
(step e). Amide coupling of this type are widely described in the literature (e.g. , Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g. , N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexyl- carbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1- [bz5(dimethylamino)methylene]- lH-l,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluoro- phosphate (HATU), 1 -hydroxy- 1, 2,3 -benzotriazole (HOBT), <9-benzotriazol- l-yl-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo- l-methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g. , N,N-dimethylformamide (DMF), dimethylacetamide (DM Ac), dichloromethane or dioxane, optionally in the presence of a base (e.g. , triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the acid functionality in intermediates 36 can be converted into the acid chloride by treatment with, e.g. , thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with amines of the type HNR16R17 in an appropriate solvent such as dichloromethane or DMF (N,N-dimethylformamide) and a base, e.g. triethylamine, N,N- diisopropylethylamine (Huenig' s base), pyridine, 4-(dimethylamino)pyridine or lithium bzs(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture furnishes intermediates 37. Removal of the Boc protective group in intermediates 37 applying methods known to those skilled in the art (e.g. using trifluoroacetic acid in dichloromethane at temperatures between 0 °C and room
temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.) furnishes intermediates 38 (step f). Acylation of intermediates 38 with aryl- or heteroaryl carboxylic acids II (either commercially available or accessible by methods known in the art) furnishes target structures I-I (step g). Amide couplings of this type are widely described in the literature (e.g., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g., N,N'-carbonyldiimidazole (CDI), N,N'-dicyclohexyl- carbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1- [bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3-oxide
hexafluorophosphate (HATU), l-hydroxy-l,2,3-benzotriazole (HOBT), Obenzotriazol-l-yl- N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l- methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N-dimethyl- formamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4- (dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with intermediates 38 in an appropriate solvent such as dichloromethane or DMF (N,N-dimethylformamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig's base), pyridine, 4-(dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture to furnish compounds of the general formula I-I.
Compounds of the general formula IJ in which R 1 is (alkyl-substituted) piperidinyl and R 2 and R2a signify hydrogen may be prepared according to Scheme 9.
Reacting commercially available 3-nitro-4-chloropyridine 39 with an excess of an optionally substituted piperidine with or without solvent at elevated temperatures, for example 150 °C, gives rise to direct displacement of the 4-chloro substituent to give intermediates 40 (step a). Reactions of this general type are well-described in literature (WO 2008/106692; WO 2007/072017; C. Temple, Jr. et al, J. Med. Chem. 1983, 26, 91-95). If a solvent is used then a polar solvent such as DMF, NMP or ethanol is preferable. Microwave irradiation may facilitate the displacement of the 4-chloro substituent by the piperidine.
The resulting 3-nitro-4-piperidinopyridine intermediates 40 can then be reduced to 3- amino-4-piperidinopyridine intermediates 41 using a variety of reducing agents well-known to those skilled in the art of chemical synthesis, for example, tin (II) chloride or a catalytic amount of palladium on carbon under an atmosphere of hydrogen gas (step b).
Figure imgf000080_0001
Figure imgf000080_0002
Figure imgf000080_0003
IJ (R1 = (alkyl-substituted) piperidinyl); R2 = R2a = H)
Intermediates 41 are transformed into intermediates 42 using reductive alkylations (or sometimes called reductive aminations) that are widely described in literature and are well known in the art (step c). For example, intermediates 42 in which R is a methyl group can be synthesized by reaction with trimethyl orthoformate in the presence of catalytic amounts of acid such as trifluoroacetic acid at elevated temperatures and reducing the in situ formed iminium species with a suitable reducing agent such as, e.g. lithium aluminum hydride in tetrahydrofuran at temperatures preferably between 0 °C and room temperature. Alternatively, for intermediates 42 wherein R is a -CH2-R9 or -CHR9R10 substituent, the amine functionality in compounds 41 can be reacted with (optionally substituted) aldehydes R9CHO or ketones R9C(0)R10 using a reducing system such as, e.g. sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride or di-n-butyltin dichloride with triphenylsilane, in an appropriate solvent such as 1,2-dichloroethane or tetrahydrofuran to furnish intermediates 42 (step n). Acetic acid may be used as catalyst for the reactions with ketones. Indium trichloride with triethylsilane in methanol might be used as well. Intermediates 42 may be also synthesized from intermediates 41 by protection of the amine functionality in 41 with a suitable protective group such as, e.g. a Boc protective group using methods described in literature and known in the art (step e), alkylating the resulting ieri-butyl carbamate 43 with R X, in which X is a suitable leaving group such as chlorine, bromine, iodine, OS02alkyl (e.g. mesylate (methanesulfonate), OSOifluoroalkyl (e.g. triflate
(trifluoromethanesulfonate) or OSOiaryl (e.g. tosylate (p-toluenesulfonate)) using a suitable base in an appropriate solvent (e.g. sodium hydride in DMF) at temperatures between 0 °C and the boiling temperature of the solvent (step f) and removing the Boc protective group from
intermediates 44 by methods known to those skilled in the art (e.g. using trifluoroacetic acid in dichloromethane at temperatures between 0 °C and room temperature) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y., step g).
The 3 -amino intermediates 42 may then be converted to compounds of general formula I J by acylation with aryl- or heteroaryl carboxylic acids II (either commercially available or accessible by methods known in the art; step d). Amide couplings of this type are widely described in the literature (e.g. , Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g. , N,N'-carbonyl- diimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDCI), l-[bz5(dimethylamino)methylene]- lH- 1,2,3- triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU), l-hydroxy- l,2,3-benzotriazole (HOBT), 0-benzotriazol-l-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) or 2- chloro- or 2-bromo- l-methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g. , N,N-dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g. , triethylamine, N,N-diisopropylethylamine (Huenig' s base) or 4-(dimethylamino)pyridine). Alternatively, the aryl- or heteroaryl carboxylic acids II can be converted into their acid chlorides by treatment with, e.g. , thionyl chloride, neat or optionally in a solvent such as dichloromethane and reaction of the acid chloride with intermediates 42 in an appropriate solvent such as dichloromethane or DMF (N,N-dimethyl- formamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine (Huenig' s base), pyridine, 4-(dimethylamino)pyridine or lithium bzs(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture to furnish compounds of the general formula IJ. The sequence of synthetic steps can be changed as required and as outlined in Scheme 1.
Scheme 10
Figure imgf000082_0001
45 46 47
Aryl- or heteroaryl carboxylic acids II that are not commercially available they can be prepared by methods described in literature and known to those skilled in the art. For example, the pyridine carboxylic acid 47 can be prepared according to Scheme 10.
2-Chloro-6-(trifluoromethyl)isonicotinic acid 45 (prepared according to M. Schlosser et ah, Eur. J. Org. Chem. 2004, 18, 3793-3798) can be reacted with sodium thiomethoxide in an appropriate solvent such as tetrahydrofuran at elevated temperatures such as 70 °C to give intermediate 46 (step a). Oxidation of the sulfur in intermediates 46 using an oxidizing agent such as, oxone® in an appropriate solvent or solvent system such as water and methanol furnishes compound 47 (step b).
Another example for the synthesis of an arylcarboxylic acid II is shown in Scheme 11.
Scheme 11
Figure imgf000083_0001
51
Figure imgf000083_0002
53
Cross -coupling of commercially available 3-bromo-5-trifluoromethyl-benzoic acid methyl ester 48 with 2-(trimethylsilyl)ethanethiol using a suitable catalytic system such as tris(di- benzylideneacetone)dipalladium(0)/Xantphos in the presence of a base such as diisopropyl- ethylamine in a suitable solvent such as dioxane, preferably at elevated temperatures, yields the thioether intermediate 49 (step a). Cleavage of the trimethylsilylethyl group in 49 with, e.g. tetrabutylammonium fluoride in tetrahydrofuran gives thiol 50 (step b). Reactions of this type have been described in the literature, for example in WO2008055847. Alkylation of the thiol group in 50 with commercially available 4-bromo-butyric acid ieri-butyl ester using an appropriate base and solvent such as, e.g. triethyl- or diisopropylethyl-amine in acetonitrile or Ν,Ν-dimethylformamide, furnishes intermediate 51 (step c). Oxidation of the sulfur atom with oxidizing agents such as oxone® in suitable solvents such as methanol or water or mixture of said solvents affords the arylsulfonyl compound 52 (step d). Cleavage of the methyl ester group using for example lithium or sodium hydroxide as base in an appropriate solvent or solvent mixture such as dioxane and water furnishes acid intermediate 53 (step e).
Yet another example for the synthesis of an aryl carboxylic acid II is shown in Scheme 12.
Scheme 12
Figure imgf000084_0001
54 55 56
The iodine in commercially available methyl 3-chloro-5-iodobenzoate 54 can be
exchanged for a methylsulfone group to give intermediate 55 (step a). Reactions of this type have been described in the literature (e.g. W. Zhu, D. Ma J. Org. Chem. 2005, 70(7), 2696-2700). For example, reaction of 54 with sodium methanesulfinate in the presence of a metal catalyst such as copper(I)iodide, L-proline and a base such as sodium hydroxide in an appropriate solvent such as DMSO gives intermediate 55. Heating may be applied to facilitate the reaction. The chloro group in intermediate 55 can be converted into a cyclopropyl group using for example cyclopropylzinc(II) bromide in the presence of a suitable catalyst system such as PEPPSI-IPr ([1 ,3 -bz5(2,6-diisopropylphenyl)imidazol-2-ylidene] (3 -chloropyridyl)palladium(II) dichloride) with l,3-dimethyl-2-imidazolidinone in a solvent such as tetrahydrofuran, preferably at higher temperatures up to the boiling point of the solvent to give intermediate 56. Pd-catalyzed reactions of that type using cyclopropylzinc bromide have been described in the literature (e.g. WO2008154271; WO2010011316). Under the applied reaction conditions cleavage of the methyl ester may occur to give directly intermediates 56. If no ester cleavage occurs under the applied reaction conditions, the ester group can be cleaved by methods known in the art and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.) to give compounds 56 (step b). Scheme 13
Figure imgf000085_0001
IK(n=0) —1
IL(n=2) .J stePd
step i R9=(CH2)2OH, (CH2)2OMe, 3-oxetanyl ste e
Figure imgf000085_0002
S02Me, S02NH2 IT (Rc=Me)
IO (n=0) IU (RC=NH2)
teph
IP ( ^nn==2^) — I s
P Compounds of the general formula IK-IU (B 1 =B 2 =CH) can be prepared for example according to Scheme 13 from compounds IA-IJ and IA' in which B^B^CH and R5 or R6 is bromine. Cross -coupling of IA-IJ and IA' (B 1 =B 2 =CH) with 2-(trimethylsilyl)ethanethiol using a suitable catalytic system such as, e.g. tris(dibenzylideneacetone)dipalladium(0)/Xantphos in the presence of a base such as, e.g. diisopropylethylamine in a suitable solvent such as, e.g. dioxane, preferably at elevated temperatures, yields the thioether intermediate 57 (step a).
Cleavage of the trimethylsilylethyl group in 57 with, e.g. tetrabutylammonium fluoride in tetrahydrofuran gives thiol 58 (step b).
Alkylation of the thiol group in 58 with commercially available compounds R9-LG in which R9 is a methoxyethyl or hydroxyethyl or 3-oxetanyl substituent and LG signifies a suitable leaving group such as, e.g. bromo (or another leaving group such as, e.g. chloro, iodo or
OS02alkyl, OSOifluoroalkyl, OSC^aryl) using an appropriate base and solvent such as, e.g. triethyl- or diisopropylethyl-amine in acetonitrile or Ν,Ν-dimethylformamide, furnishes compounds IK (step c). The sulfur atom in compounds IK can be oxidized by methods known in the art, e.g. using an oxidizing agent such as oxone® in suitable solvents such as, e.g. methanol or water or mixture of said solvents to afford compounds IL (step d).
The thiol group in intermediates 58 can also be alkylated with amines of the type
LG-(CH2)2NRaRb in which LG signifies a suitable leaving group such as, e.g. bromo (or another leaving group such as, e.g. chloro, iodo or OSC^alkyl, OS02fluoroalkyl, OSC^aryl) and one of Ra and Rb is hydrogen while the other is alkyl or a protective group such as, e.g. tert- butoxycarbonyl, or Ra and Rb together form a four- (e.g. azetidine) to six-membered ring (e.g. morpholine), in an appropriate solvent such as, e.g. Ν,Ν-dimethylformamide or acetonitrile and a suitable base such as, e.g. diisopropylethyl-amine or cesium carbonate to give compounds IM (step e). The sulfur atom in compounds IM can be oxidized by methods known in the art and as described above to furnish compounds IN (step f). Compounds IM or IN in which Ra=Rb=H
(prepared for example from intermediates 58 and compounds LG-(CH2)2NRaRb in which LG is a leaving group as defined before and Ra or Rb is a protective group such as e.g. a tert- butoxycarbonyl group while the other substituent is hydrogen and subsequent cleavage of the protective group using methods kown in the art) can be reacted with sulfonylchlorides (e.g. methanesulfonyl chloride) or sulfamoyl chlorides to give compounds IO and IP, respectively (step h). Compounds IO (prepared from compounds IM) may be oxidized using methods described above to give compounds IP (step h).
Compounds IQ-IU can also be synthesized from intermediate 58. Alkylation of the thiol group in 58 with tert-buty\ 3-iodoazetidine-l-carboxylate using a suitable base and solvent such as diisopropylethylamine in acetonitrile gives compounds IQ. Heating may be applied to facilitate the conversion (step i). The ie/t-butoxycarbonyl group is removed using methods described in literature (e.g. with trifluoroacetic acid in dichlorormethane, step j) and the sulfur in the resulting compounds IR is oxidized by methods known in the art, e.g. using an oxidizing agent such as oxone® in suitable solvents such as methanol or water or mixture of said solvents to afford compounds IS (step k). The secondary azetidine nitrogen can be acylated using literature procedures with sulfonylchlorides (e.g. methanesulfonyl chloride) or sulfamoyl chlorides to give compounds IT and IU, respectively (step 1).
Scheme 14
Figure imgf000087_0001
IZ (R-alkyl) -, f
IAA (Rb=H) -J V Compounds of the general formula IV-IAC (B 1 =B 2 =CH) can be synthesized for example according to Scheme 14.
The thiol group of intermediates 58 (prepared as described under Scheme 13) can be alkylated with compounds of the type LG-(CH2)3-6COORa in which LG is a leaving group as defined before and Ra is hydrogen or an alkyl group using the methods outlined before to yield compounds IV and IW, respectively (step a). Compounds IW can alternatively be synthesized by cleavage of the ester group in compounds IV by methods known in the art (e.g. a ie/ -butyl group under acidic conditions such as trifluoroacetic acid in dichloromethane or formic acid in isopropanol) and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y) (step b).
The sulfur atom in compounds IV and IW can be oxidized by methods described in the literature, e.g. using an oxidizing agent such as oxone® in suitable solvents such as, e.g.
methanol or water or mixture of said solvents to give the sulfone compounds IX and IY (step c). Compounds IY can alternatively be synthesized by cleavage of the ester group in compounds IX by methods outlined above (step d).
Compounds IY can be further converted into compounds IZ (step e) by reaction of IY with a- or β-amino acid esters (Rb=alkyl) which are either commercially available or accessible by methods known in the art (step e). Amide couplings of this type are widely described in the literature (e.g., Comprehensive Organic Transformations: A Guide to Functional Group
Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons , New York, NY. 1999) and can be accomplished by the usage of coupling reagents such as, e.g., N,N'-carbonyl-diimidazole (CDI), N,N'-dicyclohexylcarbodiimide (DCC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l-[bz5(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium-3- oxide hexafluorophosphate (HATU), l-hydroxy-l,2,3-benzotriazole (HOBT), Obenzotriazol-1- yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) or 2-chloro- or 2-bromo-l- methylpyridinium iodide (Mukaiyama reagent) in a suitable solvent, e.g., N,N- dimethylformamide (DMF), dimethylacetamide (DMAc), dichloromethane or dioxane, optionally in the presence of a base (e.g., triethylamine, N,N-diisopropylethylamine (Huenig's base) or 4-(dimethylamino)pyridine). Alternatively, the carboxylic acid group in compounds IY can be converted into the acid chloride by treatment with, e.g., thionyl chloride, neat or optionally in a solvent such as dichloromethane and the acid chloride is reacted with a- or β- amino acid esters (Rb=alkyl) in an appropriate solvent such as dichloromethane or DMF (N,N- dimethyl-formamide) and a base, e.g. triethylamine, N,N-diisopropylethylamine, pyridine, 4- (dimethylamino)pyridine or lithium bz's(trimethylsilyl)amide at temperatures ranging from ambient temperature to the reflux temperature of the solvent or solvent mixture to furnish compounds of the general formula IZ. Cleavage of the ester group in compounds IZ by methods known in the art and as described before furnishes the compounds IAA (step f).
Alternatively, compounds IZ and IAA can be prepared from compounds IAB and IAC, respectively, applying the methods described before (step i). Compounds IAB can be
synthesized from compounds IW by amide coupling with a- or β-amino acid esters (Rb=alkyl) using the methods described above. Ester clevage in compounds IAB using the methods outlined before furnishes compounds IAC (step h).
Compounds of the general formula IAD-IAI (B 1 =B 2 =CH) can be prepared for example according to Scheme 15 from compounds IA-IJ and IA' in which B1=B2=CH and R5 or R6 is bromine.
For example, compounds of the general formula IAD and IAE in which R6 signifies a 3- oxetanyl and a ie/t-butoxycarbonyl-substituted 3-azetidinyl substituent, respectively can be synthesized by first converting the bromo into a boronic acid group (for example via reaction of the bromo compound with n-butyllithium in the presence of triisopropyl borate preferably at low temperatures (e.g. -75°C) and hydrolysis of the resulting boron ester with, e.g. acetic acid in water) and reacting the boronic acid intermediate with 3-iodo-oxetane or 3-iodo-azetidine-l- carboxylic acid tert-butyl ester using a suitable catalyst system such as, e.g. nickel(II) iodide and (1 ?,2 ?)-2-aminocyclohexanol in the presence of a base such as sodium hexamethyldisilazane in a suitable solvent such as, e.g. 2-propanol. Heating or microwave irradiation may facilitate the reaction (step a).
Compounds IAF in which R6 signifies a hydroxyethoxy or methoxyethoxy group can be prepared by first converting the bromo into a hydroxyl group (e.g. via conversion of the bromine into a boronic acid group as described above and in situ oxidation of the boronic acid group using, e.g. hydrogen peroxide in acetic acid and water) and alkylating the phenolic hydroxy group with bromo-ethanol or bromo-2-methoxyethane using a suitable base such as, e.g.
diisopropylethylamine or potassium carbonate in an appropriate solvent such as, e.g. acetonitrile. Heating or microwave irradiation may facilitate the reaction (step b). Scheme 15
Figure imgf000090_0001
Compounds IAG can prepared for example by reacting the bromo derivatives of compounds IA-IJ and IA' with 3,3-diethoxyprop-l-ene preferably at elevated temperatures applying a suitable catalyst system such as, e.g. palladium(II) acetate with n-tributylamine in presence of tetrabutylammonium chloride and using a suitable solvent such as, e.g. N,N- dimethylformamide (step c). The ester group in compounds IAG can be cleaved by methods known in the art and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.) to give compounds IAH (step d). The acid functionality in compounds IAH can then be converted into an amide function by methods described in literature such as, e.g. activating the acid group with l-ethyl-3-(3- dimethylaminopropyl) carbodiimide and l-hydroxy-7-azabenzotriazole in the presence of a base such as, e.g. diisopropylethylamine in a suitable solvent such as Ν,Ν-dimethylformamide and treating the activated ester with an ammonia source such as, e.g. ammonium chloride in the repsence of a base such as, e.g. diisopropylethylamine to furnish compounds IAI (step e). If desired or required, functional groups present in I (such as -C02alkyl, -C02H, halogens such as chlorine, bromine or iodine, amino groups, cyano groups) may be derivatized to other functional groups using typical standard procedures known to those skilled in the art (e.g.
reduction of -C02alkyl to -CH2OH with LiAlH4 or NaBH4 and the like, hydrolysis of -C02alkyl to C02H and subsequent optional conversion to an amide, acylation or reductive amination of amino groups, conversion of halogens such as chlorine, bromine or iodine to C02alkyl or alkyl and the like).
If compounds IA to IAI contain stereogenic centers, compounds of the general formula I can be obtained as mixtures of enantiomers or diastereomers, which can be separated by methods well known in the art, e.g. (chiral) HPLC or crystallization. Racemic compounds can e.g. be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbent or a chiral eluant.
If one of the starting materials or compounds of formula (I) contains one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described, e.g. in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.) can be introduced before the critical step applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature. As described herein before, the compounds of formula I of the present invention can be used as medicaments for the treatment of diseases which are associated with the modulation of GPBAR1 activity.
As compounds of formula I of the invention are agonists of the GPBAR1 receptor, the compounds will be useful for lowering glucose, lipids, and insulin resistance in diabetic patients and in non-diabetic patients who have impaired glucose tolerance or who are in a pre-diabetic condition. The compounds of formula I are further useful to ameliorate hyperinsulinemia, which often occurs in diabetic or pre-diabetic patients, by modulating the swings in the level of serum glucose that often occurs in these patients. The compounds of formula I are also useful in reducing the risks associated with metabolic syndrome, in reducing the risk of developing atherosclerosis or delaying the onset of atherosclerosis, and reducing the risk of angina, claudication, heart attack, stroke, and coronary artery disease. By keeping hyperglycemia under control, the compounds are useful to delay or for preventing vascular restenosis and diabetic retinopathy. The compounds of formula I of the present invention are useful in improving or restoring β-cell function, so that they may be useful in treating type 1 diabetes or in delaying or preventing a patient with type 2 diabetes from needing insulin therapy. The compounds may be useful for reducing appetite and body weight in obese subjects and may therefore be useful in reducing the risk of co-morbidities associated with obesity such as hypertension, atherosclerosis, diabetes, and dyslipidemia. By elevating the levels of active GLP-1 in vivo, the compounds are useful in treating neurological disorders such as Alzheimer's disease, multiple sclerosis, and
schizophrenia.
Thus, the expression "diseases which are associated with the modulation of GPBAR1 activity" means diseases such as metabolic, cardiovascular, and inflammatory diseases, particularly for the treatment of diabetes, particularly type 2 diabetes or gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ischemia, myocardial infarction, retinopathy, vascular restenosis, hypercholesterolemia, hypertriglyceridemia, dyslipidemia or hyperlipidemia, lipid disorders such as low HDL cholesterol or high LDL cholesterol, high blood pressure, angina pectoris, coronary artery disease, atherosclerosis, cardiac hypertrophy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), psoriasis, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during small bowl syndrome, irritable bowl syndrome (IBS), allergy diseases, particularly disorders associated with the liver and the kidneys, e.g. including renal disorders, kidney disorders, e.g. diabetic nephropathy, acute kidney injury, acute renal disease, kidney fibrosis, liver disorders, e.g. hepatitis, liver failure, acute/chronic hepatitis, acute/chronic interstitial/glomerulonephritis, granulomatous diseases, fatty liver (e.g. non-alcoholic fatty liver disease, NAFLD), liver fibrosis (e.g. non-alcoholic steatohepatitis, NASH), primary sclerosing cholangitis (PSC), liver cirrhosis, primary biliary cirrhosis (PBC), liver colestasis, kidney fibrosis, anorexia nervosa, bulimia nervosa and neurological disorders such as Alzheimer's disease, multiple sclerosis, schizophrenia and impaired cognition. In a particular aspect, the expression 'diseases which are associated with the modulation of GPBAR1 activity' relates to diabetes, particularly type II diabetes, impaired fasting glucose, impaired glucose tolerance, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and dyslipidemia. The invention also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant. More specifically, the invention relates to pharmaceutical compositions useful for the treatment of diseases which are associated with the modulation of GPBAR1 activity.
Further, the invention relates to compounds of formula I as defined above for use as therapeutically active substances, particularly as therapeutically active substances for the treatment of diseases which are associated with the modulation of GPBAR1 activity. In particular, the invention relates to compounds of formula I for use in the treatment of diabetes, particularly type 2 diabetes or gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ischemia, myocardial infarction, retinopathy, vascular restenosis, hypercholesterolemia, hypertriglyceridemia, dyslipidemia or hyperlipidemia, lipid disorders such as low HDL cholesterol or high LDL cholesterol, high blood pressure, angina pectoris, coronary artery disease, atherosclerosis, cardiac hypertrophy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), psoriasis, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during small bowl syndrome, irritable bowl syndrome (IBS), allergy diseases, particularly disorders associated with the liver and the kidneys, e.g. including renal disorders, kidney disorders, e.g. diabetic nephropathy, acute kidney injury, acute renal disease, kidney fibrosis, liver disorders, e.g. hepatitis, liver failure, acute/chronic hepatitis, acute/chronic interstitial/glomerulonephritis, granulomatous diseases, fatty liver (e.g. non-alcoholic fatty liver disease, NAFLD), liver fibrosis (e.g. non-alcoholic steatohepatitis, NASH), primary sclerosing cholangitis (PSC), liver cirrhosis, primary biliary cirrhosis (PBC), liver colestasis, kidney fibrosis, anorexia nervosa, bulimia nervosa and neurological disorders such as Alzheimer's disease, multiple sclerosis, schizophrenia and impaired cognition. More particularly, the invention relates to compounds of formula I for use in the the treatment of diabetes, particularly type II diabetes, impaired fasting glucose, impaired glucose tolerance, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and dyslipidemia, most particularly for use in diabetes, preferably type II diabetes, or hyperglycemia.
In another aspect, the invention relates to a method for the treatment of diseases which are associated with the modulation of GPBAR1 activity, which method comprises administering a therapeutically active amount of a compound of formula I to a human being or animal. In particular, the invention relates to a method for the treatment of diabetes, particularly type II diabetes, impaired fasting glucose, impaired glucose tolerance, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and dyslipidemia, more particularly for the treatment of diabetes, preferably type II diabetes, or hyperglycemia.
The invention further relates to the use of compounds of formula I as defined above for the treatment of diseases which are associated with the modulation of GPBAR1 activity.
In addition, the invention relates to the use of compounds of formula I as defined above for the preparation of medicaments for the treatment of diseases which are associated with the modulation of GPBAR1 activity. In particular, the invention relates to the use of compounds of formula I as defined above for the preparation of medicaments for the treatment of diabetes, particularly type II diabetes, impaired fasting glucose, impaired glucose tolerance,
hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and dyslipidemia, more particularly for the preparation of medicaments for the treatment of diabetes, preferably type II diabetes, or hyperglycemia..
Also contemplated herein is a combination therapy using one or more compounds of formula I or compositions of the present invention, or a pharmaceutically acceptable salts thereof, in combination with one or more other pharmaceutically active compounds independently selected from the group consisting of the following:
(a) human peroxisome proliferator activated receptor (PPAR) gamma agonists (e.g. ,
thiazolidinediones and glitazones, e.g., rosiglitazone, troglitazone, pioglitazone, englitazone, balaglitazone, and netoglitazone),
(b) biguanides such as metformin, metformin hydrochloride, buformin and phenformin,
(c) dipeptidyl peptidase IV (DPP-4) inhibitors, such as sitagliptin, sitagliptin phosphate, saxagliptin, vildagliptin, alogliptin, carmegliptin, gosogliptin, dutogliptin and linagliptin,
(d) incretins such as glucagon-like peptide- 1 (GLP- 1) receptor agonists (e.g., exenatide, liraglutide), GLP-l(7-36) amide and its analogs, GLP- l(7-37) and its analogs, lixisenatide, taspoglutide, albiglutide, , BRX-0585 (Pfizer/Biorexis) and CJC-1134-PC (Exendin-4:PC- DAC™) or glucose-dependent insulinotropic peptide (GIP),
(e) insulin or insulin analogs such as LysPro insulin or inhaled formulations comprising insulin,
(f) sulfonylureas such as tolazamide, chlorpropamide, glipizide, glimepiride, glyburide, glibenclamide, tolbutamide, acetohexamide or glypizide,
(g) oc-glucosidase inhibitors such as miglitol, acarbose, epalrestat, or voglibose,
(h) cholesterol biosynthesis inhibitors such as HMG CoA reductase inhibitors, e.g. , lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, itavastin, nisvastatin and rivastatin, or squalene epoxidase inhibitors, e.g. , terbinafine,
(i) plasma HDL-raising agents such as CETP inhibitors e.g., anacetrapib, torcetrapib and dalcetrapib, or PPAR alpha agonists, e.g., gemfibronzil, clofibrate, fenofibrate and bezafibrate, j) PPAR dual alpha/gamma agonists such as muraglitazar, naveglitazar, aleglitazar, tesaglitazar, peliglitazar, farglitazar and JT-501,
(k) bile acid sequestrants , e.g. , anion exchange resins, or quaternary amines (e.g. ,
cholestyramine or colestipol)), or ileal bile acid transporter inhibitors (BATi);
(1) nicotinyl alcohol, nicotinic acid, niacinamide or salts thereof,
(m) cholesterol absorption inhibitors such as ezetimibe or acyl-Coenzyme A holesterol O-acyl transferase (ACAT) inhibitors such as avasimibe,
(n) selective estrogen receptor modulators such as raloxifene or tamoxifen) or LXR alpha or beta agonists, antagonists or partial agonists (e.g. , 22(7?)-hydroxycholesterol, 24(5)- hydroxycholesterol, T0901317 or GW3965);
(o) microsomal triglyceride transfer protein (MTP) inhibitors, alpha2-antagonists and
imidazolines (e.g., midaglizole, isaglidole, deriglidole, idazoxan, efaroxan, fluparoxan),
(p) insulin secretagogues such as linogliride, nateglinide, repaglinide, mitiglinide calcium hydrate or meglitinide);
(q) SGLT-2 inhibitors (e.g., dapagliflozin, sergliflozin, canagliflozin and tofogliflozin,
(s) glucokinase activators such as the compounds disclosed in e.g. , WO00/58293 Al ;
(t) protein tyrosine phosphatase- IB (PTP- 1B) inhibitors,
(u) glucagon receptor antagonists,
(v) anti-obesity agents such as fenfluramine, dexfenfluramine, phentiramine, sibutramine, orlistat, neuropeptide Yl or Y5 antagonists, neuropeptide Y2 agonists, MC4R (melanocortin 4 receptor) agonists, cannabinoid receptor 1 (CB-1) antagonists/inverse agonists, and B3 adrenergic receptor agonists (e.g., GW-320659), nerve growth factor agonist (e.g., axokine), growth hormone agonists (e.g., AOD-9604), 5-HT (serotonin) reuptake/transporter inhibitors (e.g., Prozac), DA (dopamine) reuptake inhibitors (e.g. , Buproprion), 5-HT, NA and DA reuptake blockers, steroidal plant extracts (e.g., P57), CCK-A (cholecystokinin-A) agonists, GHSRla (growth hormone secretagogue receptor) antagonist/inverse agonists, ghrelin antibody, MCHIR (melanin concentrating hormone 1R) antagonists (e.g. , SNAP 7941), MCH2R (melanin concentrating hormone 2R) agonist/antagonists, H3 (histamine receptor 3) inverse agonists or antagonists, HI (histamine 1 receptor) agonists, FAS (Fatty acid synthase) inhibitors, ACC-2 (acetyl-CoA carboxylase- 1) inhibitors, DGAT-2 (diacylglycerol acyltransferase 2) inhibitors, DGAT-1 (diacylglycerol acyltransferase 1) inhibitors, CRF (corticotropin releasing factor) agonists, Galanin antagonists, UCP- 1 (uncoupling protein- 1), 2 or 3 activators, leptin or a leptin
derivatives, opioid antagonists, orexin antagonists, BRS3 agonists, GLP- 1 (glucagon-like peptide- 1) agonists, IL-6 agonists, a-MSH agonists, AgRP antagonists, BRS3 (bombesin receptor subtype 3) agonists, 5-HT IB agonists, POMC antagonists, CNTF (ciliary neurotrophic factor or CNTF derivative), NN2211, topiramate, glucocorticoid antagonist, Exendin-4 agonists, 5-HT2c (serotonin receptor 2C) agonists (e.g. , Lorcaserin), PDE (phosphodiesterase) inhibitors, fatty acid transporter inhibitors, dicarboxylate transporter inhibitors, glucose transporter inhibitors,
(w) anti-inflammatory agents such as cyclooxygenase-2 (COX-2) inhibitors (e.g., rofecoxib and celecoxib); glucocorticoids, azulfidine, thrombin inhibitors (e.g. , heparin, argatroban, melagatran, dabigatran) and platelet aggregation inhibitors (e.g., glycoprotein Ilb/IIIa fibrinogen receptor antagonists or aspirin), and ursodeoxycholic acid (UDCA) and norursodeoxycholic acid
(norUDCA) and
(y) antihypertensives such as beta blockers (e.g. , angiotensin II receptor antagonists such as losartan, eprosartan, irbesartan, tasosartan, telmisartan or valsartan; angiotensin converting enzyme inhibitors such as enalapril, captopril, cilazapril, ramapril, zofenopril, lisinopril and fosinopril; calcium channel blockers such as nifedipine and diltiazam and endothelian
antagonists.
Such other pharmaceutically active compounds may be administered in an amount commonly used therefore, contemporaneously or sequentially with a compound of the formula I or a pharmaceutically acceptable salt thereof. In the treatment of patients who have type 2 diabetes, insulin resistance, obesity, metabolic syndrome, neurological disorders, and comorbidities that accompany these diseases, more than one pharmaceutically active compound is commonly administered. The compounds of formula I of this invention may generally be administered to a patient who is already taking one or more other drugs for these conditions. When a compound of formula I is used contemporaneously with one or more other
pharmaceutically active compounds, a pharmaceutical composition in an unit dosage form containing such other pharmaceutically active compounds and the compound of the formula I is preferred. Thus, the invention also relates to a pharmaceutical composition containing a compound of formula I in combination with one or more other pharmaceutically active compounds as defined above. When used in combination with one or more other active ingredients, the compound of formula I of the present invention and the other pharmaceutically active compounds may be used in lower doses than when each is used singly. These kinds of pharmaceutical compositions are also included in the invention.
However, the combination therapy also includes therapies in which the compound of formula I and one or more other pharmaceutically active compounds are administered in different dosage forms, but with overlapping schedules. The invention thus also relates to a method for the treatment a of diseases which are associated with the modulation of GPBAR1 activity, which method comprises administering a therapeutically active amount of a compound of formula I in combination with one or more other pharmaceutically active compounds to a human being or animal. The following test was carried out in order to determine the activity of the compounds of formula I:
The cDNA of the human GPBAR1 receptor (Genbank: NM_170699 with the exception of a silent C:G mutation at position 339 from the start codon) was amplified by polymerase chain reaction (PCR) from human cDNA and inserted into pCineo (Promega) by standard methods (Current Protocols in Molecular Biology, Wiley Press, ed. Ausubel et ah). The final clone was verified by DNA sequence analysis. The plasmid was transfected into CHO cells deficient in dihydrofolate reductase activity (CHO-dhfr-) using Lipofectamine plus (Invitrogen). Clones were isolated in limited dilution conditions and identified by activities in the cAMP assay using lithocholic acid as agonist. A clonal cell line displaying the greatest activity in cAMP increases was selected and identified as giving consistently good responses for up to at least 20 passages. cAMPAssay
CHO-dhfr(minus) cells expressing human GPBAR1 receptors are seeded 17-24 hours prior to the experiment 50.000 cells per well in a black 96 well plate with flat clear bottom (Corning Costar # 3904) in DMEM (Invitrogen No. 31331), lx HT supplement, with 10 % fetal calf serum and incubated at 5% C02 and 37°C in a humidified incubator. The growth medium was exchanged with Krebs Ringer Bicarbonate buffer with 1 mM IB MX and incubated at 30°C for 30 min. Compounds were added to a final assay volume of 100 μΐ and incubated for 30 min at 30°C. The assay was stopped by the addition of 50 μΐ lysis reagent (Tris, NaCl, 1.5% Triton X100, 2.5% NP40, 10% NaN3) and 50 μΐ detection solutions (20 μΜ mAb Alexa700-cAMP 1 : 1, and 48 μΜ Ruthenium-2-AHA-cAMP) and shaked for 2h at room temperature. The time- resolved energy transfer is measured by a TRF reader (Evotec Technologies GmbH, Hamburg Germany), equipped with a ND:YAG laser as excitation source. The plate is measured twice with the excitation at 355 nm and at the emission with a delay of 100 ns and a gate of 100 ns, total exposure time 10s at 730 (bandwith 30 nm) or 645 nm (bandwith 75 nm), respectively. The measured signal at 730 nm has to be corrected for the ruthenium background, the direct excitation of Alexa and the buffer control. The FRET signal is calculated as follows: FRET = T730-Alexa730-P(T645-B645) with P = Ru730-B730/Ru645-B645, where T730 is the test well measured at 730 nM, T645 is the test well measured at 645 nm, B730 and B645 are the buffer controls at 730 nm and 645 nm, respectively. cAMP content is determined from the function of a standard curve spanning from 10 μΜ to 0.13 nM cAMP.
EC50 values were determined using Activity Base analysis (ID Business Solution, Limited). The EC50 values for a wide range of bile acids generated from this assay were in agreement with the values published in the scientific literature. Specificity for GPBAR1 was tested in non- transfected CHO cells in the same assay as above. The compounds according to formula I have an activity in the above assay (EC50) preferably of 0.5 nM to 10 μΜ, more preferably of 0.5 nM to 1 μΜ and most preferably of 0.5 nM to 100 nM.
For example, the following compounds showed the following human EC50 values in the functional cAMP assay described above: human EC50 human EC50
Example Example
[μΜ] [μΜ]
1 0.022 165 0.153
2 0.727 166 1.783
3 0.902 167 2.723
4 0.247 168 0.041
5 0.112 169 0.026
6 0.091 170 0.118
7 1.051 171 0.056
8 0.075 172 0.632
9 1.227 173 0.053
10 0.238 174 0.054
11 0.406 175 0.571
12 0.349 176 0.014
13 0.58 177 0.036
14 0.395 178 0.049
15 0.323 179 0.4
16 0.184 180 0.197
17 0.336 181 2.952
18 0.85 182 0.027
19 0.34 183 0.206
20 0.143 184 0.015
21 0.388 185 2.405
22 0.035 186 0.055
23 0.038 187 0.478
24 0.146 188 0.07
25 0.014 189 0.047
26 0.686 190 0.089
27 1.048 191 0.111
28 0.863 192 0.105 human EC50 human EC50
Example Example
[μΜ] [μΜ]
29 0.011 193 0.456
30 1.618 194 0.258
31 0.029 195 0.013
32 0.009 196 0.023
33 0.349 197 0.105
34 0.502 198 0.092
35 0.163 199 0.033
36 0.362 200 1.202
37 0.04 201 0.267
38 0.011 202 0.157
39 0.038 203 0.054
40 0.107 204 0.619
41 0.09 205 0.017
42 0.119 206 0.023
43 2.054 207 0.318
44 0.03 208 2.955
45 0.302 209 1.47
46 0.924 210 0.241
47 0.068 211 0.959
48 0.307 212 0.075
49 0.629 213 0.253
50 0.678 214 0.265
51 0.06 215 0.216
52 0.463 216 0.038
53 1.098 217 0.031
54 1.966 218 0.073
55 0.435 219 3.03
56 0.43 220 1.98
57 0.351 221 0.059
58 0.026 222 0.183
59 0.19 223 0.046
60 0.114 224 0.046
61 0.072 225 0.241
62 0.337 226 0.958 human EC50 human EC50
Example Example
[μΜ] [μΜ]
63 0.023 227 0.093
64 0.014 228 0.057
65 0.102 229 0.027
66 0.008 230 0.073
67 0.056 231 3.5
68 0.801 232 0.335
69 0.377 233 0.054
70 0.485 234 0.405
71 1.535 235 0.085
72 0.593 236 0.886
73 1.834 237 0.34
74 0.034 238 0.023
75 0.452 239 0.508
76 1.964 240 1.148
77 0.715 241 0.105
78 0.021 242 0.011
79 1.381 243 0.61
80 0.299 244 1.15
81 0.228 245 0.933
82 0.234 246 0.168
83 0.376 247 0.413
84 2.017 248 0.323
85 0.2 249 0.019
86 0.267 250 2.963
87 1.332 251 0.03
88 0.066 252 0.17
89 0.008 253 3.042
90 2.74 254 0.054
91 0.152 255 0.053
92 0.236 256 0.02
93 2.264 257 0.079
94 2.159 258 1.864
95 0.092 259 0.134
96 0.127 260 0.153 human EC50 human EC50
Example Example
[μΜ] [μΜ]
97 0.721 261 0.19
98 0.109 262 0.231
99 2.937 263 0.017
100 0.207 264 2.411
101 0.298 265 0.121
102 0.144 266 0.177
103 0.329 267 3.46
104 1.641 268 0.768
105 0.485 269 0.094
106 0.043 270 0.133
107 0.038 271 3.126
108 0.07 272 0.064
109 0.022 273 1.496
110 0.152 274 0.034
111 0.256 275 1.228
112 0.237 276 0.162
113 2.012 277 0.008
114 0.03 278 0.107
115 0.066 279 0.077
116 0.088 280 0.268
117 0.052 281 0.574
118 2.471 282 0.069
119 0.61 283 2.202
120 0.17 284 0.353
121 1.92 285 2.900
122 2.433 286 0.379
123 0.473 287 0.539
124 1.976 288 1.479
125 1.488 289 0.275
126 0.62 290 1.739
127 0.075 291 2.842
128 0.029 292 0.088
129 0.076 293 2.463
130 0.166 294 0.042 human EC50 human EC50
Example Example
[μΜ] [μΜ]
131 0.019 295 0.445
132 1.332 296 1.335
133 0.039 297 0.521
134 0.912 298 0.788
135 0.091 299 0.952
136 0.247 300 0.831
137 0.166 301 0.219
138 0.042 302 >10
139 0.606 303 0.018
140 0.124 304 0.015
141 1.663 305 0.005
142 0.396 306 0.19
143 0.012 307 0.3
144 0.022 308 0.936
145 0.03 309 0.273
146 0.069 310 0.041
147 0.018 311 0.081
148 0.006 312 2.417
149 0.242 313 1.225
150 0.09 314 0.115
151 0.047 315 0.451
152 0.558 316 0.926
153 0.019 317 0.418
154 0.039 318 1.111
155 0.038 319 3.336
156 0.036 320 2.722
157 0.088 321 1.885
158 0.21 322 0.011
159 0.326 323 0.104
160 0.281
161 0.029
162 0.101
163 0.099
164 1.695 The compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, e.g., in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g., in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. , in the form of suppositories, parenterally, e.g., in the form of injection solutions or suspensions or infusion solutions, or topically, e.g., in the form of ointments, creams or oils. Oral administration is preferred.
The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants. Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 300 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g., in 1 to 3 dosage units.
The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.
The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.
Examples
Abbreviations: AcOH = acetic acid, CAS RN = chemical abstracts registration number, CO = carbon monoxide, CuCl = copper (I) chloride, DMAP = 4-dimethylaminopyridine, DME = dimethoxyethane , DMF = N,N-dimethylformamide, DIPEA = N,N-diisopropylethylamine, dppf = 1,1
bzs(diphenylphosphino)ferrocene, EI = electron impact, ESI = electrospray ionization, EtOAc = ethyl acetate, h = hour, H20 = water, HATU = l-[bz5(dimethylamino)methylene]-lH-l,2,3- triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HQ = hydrogen chloride, HPLC = high performance liquid chromatography, iPrMgCl = isopropylmagnesium chloride, ISP = ion spray positive (mode), ISN = ion spray negative (mode), min = minutes, K2C03 = potassium carbonate, LiAlH4 or LAH = lithium aluminium hydride, LiHMDS = lithium bz's(trimethylsilyl)amide, LiOH = lithium hydroxide, MgS04 = magnesium sulfate, MPLC = medium performance liquid chromatography, MS = mass spectrum, NaH = sodium hydride, nBuLi = n-butyllithium,
NaHC03 = sodium hydrogen carbonate, NaOH = sodium hydroxide, Na2C03 = sodium
carbonate, Na2S04 = sodium sulfate, Na2S203 = sodium thiosulfate, NEt3 = triethylamine, NH4C1 = ammonium chloride, KOH = potassium hydroxide, P = protecting group, Pd-C = palladium on activated carbon, PdCl2(dppf)-CH2Cl2 = l,l'-bz'5(diphenylphosphino)ferrocene- palladium(II)dichloride dichloromethane complex, Pd(OAc)2 = palladium(II) acetate, Pd(PPh3)4 = ieirafo's(triphenylphosphine)palladium(0), R = any group, rt = room temperature, S-PHOS = 2- dicyclohexylphosphino-2',6'-dimethoxybiphenyl, TFA = trifluroacetic acid, THF =
tetrahydrofuran, TMEDA = Ν,Ν,Ν',Ν'-tetramethylethylenediamine, ZnCl2 = zinc chloride, X = halogen. Example 1
N-Methyl-N-(4-o-tolyl-pyridin-3-yl)-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000105_0001
3,5-fiz's-trifluoromethylbenzoyl chloride (36 mg, 0.13 mmol, CAS RN 1271-19-8) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (20 mg, 0.10 mmol) and DIPEA (40 μί, 0.23 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the desired product as a waxy solid (23 mg, 41%). MS (ESI): m/z = 439.0 [M+H]+.
Intermediates a) Methyl-(4-o-tolyl-pyridin-3-yl)-amine
N-Boc-4-o-tolyl-pyridin-3-ylamine (45 mg, 0.158 mmol) in THF (0.5 mL) under argon was treated with LAH in THF (1.0M, 0.20 mL, 0.2 mmol). The reaction mixture was then heated to reflux for 6 hours. After cooling, Na2S04 x 10 ¾0 was carefully added and the reaction mixture was stirred for 1 h after which a colorless solid formed. The solid was removed by filtration and all volatiles were evaporated to yield the desired compound as a solid (29 mg, 93%). b) N-Boc-4-o-tolyl-pyridin-3-ylamine
Di-ie/ -butyldicarbonate (655 mg, 3.0 mmol, CAS RN 24424-99-5) was added to a solution of 4-o-tolyl-pyridin-3-ylamine (500 mg, 2.7 mmol), DMAP (66 mg, 0.54 mmol) and DIPEA (05.7 mL, 3.3 mmol) in CH2CI2 (14 mL). The reaction mixture was stirred for 16 hours at room temperature. After evaporating the reaction mixture to dryness, the desired product was isolated by flash chromatography on silica gel (33-50% EtOAc in n-hexane) as a waxy solid (360 mg, 42%). c) 4-o-Tolyl-pyridin-3-ylamine
Zinc dust (3.0 g, 46 mmol) was added to 3-nitro-4-o-tolyl-pyridine (1.35 g, 6.3 mmol) in acetic acid (32 mL). The reaction mixture was heated to 70 °C for 90 min. After cooling to room temperature, solids were removed from the reaction mixture by filtration. Evaporation of volatiles in vacuo gave a solid that was triturated with toluene. Removal of solids by filtration followed by evaporation of volatiles in vacuo gave a heavy oil. The product 4-o-tolyl-pyridin-3- ylamine was isolated by flash chromatography on silica gel eluting with EtOAc to 5% CH3OH in EtOAc (1.0 g, 86%). d) 3-Nitro-4-o-tolyl-pyridine
Triphenylphosphine (2.10 g, 1.89 mmol) and potassium carbonate (7.80 g, 56.7 mmol) were added to a slurry of 4-chloro-3-nitropyridine (3.00 g, 18.9 mmol, CAS RN 13091-23-1) and 2-tolylboronic acid (2.83 g, 20.8 mmol, CAS RN 16419-60-6) in dioxane stirring under an argon atmosphere. The reaction mixture was heated to 120 °C for 16 hours and then cooled to room temperature. The solids were removed by filtration through celite and all volatiles were removed in vacuo resulting in a dark colored heavy oil. The product was isolated as a heavy oil by flash chromatography on silica gel (25-33% EtOAc in n-hexane) (1.75 g, 43%).
Example 2
N-Methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide
Figure imgf000106_0001
3-Trifluoromethylbenzoyl chloride (30 mg, 0.14 mmol, CAS RN 2251-65-2) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (20 mg, 0.10 mmol, example 1, intermediate a) and DIPEA (30 μί, 0.17 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n- hexane to yield the desired product as a waxy solid (17 mg, 46%). MS (ESI): m/z = 371.0
[M+H]+.
Example 3
N-Methyl-N-(4-o-tolyl-pyridin-3-yl)-3-chloro-benzamide
Figure imgf000106_0002
3-Chlorobenzoyl chloride (30 mg, 0.17 mmol, CAS RN 618-46-2) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (20 mg, 0.10 mmol, example 1, intermediate a) and DIPEA (30 μί, 0.17 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the title product as a waxy solid (12 mg, 36%). MS (ESI): m/z = 337.0 [M+H]+.
Example 4
2-Fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000107_0001
2-Fluoro-5-trifluoromethylbenzoyl chloride (80 mg, 0.35 mmol, CAS RN 207981-46-2) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (35 mg, 0.18 mmol, example 1, intermediate a) and DIPEA (92 μί, 0.53 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the desired product as a waxy solid (36 mg, 53%). MS (ESI): m/z = 389.0 [M+H]+. Example 5
4-Fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000107_0002
4-Fluoro-5-trifluoromethylbenzoyl chloride (80 mg, 0.35 mmol, CAS RN 67515-56-4) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (35 mg, 0.18 mmol, example 1, intermediate a) and DIPEA (92 μί, 0.53 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the desired product as a waxy solid (33 mg, 48%) MS (ESI): m/z = 388.9 [M+H]+. Example 6
3-Fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000108_0001
3-Fluoro-5-trifluoromethylbenzoyl chloride (92 mg, 0.41 mmol, CAS RN 171243-30-4) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (40 mg, 0.20 mmol, example 1, intermediate a) and DIPEA (70 μί, 0.40 mmol) in THF (1 mL). After 2 h, an additional 25 of acyl chloride was added. The reaction mixture was stirred overnight, filtered and all volatiles removed. The resulting oil was purified by flash chromatography on silica gel eluting with 33- 50% EtOAc in n-hexane to yield the product as a waxy solid (45 mg, 57%). MS (ESI): m/z = 470.0 [M+H]+.
Example 7
2-Fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide
Figure imgf000108_0002
2-Fluoro-3-trifluoromethylbenzoyl chloride (92 mg, 0.41 mmol, CAS RN 208173-19-7) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (40 mg, 0.20 mmol, example 1, intermediate a) and DIPEA (70 μί, 0.40 mmol) in THF (1 mL). The reaction mixture was stirred overnight, filtered and all volatiles removed. The resulting oil was purified by flash
chromatography on silica gel eluting with 33-50% EtOAc in n-hexane to yield the product as a waxy solid (65 mg, 83%). MS (ESI): m/z = 470.0 [M+H]+. Example 8
3,5-Dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)- benzamide
Figure imgf000109_0001
3,5-Dichlorobenzoyl chloride (85 mg, 0.40 mmol, CAS RN 2905-62-6) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (40 mg, 0.20 mmol, example 1, intermediate a) and DIPEA (70 μί, 0.40 mmol) in THF (1 mL). The reaction mixture was stirred overnight, filtered and all volatiles removed. The resulting oil was purified by flash chromatography on silica gel eluting with 33-50% EtOAc in n-hexane to yield the product as a waxy solid (65 mg, 87%). MS (ESI): m/z = 470.0 [M+H]+. Example 9
3,5-Difluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide
Figure imgf000109_0002
3,5-Difluorobenzoyl chloride (50 mg, 0.28 mmol, CAS RN 129714-97-2) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (45 mg, 0.23 mmol, example 1, intermediate a) and DIPEA (79 μί, 0.45 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the desired compound as a waxy solid (26 mg, 34%). MS (ESI): m/z = 339.1 [M+H]+. Example 10
3,4-Dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide
Figure imgf000110_0001
3,4-Dichlorobenzoyl chloride (60 mg, 0.29 mmol, CAS RN 2905-60-4) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (45 mg, 0.23 mmol, example 1, intermediate a) and DIPEA (79 μί, 0.45 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the product as a waxy solid (18 mg, 21%). MS (ESI): m/z = 371.0 [M+H]+.
Example 11 3-Chloro-4-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide
Figure imgf000110_0002
3-Chloro-4-fluorobenzoyl chloride (60 mg, 0.31 mmol, CAS RN 65055-17-6) was added to a solution of methyl-(4-o-tolyl-pyridin-3-yl)-amine (45 mg, 0.23 mmol, example 1, intermediate a) and DIPEA (79 μί, 0.45 mmol) in CH2CI2 (1 mL). The reaction mixture was stirred overnight and then loaded directly onto a silica gel column and eluted with 50% EtOAc in n-hexane to yield the product as a waxy solid (23 mg, 29%). MS (ESI): m/z = 355.0 [M+H]+. Example 12
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-N-m
Figure imgf000111_0001
3,5-fiz's-trifluoromethylbenzoyl chloride (76 mg, 0.28 mmol, CAS RN 1271- 19-8) was added to a solution of 6-chloro-N-methyl-4-o-tolylpyridin-3-amine (30 mg, 0.13 mmol, prepared as described in WO2005/002577) and DIPEA (50 μί, 0.29 mmol) in THF (1.5 mL). The reaction mixture was stirred overnight, filtered and all volatiles removed in vacuo. The desired product was isolated by flash chromatography on silica gel (25% EtOAc in n-hexane) as a waxy solid (48 mg, 79%). MS (ESI): m/z = 472.9 [M+H]+. Example 13
3,5-Dichloro-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-benzamide
Figure imgf000111_0002
3,5-Dichlorobenzoyl chloride (635 mg, 3.03 mmol, CAS RN 2905-62-6) was added to a solution of 6-chloro-N-methyl-4-o-tolylpyridin-3-amine (470 mg, 2.02 mmol, prepared as described in WO2005/002577) and DIPEA (705 μΐ,, 4.04 mmol) in CH2C12 (15 mL). The reaction mixture was stirred for 1 h after which the reaction mixture was loaded directly onto a silica gel column. The title compound was isolated by flash chromatography (25% EtOAc in n- hexane) as a foamy oil (641 mg, 78%). MS (ESI): m/z = 404.9 [M+H]+. -I l l- Example 14
N-(6-Methoxy-4-o-tolyl-pyridin-3-yl)-N^
Figure imgf000112_0001
3,5-fiz's-trifluoromethylbenzoyl chloride (126 μί, 0.69 mmol, CAS RN 1271-19-8) was added to a solution of 6-methoxy-N-methyl-4-o-tolylpyridin-3-amine (105 mg, 0.46 mmol) and DIPEA (240 μί, 1.38 mmol) in CH2CI2 and stirred for 2 h. The reaction mixture was then loaded directly onto a silica gel column. Elution with 20% EtOAc in n-hexane gave the title product as a colorless foam (161 mg, 76%). MS (ESI): m/z = 469.0 [M+H]+.
Intermediate 6-Methoxy-N-methyl-4-o-tolylpyridin-3-amine
6-Chloro-N-methyl-4-o-tolylpyridin-3-amine (150 mg, 0.645 mmol, prepared as described in WO2005/002577) in a 10% NaOH solution in CH3OH (300 mg NaOH in 3 mL CH3OH) was heated to 160 °C for 3 hours. After cooling, the reaction mixture was neutralized with 6M aqueous HC1 and extracted three times with EtOAc. The combined organic layers were washed with brine and dried over MgS04. Filtration followed by removal of volatiles in vacuo gave a gummy oil. The desired compound was isolated by flash chromatography on silica gel (20% EtOAc in ft-hexane) as a white waxy solid (115 mg, 78%).
Example 15
N-Methyl-N-(6-methylamino-4-o-tolyl-py
Figure imgf000112_0002
N-Methyl-N-(4-o-tolyl-6-(2,2,2-trifluoro-N-methylacetamido)pyridin-3-yl)-3,5-bz5
(trifluoromethyl)benzamide (70 mg, 0.12 mmol) was stirred in CH3OH (1.5 mL) with potassium carbonate (75 mg, 0.54 mmol) for 1 h. The reaction mixture was then filtered and all volatiles removed under reduced pressure. The residue was dissolved in EtOAc and washed twice with water and twice with brine. The aqueous phases were back-extracted twice with EtOAc and washed with brine. The combined organic layers were dried over Na2S04. Filtration followed by removal of volatiles under reduced pressure gave a waxy residue. N-Methyl-N-(6-methylamino- 4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide was isolated from this residue by flash chromatography on silica gel (50-67% EtOAc in n-hexane) as a white foam (40 mg, 69%). MS (ESI): m z = 468.0 [M+H]+.
Intermediates a) N-Methyl-N-(4-o-tolyl-6-(2,2,2-trifluoro-N-methylacetamido)pyridin-3-yl)-3,5-b^
(trifluoromethyl)benzamide
2,2,2-Trifluoro-N-methyl-N-(5-(methylamino)-4-o-tolylpyridin-2-yl)acetamide (46 mg, 0.14 mmol) and DIPEA (61 μΐ,, 0.35 mmol) in THF (1.5 mL) were treated with 3,5-bis- trifluoromethylbenzoyl chloride (51 μί, 0.28 mmol, CAS RN 1271-19-8). 3,5-Bis- trifluorobenzoyl chloride (25 μί, 0.14 mmol, CAS RN 1271-19-8) was added again at 90 min. and 4 hours. The reaction mixture was stirred for 60 hours and then evaporated to dryness. From the resulting residue, the product N-methyl-N-(4-o-tolyl-6-(2,2,2-trifluoro-N- methylacetamido)pyridin-3-yl)-3,5-bz5 (trifluoromethyl)benzamide was isolated by flash chromatography on silica gel (33-50% EtOAc in n-hexane) as a foam (70 mg, 87% over two steps). The compound was used in the next step without further purification. b) 2,2,2-Trifluoro-N-methyl-N-(5-(methylamino)-4-o-tolylpyridin-2-yl)acetamide
A solution of N2,N5-dimethyl-4-o-tolylpyridine-2,5-diamine and DIPEA (94 μί, 0.54 mmol) in CH2C12 was treated with trifluoroacetic anhydride (55 μί, 0.39 mmol, CAS RN 407- 25-0). After stirring for 90 min, the reaction mixture was loaded directly onto a silica gel column. Flash chromatography (33-50% EtOAc in n-hexane) gave the desired compound as a white gummy solid (46 mg, 45% from 6-chloropyridine starting material) which was pure enough to be used in the next step. c) N2,N5-dimethyl-4-o-tolylpyridine-2,5-diamine
To a solution of 6-chloro-N-methyl-4-o-tolylpyridin-3-amine (74 mg, 0.318 mmol, prepared as described in WO2005/002577), palladium(II) acetate (7 mg, 0.031 mmol, CAS RN 3375-31-3) and ( ?)-(+)-2,2'-bz5(diphenylphosphino)-l,l'-binaphthyl (60 mg, 0.96 mmol, CAS RN 76189-55-4) in toluene (2.5 mL) was added sodium ie/ -butoxide (92 mg, 0.96 mmol). After stirring for 5 min, methylamine (2.0 M solution in THF, 400 μΐ,, 0.80 mmol, CAS RN 74-89-5) was added and the reaction mixture was heated by microwave irradiation to 150 °C for 30 min. The reaction mixture was applied directly to a silica gel column. Flash chromatography (33-50% EtOAc in ft-hexane) gave the product, as a light brown oil which was used in the next step without further purification. Example 16
N-(6-Amino-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000114_0001
N-(6-Iodo-4-o-tolylpyridin-3-yl)-N-methyl-3,5-bz5(trifluoromethyl)benzamide (60 mg, 0.11 mmol), sodium ie/t-butoxide (31 mg, 0.32 mmol), palladium acetate (2.4 mg, 0.011 mmol, CAS RN 3375-31-3) and BINAP (19.9 mg; 0.032 mmol, CAS RN 76189-55-4) were dissolved in toluene (4 mL) and stirred under an argon atmosphere for 10 min. Benzophenone imine (38 mg, 0.21 mmol, CAS RN 1013-88-3) was added and the reaction mixture was sealed and heated to 150 °C by microwave irradiation for 30 minutes. The reaction mixture was cooled, unsealed and 200 μΐ^ of 1M aqueous HC1 was added. After stirring for 1 h, the reaction mixture was neutralized with saturated aqueous NaHC03 solution and extracted three times with EtOAc. The combined organic layers were washed with brine and dried over MgS04. Filtration followed by removal of volatiles under reduced pressure afforded a brown solid. Column chromatography on silica gel (50% EtOAc in n-hexane) afforded the title compound as a yellow solid (17 mg, 35%). MS (ESI): m z = 453.9 [M+H]+. Intermediate
N-(6-Iodo-4-o-tolylpyridin-3-yl)-N-methyl-3,5-b¾ (trifluoromethyl)benzamide
To N-(6-chloro-4-o-tolylpyridin-3-yl)-N-methyl-3 ,5-bzs(trifluoromethyl)benzamide (460 mg, 0.97 mmol, example 12) in acetone (3 mL) was added sodium iodide (1.17 g, 7.8 mmol) and hydriodic acid (170 μί, 1.07 mmol). The reaction mixture was heated to reflux for 4 hours. Acetone was evaporated and acetonitrile (3 mL) was added and the reaction mixture heated again to reflux. After 16 hours, the reaction mixture was carefully neutralized with saturated aqueous NaHC03 solution and extracted three times with EtOAc. The combined organic layers were washed with brine and dried over MgS04. Filtration and removal of volatiles under reduced pressure afforded a brown solid. The desired compound was isolated by flash chromatography on silica gel (50% EtOAc in n-hexane) as an amber oil (324 mg, 59%).
Example 17
N-r6-(4-Methanesulfonyl-piperazin-l-yl)-4-o-tolyl-pyridin-3-yll-N-methyl-3,5-b¾' - trifluoromethyl-benzamide
Figure imgf000115_0001
A solution of N-methyl-6-(4-(methylsulfonyl)piperazin-l-yl)-4-o-tolylpyridin-3-amine (37 mg, 0.10 mmol) and DIPEA (50 μί, 0.29 mmol) in CH2C12 was treated with 3,5-bis- trifluoromethylbenzoyl chloride (43 mg, 0.15 mmol, CAS RN 1271-19-8). After stirring for 1 h, the reaction mixture was loaded directly onto a silica gel column. Elution with 50% EtOAc in n- hexane afforded the title compound as a yellow solid (48 mg, 80%). MS (ESI): m/z = 601.0 [M+H]+.
Intermediate
N-Methyl-6-(4-(methylsulfonyl)piperazin-l-yl)-4-o-tolylpyridin-3-amine 6-Chloro-N-methyl-4-o-tolylpyridin-3-amine (58 mg, 0.25 mmol, prepared as described in
WO2005/002577), sodium ie/t-butoxide (72 mg, 0.75 mmol), palladium acetate (5.6 mg, 0.025 mmol, CAS RN 3375-31-3) and BINAP (47 mg, 0.075 mmol, CAS RN 76189-55-4) were dissolved in toluene (3 mL) and stirred under an argon atmosphere for 10 minutes. 1- (Methylsulfonyl)piperazine (82 mg, 0.5 mmol, CAS RN 55276-43-2) was added and the reaction mixture was sealed and heated to 150 °C under microwave irradiation for 30 min. The reaction mixture was loaded directly onto a silica gel column (elute with EtOAc) to yield the desired compound (39 mg, 43%) as a brown oil which was used in the next step without further purification. Example 18
N-{ 6-r(2-Methoxy-ethyl)-methyl-aminol-4-o-to
trifluoromethyl-benzamide
Figure imgf000116_0001
A solution of N2-(2-methoxyethyl)-N2,N5-dimethyl-4-o-tolylpyridine-2,5-diamine (32 mg,
0.11 mmol) and DIPEA (43 μΐ,, 0.25 mmol) in CH2C12 (1 mL) was treated with 3,5-bis- trifluoromethylbenzoyl chloride (46 mg, 0.17 mmol, CAS RN 1271-19-8). After stirring for 1 h, the reaction mixture was loaded directly onto a silica gel column. Elution with 25% EtOAc in n- hexane afforded the title compound as a yellow solid (19 mg, 33%). MS (ESI): m/z = 526.2 [M+H]+.
Intermediate
N2-(2-Methoxyethyl)-N2,N5-dimethyl-4-o-tolylpyridine-2,5-diamine
6-Chloro-N-methyl-4-o-tolylpyridin-3-amine (60 mg, 0.26 mmol, prepared as described in WO2005/002577), sodium ie/t-butoxide (74 mg, 0.77 mmol), palladium acetate (5.8 mg, 0.026 mmol, CAS RN 3375-31-3) and BINAP (48 mg, 0.077 mmol, CAS RN 76189-55-4) were dissolved in toluene (3 mL) and stirred under an argon atmosphere for 10 minutes. N- 2- Methoxyethyl)methylamine (46 mg, 0.52 mmol, CAS RN 38256-93-8) was added and the reaction mixture was sealed and heated to 150 °C under microwave irradiation for 30 min. The reaction mixture was columned directed on silica gel (EtOAc) to yield the product as a light brown oil (36 mg, 49%). This material was used in the next step without further purification. Example 19 N-(6-Cvano-4-o-tolyl-pyridin-3-yl)-N-me^^
Figure imgf000117_0001
A stirring solution of N-(6-chloro-4-o-tolylpyridin-3-yl)-N-methyl-3,5- bz's(trifluoromethyl)benzamide (100 mg, 0.21 mmol, example 12), ieirafo's-triphenylphosphine palladium(O) (24 mg, 0.020 mmol, CAS RN 14221-01-3) and zinc cyanide (31 mg, 0.26 mmol, CAS RN 557-21-1) in DMF (1.5 mL) was heated to 100 °C for 30 min, 120 °C for 30 min and 150 °C for 30 min by microwave irradiation. After cooling, the reaction mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were washed three times with water and once with brine and dried over Na2S04. Filtration followed by removal of volatiles under reduced pressure gave crude product. The title compound was isolated by flash chromatography (25% EtOAc in n-hexane) as a viscous oil (7.5 mg, 8%). MS (ESI): m/z = 463.9 [M+H]+.
Example 20 N-Methyl-N-(2-methyl-3,4,5,6-tetrahvdro-2H-ri,4nbipyridinyl-3'-yl)-3,5-b^-trifluoromethyl- benzamide
Figure imgf000117_0002
Methyl-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-amine trifluoroacetic acid salt was dissolved in CH2C12 (2 mL) and treated with DIPEA (100 μί, 0.59 mmol) and 3,5-bis- trifluoromethylbenzoyl chloride (76 mg, 0.28 mmol, CAS RN 1271-19-8). The reaction mixture was loaded directly on a silica gel column and the title product (23 mg, 26% over two steps) was isolated by elution with 66% EtOAc in n-hexane. MS (ESI): m/z = 445.9 [M+H]+. Intermediates a) Methyl-(2-methyl-3^,5,6-tetrahvdro-2H-ri^'lbipyridinyl-3'-yl)-amine trifluoroacetic acid salt
Methyl-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-carbamic acid tert-butyl ester (60 mg, 0.20 mmol) was stirred in a solution of TFA (300 μί) and CH2CI2 (2 mL) for 1 h after which all volatiles were removed under reduced pressure. The resulting compound was pure enough to be used directly in the next step without further purification. b) Methyl-(2-methyl-3,4,5,6-tetrahvdro-2H-ri,4'lbipyridinyl-3'-yl)-carbamic acid fe/ -butyl ester
(2-Methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-carbamic acid tert-butyl ester was dissolved in THF (5 mL) and stirred under argon. NaH (24 mg, 0.98 mmol) was added and after 10 min, iodomethane (61 μί, 0.98 mmol) was added. After stirring for 3 hours, NaH (12 mg, 0.49 mmol) and iodomethane (30 μί, 0.49 mmol) were added again. After 1 h, the reaction mixture was poured into saturated, aqueous NH4C1 solution and extracted three times with EtOAc. The combined organic phases were dried over MgS04. Filtration followed by removal of volatiles gave crude product. Column chromatography on silica gel (50% EtOAc in n-hexane) gave the desired compound (159 mg, 59% over two steps) that was used in the next step without further purification. c) (2-Methyl-3,4,5,6-tetrahvdro-2H-ri,4'lbipyridinyl-3'-yl)-carbamic acid tert-butyl ester
Di-ferf-butyl dicarbonate (233 mg, 1.07 mmol, CAS RN 24424-99-5) was added to a stirring solution of 2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-ylamine (170 mg, 0.89 mmol) and DMAP (33 mg, 0.27 mmol) in CH2CI2 (5 mL). After 16 hours, the reaction mixture was poured into saturated, aqueous NH4C1 solution and extracted three times with CH2CI2. The combined organic phases were dried over MgS04. Filtration followed by removal of volatiles gave the desired product as a foam which was pure enough to be used in the next step without further purification. d) 2-Methyl-3,4,5,6-tetrahvdro-2H-ri,4'lbipyridinyl-3'-ylamine
2-Methyl-3'-nitro-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl (650 mg, 2.94 mmol) and 10% palladium on carbon (156 mg, 0.15 mmol) in EtOH were stirred under 1 atmosphere of hydrogen gas for 16 hours. Filtration followed by removal of volatiles under reduced pressure gave the title compound (200 mg, 36%) which was used in the next step without further purification. e) 2-Methyl-3'-nitro-3,4,5,6-tetrahvdro-2H-ri,4'lbipyridine
2-Methylpiperidine (938 mg, 9.5 mmol, CAS RN 109-05-7) and 3-chloro-4-nitropyridine (750 mg, 4.73 mmol, CAS RN 13194-60-0) were heated at 90 °C for 1 h. Direct column chromatography of the cooled reaction mixture gave the product as a yellow solid (655 mg, 63%). This material was pure enough to be used in the next step without further purification.
Example 21
3,5-Dichloro-N-methyl-N-(2-methyl-3,4,5,6-tetrahvdro-2H-ri,4'lbipyridinyl-3'-yl)-benzamide hydrochloride salt
Figure imgf000119_0001
Methyl-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-carbamic acid tert-butyl ester (60 mg, 0.20 mmol, example 20, intermediate b) was stirred in a solution of TFA (300 μί) and CH2CI2 (2 mL) for 1 h after which all volatiles were removed under reduced pressure to give crude methyl-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-3'-yl)-amine TFA salt. The crude TFA salt was dissolved in CH2C12 (2 mL) and treated with DIPEA (100 μί, 590 mmol) and 3,5-dichlorobenzoyl chloride (54 mg, 0.26 mmol, CAS RN 2905-62-6). The reaction mixture was loaded directly on a silica gel column and elution with 66% EtOAc in n-hexane gave the title product (12 mg, 16%). MS (ESI): m z = 378.0 [M+H]+.
Example 22
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-oxazol-2-ylmethyl-5- trifluoromethyl-benzamide
Figure imgf000119_0002
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-oxazol-2-ylmethyl-amine and 3-methanesulfonyl-5-trifluoromethyl- benzoic acid (example 144, intermediate a) after a reaction time of 72 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product-containing fractions were pooled and evaporated. The remaining red solid was purified by preparative HPLC (Gemini NX) with a gradient of methanol : water containing 0.05% formic acid (80 : 20 to 98 : 2). Colorless foam (41%). MS (ESI): m/z = 550.105 [M+H]+.
Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-oxazol-2-ylmethyl-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(4- fluoro-2-methoxy-phenyl)-pyridin-3-yl]-oxazol-2-ylmethyl-carbamic acid ie/ -butyl ester. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (86%). MS (ESI): m/z = 300.115 [M+H]+. b) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-oxazol-2-ylmethyl-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- oxazol-2-ylmethyl-carbamic acid ieri-butyl ester and 4-fluoro-2-methoxyphenyl-boronic acid (CAS RN 179899-07-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Colorless solid (70%). MS (ESI): m/z = 400.167 [M+H]+. c) (4-Iodo-pyridin-3-yl)-oxazol-2-ylmethyl-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and 2-chloromethyl- oxazole (CAS RN 185246-17-7). Light yellow oil (93%). MS (ESI): m/z = 402.031 [M+H]+. Example 23
N-r4-(4-Fluoro-2-methyl-phenyl)^
Figure imgf000121_0001
To a solution of 4-(4-fluoro-2-methylphenyl)-N-methylpyridin-3-amine (47 mg, 0.22 mmol) and DIPEA (57 μί, 0.33 mmol) was added 3,5-bzs(trifluoromethyl)benzoyl chloride (78 mg, 0.28 mmol, CAS RN 1271-19-8) in CH2C12 (2 mL). After stirring for 16 hours, the reaction mixture was loaded directly onto a silica gel column and elution with EtOAc gave the title compound as a waxy oil which solidified upon standing (56 mg, 56%). MS (ESI): m/z = 457.0 [M+H]+. Intermediates a) 4- (4 -Fluoro -2-meth ylphen yl) -N-meth yip yridin- 3 -amine
To a stirring solution of ie/ -butyl 4-(4-fluoro-2-methylphenyl)pyridin-3-ylcarbamate (230 mg, 0.76 mmol) in THF (5 mL) under argon was added NaH (23.9 mg, 1 mmol). After 15 min iodomethane (62 μί, 1 mmol) was added and the reaction mixture was stirred for 1 h. The reaction mixture was poured into saturated aqueous NH4C1 solution and extracted three times with EtOAc. The combined organic phases were washed with brine and dried over MgS04.
Filtration followed by removal of volatiles under reduced pressure gave the N-methylated product [4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-carbamic acid ieri-butyl ester as a light brown oil. This oil was treated with 4M HCl in dioxane for 1 h. Removal of volatiles gave an oily solid which was suspended in CH2C12 and washed with 1M aqueous K2C03 solution. The aqueous phase was extracted twice more with CH2C12 and the combined organic phases were dried over MgS04. Filtration followed by removal of volatiles gave the desired product (113 mg, 69%) which was pure enough for the next step without further purification. b) Tert-but \ 4-(4-fluoro-2-methylphenyl)pyridin-3-ylcarbamate
DMAP (130 mg, 1.07 mmol) was added to a solution of 4-(4-fluoro-2- methylphenyl)pyridin-3 -amine (720 mg, 3.56 mmol) and di-ie/ -butyl dicarbonate (1.01 g, 4.63 mmol, CAS RN 24424-99-5) in CH2C12 (20 mL). The reaction mixture was stirred for 16 hours at room temperature. All volatiles were then removed under reduced pressure and the title compound was isolated by chromatography on silica gel (50% EtOAc in n-hexane) as a colorless solid (268 mg, 25%) which was pure enough for the next step without further purification. c) 4-(4-Fluoro-2-methylphenyl)pyridin-3-amine Zinc dust (4.37 g, 66.7 mmol) was added in three portions over 15 min to 4-(4-fluoro-2- methylphenyl)-3-nitropyridine (3.1 g, 13.3 mmol) in acetic acid (30 mL). The reaction mixture was then heated to 70 °C for two hours. After cooling to room temperature, the reaction mixture was filtered through Celite and all volatiles were removed under reduced pressure. The resulting oil was suspended in EtOAc and washed with saturated aqueous NaHC03 solution and brine. The organic phase was dried over MgS04 and filtered. Evaporation of volatiles under reduced pressure gave the crude product which was purified by flash chromatography (EtOAc) to yield the desired compound (890 mg, 33%). The material was used in the next step without further purification. d) 4-(4-Fluoro-2-methylphenyl)-3-nitropyridine A solution of 4-chloro-3-nitropyridine (2.4 g, 15.1 mmol, CAS RN 13091-23-1), 4-fluoro-
2-methylphenylboronic acid (2.8 g, 18.2 mmol, CAS RN 139911-29-8), potassium carbonate (6.28 g, 45.4 mmol) and palladium ieirafo's-triphenylphosphine (794 mg, 0.76 mmol, CAS RN 14221-01-3) in dioxane (75 mL) was heated to reflux for 16 hours. After cooling to room temperature, the reaction mixture was filtered through Celite and all volatiles were removed under reduced pressure. Column chromatography on silica gel (20-33% EtOAc in n-hexane) afforded 4-(4-fluoro-2-methylphenyl)-3-nitropyridine as a yellow crystalline solid (3.2 g, 90%) which was used in the next step without further purification.
Example 24
3,5-Dichloro-N-r4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yll-N-methyl-benzamide
Figure imgf000122_0001
To a solution of 4-(4-fluoro-2-methylphenyl)-N-methylpyridin-3-amine (60 mg, 0.28 mmol, example 23, intermediate a) and DIPEA (97 μί, 0.56 mmol) was added 3,5-dichlorobenzoyl chloride (87 mg, 0.42 mmol, CAS RN 2905-62-6) in CH2C12 (2 mL). After stirring for 16 hours, the reaction mixture was loaded directly onto a silica gel column and elution with EtOAc gave the title compound (43 mg, 40%). MS (ESI): m/z = 388.9 [M+H]+.
Example 25 N-r4-(2-Fluoro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000123_0001
A solution of N-(4-bromo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (120 mg, 0.281 mmol), 2-fluorophenylboronic acid (472 mg, 0.337 mmol, CAS RN 1993-03-9) and K2C03 (155 mg, 1.124 mmol) in a mixture of water : ethanol : toluene (10 mL; 0.5 : 1 : 3) was thoroughly degassed for 30 min at 25 °C under an atmosphere of argon in a sealed tube.
Pd(PPh3)4 (32.5 mg, 0.0281 mmol, CAS RN 14221-01-3) was then added to the mixture, and continued degassing for another 15 min. The reaction mixture was heated to 90-100 °C for 14 hours. After the completion of reaction, the mixture was filtered though a bed of celite and the residue washed with EtOAc. The combined filtrates were evaporated in vacuo and the resultant residue was diluted with EtOAc. The organic layer washed with brine, dried over anhydrous Na2S04, filtered and concentrated in vacuo. The crude residue thus obtained was purified by preparative HPLC to afford the desired compound as an off-white solid (69%). MS (ESI): m/z = 443.2 [M+H]+.
Intermediates a) N-(4-Bromo-pyridin-3-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
To a solution of (4-bromo-pyridin-3-yl)-methyl-amine (lg, 5.376 mmol) in THF (8 mL) was added LiHMDS (1M solution in THF, 10.7 mL, 10.7 mmol, CAS RN 4039-32-1) dropwise at -78 °C, and stirred for 15 minutes before 3, 5-bzs-trifluoromethyl -benzoyl chloride (1.5 mL, 8.06 mmol, CAS RN 785-56-8) was added to the reaction mixture. After stirring at -78 °C for 1 h the reaction mixture was quenched with saturated aqueous NH4C1 solution (10 mL) and diluted with EtOAc (40 mL). The combined organic layers were washed with brine (15 mL), dried over anhydrous Na2S04, filtered, and evaporated off in vacuo. The residue was purified by column chromatography over silica gel (15% EtOAc in n-hexane) to afford the title compound. Pale yellow solid (985 mg, 43%). MS (ESI): m/z = 427.2 [M+H]+. b) (4-Bromo-pyridin-3-yl)-methyl-amine
A mixture of 4-bromo-pyridin-3-ylamine (2 g, 11.56 mmol, CAS RN 239137-39-4) in trimethyl orthoformate (19 mL, 173.4 mmol, CAS RN 149-73-5) and a catalytic amount of TFA (1 drop) was heated to reflux for 2 hours. Volatiles were removed in vacuo, the resultant dark brown material was dissolved in THF (40 mL), treated portionwise with LiAlH4 (440 mg, 11.56 mmol) at 0 °C and then left stirring at 0 °C for 30 minutes. The reaction mixture was quenched with saturated aqueous NH4C1 solution (15 mL), filtered through a bed of celite, and the residue further washed with EtOAc (30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2S04, filtered, and evaporated off in vacuo. The residue was purified by column chromatography over alumina (10% EtOAc in n-hexane) to afford the title compound. Light yellow oil (875 mg, 40%). MS (ESI): m/z = 187.2 [M+H]+.
Example 26
N-r4-(2^-Dimethyl-phenyl)-pyridin-3-yll-N-methyl-3,5-fa' -trifluoromethyl-benzamide
Figure imgf000124_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2,4- dimethylbenzeneboronic acid (CAS RN 55499-44-0). Colorless solid (52%). MS (ESI): m/z = 453.4 [M+H]+.
Example 27 N-r4-(4-Methoxy-2-methyl-phenyl)-pyridin-
Figure imgf000124_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 4-methoxy-2- methylphenylboronic acid (CAS RN 208399-66-0). Pale yellow sticky solid (67%). MS (ESI): m/z = 469.2 [M+H]+.
Example 28
N-Methyl-3,5-b¾s-trifluoromethyl-N^
Figure imgf000125_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2- trifluoromethylphenylboronic acid (CAS RN 1423-27-4). Off-white solid (60%). MS (ESI): m/z = 493.4 [M+H]+.
Example 29
N-r4-(2-Methoxy-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000125_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2- methoxyphenylboronic acid (CAS RN 5720-06-9). Off-white solid (45%). MS (ESI): m/z = 455.4 [M+H]+. Example 30
N-r4-(4-Chloro-2-methyl-phenyl)^
Figure imgf000126_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 4-chloro-2- methylphenylboronic acid (CAS RN 209919-30-2). Off-white solid (27%). MS (ESI): m/z = 472.8 [M+H]+.
Example 31 N-Methyl-N-r4-(2-trifluoromethoxy-phenyl)-^
Figure imgf000126_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2- (trifluormethoxy)phenylboronic acid (CAS RN 175676-65-0). Off-white solid (34%). MS (ESI) m/z = 509.4 [M+H]+. Example 32
N-(2-Methoxy-r3^1bipyridinyl-3 ^
Figure imgf000127_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-methoxy-3- pyridinyl boronic acid (CAS RN 163105-90-6) and using DMF as reaction solvent. Colorless solid (23%). MS (ESI): m/z = 455.8 [M+H]+.
Example 33
N-Methyl-N-(2-methyl-r3^nbipyridinyl-3'-yl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000127_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2- methylpyridine-3-boronic acid (CAS RN 899436-71-6) and using DMF as solvent for the reaction. Yellow sticky liquid (11%). MS (ESI): m/z = 439.8 [M+H]+.
Example 34
N-Methyl-N-(3'-methyl-r4,4'lbipyridinyl-3-yl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000127_0003
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 3- methylpyridine-4-boronic acid (CAS RN 894808-72-1) and using DMF as solvent for the reaction. Colorless solid (13%). MS (ESI): m/z = 440.2 [M+H]+.
Example 35
N-r4-(2-Isopropoxy-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000128_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2- isopropoxyphenylboronic acid (CAS RN 138008-97-6). Black solid (25%). MS (ESI): m/z = 483.0 [M+H]+.
Example 36
N-r4-(2-Cvano-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000128_0002
The title compound was prepared in analogy to example 25, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide and 2-cyanophenylboronic acid (CAS RN 138642- 62-3) and using DMF as solvent for the reaction. Off-white solid (21%). MS (ESI): m/z = 450.0 [M+H]+. Intermediates a) N-(4-Iodo-pyridin-3-yl)-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
The title compound was prepared in analogy to example 25, intermediate a, from (4-iodo- pyridin-3-yl)-methyl-amine and 3,5-bzs-trifluoromethyl-benzoyl chloride (CAS RN 785-56-8). Pale yellow liquid (15%). MS (ESI): m/z = 475 [M+H]+. b) (4-Iodo-pyridin-3-yl)-methyl-amine
The title compound was prepared in analogy to example 25, intermediate b, from 4-iodo- pyridin-3-ylamine. Brown oil (22%) which was pure enough to be used in the next step. c) 4-Iodo-pyridin-3-ylamine A solution of N-(4-iodo-pyridin-3-yl)-2,2-dimethyl-propionamide (6 g, 19.73 mmol) in aqueous 3M HC1 (50 mL) was heated to 100 °C for 18 hours. After the completion of reaction, the reaction mass was washed with EtOAc. Under cooling the pH of the aqueous layer was adjusted to pH 9 using solid Na2C03 and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2S04, filtered, and concentrated in vacuo to afford 4-iodo-pyridin-3-ylamine (3.2g crude, 73%) as a brown sticky solid that was used in the next step without further purification. d) N-(4-Iodo-pyridin-3-yl)-2,2-dimethyl-propionamide
To a solution of 2,2-dimethyl-N-pyridin-3-yl-propionamide (7 g, 39.32 mmol) in THF (50 mL) was added TMEDA (20 mL, CAS RN 110-18-9) at 25 °C. The mixture was cooled to -70 °C, n-butyllithium was added (66 mL, 1.6M solution in n-hexane, CAS RN 109-72-8) within a period of 30 min under an atmosphere of argon. The reaction mixture was allowed to stir at -15 °C for 1 h, followed by another 1 h at 0 °C. The reaction mixture was re-cooled to -70 °C, then a solution of iodine (29.2 g, 115.1 mmoL) in THF (120 mL) was added slowly during 1 h, and the resultant mixture was allowed to stir at 25 °C for 16 h. Water and saturated aqueous Na2S203 solution was added to the mixture, and then extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2S04, filtered and concentrated in vacuo to afford the crude residue which was purified by column chromatography over silica gel (40% EtOAc in n-hexane) to give the title compound. Pale yellow solid (800 mg, 37%). MS (ESI): m/z = 305.4 [M+H]+. e) 2,2-Dimethyl-N-pyridin-3-yl-propionamide
To a solution of pyridin-3-ylamine (20 g, 212.49 mmol, CAS RN 462-08-8) in a mixture of THF : Et20 (175 mL; 2.5 : 1 v/v) was added slowly a solution of pivaloyl chloride (26 mL, 212.5 mmol, CAS RN 3282-30-2) in THF (50 mL) and Et3N (44 mL, 318.7 mmol) at 0 °C and left stirring at that temperature for 1 h. After the completion of reaction, the reaction mixture was filtered, and the filtrate was evaporated in vacuo. The crude filter cake was washed with n- hexane to yield the title compound. Colorless crystalline solid (32 g, 85%). MS (ESI): m/z = 179.4 [M+H]+.
Example 37 N-r4-(2^-Difluoro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000130_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2,4- difluorophenylboronic acid (CAS RN 144025-03-6) and using DMF as reaction solvent. Off- white solid (60%). MS (ESI): m/z = 461.0 [M+H]+.
Example 38
N 4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-m
Figure imgf000130_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 4-fluoro-2- methoxyphenylboronic acid (CAS RN 179899-07- 1) and using DMF as reaction solvent. Off- white solid (38%). MS (ESI): m/z = 473.4 [M+H]+.
Example 39
N-r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl- benzamide
Figure imgf000131_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 4,5-difluoro- 2-methoxy phenylboronic acid (CAS RN 870777-32-5) and using DMF as reaction solvent. Off- white solid (27%). MS (ESI): m/z = 491.4 [M+H]+.
Example 40
N-r4-(2,3-Difluoro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000131_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2,3- difluorophenylboronic acid (CAS RN 121219- 16-7) and using DMF as reaction solvent. Off- white solid (14%). MS (ESI): m/z = 461.2 [M+H]+. Example 41
N-r4-(3-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N^
Figure imgf000132_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 3-fluoro-2- methoxyphenylboronic acid (CAS RN 762287-59-2) and using DMF as reaction solvent. Off- white solid (27%). MS (ESI): m/z = 473.2 [M+H]+.
Example 42
N-r4-(2-Fluoro-5-methyl-phenyl)-pyridin-3-yll-N^
Figure imgf000132_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-fluoro-5- methylphenylboronic acid (CAS RN 166328-16-1) and using DMF as reaction solvent. Pale yellow solid (26%). MS (ESI): m/z = 457.2 [M+H]+.
Example 43
N-r4-(2-Benzyloxy-4-fluoro-phenyl)-pyridin-3-yll^
Figure imgf000133_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-benzyloxy- 4-fluorophenylboronic acid (CAS RN 848779-87-3) and using DMF as reaction solvent. Off- white solid (29%). MS (ESI): m/z = 549.0 [M+H]+.
Example 44
N-(5-Fluoro-2-methoxy-r3^nbipyridinyl-3'-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000133_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 5-fluoro-2- methoxypyridine-3-boronic acid (CAS RN 957120-32-0) and using DMF as reaction solvent. Off-white solid (27%). MS (ESI): m/z = 474.1 [M+H]+. Example 45
N-(5-Chloro-2-methoxy-r3^1bipyridm
Figure imgf000134_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 5-chloro-2- methoxypyridine-3-boronic acid (CAS RN 943153-22-8) and using DMF as reaction solvent. Off-white solid (28%). MS (ESI): m/z = 490.0 [M+H]+.
Example 46
N-(2-Isopropoxy-r3^'lbipyridinyl-3'-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000134_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2- isopropoxypyridine-3-boronic acid pinacol ester (CAS RN 848243-25-4) and using DMF as reaction solvent. Off-white solid (13%). MS (ESI): m/z = 483.8 [M+H]+.
Example 47
N-(2-Methoxy-6-methyl-r3^nbipyrM^
Figure imgf000135_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-methoxy-6- methylpyridine-3-boronic acid (CAS RN 1000802-75-4) and using DMF as reaction solvent. Off-white solid (42%). MS (ESI): m/z = 469.8 [M+H]+.
Example 48
N-r4-(4-Fluoro-2-hydroxy-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000135_0002
A solution of N-[4-(2-benzyloxy-4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5- trifluoromethyl-benzamide (65 mg, 0.118 mmol, example 43) in MeOH (10 mL) was purged with argon for 20 minutes before 10% Pd-C (10 mg) was added. The resulting reaction mixture was hydrogenated under balloon pressure hydrogen at 25 °C for 16 hours. The reaction mixture was filtered through a bed of celite and the residue was further washed with EtOAc. The combined filtrate was concentrated in vacuo, and the crude material thus obtained was purified by column chromatography over silica gel (25-35% EtOAc in n-hexane) to give 45 mg of the desired compound. Off-white solid (60%). MS (ESI): m/z = 459.0 [M+H]+. Example 49
(2-{3-r(3,5-fi*s-trifluoromethyl-benzoyl)-mem^
acid methyl ester
Figure imgf000136_0001
To a solution of N-[4-(4-fluoro-2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5- trifluoromethyl-benzamide (150 mg, 0.327 mmol, example 48) in DMF (5 mL) was added K2C03 (90 mg, 0.654 mmol) and methyl chloroacetate (0.06 mL, 0.654 mmol, CAS RN 96-34-4) at 25 °C and the resulting mixture was heated to 70 °C for 16 hours. The mixture was diluted with EtOAc (25 mL), washed with brine (10 mL), dried over anhydrous Na2S04, filtered and evaporated in vacuo. The crude material thus obtained was purified by column chromatography over silica gel (30% EtOAc in n-hexane) to give 100 mg of the title compound . Pale yellow solid (58%). MS (ESI): m/z = 531.0 [M+H]+.
Example 50
N-(3'-Chloro-2'-methoxy-r4^1bipyridinyl-3-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000136_0002
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 3-chloro-2- methoxypyridine-4-boronic acid (CAS RN 957060-88-7) and using DMF as solvent. Pale yellow sticky solid (11%). MS (ESI): m/z = 489.9 [M+H]+. Example 51
N-r4-(2-Cvanomethoxy-4-fluoro-phenyiy^^
benzamide
Figure imgf000137_0001
The title compound was prepared in analogy to example 49, from N-[4-(4-fluoro-2- hydroxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 48) and bromoacetonitrile (CAS RN 590-17-0). Yellow solid (32%). MS (ESI): m/z = 497.8 [M+H]+.
Example 52
N-{4-r4-Fluoro-2-(2-hvdroxy-ethoxy)-phenyll^
benzamide
Figure imgf000137_0002
The title compound was prepared in analogy to example 49, from N-[4-(4-fluoro-2- hydroxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 48) and 2- chloroethanol (CAS RN 107-07-3). Off-white solid (62%). MS (ESI): m/z = 502.9 [M+H]+. Example 53
N-{4-r2-(Cyano-methyl-methoxy)-4-fl
trifluoromethyl-benzamide
Figure imgf000138_0001
The title compound was prepared in analogy to example 49, from N-[4-(4-fluoro-2- hydroxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 48) and 2- bromopropionitrile (CAS RN 19481-82-4). Off-white solid (74%). MS (ESI): m/z = 512.0
[M+H]+.
Example 54 N-r4-(3,6-Dimethoxy-pyridazin-4-yl)-pyri
Figure imgf000138_0002
A solution of N-(4-bromo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) (200 mg, 0.468 mmol), 3,6-dimethoxylpyridazine-4-boronic acid (129 mg, 0.702 mmol, CAS RN 1015480-87-1) and K2C03 (194 mg, 1.404 mmol) in DMF (6 mL) in a sealed tube was degassed with argon for 30 minutes. To this mixture were added S- PHOS (96 mg, 0.234 mmol, CAS RN 657408-07-6) and Pd(PPh3)4 (44 mg, 0.046 mmol), degassed for another 15 minutes, and heated to 90 °C for 1 h in microwave. Work up and purification as described in example 25 yielded 15 mg of the title compound. Off-white solid (7%). MS (ESI): m/z = 487.0 [M+H]+. Example 55 N-(2-Chloro-5-fluoro-r3^1bipyridinyl-3 ^
Figure imgf000139_0001
To a solution of (2-chloro-5-fluoro-[3,4']bipyridinyl-3'-yl)-methyl-amine (80 mg, 0.34 mmol) in CH2CI2 (10 mL) were added Et3N (0.187 mL, 1.35 mmol) and 3,5-bw(trifluoromethyl)- benzoyl chloride (0.061 mL, 0.34 mmol, CAS RN 1271-19-8) at 25 °C and the resulting reaction mixture was stirred for 4 hours at 25 °C. The mixture was diluted with CH2CI2 (20 mL), the organic layer was washed with saturated aqueous NaHC03 solution (2x20 mL) and brine (25 mL), dried over Na2S04, filtered and concentrated under vacuum to afford the crude product which was purified using preparative HPLC. Off-white solid (22 mg, 14%). MS (ESI): m/z = 478.4 [M+H]+.
Intermediate
(2-Chloro-5-fluoro-r3,4'lbipyridinyl-3'-yl)-methyl-amine
To a solution of 2-chloro-5-fluoro-3-iodo-pyridine (100 mg, 0.388 mmol, CAS RN 884494-33-1) in THF (3 mL) was added iPrMgCl (2M solution in THF, 0.194 mL, 0.388 mmol, CAS RN 1068-55-9) at -20 °C, and the mixture was stirred at this temperature for 1 hour. To this mixture was added a freshly prepared ZnC½ solution (1M solution in THF; 1.55 mL, 1.55 mmol) at -20 °C. The reaction mixture was allowed to stir at 25 °C for 1.5 hours to give the
corresponding zinc reagent. A solution of (4-iodo-pyridin-3-yl)-methyl-amine (91 mg, 0.388 mmol, example 36, intermediate b) in THF (2 mL) and Pd(PPh3)4 (22.44 mg, 0.019 mmol) were then added to this solution, and the reaction mixture was refluxed for 2 hours. The mixture was poured into 10% NaHC03 solution (15 mL), and extracted with EtOAc (2x15 mL). The combined organic layers were washed with brine (30 mL), dried over Na2S04, filtered, and evaporated in vacuo to afford the desired compound (72 mg, 78%) as a brown sticky solid which was used in the next step without further purification. MS (ESI): m/z = 238.1 [M+H]+. Example 56
N-(2'-Chloro-3'-fluoro-r4^1bipyridm
Figure imgf000140_0001
The title compound was prepared in analogy to example 55, from (2'-chloro-3'-fluoro- [4,4']bipyridinyl-3-yl)-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using preparative HPLC for the chromatographic purification. Off-white solid (12%). MS (ESI): m/z = 478.0 [M+H]+.
Intermediate
(2'-Chloro-3'-fluoro-r4,4'lbipyridinyl-3-yl)-methyl-amine
The title compound was prepared in analogy to example 55, intermediate, from 2-chloro-3- fluoro-4-iodo-pyridine (CAS RN 148639-07-0) and (4-iodo-pyridin-3-yl)-methyl-amine
(example 36, intermediate b). Brown sticky solid (86%). MS (ESI): m/z = 238.0 [M+H]+.
Example 57
N-Methyl-N-(3-methyl-r2^nbipyridinyl-3'-yl)-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000140_0002
The title compound was prepared in analogy to example 55, from methyl-(3-methyl- [2,4']bipyridinyl-3'-yl)-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using preparative HPLC for the chromatographic purification. Off-white solid (20%). MS (ESI): m/z = 440.4 [M+H]+. Intermediate
Methyl-(3-methyl-r2,4'1bipyridinyl-3'-yl)-amine
The title compound was prepared in analogy to example 55, intermediate, from 3-methyl-2- pyridylzinc bromide (CAS RN 308795-91-7) and (4-iodo-pyridin-3-yl)-methyl-amine (example 36, intermediate b). Light yellow sticky solid (93%). MS (ESI): m/z = 200.3 [M+H]+.
Example 58
N-r4-(5-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000141_0001
To a solution of N-(4-bromo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (100 mg, 0.23 mmol, example 25, intermediate a) and 5-fluoro-2-methoxybenzeneboronic acid (CAS RN 179897-94-0) (59.7 mg, 0.35 mmol) in dry DMF (3 mL) was added potassium carbonate (129.4 mg, 0.94 mmol) at 25 °C in a sealed tube and the reaction mixture was purged with argon for 10 min. Then Pd(PPh3)4 (27.05 mg, 0.023 mmol) was added and again purged with argon for 15 min. The reaction mixture was heated at 100 °C for 16 hours. The reaction mass was cooled to 25 °C, filtered through a bed of celite and washed with EtOAc. The solvent was evaporated and the residue was dissolved in EtOAc and washed with water. The organic layer was washed with brine, dried over Na2S04 and evaporated. The resulting crude product was purified by preparative HPLC. Off-white solid (55 mg, 50%). MS (ESI): m/z = 473.2 [M+H]+. Example 59
N-r4-(3,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-/V-methyl-3,5-b¾' -trifluoromethyl- benzamide
Figure imgf000141_0002
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3 yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-methoxy 3,5-difluorophenylboronic acid (CAS RN 737000-76-9) and using preparative HPLC for the chromatographic purification. Off-white solid (49%). MS (ESI): m/z = 491.1 [M+H]+.
Example 60
N-r4-(3^-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl- benzamide
Figure imgf000142_0001
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3 yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-methoxy 3,4-difluorophenylboronic acid (CAS RN 905583-06-4) and using preparative HPLC for the chromatographic purification. Off-white solid (49%). MS (ESI): m/z = 491.1 [M+H]+.
Example 61
N-r4-(2,5-Difluoro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000142_0002
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2,5- difluorophenyl-boronic acid (CAS RN 193353-34-3) and using preparative HPLC for the chromatographic purification. Off-white solid (36%). MS (ESI): m/z = 461.2 [M+H]+. Example 62
N-r4-(2-Fluoro-3 -methoxy-phenyl)-pyridin-3 -yll -N-methyl-3 ,5-bz's-trifluoromethyl-benzamide
Figure imgf000143_0001
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-fluoro-3- methoxy-phenylboronic acid (CAS RN 352303-67-4) and using preparative HPLC for the chromatographic purification. Off-white solid (42%). MS (ESI): m/z = 472.8 [M+H]+.
Example 63
N-r4-(2-Fluoro-5-methoxy-phenyl)-pyridin-3-y^^
Figure imgf000143_0002
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-fluoro-5- methoxy-phenylboronic acid (CAS RN 406482- 19-7) and using preparative HPLC for the chromatographic purification. Off-white solid (45%). MS (ESI): m/z = 473.2 [M+H]+. Example 64
N-r4-(2,6-Difluoro-phenyl)-pyridin-3-^
Figure imgf000144_0001
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2,6- difluorophenyl-boronic acid (CAS RN 162101-25-9) and using preparative HPLC for the chromatographic purification. Off-white solid (16%). MS (ESI): m/z = 461.2 [M+H]+.
Example 65
N-r4-(2-Chloro-3-fluoro-phenyl)-pyridin-3-yll-N^
Figure imgf000144_0002
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-chloro-3- fluoro-benzeneboronic acid (CAS RN 871329-52-1) and using preparative HPLC for the chromatographic purification. Off-white sticky solid (36%). MS (ESI): m/z = 477.2 [M+H]+. Example 66
N-r4-(2-Fluoro-6-methoxy-phenyl)-pyri
Figure imgf000145_0001
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-fluoro-6- methoxy-phenylboronic acid (CAS RN 78495-63-3) and using preparative HPLC for the chromatographic purification. Off-white solid (36%). MS (ESI): m/z = 473.2 [M+H]+.
Example 67
N-r4-(2-Chloro-4-fluoro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000145_0002
The title compound was prepared in analogy to example 58, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 2-chloro-4- fluorophenyl-boronic acid (CAS RN 313545-72-1) and using preparative HPLC for the chromatographic purification. Brown sticky solid (33%). MS (ESI): m/z = 476.8 [M+H]+. Example 68
N-(3-Fluoro-r2^1bipyridinyl-3'-vP
Figure imgf000146_0001
The title compound was prepared in analogy to example 55, from (3-fluoro- [2,4']bipyridinyl-3'-yl)-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using preparative HPLC for the chromatographic purification. Brown Solid (13%). MS (ESI): m/z = 444.4 [M+H]+.
Intermediate (3-Fluoro-r2,4'lbipyridinyl-3'-yl)-methyl-amine To a solution of compound (4-bromo-pyridin-3-yl)-methyl-amine (50 mg, 0.267 mmol, example 25, intermediate b) and 3-fluoro pyridine-2-boronic acid pinacol ester (Milestone Pharmtech LLC) (89.4 mg. 0.4 mmol) dissolved in dry DMF (3 mL) in a sealed tube was added cesium carbonate (348.4 mg, 1.07 mmol) and the reaction mixture was purged with argon for 10 min. Then Pd(OAc)2 (9.38 mg, 0.013 mmol), dppf (1.48 mg, 0.0026 mmol) and CuCl (26.46 mg, 0.27 mmol) were added to the reaction mixture and again purged with nitrogen for 15 min. The reaction mixture was heated at 100 °C for 16 hours. The reaction mixture was cooled to 25 °C, filtered through a bed of celite and washed with EtOAc. The organic layer was washed with water, dried over sodium sulphate and evaporated to yield the desired compound as a light yellow solid (50 mg, 92%) which was used in next step without further purification. MS (ESI): m/z = 204.2 [M+H]+.
Example 69
N-(3'-Methoxy-r4^1bipyridinyl-3-yl)-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000146_0002
The title compound was prepared in analogy to example 55, from (3'-methoxy- [4,4']bipyridinyl-3-yl)-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using preparative HPLC for the chromatographic purification. Off-white solid (24%). MS (ESI): m/z = 456.2 [M+H]+. Intermediate
(3'-Methoxy-r4,4'lbipyridinyl-3-yl)-methyl-amine
To a solution of (4-bromo-pyridin-3-yl)-methyl-amine (50 mg, 0.267 mmol, example 25, intermediate b) and 3-methoxypyridine-4-boronic acid (CAS RN 1008506-24-8) (61.35 mg, 0.4 mmol) in dry DMF (3 mL) in a sealed tube was added potassium carbonate (2.14 mmol) and the reaction mixture was purged with argon for 10 min. Then, Pd(PPh3)4 (30.89 mg, 0.03 mmol) was added and again purged with nitrogen for 15 min. The reaction mixture was heated at 100 °C for 16 hours. After cooling to room temperature the reaction mixture was filtered through a bed of celite and the filter cake washed with EtOAc. The solvent was evaporated, the residue was dissolved in EtOAc and washed with water. The organic layer was dried over sodium sulphate and evaporated to get compound that was used in next step without further purification. Brown solid (55 mg, 95%). MS (ESI): m/z = 216.2 [M+H]+.
Example 70
N-(3'-Fluoro-r4^1bipyridinyl-3-yl)-/V-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000147_0001
The title compound was prepared in analogy to example 55, from (3'-fluoro-
[4,4']bipyridinyl-3-yl)-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using preparative HPLC for the chromatographic purification. Off-white solid (5%). MS (ESI): m/z = 444.4 [M+H]+. Intermediate
(3'-Fluoro-r4,4'lbipyridinyl-3-yl)-methyl-amine
The title compound was prepared in analogy to example 69, intermediate, from (4-bromo- pyridin-3-yl)-methyl-amine (example 25, intermediate b) and 3-fluoropyridine-4-boronic acid (CAS RN 458532-97-3). Brown solid (92%). MS (ESI): m/z = 204.2 [M+H]+.
Example 71
N-(6-Chloro-r2^nbipyridinyl-3'-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000148_0001
The title compound was prepared in analogy to example 55, from (6-chloro- [2,4']bipyridinyl-3'-yl)-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using preparative HPLC for the purification. Off-white sticky solid (20%). MS (ESI): m/z = 460.2 [M+H]+.
Intermediate
(6-Chloro-r2,4'lbipyridinyl-3'-yl)-methyl-amine The title compound was prepared in analogy to example 68, intermediate, from (4-bromo- pyridin-3-yl)-methyl-amine (example 25, intermediate b) and 6-chloropyridine-2-boronic acid (CAS RN 652148-90-8). Brown sticky solid (90%). MS (ESI): m/z = 220.0 [M+H]+.
Example 72
N-r6-Chloro-4-(4-fluoro-2-methyl-ph^
benzamide
Figure imgf000149_0001
To a solution of N-(6-chloro-4-iodo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl- benzamide (200 mg, 393 μηιοΐ) in DME (4 mL) under argon atmosphere was added 4-fluoro-2- methylphenylboronic acid (66.6 mg, 433 μιηοΐ, CAS RN 39911-29-8) and 2M aqueous Na2C03 solution (1 mL). The reaction mixture was stirred for 15 minutes. Pd(II)acetate (4.41 mg, 19.7 μιηοΐ) and triphenylphosphine (10.3 mg, 39.3 μιηοΐ) were added and the reaction was stirred at 90 °C for 18 hours. The reaction mixture was poured on 10% aqueous NaHC03 solution (30 mL) and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless solid (157 mg, 81.3%). MS (TurboSpray): m/z = 491.075 [M+H]+.
Intermediate
N-(6-Chloro-4-iodo-pyridin-3-yl)-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
To a solution of (6-chloro-4-iodo-pyridin-3-yl)-methyl-amine (300 mg, 1.12 mmol, prepared according to WO2006013050) in THF (3 mL) was added dropwise at -78 °C lithium bzs(trimethylsilyl)amide (1M solution in THF, 1.17 mL, 1.17 mmol). The reaction mixture was stirred at -78 °C for 30 minutes. Then, 3,5-bzs(trifluoromethyl)benzoyl chloride (340 mg, 1.23 mmol, CAS RN 1271-19-8) was added at -78 °C and the reaction was stirred for 30 minutes at this temperature. The reaction mixture was allowed to warm to room temperature, stirred for another 1 hour and then poured on 30 mL H20 and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 70 : 30).
Colorless solid (328 mg, 57.7%). MS (TurboSpray): m/z = 508.0 [M+H]+.
Example 73
N-(3,6'-Dichloro-r2^1bipyridinyl-3'-yl)-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000150_0001
To a solution of 3-chloro-2-iodopyridine (94.2 mg, 393 μιηοΐ, CAS RN 77332-89-9) in THF (3 mL) was added isopropylmagnesium chloride (2M solution in THF, 197 μΐ, 393 μιηοΐ) at -40 °C and the reaction mixture stirred for 20 minutes at this temperature. Freshly prepared ZnCl2 solution (1M in THF, 1.57 mL, 1.57 mmol) was added at -40°C. The reaction mixture was allowed to warm to room temperature and was stirred for 90 minutes. A solution of N-(6-chloro- 4-iodo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (200 mg, 393 μιηοΐ, Ex. 72, intermediate) in THF (3 mL) and ieirafo's(triphenylphosphine)palladium(0) (22.7 mg, 19.7 μιηοΐ) was added. The reaction mixture was stirred for 1 hour at reflux. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). The product was further purified by preparative HPLC (phenomenex gemini column) with a gradient of acetonitrile : water (50 : 50 to 95 : 5). Colorless foam (85 mg, 44%). MS (ESI): m/z = 494.025 [M+H]+.
Example 74
3-Bromo-N-r4-(2-chloro-phenyl)-pyridin-3-yll-N-methyl-5-trifluoromethyl-benzamide
Figure imgf000150_0002
To a solution of [4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine (300 mg, 1.37 mmol, prepared according to DEI 0008042) in THF (3 mL) was added dropwise lithium
bzs(trimethylsilyl)amide (1M solution in THF, 1.44 mL, 1.44 mmol) at -78 °C. The reaction mixture was stirred for 10 minutes at -78 °C. A solution of 3-bromo-5-trifluoromethyl-benzoyl chloride (prepared by stirring 3-bromo-5-(trifluoromethyl)benzoic acid (406 mg, 1.51 mmol, CAS RN 328-67-6) in thionylchloride (3 mL) at 100 °C for 1 hour. The reaction mixture was evaporated and the residue was dissolved in 5 mL toluene and concentrated under vacuum. This procedure was repeated three times to completely remove remainder of thionylchloride) in THF (3 mL) was added at -78 °C. The reaction mixture was stirred for 1 hour at this temperature and then poured on 30 mL H20 and 30 mL EtOAc. The layers were separated and the aqueous layer extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Yellow solid (265 mg, 41%). MS (TurboSpray): m/z = 470.991 [M+H]+.
Example 75
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-methyl-5-trifluoromethyl-isophthalamic acid methyl ester
Figure imgf000151_0001
To a solution of 3-bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide (100 mg, 213 μιηοΐ, example 74) in MeOH (1.5 mL) and EtOAc (1.5 mL) was added PdCl2(dppf)-CH2Cl2 complex (20.0 mg, 24.5 μιηοΐ, CAS RN 851232-71-8) and NEt3 (32.3 mg, 44.5 μΐ, 319 μιηοΐ). The reaction mixture was stirred at 100 °C at 80 bar under CO atmosphere for 18 hours. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (93 mg, 97%). MS (TurboSpray): m/z = 449.088 [M+H]+. Example 76
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-hvdroxymethyl-N-methyl-5-triiluoro
Figure imgf000152_0001
To a solution of N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl- isophthalamic acid methyl ester (300 mg, 668 μιηοΐ, example 75) in THF (5 mL) was added LiAlH4 (26.6 mg, 702 μιηοΐ) at 0 °C. The reaction mixture was stirred at this temperature for 1 hour. The reaction mixture was poured on 30 mL aqueous 10% potassium- sodium-tartrate solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (102 mg, 36%). MS (ESI): m z = 421.092 [M+H]+.
Example 77 N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-(l-hvdroxy-l-methyl-ethyl)-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000152_0002
To a solution of N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl- isophthalamic acid methyl ester (200 mg, 446 μΜ, example 75) in THF (3.3 mL) were added methyl magnesium bromide (1M solution in butyl ether, 1.6 mL, 1.56 mmol) within 2 min. The reaction was poured on EtOAc (20 mL) and aqueous sodium potassium tartrate solution (20 mL) and the phases were separated. The aqueous phase was extracted with EtOAc (20 mL) and the combined organic phases were washed with brine, dried over magnesium sulfate, filtered and evaporated. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 100). Colorless solid (115 mg, 57%). MS (ESI): m/z = 449.123 [M+H]+.
Example 78
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000153_0001
The title compound was prepared in analogy to example 72, intermediate, from 4-(2- chloro-phenyl)-pyridin-3-yl]-methyl-amine (prepared according DE10008042) and 3,5- bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light yellow solid (52%). MS (ESI): m/z = 459.068 [M+H]+.
Example 79
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-hydroxy-N-methyl-5-trifluoromethyl-benzamide
Figure imgf000153_0002
To a solution of 3-bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide (332 mg, 707 μιηοΐ, example 74) in dry THF (5 ml) was added triisopropyl borate (257 mg, 317 μΐ, 1.36 mmol, CAS RN 5419-55-6). n-BuLi (552 μΐ, 884 μιηοΐ, 1.6 M solution in n-hexane) was added dropwise at -78 °C. The reaction mixture was stirred at - 78 °C for 1.5 hours. A solution of AcOH (180 mg, 172 μΐ, 3.0 mmol) in water (0.2 ml) and hydrogen peroxide (103 mg, 92.8 μΐ, 1.06 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 18 hours and then poured on 30 ml 10% aqueous NaHC03 solution and 30 ml EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 ml EtOAc. The combined organic layers were washed with 30 ml brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (77 mg, 27%). MS (ESI): m/z = 407.077 [M+H]+.
Example 80 4-Bromo-N-r4-(2-chloro-phenyl)-pyridin-3-yll-N-methyl-3-trifluoromethyl-benzamide
Figure imgf000154_0001
To a solution of 4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine (1.0 g, 4.57 mmol, prepared according to DEI 0008042) in THF (10 mL) was added dropwise lithium
bzs(trimethylsilyl)amide (1M solution in THF, 4.8 mL, 4.8 mmol) at -78 °C. After 10 min. a solution of 4-bromo-3-trifluoromethyl-benzoyl chloride (prepared by stirring a solution of 4- bromo-3-(trifluoromethyl)benzoic acid (1.23 g, 4.57 mmol, CAS RN 161622-14-6) in thionylchloride (10 mL) at 100 °C for 1 hour. The reaction mixture was evaporated and the residue was dissolved in 5 mL toluene and concentrated under vacuum. This was repeated for 3 times to completely remove remains of thionylchloride) in THF (10 mL) was added at -78 °C. The reaction mixture was stirred at -78 °C for 1 hour and then poured on 30 mL H20 and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 ml EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (741 mg, 34%). MS (ESI): m/z = 470.990 [M+H]+.
Example 81
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-methoxy-N-methyl-5-trifluoromethyl-benzamide
Figure imgf000154_0002
The title compound was prepared in analogy to example 74, from 4-(2-chloro-phenyl)- pyridin-3-yl]-methyl-amine (prepared according to DE10008042) and 3-methoxy-5- trifluoromethyl-benzoyl chloride (prepared in analogy to example 74 from 3-methoxy-5- trifluoromethyl-benzoic acid (CAS RN 53985-48-1) and thionyl chloride). Yellow oil (45%). MS (GC_MS (EI)): m/z = 420.0 [M].
Example 82
N-r4-(5-Chloro-2-methyl-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000155_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(5- chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 70 : 30) for the chromatographic purification. Colorless solid (35%). MS (ESI): m/z = 473.084 [M+H]+.
Intermediates a) r4-(5-Chloro-2-methyl-phenyl)-pyridin-3-yll-methyl-amine To a solution of 4-(5-chloro-2-methyl-phenyl)-pyridin-3-ylamine (500 mg, 2.29 mmol) in trimethyl orthoformate (1.94 g, 2.00 mL, 18.3 mmol, CAS RN 149-73-5) was added 2-3 drops of TFA. The reaction mixture was stirred at reflux for 2 hours and then concentrated under vacuum. The residue was dissolved in 5 ml toluene and evaporated (repeated 3 times). The residue was dissolved in THF (10 mL) and LiAlH4 (260 mg, 6.86 mmol) was added in portions at 0 °C. The cooling bath was removed, the reaction mixture stirred at room temperature for 1 hour and then poured on 30 mL 10% aqueous NH4C1 solution and 30 mL EtOAc. The layers were separated and the aqueous layer extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (331 mg, 62%). MS (ESI): m/z = 233.084 [M+H]+. b) 4-(5-Chloro-2-methyl-phenyl)-pyridin-3-ylamine
A solution of N-[4-(5-chloro-2-methyl-phenyl)-pyridin-3-yl]-2,2-dimethyl-propionamide (1 g, 3.3 mmol) in 3M aqueous HC1 (50 niL) was stirred at 90 °C for 18 hours. The reaction mixture was poured on 200 mL 1M aqueous NaOH solution and 150 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 150 mL EtOAc. The combined organic layers were washed with 150 mL brine, dried over MgS04, filtered and concentrated under vacuum. Light brown viscous oil (720 mg, 99%). MS (ESI): m/z = 219.068 [M+H]+. c) N-r4-(5-Chloro-2-methyl-phenyl)-pyridin-3-yll-2,2-dimethyl-propionamide The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)-
2,2-dimethyl-propionamide (CAS RN 113975-32-9) and 5-chloro-2-methylphenylboronic acid (CAS RN 148839-33-2) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (99%). MS (ESI): m/z = 303.126 [M+H]+.
Example 83 3-|3-r(3,5-fi¾' -trifluoromethyl-benzoyl)-methyl-aminol-pyridin-4-yl|-4-methyl-benzoic acid methyl ester
Figure imgf000156_0001
To a solution of N-[4-(5-chloro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5- trifluoromethyl-benzamide (160 mg, 338 μιηοΐ, example 82) in MeOH (1.2 mL) and EtOAc (1.2 mL) was added PdCl2(dppf)-CH2Cl2 complex (31.8 mg, 38.9 μιηοΐ, CAS RN 851232-71-8) and NEt3 (51.4 mg, 70.7 μί, 508 μιηοΐ). The reaction mixture was stirred at 150 °C at 70 bar under CO atmosphere for 24 hours. The reaction mixture was treated with silica gel and directly purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (39 mg, 23%). MS (ESI): m/z = 497.129 [M+H]+. Example 84
3-j3-r(3,5-fi¾s-trifluoromethyl-benzovP acid
Figure imgf000157_0001
To a solution of 3-{3-[(3,5-bz5-trifluoromethyl-benzoyl)-methyl-amino]-pyridin-4-yl}-4- methyl-benzoic acid methyl ester (33 mg, 66.5 μιηοΐ, example 83) in dioxane (1 mL) was added water (2 mL) and LiOH.H20 (3.49 mg, 83.1 μιηοΐ). The reaction mixture was stirred at room temperature for 2 hours and then poured on 20 mL 1M aqueous HC1 and 20 mL EtOAc. The layers were separated and the aqueous layer extracted a second time with 20 mL EtOAc. The combined organic layers were washed with 20 ml brine, dried over MgS04, filtered and concentrated under vacuum. Colorless solid (32 mg, 99%). MS (ESI): m/z = 483.113 [M+H]+.
Example 85
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-(2,2,2-trifluoro-ethyl)-3,5-b^-trifluoromethyl- benzamide
Figure imgf000157_0002
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic purification. Light yellow solid (138 mg, 63%). MS (ESI): m/z = 527.057 [M+H]+. Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-amine
To a solution of [4-(2-chloro-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester (120 mg, 310 μπιοΐ) in CH2C12 (2 mL) at 0 °C was added TFA (2 mL). The reaction mixture was stirred at room temperature for 2 hours and then concentrated under vacuum. The residue was extracted with 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. Light yellow solid (79 mg, 89%). MS (ESI): m/z = 287.055 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2,2,2- trifluoro-ethyl)-carbamic acid tert-butyl ester and 2-chlorophenylboronic acid (CAS RN 1679- 18-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Colorless oil (69%). MS (ESI): m/z = 403.012 [M+H]+. c) (4-Iodo-pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester
To a solution of (4-iodo-pyridin-3-yl)-carbamic acid tert-butyl ester (280 mg, 875 μιηοΐ) in DMF (4 mL) was added NaH (42.0 mg, 962 μιηοΐ, 60% dispersion in mineral oil) at 0 °C. The reaction mixture was stirred at room temperature for 30 minutes. 2,2,2-Trifluoroethyl trifluoromethanesulphonate (203 mg, 126 μί, 875 μιηοΐ, CAS RN 6226-25-1) was added and the reaction stirred at room temperature for 2 hours. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc and the combined organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70). Colorless solid (207 mg, 59%). MS (ESI): m/z = 403.012 [M+H]+. d) (4-Iodo-pyridin-3-yl)-carbamic acid tert-butyl ester
In heat-dried argon purged 4-neck flask was placed a solution of pyridin-3-yl-carbamic acid tert-butyl ester (10 g, 51.5 mmol, CAS RN 56700-70-0) in THF (100 mL). After cooling down to -75 °C, tert-butyllithium (1.7M solution in n-pentane, 66.6 mL, 113 mmol) was added dropwise over 15 min. keeping the temperature below -60 °C. The resulting light brown suspension was stirred at -75 °C for 3.75 h. A solution of iodine (28.7 g, 113 mmol) in THF (50 niL) was added dropwise over 20 min. below -63 °C. The reaction mixture was stirred at -75 °C for 1.5 h and then poured on saturated aqueous NH4C1 solution (1000 mL) and EtOAc (500 mL). The layers were separated. The organic layer was washed once with 10% aqueous Na2S203 solution (300 mL) and once with brine (250 mL), dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 120 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Yellow solid (11.7 g; 71%). MS (ESI): m/z = 321.1 [M+H]+.
Example 86
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-cvclopropylmethyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000159_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-cyclopropylmethyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271- 19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic purification. Light yellow oil (27%). MS (ESI): m/z = 499.1005 [M+H]+. Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-cyclopropylmethyl-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- chloro-phenyl)-pyridin-3-yl]-cyclopropylmethyl-carbamic acid ieri-butyl ester. Colorless solid (99%). MS (ESI): m/z = 259.100 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-cyclopropylmethyl-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 72, from cyclopropylmethyl-(4- iodo-pyridin-3-yl)-carbamic acid ieri-butyl ester and 2-chlorophenylboronic acid (CAS RN 1679- 18-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the
chromatographic purification. Light yellow oil (85%). MS (ESI): m/z = 359.152 [M+H]+. c) Cvclopropylmethyl-(4-iodo-pyridin-3-yl)-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and
(bromomethyl)cyclopropane (CAS RN 7051-34-5) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Colorless solid (76%). MS (ESI): m/z = 375.056 [M+H]+.
Example 87
N-(6,5'-Dichloro-2'-fluoro-r4^nbipyridinyl-3^
Figure imgf000160_0001
The title compound was prepared in analogy to example 73, from N-(6-chloro-4-iodo- pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 72, intermediate) and 5- chloro-2-fluoro-4-iodopyridine (CAS RN 659731-48-3) and using a gradient of n-heptane :
EtOAc (100 : 0 to 30 : 70) for the chromatographic separation. Colorless oil (89%). MS (ESI): m/z = 511.009 [M+H]+.
Example 88
| (3,5-fi¾ -trifluoromethyl-benzoyl)-r4-(2-chloro-phenyl)-pyridin-3-yll-amino|-acetic acid methyl ester
Figure imgf000160_0002
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-ylamino]-acetic acid methyl ester and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271- 19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Yellow solid (26%). MS (ESI): m/z = 517.075 [M+H]+. a) r4-(2-Chloro-phenyl)-pyridin-3-ylaminol-acetic acid methyl ester
The title compound was prepared in analogy to example 85, intermediate a, from {tert- butoxycarbonyl-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester. Off-white solid (95%). MS (ESI): m/z = 277.074 [M+H]+. b) { fer?-Butoxycarbonyl-r4-(2-chloro-phenyl)-pyridin-3-yll-amino|-acetic acid methyl ester
The title compound was prepared in analogy to example 72, from [ie/ -butoxycarbonyl-(4- iodo-pyridin-3-yl)-amino] -acetic acid methyl ester and 2-chlorophenylboronic acid (CAS RN 1679-18-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 60 : 40) for the
chromatographic purification. Colorless oil (49%). MS (ESI): m/z = 377.126 [M+H]+. c) rfer?-Butoxycarbonyl-(4-iodo-pyridin-3-yl)-aminol-acetic acid methyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 14, intermediate d) and methyl bromoacetate (CAS RN 96-32-2) and using a gradient of n-heptane : EtOAc (100 : 0 to 55 : 45) for the chromatographic purification. Yellow oil (77%). MS (ESI): m/z = 393.031 [M+H]+.
Example 89
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-(2-methoxy-ethyl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000161_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2-methoxy-ethyl)-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Yellow solid (53%). MS (ESI): m/z = 503.095 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-methoxy-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2-methoxy-ethyl)-carbamic acid ieri-butyl ester and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Colorless oil (72%). MS (ESI): m/z = 263.094 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-methoxy-ethyl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methoxy-ethyl)-carbamic acid ie/ -butyl ester and 2-chlorophenylboronic acid (CAS RN 1679- 18-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless oil (70%). MS (ESI): m/z = 363.147 [M+H]+. c) (4-Iodo-pyridin-3-yl)-(2-methoxy-ethyl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and l-bromo-2- methoxyethane and using a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80) for the
chromatographic purification. Light yellow oil (65%). MS (ESI): m/z = 379.051 [M+H]+.
Example 90
N-Methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide
Figure imgf000162_0001
To a solution of 4-(trifluoromethyl)benzoic acid (115 mg, 605 μιηοΐ, CAS RN 328-90-5) in CH2CI2 (2 mL) were added N-methyl-4-o-tolylpyridin-3-amine (0.1 g, 504 μιηοΐ, example 1, intermediate a), 2-bromo-l-ethylpyridinium tetrafluoroborate (166 mg, 605 μιηοΐ, CAS RN 878- 23-9) and DIPEA (130 mg, 176 μί, 1.01 mmol). The reaction mixture was stirred at room temperature for 66 h. The red solution was poured on 10% aqueous citric acid and
dichloromethane and the layers were separated. The aqueous layer was extracted twice with dichloromethane. The combined organic layers were washed with 10% aqueous citric acid solution and brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with EtOAc (isocratic). The compound-containing fractions were evaporated and the residue was dissolved in dichloromethane and the solution washed twice with 2M aqueous Na2C03 solution, twice with 1M aqueous HCl and once with brine, dried over MgS04, filtered and evaporated. Brown solid (16%). MS (ESI): m/z = 371.14 [M+H]+. Example 91
4 V-Dimethyl-N-(4-o-tolyl-pyridin-3-yl^^
Figure imgf000163_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4-methyl-3-trifluoromethyl-benzoic acid (CAS RN 261952-01-6) after a reaction time of 90 hours. Grey solid (32%). MS (ESI): m/z = 385.15 [M+H]+.
Example 92
4-Methoxy-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide
Figure imgf000163_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4-methoxy-3-(trifluoromethyl)benzoic acid (CAS RN 213598-09-5) after a reaction time of 88 hours. Brown solid (4%). MS (ESI): m/z = 401.15 [M+H]+.
Example 93
N- 14- r2-(2-Hvdroxy-ethyl)-phenyll -pyridin-3 - yl I -N-methyl-3 ,5 -bzs-trifluoromethyl-benzamide
Figure imgf000163_0003
To the solution of N-(4-iodo-pyridin-3-yl)-N-methyl-3,5-b¾ -trifluoromethyl-benzamide (150 mg, 316 μιηοΐ, example 36, intermediate a) in DME (3 mL) was added 2-(2-(tert- butyldimethylsilyloxy)ethyl)phenylboronic acid (88.7 mg, 316 μιηοΐ, CAS RN 913835-62-8) and 2M aqueous Na2C03 solution (1 mL). The reaction mixture was stirred under argon atmosphere for 15 minutes. Pd(II)acetate (3.55 mg, 15.8 μιηοΐ) and triphenylphosphine (8.3 mg, 31.6 μιηοΐ) were added. The reaction mixture stirred at 90 °C for 18 hours and then poured on 30 mL 1M aqueous HCl and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 60 : 40). Colorless solid (95 mg, 52%). MS (ESI): m/z = 469.134 [M+H]+.
Example 94
3-Fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide
Figure imgf000164_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-fluoro-4-(trifluoromethyl)benzoic acid (CAS RN 115754-21-7) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown solid (20%). MS (ESI): m/z = 389.13 [M+H]+. Example 95
4-Chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide
Figure imgf000164_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4-chloro-3-(trifluoromethyl)benzoic acid (CAS RN 1737-36-6 ) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown solid (30%). MS (ESI): m/z = 405.10 [M+H]+.
Example 96
Figure imgf000165_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3,5-dimethylbenzoic acid (CAS RN 499 06-9) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Brown oil (3%). MS (ESI): m/z = 331.18 [M+H]+.
Example 97
3-Chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide
Figure imgf000165_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-chloro-4-(trifluoromethyl)benzoic acid (CAS RN 115754-20-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown solid (37%). MS (ESI): m/z = 405.10 [M+H]+. Example 98
N-(6-Methoxy-r2^1bipyridinyl-3 ^
Figure imgf000166_0001
The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide and 6-methoxypyridin-2-ylboronic acid (CAS RN 372963-51-4) and using a gradient of n-heptane : EtOAc (100 : 0 to 60 : 40) for the
chromatographic purification. The product was purified a second time by preparative HPLC (Phenomenex Gemini® column) eluting with a gradient of acetonitrile : water (50 : 50 to 95 : 5). Colorless oil (17%). MS (ESI): m/z = 456.114 [M+H]+.
Intermediate a) N-(4-Iodo-pyridin-3-yl)-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
The title compound was prepared in analogy to example 72, intermediate, from (4-iodo- pyridin-3-yl)-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic purification. Light yellow solid (18%). MS (ESI): m/z = 474.9738 [M+H]+. b) (4-Iodo-pyridin-3-yl)-methyl-amine
The title compound was prepared in analogy to example 85, intermediate a, from (4-iodo- pyridin-3-yl)-methyl-carbamic acid ieri-butyl ester. Brown oil (99%). MS (ESI): m/z = 234.973 [M+H]+. c) (4-Iodo-pyridin-3-yl)-methyl-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 14, intermediate d), sodium hydride and iodomethane (CAS RN 74-88-4). The compound was purified by silica gel chromatography eluting with n-heptane : EtOAc (2 : 1). Colorless solid (58%). MS (ESI): m/z = 355.025 [M+H]+. Example 99
Figure imgf000167_0001
The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 98, intermediate a) and 6- methoxypyridin-3-ylboronic acid (CAS RN 163105-89-3) and using a gradient of n-heptane : EtOAc (100 : 0 to 60 : 40) for the chromatographic separation. Colorless solid (74%). MS (ESI): m/z = 456.113 [M+H]+.
Example 100 3-Chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethoxy-benzamide
Figure imgf000167_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-chloro-5-(trifluoromethoxy)benzoic acid (CAS RN 158580-93-9) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Yellow solid (31%). MS (ESI): m/z = 421.09 [M+H]+. Example 101
N-Methyl-N-(4-o-tolyl-pyridin-3^
Figure imgf000168_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3,4-bzs(trifluoromethyl)benzoic acid (CAS RN 133804-66-7) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Yellow solid (43%). MS (ESI): m/z = 439.12 [M+H]+.
Example 102
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-methylcarbamoylmethyl-3,5-b¾ -trifluoromethyl- benzamide
Figure imgf000168_0002
To a solution of {(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]- aminoj-acetic acid (100 mg, 199 μπιοΐ) in DMF (2 mL) was added DIPEA (129 mg, 169 μΐ,, 994 μιηοΐ), HATU (91.5 mg, 239 μιηοΐ) and methylamine hydrochloride (16.1 mg, 239 μιηοΐ). The reaction mixture was stirred at room temperature for 2 hours and then poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (67 mg, 65%). MS (ESI): m/z = 516.091 [M+H]+. Intermediate j(3,5-fi¾s-trifluoromethyl-benzoyl)-r^ acid
To a solution of {(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]- aminoj-acetic acid methyl ester (109 mg, 211 μιηοΐ, example 88) in dioxane (2 mL) was added water (2 mL) and lithium hydroxide hydrate (11.1 mg, 264 μιηοΐ). The reaction mixture was stirred at room temperature for 2 hours and then poured on 30 mL 1M aqueous HCl and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and evaporated to give a yellow solid which was pure enough for the next step (119 mg, 112%). MS (ESI): m/z = 503.060 [M+H]+.
Example 103
3-Chloro-5-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide
Figure imgf000169_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-chloro-5-fluorobenzoic acid (CAS RN 25026-64-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the
chromatographic purification. Yellow solid (17%). MS (ESI): m/z = 355.10 [M+H]+.
Example 104
3,4,5-Trifluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide
Figure imgf000169_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3,4,5-trifluorobenzoic acid (CAS RN 121602-93-5) after a reaction time of 64 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). The product-containing fractions were pooled and evaporated. The resulting brown solid was chromatographed a second time by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (22%). MS (ESI): m/z = 357.12 [M+H]+.
Example 105
N-r4-(2,3-Dimethyl-phenyl)-pyridin-3-yll-N-methyl-3,5-fa' -trifluoromethyl-benzamide
Figure imgf000170_0001
The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)-
N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 98, intermediate a) and 2,3- dimethylphenylboronic acid (CAS RN 183158-34-1) and using gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Colorless solid (81%). MS (ESI): m/z = 453.140 [M+H]+. Example 106
N-Methyl-N-r2-(2 ,2-trifluoro-ethoxy)-r3,41bipyridinyl-3'-yll-3,5-b^-trifluoromethyl- benzamide
Figure imgf000170_0002
The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 98, intermediate a) and 2-(2,2,2- trifluoroethoxy)pyridin-3-ylboronic acid (Combi-Blocks Inc.) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Colorless solid (58%). MS (ESI): m/z = 524.103 [M+H]+. Example 107 N-(2-Cvclopropylmethoxy-r3^1bipyridm^
Figure imgf000171_0001
The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 98, intermediate a) and 2-
(cyclopropylmethoxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (CAS RN 848243-26-5) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the
chromatographic purification. Light yellow oil (63%). MS (ESI): m/z = 498.146 [M+H]+.
Example 108 3,N-Dimethyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000171_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-methyl-5-(trifluoromethyl)benzoic acid (CAS RN 117186-02-4) after a reaction time of 67 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 30 : 70). Light brown oil (9%). MS (ESI): m/z = 385.15[M+H]+. Example 109
3-Chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000172_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-chloro-5-(trifluoromethyl)benzoic acid (CAS RN 39226-97-6) after a reaction time of 68 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 30 : 70). The product-containing fractzions were pooled and evaporated. The product was dissolved in EtOAc and extracted three time with 1M aqueous HC1. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified a second time by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70). Light brown solid (47%). MS (ESI): m/z = 405.10 [M+H]+.
Example 110 N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-(2-fluoro-ethyl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000172_0002
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2-fluoro-ethyl)-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification to give a first batch of compound (light yellow solid). A second chromatographic purification of the remaining impure fractions and mother liquor gave a second batch of compound. Yellow solid (25% overall). MS (ESI): m/z = 491.08 [M+H]+. Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-fluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2-fluoro-ethyl)-carbamic acid ieri-butyl ester. Light brown solid (98%). MS (ESI): m/z = 251.07 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-fluoro-ethyl)-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 72, from (2-fluoro-ethyl)-(4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester and 2-chlorophenylboronic acid (CAS RN 1679-18- 1). Yellow oil (86%). MS (ESI): m/z = 351.13 [M+H]+. c) (2-Fluoro-ethyl)-(4-iodo-pyridin-3-yl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and l-bromo-2- fluoroethane (CAS RN 762-49-2) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Light brown solid (71%). MS (ESI): m/z = 367.03 [M+H]+.
Example 111
N-r4-(3-Chloro-2-fluoro-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000173_0001
The title compound was prepared in analogy to example 72, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 98, intermediate a) and 3-chloro-2- fluorophenylboronic acid (CAS RN 352535-82-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Light yellow oil (64%). MS (ESI): m/z = 477.061 [M+H]+. Example 112
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-(2-mem^
benzamide
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine and 3,5-bzs(trifluoromethyl) benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 100) for the chromatographic purification. Light yellow foam (36%). MS (ESI): m/z = 551.06 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-methanesulfonyl-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2-methanesulfonyl-ethyl)-carbamic acid ieri-butyl ester. Colorles foam (84%). MS (ESI): m/z = 311.02 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-methanesulfonyl-ethyl)-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methanesulfonyl-ethyl)-carbamic acid ieri-butyl ester and 2-chlorophenylboronic acid (CAS RN 1679-18-1). The product was purified by preparative HPLC (phenomenex gemini column) with a gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2). Light brown foam (67%). MS (ESI): m/z = 411.11 [M+H]+. c) (4-Iodo-pyridin-3-yl)-(2-methanesulfonyl-ethyl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 14, intermediate d) and l-bromo-2- methanesulfonyl-ethane (CAS RN 16523-02-7) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown solid (11%). MS (ESI): m/z = 427.02 [M+H]+. Example 113 N-Methyl-N-r6-(lH-pyrrol-2-yl)-4-o-tolyl-pyridm^
Figure imgf000175_0001
To a solution of 2-{5-[(3,5-bz5-trifluoromethyl-benzoyl)-methyl-amino]-4-o-tolyl-pyridin- 2-yl} -pyrrole- l-carboxylic acid tert-butyl ester (39 mg, 64.6 μιηοΐ) in CH2CI2 (2 mL) was added TFA (2 mL) at 0 °C. The reaction mixture was stirred for at room temperature for 1 hour and then concentrated under vacuum. The residue was poured on 30 mL aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. Light yellow solid (32 mg, 98%). MS (ESI): m/z = 504.151 [M+H]+.
Intermediate
2- { 5- Γ(3 ,5-fizs-trifluoromethyl-benzo vD-methyl-aminol -4-o-tolyl-p yridin-2- yl I -pyrrole- 1 - carboxylic acid tert-butyl ester
The title compound was prepared in analogy to example 72, from N-(6-chloro-4-o-tolyl- pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 12) and l-(tert- butoxycarbonyl)pyrrole-2-boronic acid (CAS RN 135884-31-0) and using a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow oil (18%). MS (ESI): m/z = 604.202 [M+H]+.
Example 114
3-Methanesulfonyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000175_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-methanesulfonyl-5-trifluoromethyl- benzoic acid (example 114, intermediate a) after a reaction time of 64 hours. The compound was purified by two silica gel chromatographies on a 10 g column using a MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (30%). MS (ESI): m/z = 449.11 [M+H]+.
Intermediates a) 3-Methanesulfonyl-5-trifluoromethyl-benzoic acid
To a solution of 3-methanesulfonyl-5-trifluoromethyl-benzoic acid methyl ester (1.0 g, 3.54 mmol) in dioxane (15 mL) was added water (15 mL) and lithium hydroxide monohydrate (186 mg, 4.43 mmol). The reaction mixture was stirred at room temperature for 2 hours and then poured on 100 ml 1M aqueous HC1 and 100 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 100 mL EtOAc. The organic layers were washed with 100 mL brine, dried over MgS04, filtered and concentrated under vacuum. Colorless solid (930 mg, 98%). MS (ESI): m/z = 266.995 [M-H]~. b) 3-Methanesulfonyl-5-trifluoromethyl-benzoic acid methyl ester
The mixture consisting of l-bromo-3-(methylsulfonyl)-5-(trifluoromethyl)benzene (0.20 g, 0.66 mmol, Combi-Blocks, Inc.), l, -bz5(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (20.4 mg, 0.025 mmol, CAS RN 72287-26-4) and NEt3 (0.134 g, 0.184 mL, 1.32 mmol) in EtOAc (2 mL) and methanol (2 mL) was stirred at 110 °C under a 70 bar carbon monoxide atmosphere for 20 h. After cooling to room temperature silica gel was added and the brown suspension evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown oil (0.156 g; 83%). MS (GC_MS (EI)): m/z = 282.0 [M]
Example 115
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-(2-hvdroxy-ethyl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000176_0001
The solution of methyl 2-(N-(4-(2-chlorophenyl)pyridin-3-yl)-3,5-bz5(trifluoromethyl) benzamido)acetate (0.15 g, 0.29 mmol, example 88) in methanol (2.00 mL) was cooled down to 0 °C. To the light yellow suspension was added NaBH4 (22.0 mg, 0.58 mmol) and the reaction was stirred for 2 h at room temperature. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70). The product containing fractions were combined and partially evaporated upon which
crystallisation started. The supernatant light brown solution was pipetted off and the remaining solid dried under high vacuum. Colorless crystals (0.024 g; 16%). MS (ESI): m/z = 489.08
[M+H]+.
Example 116
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-(2,2-difluoro-ethyl)-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000177_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2,2-difluoro-ethyl)-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 70 : 30) for the chromatographic purification. Light brown solid (0.053 g; 11%). MS (ESI): m/z = 509.07 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2,2-difluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- chloro-phenyl)-pyridin-3-yl]-(2,2-difluoro-ethyl)-carbamic acid ieri-butyl ester. Light brown solid (94%). MS (ESI): m/z = 269.07 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2,2-difluoro-ethyl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 72, from (2,2-difluoro-ethyl)-(4- iodo-pyridin-3-yl)-carbamic acid tert-butyl ester and 2-chlorophenylboronic acid (CAS RN 1679-18-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the
chromatographic purification. Light brown oil (0.726 g; 89%). MS (ESI): m/z = 369.12 [M+H]+. c) (2,2-Difluoro-ethyl)-(4-iodo-pyridin-3-yl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid tert-butyl ester (example 85, intermediate d) and 2-bromo-l,l- difluoroethane (CAS RN 359-07-9). Light brown solid (0.85 g; 77%). MS (ESI): m/z = 385.02 [M+H]+.
Example 117
N-Carbamoylmethyl-N-r4-(2-chloro-phenyl)-pyridin-3-yll-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000178_0001
A suspension of {(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]- aminoj-acetic acid (0.15 g, 298 μιηοΐ, example 102, intermediate) and EDC (172 mg, 895 μιηοΐ) in DMF (2 mL) was treated with l-hydroxy-7-azabenzotriazole (122 mg, 895 μιηοΐ, CAS RN 39968-33-7) and stirred at room temperature for 20 min. to give a yellow solution. Ammonium chloride (160 mg, 2.98 mmol) and DIPEA (386 mg, 521 μΐ,, 2.98 mmol) were added and the reaction was stirred for another 3.75 h. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with water and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (0.099 g; 66%). MS (ESI): m/z = 502.07 [M+H]+. Example 118
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-dim
benzamide
Figure imgf000179_0001
A solution of {(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}- acetic acid (0.15 g, 298 μηιοΐ, example 102, intermediate), HATU (136 mg, 358 μιηοΐ) and diethylamin hydrochloride (29.2 mg, 358 μιηοΐ) in DMF (2 mL) was treated with DIPEA (116 mg, 156 μί, 895 μιηοΐ) and stirred at room temperature for 1.75 h. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with water and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Light yellow foam (0.127 g; 80%). MS (ESI): m/z = 530.12 [M+H]+. Example 119
2-Chloro-6,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-isonicotinamide
Figure imgf000179_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 2-chloro-6-methylisonicotinic acid (CAS RN 25462-85-5) after a reaction time of 64 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (7%). MS (ESI): m/z = 352.12 [M+H]+. Example 120
2,6-Dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-isonicotinamide
Figure imgf000180_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 2,6-dichloro-isonicotinic acid (CAS RN 5398-44-7) after a reaction time of 18 hours. The compound was purified by silica gel chromatography on a 50 g column using a MPLC system eluting with EtOAc (isocratic). The product-containing fractions were pooled and evaporated to give a colorless foam. The foam was dissolved in EtOAc and washed three times with 2M aqueous Na2C03 solution and brine, dried over MgS04, filtered and evaporated. Colorless foam (13%). MS (ESI): m/z = 372.07 [M+H]+.
Example 121
4,6-Dimethyl-pyridine-2-carboxyric acid methyl-(4-o-tolyl-pyridin-3-yl)-amide
Figure imgf000180_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4,6-dimethylpyridine-2-carboxylic acid (CAS RN 18088-10-3) after a reaction time of 64 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Light brown oil (37%). MS (ESI): m/z = 332.18 [M+H]+. Example 122
4-Chloro-6-methyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide
Figure imgf000181_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4-chloro-6-methylpyridine-2-carboxylic acid (CAS RN 30235-19-9). Colorless solid (35%). MS (ESI): m/z = 352.12 [M+H]+.
Example 123
4,6-Dichloro-pyridine-2-carboxyric acid methyl-(4-o-tolyl-pyridin-3-yl)-amide
Figure imgf000181_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4,6-dichloro-pyridine-2-carboxylic acid (CAS RN 88912-25-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Colorless solid (7%). MS (ESI): m/z = 372.07 [M+H]+.
Example 124 N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-cvclopropyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000181_0003
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-cyclopropyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8). The compound was purified by two subsequent silical gel
chromatographies using a MPLC system (10 g column, gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) and n-heptane : EtOAc (100 : 0 to 60 : 40)) and by preparative HPLC (phenomenex gemini column) with a gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2). Colorless solid (24%). MS (ESI): m/z = 485.08 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-cvclopropyl-amine An ice-cold solution [4-(2-chloro-phenyl)-pyridin-3-yl]-(l-methoxy-cyclopropyl)-amine
(0.105 g, 0.382 mmol) in THF (2 mL) was treated with LiAlH4 (14.5 mg, 0.382 mmol) and stirred at 0 °C for 1 h. The reaction was allowed to warm to room temperature and stirring was continued for 2.25 h. The reaction mixture was poured on saturated aqueous potassium sodium tartrate solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc and the organic layers were washed with water and brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless solid (0.074 g; 79%). MS (ESI): m/z = 245.08 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-(l-methoxy-cvclopropyl)-amine Step a: A solution of 4-(2-chlorophenyl)pyridin-3-amine (0.3 g, 1.47 mmol) in MeOH (1.5 mL) and AcOH (352 mg, 0.336 mL, 5.86 mmol) was treated dropwise with (1- ethoxycyclopropoxy)trimethylsilane (294 mg, 0.338 ml, 1.69 mmol, CAS RN 27374-25-0) at room temperature. After stirring for 1 h, the reaction mixture was heated to reflux, stirred for 22.5 hours and then evaporated. The crude product was used without further purification. Step b: To an ice-cold suspension of NaBH4 (111 mg, 2.93 mmol) in THF (2 mL) was added dropwise boron trifluoride dimethyl ether complex (416 mg, 0.372 ml, 2.93 mmol, CAS RN 353-42-4) and the white suspension was stirred at 0 °C for 1 h. To this reaction mixture a solution of crude product from step a in THF (4 mL) was added dropwise over 45 min. After stirring at 0 °C for 15 min., the cooling bath was removed and stirring was continued at room temperature for 21 hours. The reaction mixture was refluxed overnight and after cooling down to room temperature 2M aqueous NaOH solution and EtOAc were added. After stirring for 15 min. the layers were separated and the aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100), followed by three additional silica gel chromatographies eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless solid (0.044 g). MS (ESI): m/z =275.10 [M+H]+. c) 4-(2-Chloro-phenyl)-pyridin-3-ylamine An ice-cold solution of [4-(2-chloro-phenyl)-pyridin-3-yl]-carbamic acid ieri-butyl ester
(1.08 g, 3.54 mmol) in CH2C12 (11 mL) was treated with TFA (4.04 g, 2.73 mL) and stirred at room temperature for 3.5 hours. The volatiles were removed at a rotary evaporator and the residue taken up in CH2C12 and saturated aqueous NaHC03 solution and the layers were separated. The aqueous layer was extracted twice with CH2C12 and the organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (0.658 g, 90%). MS (ESI): m/z = 205.05 [M+H]+. d) r4-(2-Chloro-phenyl)-pyridin-3-yll-carbamic acid fe/ -butyl ester The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- carbamic acid ie/ -butyl ester (example 85, intermediate d) and 2-chlorophenylboronic acid (672 mg, 4.3 mmol, CAS RN 1679-18-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow foam (1.08 g, 90%). MS (ESI): m/z = 305.11 [M+H]+. Example 125
(2-{(3,5-fi¾' -trifluoromethyl-benzoyl)-r4-(2-chloro-phenyl)-pyridin-3-yll-amino|-ethyl)- carbamic acid benzyl ester
Figure imgf000183_0001
The title compound was prepared in analogy to example 72, intermediate, from {2-[4-(2- chloro-phenyl)-pyridin-3-ylamino]-ethyl}-carbamic acid benzyl ester and 3,5-bzs(trifluoromethyl) benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatogrpahic purification. Light brown solid (36%). MS (ESI): m/z = 622.13 [M+H]+.
Intermediates a) {2-r4-(2-Chloro-phenyl)-pyridin-3-ylaminol-ethyl|-carbamic acid benzyl ester
The title compound was prepared in analogy to example 85, intermediate a, from (2- benzyloxycarbonylamino-ethyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-carbamic acid ie/ -butyl ester. Light brown foam (97%). MS (ESI): m/z = 382.13 [M+H]+. b) (2-Benzyloxycarbonylamino-ethyl)-r4-(2-chloro-phenyl)-pyridin-3-yll-carbamic acid tert- butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from [4-(2- chloro-phenyl)-pyridin-3-yl]-carbamic acid ie/ -butyl ester (example 124, intermediate d) and (2- bromo-ethyl)-carbamic acid benzyl ester (CAS RN 53844-02-3) and using a gradient of n- heptane : tert-buty\ methyl ether (100 : 0 to 30 : 70) for the chromatographic separation.
Colorless foam (53%). MS (ESI): m/z = 482.18 [M+H]+.
Example 126
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-isopropyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000184_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- chloro-phenyl)-pyridin-3-yl]-isopropyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Yellow solid (19%). MS (ESI): m/z = 487.10 [M+H]+. Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-isopropyl-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- chloro-phenyl)-pyridin-3-yl]-isopropyl-carbamic acid ieri-butyl ester. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless oil (88%). MS (ESI): m/z = 247.1 [M+H]+. b) r4-(2-Chloro-phenyl)-pyridin-3-yll-isopropyl-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- isopropyl-carbamic acid ie/ -butyl ester and 2-chlorophenylboronic acid (CAS RN 1679-18- 1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless oil (85%). MS (ESI): m/z = 347.15 [M+H]+. c) (4-Iodo-pyridin-3-yl)-isopropyl-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and 2-bromo-propane (CAS RN 75-26-3) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (53%). MS (ESI): m/z = 363.06 [M+H]+.
Example 127
N-Methyl-N-(6-methyl-4-o-tolyl-pyridin-3-yl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000185_0001
To a solution of N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl- benzamide (0.15 g, 0.317 mmol, example 12) in THF (2 mL) were added methylzinc chloride (0.238 mL, 0.476 mmol, 2M solution in THF), l,3-dimethyl-2-imidazolidinone (0.4 mL, CAS RN 80-73-9) and (l,3-bz5(2,6-diisopropylphenyl)imidazolidene) (3-chloropyridyl) palladium(II) dichloride (4.31 mg, 0.00635 mmol, Sigma- Aldrich) and the reaction was stirred at 50 °C (oil bath temperature) for 1 h. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc and the organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50).
Colorless oil (0.122 g; 85%). MS (ESI): m/z = 453.14 [M+H]+. Example 128
3-Dimethylsulfamoyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000186_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-[(dimethylamino)sulfonyl]-5- (trifluoromethyl)benzoic acid (Butt Park Ltd.). The product was purified a second time using preparative HPLC (Phenomenex Gemini® column) and a gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2). Light brown foam (20%). MS (ESI): m/z = 478.1 [M+H]+.
Example 129 3-Fluoro-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000186_0002
The title compound was prepared in analogy to example 72, intermediate, from [4-(4- fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-amine and 3-fluoro-5-(trifluoromethyl)benzoic acid chloride (CAS RN 171243-30-4). The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product-containing fractions were pooled and evaporated. The yellow solid was further purified by preparative HPLC (Phenomenex Gemini® column) with a gradient of acetonitrile : water (containing 0.05% formic acid) (50 : 50 to 95 : 5). Light yellow solid (23%). MS (ESI): m/z = 423.113 [M+H]+.
Intermediate r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-amine The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 98, intermediate b) and 4-fluoro-2-methoxyphenylboronic acid (CAS 179899-07-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80) for the
chromatographic purification. Light yellow oil (85%). MS (ESI): m/z = 233.108 [M+H]+.
Example 130 N-r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-3-fluoro-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000187_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(4,5- difluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-amine and 3-fluoro-5-(trifluoromethyl)benzoic acid chloride (CAS RN 171243-30-4) and using a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80) for the chromatographic purification. Yellow solid (33%). MS (ESI): m/z = 441.103 [M+H]+.
Intermediate r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 98, intermediate b) and 4,5-difluoro-2-methoxyphenylboronic acid (CAS RN 870777-32-5) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic separation. Light brown solid (91%). MS (ESI): m z = 251.099 [M+H]+. Example 131
N-Methyl-N-(4-o-tolyl-pyridm^
Figure imgf000188_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.). The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of CH2CI2 : EtOAc (100 : 0 to 70 : 30). Light yellow foam (61%). MS (ESI): m/z = 440.118 [M+H]+.
Example 132 N-r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-3-fluoro-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000188_0002
The title compound was prepared in analogy to example 72, intermediate, from [4-(4,5- difluoro-2-methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine and 3-fluoro-5- (trifluoromethyl)benzoic acid chloride (CAS RN 171243-30-4) and using a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow foam (39%). MS (ESI): m/z = 509.091 [M+H]+. Intermediates a) r4-(4,5-Difluoro-2-methoxy-phenvP^
The title compound was prepared in analogy to example 85, intermediate a, from [4-(4,5- difluoro-2-methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-carbamic acid ieri-butyl ester. Colorless solid (99%). MS (ESI): m/z = 319.087 [M+H]+. b) r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-carbamic acid tert- butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- (2,2,2-trifluoro-ethyl)-carbamic acid ie/ -butyl ester and (example 85, intermediate c) and 4,5- difluoro-2-methoxyphenylboronic acid (CAS RN 870777-32-5) and using a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (79%). MS (ESI): m/z = 419.139 [M+H].
Example 133
3-Dimethylsulfamoyl-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-(2,2,2-trifluoro-ethyl)- 5 -trifluorometh yl-benzamide
Figure imgf000189_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine and 3-dimethylsulfamoyl-5-trifluoromethyl- benzoic acid (Buttpark Ltd.) and using a gradient of CH2CI2 : EtOAc (100 : 0 to 90 : 10) for the chromatographic purification. Light yellow foam (42%). MS (ESI): m/z = 580.112 [M+H]+.
Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(4- fluoro-2-methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-carbamic acid tert-buty\ ester. Colorless solid (94%). MS (ESI): m/z = 301.096 [M+H]+. b) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- (2,2,2-trifluoro-ethyl)-carbamic acid ie/ -butyl ester (example 85, intermediate c) and 4-fluoro-2- methoxyphenylboronic acid (CAS RN 179899-07- 1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (74%). MS (ESI): m/z = 401.148 [M+H]+.
Example 134
3-Fluoro-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000190_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(4- fluoro-2-methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine (example 133,
intermediate a) and 3-fluoro-5-(trifluoromethyl)benzoic acid chloride (CAS RN 171243-30-4). The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50), followed by preparative HPLC using a gradient of methanol : water (10 : 50 to 95 : 5). Colorless solid (22%). MS (ESI): m/z = 491.099 [M+H]+.
Example 135 N-(2-Methoxy-r3,41bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-3,5-b^-trifluoromethyl- benzamide
Figure imgf000190_0002
The title compound was prepared in analogy to example 72, intermediate, from (2- methoxy-[3,4']bipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-amine and 3,5- bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow foam (21%). MS (ESI): m/z = 524.100 [M+H]+.
Intermediates a) ( 2-Methoxy- Γ3 ,4'lbipyridinyl-3 '- yl)-( 2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from (2- methoxy-[3,4']bipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester. Light yellow solid (92%). MS (EI): m/z = 283 [M]. b) (2-Methoxy-r3,4'lbipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- (2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester (example 85, intermediate c) and 2- methoxypyridine-3-boronic acid (CAS RN 163105-90-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow oil (87%). MS (ESI): m/z = 384.154 [M+H]+.
Example 136
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000191_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine (example 133, intermediate a) and 3- methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of CH2CI2 : EtOAc (100 : 0 to 85 : 15). Light yellow foam (43%). MS (ESI): m/z = 551.087 [M+H]+. Example 137
N 4-(4,5-Difluoro-2-methoxy-phenyl)-pyridm^
trifluoromethyl-benzamide
Figure imgf000192_0001
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-methyl-amine (example 114, intermediate) and 3- methanesulfonyl-5-trifluoromethyl-benzoic acid (example 43, intermediate a) after a reaction time of 5 days. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50), followed by preparative HPLC using a gradient of methanol : water (10 : 90 to 95 : 5). Colorless foam (46%). MS (ESI): m/z = 501.091 [M+H]+.
Example 138
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000192_0002
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate a) and 3-methanesulfonyl-5- trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50), followed by preparative HPLC using a gradient of methanol : water (10 : 90 to 95 : 5). Colorless foam (44%). MS (ESI): m/z = 483.099 [M+H]+. Example 139
N-r4-(4,5-Difluoro-2-methoxy-phenyl)^
ethyl)-5-trifluoromethyl-benzamide
Figure imgf000193_0001
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine (example 132, intermediate a) and 3-methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of CH2CI2 : EtOAc (100 : 0 to 85 : 15). Light brown foam (21%). MS (ESI): m/z = 569.077 [M+H]+.
Example 140
N-r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin^
ethyl)-5-trifluoromethyl-benzamide
Figure imgf000193_0002
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine (example 132, intermediate a) and 3-dimethylsulfamoyl-5-trifluoromethyl-benzoic acid (Buttpark Ltd.). The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of CH2C12 : EtOAc (100 : 0 to 90 : 10), followed by preparative HPLC using a gradient of methanol : water (10 : 50 to 95 : 5). Light brown foam (13%). MS (ESI): m/z = 598.104 [M+H]+. Example 141
3-Fluoro-N-(2-methoxy-r3,4nbipyridm^^
benzamide
Figure imgf000194_0001
The title compound was prepared in analogy to example 72, intermediate, from (2- methoxy-[3,4']bipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-amine (example 135, intermediate a) and 3-fluoro-5-(trifluoromethyl)benzoic acid (CAS RN 161622-05-5) and using a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow solid (16%). MS (ESI): m/z = 474.104 [M+H]+.
Example 142
3-Methanesulfonyl-N-(2-methoxy-r3,4'lbipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000194_0002
The title compound was prepared in analogy to example 90, from (2-methoxy- [3,4']bipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-amine (example 135, intermediate a) and 3- methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of CH2CI2 : EtOAc (100 : 0 to 85 : 15), followed by preparative HPLC using a gradient of methanol : water (10 : 50 to 95 : 5). Light yellow foam (28%). MS (ESI): m/z = 534.090 [M+H]+. Example 143
3-Dimethylsulfamoyl-N-r4-(4-nu^
trifluoromethvl-benzamide
Figure imgf000195_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate) and 3-dimethylsulfamoyl-5- trifluoromethyl-benzoic acid (Buttpark Ltd.) after a reaction time of 65 hours. The compound was purified by silica gel chromatography on a 50 g column using a MPLC system eluting with EtOAc. Light brown foam (19%). MS (ESI): m/z = 512.13 [M+H]+.
Example 144
N-r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin- isonicotinamide
Figure imgf000195_0002
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-methyl-amine (example 130, intermediate) and 2,6- bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 23 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (38%). MS (ESI): m/z = 492.10 [M+H]+. Example 145
N-(2-Methoxy-r3,41bipyridinyl-3'-yl)-N-(2,2 -trifluoro-ethyl)-2,6-b^-trifluoromethyl- isonicotinamide
Figure imgf000196_0001
The title compound was prepared in analogy to example 90, from (2-methoxy-
[3,4']bipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-amine (example 135, intermediate a) and 2,6- bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 96 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light yellow solid (41%). MS (ESI): m/z = 525.10 [M+H]+.
Example 146
N-r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-N-(2,2,2-trifluoro-ethyl)-2,6-b^- trifluoromethyl-isonicotinamide
Figure imgf000196_0002
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine (example 132, intermediate a) and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 96 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (31%). MS (ESI): m/z = 560.08 [M+H]+. Example 147
N-r4-(4-Ruoro-2-methoxy-phenyl)-pyridin-3-yll-N-(2,2,2-trifluoro-ethyl)-2,6-b^- trifluoromethyl-isonicotinamide
Figure imgf000197_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine (example 133, intermediate a) and 2,6- bz5(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 96 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (44%). MS (ESI): m/z = 542.09 [M+H]+.
Example 148
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-2,6-b¾ -trifluoromethyl- isonicotinamide
Figure imgf000197_0002
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate) and 2,6-bzs(trifluoromethyl) isonicotinic acid (Key Organics Ltd.) after a reaction time of 22 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (73%). MS (ESI): m/z = 474.11 [M+H]+. Example 149
3-Cvano-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trinuoromethyl-benzamide
Figure imgf000198_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-cyano-5-trifluoromethyl-benzoic acid after a reaction time of 94 hours. The product was purified by silica gel chromatography using a 10 g column eluting with EtOAc followed by a second chromatography on a 5 g column eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless solid (2%). MS (ESI): m/z = 396.13 [M+H]+.
Intermediates a) 3-Cvano-5-trifluoromethyl-benzoic acid
To a solution of 3-cyano-5-trifluoromethyl-benzoic acid methyl ester (0.084 g, 0.367 mmol) in dioxane (0.5 mL) was added water (0.5 mL) and lithium hydroxide monohydrate (19.2 mg, 0.458 mmol) and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated, the residue was taken up in dioxane and 10 % aqueous citric acid solution and the layers were separated. The aqueous layer was extracted twice with EtOAc and the organic layers were washed with brine, dried over MgS04, filtered and evaporated. Light brown solid (0.09 g; 98%). MS (ESI): m/z = 214.01 [M-H]". b) 3-Cyano-5-trifluoromethyl-benzoic acid methyl ester The title compound was prepared in analogy to example 114, intermediate b, from 3- bromo-5-trifluoromethyl-benzonitrile (CAS RN 691877-03-9). The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (51%). MS (GC-MS (EI)): m/z = 229 [M]. Example 150
N-(4-o-Tolyl-pyridin-3-yl)-N-(2,2,2-trin
Figure imgf000199_0001
The title compound was prepared in analogy to example 90, from (4-o-tolyl-pyridin-3-yl)- (2,2,2-trifluoro-ethyl)-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 23 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (26%). MS (ESI): m/z = 508.11 [M+H]+.
Intermediates a) (4-o-Tolyl-pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- (2,2,2-trifluoro-ethyl)-amine and 2-methylphenylboronic acid (CAS RN 16419-60-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown solid (91%). MS (ESI): m/z = 267.11 [M+H]+. b) (4-Iodo-pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from (4-iodo- pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-carbamic acid ie/ -butyl ester (example 85, intermediate c). Colorless solid (98%). MS (ESI): m/z = 302.96 [M+H]+. Example 151
N-r4-(2-Fluoro-phenyl)-pyridin-3^
isonicotinamide
Figure imgf000200_0001
The title compound was prepared in analogy to example 90, from [4-(2-fluoro-phenyl)- pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 25 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (38%). MS (ESI): m/z = 512.08 [M+H]+.
Intermediate r4-(2-Fluoro-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared from (4-iodo-pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-amine (example 150, intermediate b) and 2-fluorophenylboronic acid (CAS RN 1193-03-9) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown solid (85%). MS (ESI): m/z = 271.09 [M+H]+.
Example 152
N-Methyl-3-morpholin-4-yl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000200_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolyrpyridin-3-amine (example 1, intermediate a) and 3-morpholin-4-yl-5-trifluoromethyl- benzoic acid (CAS RN 250682-08-7) after a reaction time of 5 days. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Colorless solid (12%). MS (ESI): m/z = 456.188 [M+H]+.
Example 153
N-(2,2-Difluoro-ethyl)-N-r4-(4-fluoro-2-methoxy-ph^
isonicotinamide
Figure imgf000201_0001
The title compound was prepared in analogy to example 90, from (2,2-difluoro-ethyl)-[4- (4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 68 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (57%). MS (ESI): m/z = 524.10 [M+H]+.
Intermediates a) (2,2-Difluoro-ethyl)-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-amine
The title compound was prepared in analogy to example 72, from (2,2-difluoro-ethyl)-(4- iodo-pyridin-3-yl)-amine and 4-fluoro-2-methoxyphenylboronic acid (CAS RN 179899-07- 1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown solid (78%). MS (ESI): m/z = 283.18 [M+H]+. b) (2,2-Difluoro-ethyl)-(4-iodo-pyridin-3-yl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from (2,2- difluoro-ethyl)-(4-iodo-pyridin-3-yl)-carbamic acid ieri-butyl ester (example 116, intermediate c). Off-white solid (98%). MS (ESI): m/z = 284.97 [M+H]+. Example 154
N-(2,2-Difluoro-ethyl)-N-r4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yll-2,6-b^- trifluoromethyl-isonicotinamide
Figure imgf000202_0001
The title compound was prepared in analogy to example 90, from (2,2-difluoro-ethyl)-[4-
(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 66 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (66%). MS (ESI): m/z = 542.09 [M+H]+.
Intermediate
(2,2-Difluoro-ethyl)-r4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yll-amine
The title compound was prepared in analogy to example 72, from (2,2-difluoro-ethyl)-(4- iodo-pyridin-3-yl)-amine (example 153, intermediate b) and 4,5-difluoro-2- methoxyphenylboronic acid (CAS RN 870777-32-5) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown solid (73%). MS (ESI): m/z = 301.10 [M+H]+.
Example 155
N-(2 -Difluoro-ethyl)-N-r4-(2-fluoro-phenyl)-pyridin-3-yll-2,6-b¾ -trifluoromethyl- isonicotinamide
Figure imgf000203_0001
The title compound was prepared in analogy to example 90, from (2,2-difluoro-ethyl)-[4-
(2-fluoro-phenyl)-pyridin-3-yl]-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 68 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (44%). MS (ESI): m/z = 494.09 [M+H]+.
Intermediate
(2,2-Difluoro-ethyl)-r4-(2-fluoro-phenyl)-pyridin-3-yll -amine
The title compound was prepared in analogy to example 72, from (2,2-difluoro-ethyl)-(4- iodo-pyridin-3-yl)-amine (example 153, intermediate b) and 2-fluorophenylboronic acid (CAS RN 1193-03-9) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (87%). MS (ESI): m/z = 252.1 [M+H]+.
Example 156
N-(2 -Difluoro-ethyl)-N-(2-methoxy-r3,4'lbipyridinyl-3'-yl)-2,6-b^-trifluoromethyl- isonicotinamide
Figure imgf000203_0002
The title compound was prepared in analogy to example 90, from (2,2-difluoro-ethyl)-(2- methoxy-[3,4']bipyridinyl-3'-yl)-amine and 2,6-bz5(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 67 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (64%). MS (ESI): m/z = 507.11 [M+H]+.
Intermediate
(2,2-Difluoro-ethyl)-(2-methoxy-r3,4'lbipyridinyl-3'-yl)-amine
The title compound was prepared in analogy to example 72, from (2,2-difluoro-ethyl)-(4- iodo-pyridin-3-yl)-amine (example 153, intermediate b) and 2-methoxypyridine-3-boronic acid (CAS RN 163105-90-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (83%). MS (ESI): m/z = 266.11 [M+H]+.
Example 157
N-(2,2-Difluoro-ethyl)-N-(4-o-tolyl-pyridin-^^
Figure imgf000204_0001
The title compound was prepared in analogy to example 90, from (2,2-difluoro-ethyl)-(4-o- tolyl-pyridin-3-yl)-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 68 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (34%). MS (ESI): m/z = 490.11 [M+H]+. Intermediate
(2,2-Difluoro-ethyl)-(4-o-tolyl-pyridin-3-yl)-amine
The title compound was prepared in analogy to example 72, from (2,2-difluoro-ethyl)-(4- iodo-pyridin-3-yl)-amine (example 153, intermediate b) and 2-methylphenylboronic acid (CAS RN 16419-60-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (93%). MS (ESI): m/z = 248.1 [M+H]+. Example 158
N-r4-(4,5-Difluoro-2-methoxy-phenyl)-p^
trifluoromethyl-isonicotinamide
Figure imgf000205_0001
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine and 2,6-bzs(trifluoromethyl) isonicotinic acid (Key Organics Ltd.) after a reaction time of 15 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Brown solid (42%). MS (ESI): m/z = 584.09 [M+H]+.
Intermediates a) r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-(2-methanesulfonyl-ethyl)-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methanesulfonyl-ethyl)-amine and 4,5-difluoro-2-methoxyphenylboronic acid (CAS RN 870777- 32-5) and using a gradient of CH2CI2 : methanol (100 : 0 to 85 : 15) for the chromatographic purification. Light brown foam (76%). MS (ESI): m/z = 343.09 [M+H]+. b) (4-Iodo-pyridin-3-yl)-(2-methanesulfonyl-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from (4-iodo- pyridin-3-yl)-(2-methanesulfonyl-ethyl)-carbamic acid ieri-butyl ester (example 112,
intermediate c). Off-white solid (98%). MS (ESI): m/z = 326.97 [M+H]+. Example 159
N-r4-(2-Fluoro-phenyl)-pyridin-3-yll-N-(2-metn^
isonicotinamide
Figure imgf000206_0001
The title compound was prepared in analogy to example 90, from [4-(2-fluoro-phenyl)- pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 15 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Off-white solid (38%). MS (ESI): m/z = 536.09 [M+H]+.
Intermediate r4-(2-Fluoro-phenyl)-pyridin-3-yll-(2-methanesulfonyl-ethyl)-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methanesulfonyl-ethyl)-amine (example 158, intermediate b) and 2-fluorophenylboronic acid (CAS RN 1193-03-9) and using a gradient of CH2C12 : methanol (100 : 0 to 70 : 30) for the chromatographic purification. Light brown solid (85%). MS (ESI): m/z = 295.09 [M+H]+.
Example 160
N-(2-Methanesulfonyl-ethyl)-N-(2-mem^
isonicotinamide
Figure imgf000207_0001
The title compound was prepared in analogy to example 90, from (2-methanesulfonyl- ethyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 15 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (14%). MS (ESI): m/z = 549.10 [M+H]+.
Intermediate
(2-Methanesulfonyl-ethyl)-(2-methoxy-r3,4'lbipyridinyl-3'-yl)-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methanesulfonyl-ethyl)-amine (example 158, intermediate b) and 2-methoxypyridine-3-boronic acid (CAS RN 163105-90-6) and using a gradient of CH2C12 : methanol (100 : 0 to 85 : 15) for the chromatographic purification. Brown solid (89%). MS (ESI): m/z = 308.11 [M+H]+.
Example 161
N-Cvanomethyl-N-(4-o-tolyl-pyridin-3-yl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000207_0002
The title compound was prepared in analogy to example 90, from (4-o-tolyl-pyridin-3- ylamino)-acetonitrile and 3,5-bzs-trifluoromethyl-benzoic acid (CAS RN 725-89-3) after a reaction time of 18 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product-containing fractions were pooled and evaporated until a suspension formed. The colorless solid was filtered off and washed with a small amount of a mixture of EtOAc : n- heptane (1 : 6). Colorless solid (37%). MS (ESI): m/z = 464.12 [M+H]+.
Intermediates a) (4-o-Tolyl-pyridin-3-ylamino)-acetonitrile The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3- ylamino)-acetonitrile and 2-methylphenylboronic acid (CAS RN 16419-60-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown solid (48%). MS (ESI): m/z = 224.12 [M+H]+. b) (4-Iodo-pyridin-3-ylamino)-acetonitrile The title compound was prepared in analogy to example 85, intermediate a, from cyanomethyl-(4-iodo-pyridin-3-yl)-carbamic acid ieri-butyl ester. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Light brown oil (62%). MS (ESI): m/z = 259.97 [M+H]+. c) Cvanomethyl-(4-iodo-pyridin-3-yl)-carbamic acid fe/ -butyl ester The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and bromoacetonitrile (CAS RN 590-17-0) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow oil (95%). MS (ESI): m/z = 360.02 [M+H]+.
Example 162
N-r4-(4-Fluoro-2-methoxy-phenyl^
trifluoromethyl-isonicotinamide
Figure imgf000209_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine and 2,6-bz5(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 17 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). A second chromatography (preparative HPLC
(Phenomenex Gemini® column), gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2)) gave the desired product as an off-white foam (10%). MS (ESI): m/z = 566.10 [M+H]+.
Intermediate r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(2-methanesulfonyl-ethyl)-amine The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methanesulfonyl-ethyl)-amine (example 158, intermediate b) and 4-fluoro-2-methoxyphenyl- boronic acid (CAS RN 179899-07-1) and using a gradient of CH2C12 : methanol (100 : 0 to 85 : 15) for the chromatographic purification. Colorless foam (55%). MS (ESI): m/z = 325.10
[M+H]+. Example 163
N-(2-Methanesulfonyl-ethyl)-N-(4-o-to
Figure imgf000210_0001
The title compound was prepared in analogy to example 90, from (2-methanesulfonyl- ethyl)-(4-o-tolyl-pyridin-3-yl)-amine and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 17 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). A second chromatography (preparative HPLC (phenomenex gemini column), gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2)) yielded the desired product as an off-white solid (10%). MS (ESI): m/z = 532.11 [M+H]+.
Intermediate
(2-Methanesulfonyl-ethyl)-(4-o-tolyl-pyridin-3-yl)-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methanesulfonyl-ethyl)-amine (example 158, intermediate b) and 2-methylphenylboronic acid (CAS RN 16419-60-6) and using a gradient of CH2C12 : methanol (100 : 0 to 85 : 15) for the chromatographic purification. Brown oil (85%). MS (ESI): m/z = 291.12 [M+H]+.
Example 164
3-Amino-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000210_0002
The title compound was prepared in analogy to example 85, intermediate a, from {3- [methyl-(4-o-tolyl-pyridin-3-yl)-carbamoyl]-5-trifluoromethyl-phenyl}-carbamic acid ieri-butyl ester and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Colorless solid (94%). MS (ESI): m/z = 386.147 [M+H]+. Intermediates a) {3-rMethyl-(4-o-tolyl-pyridin-3-yl)-carbamoyll-5-trifluoromethyl-phenyl|-carbamic acid tert- butyl ester
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-ieri-butoxycarbonylamino-5- trifluoromethyl-benzoic acid and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 60) for the chromatographic purification. Light brown solid (4%). MS (ESI): m/z = 486.20 [M+H]+. b) 3-fer?-Butoxycarbonylamino-5-trifluoromethyl-benzoic acid
The title compound was prepared in analogy to example 84, from 3-tert- butoxycarbonylamino-5-trifluoromethyl-benzoic acid methyl ester. MS (ESI): m/z = 304.0809 [M-H]~. c) 3-fer?-Butoxycarbonylamino-5-trifluoromethyl-benzoic acid methyl ester
To a solution of 3-amino-5-trifluoromethyl-benzoic acid methyl ester (2 g, 9.13 mmol, CAS RN 22235-25-2) in CH2C12 (30 mL) was added di-ie/ -butyl dicarbonate (1.99 g, 9.13 mmol, CAS RN 24424-99-5) and DMAP (1.11 g, 9.13 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was treated with silica gel and
concentrated under vacuum and purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 70 : 30). Colorless solid (76%). MS (GC_MS (EI)): 319.1 (M+).
Example 165
N-(2-Cvano-ethyl)-N-(4-o-tolyl-pyridin-3-yl)-3,5-b¾ -trinuoromethyl-benzamide
Figure imgf000212_0001
The title compound was prepared in analogy to example 90, from 3-(4-o-tolyl-pyridin-3- ylamino)-propionitrile and 3,5-bzs(trifluoromethyl)benzoic acid (CAS RN 725-89-3) after a reaction time of 19 hours. The compound was purified by two silica gel chromatographies (10 g and 5 g column, respectively) using a MPLC system eluting with a gradient of n-heptane :
EtOAc (100 : 0 to 50 : 50). Colorless solid (2%). MS (ESI): m/z = 478.13 [M+H]+.
Intermediates a) 3 - (4 -o -Tolyl-pyridin- 3 -ylamino) -propionitrile
The title compound was prepared in analogy to example 72, from 3-(4-iodo-pyridin-3- ylamino)-propionitrile and 2-methylphenylboronic acid (CAS RN 16419-60-6) and using a gradient of heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown solid (81%). MS (ESI): m/z = 238.13 [M+H]+. b) 3-(4-Iodo-pyridin-3-ylamino)-propionitrile
The title compound was prepared in analogy to example 85, intermediate a, from (2-cyano- ethyl)-(4-iodo-pyridin-3-yl)-carbamic acid tert-butyX ester. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 20 : 80). Light brown solid (75%). MS (ESI): m/z = 273.98 [M+H]+. c) (2-Cyano-ethyl)-(4-iodo-pyridin-3-yl)-carbamic acid tert-butyX ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid tert-butyX ester (example 85, intermediate d) and 3- bromopropionitrile (CAS RN 2417-90-5) and using a gradient of n -heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light yellow oil (92%). MS (ESI): m/z = 374.1 [M+H]+. Example 166 N-r4-(3,6-Dihvdro-2H-pyran-4-yl)-pyridin-3-ylV
Figure imgf000213_0001
The title compound was prepared in analogy to example 73, from N-(4-iodo-pyridin-3-yl)- N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 98, intermediate a) and trifluoro- methanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester (CAS RN 188975-30-6). The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60). Colorless solid (56%). MS (ESI): m/z = 431.177 [M+H]+.
Example 167 N-r4-(2,3-Dimethoxy-phenyl)-pyridin-3-y^
Figure imgf000213_0002
The title compound was prepared in analogy to example 72, intermediate, from [4-(2,3- dimethoxy-phenyl)-pyridin-3-yl]-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and using a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic purification. Light yellow solid (72%). MS (ESI): m/z = 485.127 [M+H]+.
Intermediate r4-(2,3-Dimethoxy-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 98, intermediate b) and 2,3-dimethoxyphenylboronic acid (CAS RN 28611-39-4) and using a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Light yellow solid (79%). MS (ESI): m/z = 245.128 [M+H]+.
Example 168
N-r4-(2-Ethyl-phenyl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000214_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(2-ethyl- phenyl)-pyridin-3-yl]-methyl-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271-19-8) and a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic purification. Light yellow solid (54%). MS (ESI): m/z = 453.139 [M+H]+.
Intermediate r4-(2-Ethyl-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 2-ethylphenylboronic acid (CAS RN 90002-36-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic
purification. Light yellow solid (87%). MS (ESI): m/z = 213.138 [M+H]+.
Example 169
2-Chloro-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-6-trifluoromethyl- isonicotinamide
Figure imgf000214_0002
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate) and 2-chloro-6-trifluoromethyl- isonicotinic acid (prepared in analogy to F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2004, 18, 3793-3798) after a reaction time of 18 hours. The compound was purified by two silica gel chromatographies on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless solid (26%). MS (ESI): m/z = 440.08 [M+H]+.
Example 170
3-Dimethylsulfamoyl-N-(2-methoxy-r3,4'lbipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000215_0001
The title compound was prepared in analogy to example 72, intermediate from (2-methoxy- [3,4']bipyridinyl-3'-yl)-(2,2,2-trifluoro-ethyl)-amine (example 135, intermediate a) and 3- dimethylsulfamoyl-5-trifluoromethyl-benzoyl chloride (prepared in analogy to example 74 from 3-dimethylsulfamoyl-5-trifluoromethyl-benzoic acid, Buttpark Ltd.). The compound was purified twice by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). A final chromatography using preparative HPLC (phenomenex gemini column) and a gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2) gave the title product as a colorless solid (24%). MS (ESI): m/z = 563.12 [M+H]+. Example 171
2-Chloro-N-methyl-N-(4-o-tolyl-pyri^
Figure imgf000216_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o-tolylpyridin- 3-amine (example 1, intermediate a) and 2-chloro-6-trifluoromethyl-isonicotinic acid (prepared in analogy to F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2004, 18, 3793-3798) after a reaction time of 66 hours. The compound was purified by two silica gel chromatographies (10 g column each, gradient of n -heptane : EtOAc (100 : 0 to 50 : 50) for the first and EtOAc for the second chromatography), followed by preparative HPLC (phenomenex gemini column, gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2)). Colorless foam (49%). MS (ESI): m/z = 406.09 [M+H]+.
Example 172 rr4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl- benzovD-aminol -acetic acid methyl ester
Figure imgf000216_0002
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-ylamino]-acetic acid methyl ester and 3-methanesulfonyl-5- trifluoromethyl-benzoic acid (example 114, intermediate a) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 80) for the chromatographic purification. Colorless solid (30%). MS (ESI): m/z = 559.096 [M+H]+. Intermediates a) r4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-ylaminol-acetic acid methyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3- ylamino)-acetic acid methyl ester and 4,5-difluoro-2-methoxyphenylboronic acid (CAS RN 870777-32-5) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the
chromatographic purification. Light yellow oil (82%). MS (ESI): m/z = 309.104 [M+H]+. b) (4-Iodo-pyridin-3-ylamino)-acetic acid methyl ester
The title compound was prepared in analogy to example 85, intermediate a, from [tert- butoxycarbonyl-(4-iodo-pyridin-3-yl)-amino] -acetic acid methyl ester. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (91%). MS (ESI): m/z = 292.980 [M+H]+. c) rfer?-Butoxycarbonyl-(4-iodo-pyridin-3-yl)-aminol-acetic acid methyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and bromo-acetic acid methyl ester (CAS RN 96-32-2) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown oil (96%). MS (ESI): m/z = 393.030 [M+H]+.
Example 173
|(2,6-fi¾ -trifluoromethyl-pyridine-4-carbonyl)-r4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3- yll -amino I -acetic acid methyl ester
Figure imgf000217_0001
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-ylamino]-acetic acid methyl ester (example 172, intermediate a) and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 80). Colorless solid (48%). MS (ESI): m/z = 550.102 [M+H]+.
Example 174 N-(2-Amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- b*'s(trifluoromethyl)isonicotinamide
Figure imgf000218_0001
The title compound was prepared in analogy to example 117, from {(2,6-bz'5- trifluoromethyl-pyridine-4-carbonyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Light yellow foam (63%). MS (ESI): m/z = 535.100 [M+H]+.
Intermediate
{(2,6-fi*s-trifluoromethyl-pyridine-4^
yll -amino I -acetic acid
The title compound was prepared in analogy to example 84, from {(2,6-bz'5- trifluoromethyl-pyridine-4-carbonyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid methyl ester (example 173). Light yellow solid (99%). MS (ESI): m/z = 536.085 [M+H]+. Example 175
N-r4-(2-Cvanomethyl-phenyl)-pyridin-3-yll-N-m
Figure imgf000219_0001
The title compound was prepared in analogy to example 90, from [2-(3-methylamino- pyridin-4-yl)-phenyl]-acetonitrile and 3,5-bzs(trifluoromethyl)benzoic acid (CAS RN 725-89-3) after a reaction time of 5 days. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) followed by a second chromatography, using preparative HPLC
(Phenomenex Gemini® column, gradient of methanol : water (10 : 90 to 95 : 5)). Colorless solid (3%). MS (ESI): m/z = 464.118 [M+H]+.
Intermediate r2-(3-Methylamino-pyridin-4-yl)-phenyll-acetonitrile
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 98, intermediate b) and [2-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2- yl)-phenyl]-acetonitrile (CAS RN 325141-71-7) after a reaction time of 6 days and using a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80) for the chromatographic purification. Light yellow solid (69%). MS (ESI): m/z = 224.118 [M+H]+.
Example 176
{(2,6-fi*s-trifluoromethyl-pyridine-4-caA
amino I -acetic acid methyl ester
Figure imgf000220_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-ylamino]-acetic acid methyl ester and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Colorless solid (46%). MS (ESI): m/z =
532.109 [M+H]+.
Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-ylaminol -acetic acid methyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3- ylamino)-acetic acid methyl ester and 4-fluoro-2-methoxyphenylboronic acid (CAS RN 179899- 07-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light yellow oil (73%). MS (ESI): m/z = 291.113 [M+H]+. b) (4-Iodo-pyridin-3-ylamino)-acetic acid methyl ester
The title compound was prepared in analogy to example 85, intermediate a, from [tert- butoxycarbonyl-(4-iodo-pyridin-3-yl)-amino] -acetic acid methyl ester. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (91%). MS (ESI): m/z = 292.980 [M+H]+. c) rfer?-Butoxycarbonyl-(4-iodo-pyridin-3-yl)-aminol-acetic acid methyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and bromo-acetic acid methyl ester (CAS RN 96-32-2) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown oil (96%). MS (ESI): m/z = 393.030 [M+H]+.
Example 177
N-Carbamoylmethyl-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-2,6-b¾' -trifluoromethyl- isonicotinamide
Figure imgf000221_0001
The title compound was prepared in analogy to example 117, from {(2,6-bz'5- trifluoromethyl-pyridine-4-carbonyl)-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic separation. Colorless solid (79%). MS (ESI): m/z = 517.110 [M+H]+. Intermediate
{(2,6-fi*s-trifluoromethyl-pyridine-4-c^
amino I -acetic acid
The title compound was prepared in analogy to example 84, from {(2,6-bz'5- trifluoromethyl-pyridine-4-carbonyl)-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid methyl ester (example 176). Light yellow solid (99%). MS (ESI): m/z = 518.094 [M+H]+. Example 178
Methyl 2-(3-(N,N-dimethylsulfamoyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-5- (trifluoromethyl)benzamido)acetate
Figure imgf000222_0001
The title compound was prepared in analogy to example 90, from (2-methoxy- [3,4']bipyridinyl-3'-ylamino)-acetic acid methyl ester and 3-dimethylsulfamoyl-5- trifluoromethyl-benzoic acid (Buttpark Ltd.) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). The product-containing fractions were pooled and evaporated and the residue poured on 30 mL IM aqueous HCl and 30 mL EtOAc. The layers were separated and the aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed twice with 30 mL IM aqueous HCl followed by 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. Light yellow solid (30%). MS (ESI): m/z = 553.135 [M+H]+.
Intermediates
(2-Methoxy-r3,4'lbipyridinyl-3'-ylamino)-acetic acid methyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3- ylamino)-acetic acid methyl ester (example 176, intermediate b) and 2-methoxypyridine-3- boronic acid (CAS RN 163105-90-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 100) for the chromatographic purification. Light yellow oil (73%). MS (ESI): m/z = 274.119 [M+H]+. Example 179
N-Carbamoylmethyl-3 -dimethyl
trifluoromethyl-benzamide
Figure imgf000223_0001
The title compound was prepared in analogy to example 117, from [(3-dimethylsulfamoyl-
5-trifluoromethyl-benzoyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amino]-acetic acid (0.35 mol% NEt3) and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Colorless solid (81%). MS (ESI): m/z = 537.107 [M- H]-. Intermediate
r(3-Dimethylsulfamoyl-5-trifluoromem^
acetic acid, triethylamine salt (1 : 0.35)
The title compound was prepared in analogy to example 84, from methyl 2-(3-(N,N- dimethylsulfamoyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-5-(trifluoromethyl)benzamido)acetate. The compound was purified by preparative HPLC (Gemini NX column) with a gradient of methanol : water containing 0.1% NEt3 (80 : 20 to 98 : 2). Colorless solid (75%). MS (ESI): m/z = 537.107 [M-H]~. Example 180 r(3-Methanesulfonyl-5-trifluoromem^
acetic acid methyl ester
Figure imgf000224_0001
The title compound was prepared in analogy to example 90, from (2-methoxy-
[3,4']bipyridinyl-3'-ylamino)-acetic acid methyl ester (example 178, intermediate) and 3- methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). The product-containing fractions were pooled and evaporated. The remaining solid was purified by preparative HPLC (Gemini NX column) with a gradient of methanol : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Light yellow foam (32%). MS (ESI): m/z = 524.108 [M+H]+.
Example 181 N-Carbamoylmethyl-3-methanesulfonyl-N-(2-methoxy-r3^'lbipyridinyl-3'-yl)-5- trifluoromethyl-benzamide
Figure imgf000224_0002
The title compound was prepared in analogy to example 117, from [(3-methanesulfonyl-5- trifluoromethyl-benzoyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amino]-acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Colorless solid (72%). MS (ESI): m/z = 509.109 [M+H]+.
Intermediate r(3-Methanesulfonyl-5-trifluoromethyl-benzoyl)-(2-methoxy-r3,4'lbipyridinyl-3'-yl)-aminol- acetic acid
The title compound was prepared in analogy to example 84, from [(3-methanesulfonyl-5- trifluoromethyl-benzoyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amino]-acetic acid methyl ester.
Colorless solid (76%). MS (ESI): m/z = 510.092 [M+H]+.
Example 182 Methyl 2-(N-(2-methoxy-3^'-bipyridin-3'-yl)-2,6-b¾ (trifluoromethyl)isonicotinamido)acetate
Figure imgf000225_0001
The title compound was prepared in analogy to example 90, from (2-methoxy- [3,4']bipyridinyl-3'-ylamino)-acetic acid methyl ester (example 178, intermediate) and 2,6- bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 48 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Light yellow solid (55%). MS (ESI): m/z = 515.114 [M+H]+.
Example 183
N-(2-Amino-2-oxoethyl)-N-(2-methoxy-3^
isonicotinamide
Figure imgf000226_0001
The title compound was prepared in analogy to example 117, from [(2,6-bis- trifluoromethyl-pyridine-4-carbonyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amino]-acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Light yellow foam (80%). MS (ESI): m/z = 500.114 [M+H]+.
Intermediate
r(2,6-fi¾s-trifluoromethyl-pyridine-4-car^
acid
The title compound was prepared in analogy to example 84, from methyl 2-(N-(2-methoxy- 3,4'-bipyridin-3'-yl)-2,6-bz5(trifluoromethyl)isonicotinamido)acetate (example 182). Light yellow foam (99%). MS (ESI): m/z = 501.099 [M+H]+. Example 184
N-Methyl-3-nitro-N-(4-o-tolylpyridin-3-yl)-5-(trifluoromethyl)benzamide
Figure imgf000226_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-nitro-5-trifluoromethyl-benzoic acid (CAS RN 328-80-3) after a reaction time of 48 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 80). The product-containing fractions were pooled and concentrated under vacuum. The residue was dissolved in 30 mL 1M aqueous HCl and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed twice with 30 mL 1M aqueous HCl and with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. Light yellow solid (66%) MS (ESI): m/z = 416.121 [M+H]+.
Example 185
N-Methyl-3-(2-oxo-pyrrolidin- l-yl)-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000227_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 3-(2-oxo-pyrrolidin- l-yl)-5- trifluoromethyl-benzoic acid (Selena Chemicals Inc.) after a reaction time of 120 hours. The product was purified by preparative HPLC (Phenomenex Gemini® column) with a gradient of acetonitrile : water (containing 0.05% formic acid) (10: 90 to 98 : 2). Light brown solid (2%). MS (ESI): m/z = 454.17 [M+H]+.
Example 186 rr4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- aminol -acetic acid methyl ester
Figure imgf000227_0002
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-ylamino]-acetic acid methyl ester (example 176, intermediate a) and 3- methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a). The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product-containing fractions were pooled and evaporated. The residue was dissolved in 30 mL 1M aqueous HCl and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed twice with 30 mL 1M aqueous HCl and with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The remaining light yellow solid was purified by preparative HPLC (Gemini NX column) with a gradient of methanol : water with 0.05% formic acid (80 : 20 to 98 : 2). Colorless solid (20%). MS (ESI): m/z = 504.104 [M+H]+.
Example 187
N-Carbamoylmethyl-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-5- trifluoromethyl-benzamide
Figure imgf000228_0001
The title compound was prepared in analogy to example 117, from [[4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Colorless solid (77%). MS (ESI): m/z = 526.104 [M+H]+. Intermediate rr4-(4-Fluoro-2-methoxy-phenyl)-p
aminol -acetic acid
The title compound was prepared in analogy to example 84, from [[4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid methyl ester (example 186). Colorless solid (100%). MS (ESI): m/z = 527.089 [M+H]+.
Example 188
| (3,5-fi¾ -trifluoromethyl-benzoyl)-r4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yll-amino|- acetic acid methyl ester
Figure imgf000229_0001
The title compound was prepared in analogy to example 90, from [4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-ylamino]-acetic acid methyl ester (example 172, intermediate a) and 3,5-bzs(trifluoromethyl)benzoic acid (CAS RN 725-89-3) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product-containing fractions were pooled and evaporated and the residue purified by preparative HPLC (Gemini NX column) using a gradient of methanol : water with 0.05% formic acid (80 : 20 to 98 : 2). Colorless solid (10%). MS (ESI): m/z = 549.105 [M+H]+. Example 189
Figure imgf000230_0001
The title compound was prepared in analogy to example 117, from { (3,5-bis- trifluoromethyl-benzoyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}-acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Colorless solid (100%). MS (ESI): m/z = 534.105 [M+H]+.
Intermediate
| (3,5-fi¾ -trifluoromethyl-benzoyl)-r4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yll-amino|- acetic acid
The title compound was prepared in analogy to example 84, from { (3,5-bis- trifluoromethyl-benzoyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester (example 188). Light yellow solid (98%). MS (ESI): m/z = 535.089 [M+H]+.
Example 190
Figure imgf000230_0002
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 4,6-bzs(trifluoromethyl)-2- pyridinecarboxylic acid (Bionet Research) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light brown oil (66%). MS (ESI): m/z = 440.12 [M+H]+.
Example 191 N-r4-(2-Fluoro-phenyl)-pyridin-3-yll-N-(2-methanesulfonyl-ethyl)-3,5-b¾ -trifluoromethyl- benzamide
Figure imgf000231_0001
The title compound was prepared in analogy to example 90, from [4-(2-fluoro-phenyl)- pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine (example 159, intermediate) and 3,5- bzs(trifluoromethyl)benzoic acid (CAS RN 725-89-3) after a reaction time of 40 hours. The compound was purified by two silica gel chromatographies using a 10 g column and 5 g column, respectively, on a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of ft-heptane : EtOAc (100 : 0 to 0 : 100). The resulting brown solid was suspended in ie/ -butyl methyl ether, filtered and washed with ieri-butyl methyl ether to give the title compound as an off-white solid (8%). MS (ESI): m/z = 535.09 [M+H]+.
Example 192
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-/V-(2-methanesulfonyl-ethyl)-3,5-b¾' - trifluoromethyl-benzamide
Figure imgf000231_0002
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine (example 162, intermediate) and 3,5- bzs(trifluoromethyl)benzoic acid (CAS RN 725-89-3) after a reaction time of 40 hours. The compound was purified by silica gel chromatography using a MPLC system (ISCO) and a 10 g and 5 g column, respectively, eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). A third chromatography, using preparative HPLC (Gemini NX column) eluting with a gradient of methanol : water (containing 0.05% formic acid) (20: 80 to 98 : 2), yielded the product as a colorless solid (4%). MS (ESI): m/z = 565.10 [M+H]+.
Example 193
N-(2-Amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-3-(methylsulfonyl)- 5-(trifluoromethvl)benzamide
Figure imgf000232_0001
The title compound was prepared in analogy to example 117, from [[4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid and using a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50) for the chromatographic purification. Colorless solid (78%). MS (ESI): m/z = 588.0868
[M+HCOO]".
Intermediate rr4-(4,5-Difluoro-2-methoxy-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl- benzovlVaminol -acetic acid, triethvlamine salt (1 : 0.4)
The title compound was prepared in analogy to example 84, from [[4-(4,5-difluoro-2- methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid methyl ester (example 172). The compound was purified by preparative HPLC (Gemini NX column) using a gradient of methanol : water with 0.1% NEt3 (80 : 20 to 98 : 2). Colorless solid (53%). MS (ESI): m/z = 545.079 [M+H]+. Example 194
2-Methanesulfonyl-N-methyl-N-(4-o-to
Figure imgf000233_0001
The title compound was prepared in analogy to example 90, from N-methyl-4-o- tolylpyridin-3-amine (example 1, intermediate a) and 2-methanesulfonyl-6-trifluoromethyl- isonicotinic acid after a reaction time of 22 hours. The compound was purified by silica gel chromatography on a 50 g column using a MPLC (ISCO) system eluting with EtOAc as an eluant. The product-containing fractions were pooled, evaporated and the remaining light brown foam purified by preparative HPLC (Gemini NX column) using a gradient of methanole : water
(containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (40%). MS (ESI): m/z = 450 [M+H]+.
Intermediates a) 2-Methanesulfonyl-6-trifluoromethyl-isonicotinic acid
To an ice-cold suspension of oxone (525 mg, 854 μιηοΐ, CAS RN 10058-23-8) in methanol (0.6 mL) and water (0.6 mL) was added dropwise a solution of 2-methylsulfanyl-6- trifluoromethyl-isonicotinic acid (0.09 g, 341 μιηοΐ) in methanol (1.2 mL) and the reaction mixture was stirred in an ice-bath for 2 hours. After stirring at room temperature for another 4.5 hours the reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc and the organic layers were washed with water, 10% aqueous Na2S203 solution and brine, dried over MgS04, filtered, and evaporated. Colorless solid (0.106 g; 98%). MS (ESI): m/z = 267.99 [M-H]~. This material was used in the next step without further purification. b) 2-Methylsulfanyl-6-trifluoromethyl-isonicotinic acid spension of 2-chloro-6-(trifluoromethyl)isonicotinic acid (0.1 g, 443 μιηοΐ, prepared according to F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2004, 18, 3793-3798) in THF (5 mL) was added sodium thiomethoxide (155 mg, 2.22 mmol, CAS RN 50615-16-2) and the reaction mixture was heated to 70 °C (oil bath temperature) for 15 hours. After cooling down to room temperature, EtOAc (5 mL) and 1M aqueous HC1 (2 mL) were added and the reaction mixture was stirred at room temperature for 30 min. The layers were separated and the aqueous layer was extracted with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered and evaporated to give the desired compound as an off-white solid (0.105 g; 99%) which was used in the next step without further purification. MS (ESI): m/z = 236.01 [M-H]~.
Example 195
Methyl 2-(N-(4-(2-fluoro-6-methoxyphenyl)pyridin-3-yl)-2,6-b¾' (trifluoromethyl)
isonicotinamido)acetate
Figure imgf000234_0001
The title compound was prepared in analogy to example 90, from [4-(2-fluoro-6-methoxy- phenyl)-pyridin-3-ylamino]-acetic acid methyl ester and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Light yellow solid (48%). MS (ESI): m/z = 532.109 [M+H]+.
Intermediate r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-ylaminol-acetic acid methyl ester
The title compound was prepared in analogy to example 72, from 4-iodo-pyridin-3- ylamino)-acetic acid methyl ester (example 176, intermediate b) and 2-fluoro-6- methoxyphenylboronic acid (CAS RN 78495-63-3) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light yellow oil (34%). MS (GC_MS (TIC): m/z = 290.1 [M+\|. Example 196 Methyl 2-(N-(4-(2-fluorophenyl)pyridin-3-yl)-^^
Figure imgf000235_0001
The title compound was prepared in analogy to example 90, from [4-(2-fluoro-phenyl)- pyridin-3-ylamino]-acetic acid methyl ester and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 72 hours. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Light yellow solid (39%). MS (ESI): m/z = 502.099 [M+H]+.
Intermediate r4-(2-Fluoro-phenyl)-pyridin-3-ylaminol-acetic acid methyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3- ylamino)-acetic acid methyl ester (example 176, intermediate b) and 2-fluorophenylboronic acid (CAS RN 1193-03-9) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Off-white solid (37%). MS (ESI): m/z = 261.104 [M+H]+.
Example 197
N-Carbamoylmethyl-N-r4-(2-fluoro-phenyl)-pyridin-3-yll-2,6-b¾' -trifluoromethyl- isonicotinamide
Figure imgf000235_0002
The title compound was prepared in analogy to example 117, from {(2,6-bz'5- trinuoromethyl-pyridine-4-carbonyl)-[4-(2-fluoro-phenyl)-pyridin-3-yl]-amino}-acetic acid. The compound was purified by silica gel chromatography using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50). Light yellow solid (74%). MS (ESI): m/z = 487.099 [M+H]+.
Intermediate
| (2,6-Bis-trifluoromethyl-pyridine-4-carbonyl)-r4-(2-fluoro-phenyl)-pyridin-3-yll-amino|-acetic acid
The title compound was prepared in analogy to example 72, from { (2,6-bis- trifluoromethyl-pyridine-4-carbonyl)-[4-(2-fluoro-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester (example 196). White solid (89%). MS (ESI): m/z = 488.083 [M+H]+.
Example 198
2-Chloro-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-6-methoxy-N-methyl-isonicotinamide
Figure imgf000236_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate) and 2-chloro-6-methoxy- isonicotinic acid (CAS RN 15855-06-8). Colorless solid (21%). MS (ESI): m/z = 402.10 [M+H]+.
Example 199
N-Carbamoylmethyl-N-r4-(2-fluoro^
isonicotinamide
Figure imgf000237_0001
The title compound was prepared in analogy to example 117, from {(2,6-bz'5- trifluoromethyl-pyridine-4-carbonyl)-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid. The compound was purified by silica gel chromatography using an MPLC system (Flashmaster) eluting with a gradient of n-heptane : EtOAc : methanol (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50). Light yellow solid (78%). MS (ESI): m/z = 517.109 [M+H]+. Intermediate j(2,6-fi¾s-trifluoromethyl-pyridine-4-ca^
amino I -acetic acid
The title compound was prepared in analogy to example 84, from {(2,6-bz'5- trifluoromethyl-pyridine-4-carbonyl)-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-amino}- acetic acid methyl ester (example 195). White solid (99%). MS (ESI): m/z = 518.094 [M+H]+.
Example 200
N-Qxetan-3-yl-N-(4-o-tolyl-pyridin-3-yl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000237_0002
The title compound was prepared in analogy to example 72, intermediate, from oxetan-3- yl-(4-o-tolyl-pyridin-3-yl)-amine and 3,5-bzs(trifluoromethyl)benzoyl chloride (CAS RN 1271- 19-8) and using a gradient of gradient of n-heptane : EtOAc (100 : 0 to 30 : 70) for the chromatographic purification. Light yellow solid (34%). MS (ESI): m/z = 481.13 [M+H]+.
Intermediates a) Oxetan-3-yl-(4-o-tolyl-pyridin-3-yl)-amine A solution of 4-o-tolylpyridin-3-amine (0.125 g, 678 μιηοΐ) and oxetan-3-one (147 mg,
2.04 mmol, CAS RN 6704-31-0) in methanol (2 mL) was treated with zinc chloride (370 mg, 2.71 mmol). The reaction mixture got slightly warm and a solution formed. Then, molecular sieves 4A (100 mg, 678 μιηοΐ) were added and the reaction mixture refluxed for 19 hours. After cooling to room temperature another batch of oxetan-3-one (147 mg, 2.04 mmol) was added and the reaction mixture was heated again to reflux for another 24 hours before zinc chloride (185 mg, 1.36 mmol) was added. After stirring for another 2 hours sodium cyanoborohydride (128 mg, 2.04 mmol, CAS RN 25895-60-7) was added and the reaction mixture was stirred at reflux for 2 hours. After stirring at room temperature overnight, the reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the mixture was filtered over dicalite. The layers were separated and the aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified twice by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Off-white foam (0.072 g; 42%). MS (ESI): m/z = 241.13 [M+H]+. b) 4-o-Tolylpyridin-3-amine
The title compound was prepared in analogy to example 85, intermediate a, from (4-o-tolyl- pyridin-3-yl)-carbamic acid tert-butyl ester. Brown solid (100%). MS (ESI): m/z = 185.1
[M+H]+. a) (4-o-Tolyl-pyridin-3-yl)-carbamic acid tert-butyl ester The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- carbamic acid tert-butyl ester (example 85, intermediate d) and 2-methylphenylboronic acid (CAS RN 16419-60-6) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Light brown solid (94%). MS (ESI): m/z = 285.16 [M+H]+. Example 201
N-r6-Chloro-4-(4-nuoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl- trifluoromethyl-benzamide
Figure imgf000239_0001
The title compound was prepared in analogy to Example 90, from [6-chloro-4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-yl]-methyl-amine and 3-methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 17 hours. The compound was purified by silica gel chromatography using an MPLC (ISCO) system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50). The volatiles were evaporated until a precipitate formed. The suspension was filtered and the filter cake was washed three times with a small amount of a mixture of EtOAc : n-heptane (1 : 4) to give the title compound as a colorless solid (61%). MS (ESI): m/z = 517.06 [M+H]+.
Intermediates a) r6-Chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (6-chloro-4-iodo-pyridin- 3-yl)-methyl-amine (prepared according to WO2006013050) and 4-fluoro-2- methoxyphenylboronic acid (CAS RN 179899-07-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Off-white solid (81%). MS (ESI): m/z = 267.07 [M+H]+. Example 202
N-r4-(4-Fluoro-2-methoxy-phenyl)-6-m
trifluoromethyl-benzamide
Figure imgf000240_0001
To a solution of N-(6-chloro-4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3-
(methylsulfonyl)-5-(trifluoromethyl)benzamide (0.1 g, 0.193 mmol, example 201) in THF (2 mL) were added methylzinc chloride (0.145 mL, 0.29 mmol, 2M solution in THF, CAS RN 5158-46- 3), l,3-dimethyl-2-imidazolidinone (0.4 mL, CAS RN 80-73-9) and (l,3-Ws(2,6-diisopropyl- phenyl)imidazolidene) (3-chloropyridyl) palladium(II) dichloride (PEPPSI-IPr, 2.63 mg, 3.87 μιηοΐ, Aldrich). The reaction mixture was stirred at 50 °C for 30 min. and then poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100), followed by a second chromatography, using preparative HPLC
(Gemini NX column) eluting with a gradient of methanol : water (containing 0.1% formic acid) (20 : 80 to 98 : 2). Colorless solid (0.073 g; 76%). MS (ESI): m/z = 497.11 [M+H]+.
Example 203
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-(2-oxo-butyl)-2,6-bis-trifluoromethyl- isonicotinamide
Figure imgf000240_0002
The title compound was prepared in analogy to example 90, from l-[4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-ylamino]-butan-2-one and 2,6-bzs(trifluoromethyl)isonicotinic acid (Key Organics Ltd.) after a reaction time of 24 hours. The compound was purified by silica gel chromatography on a 5 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100), followed by a second chromatography using preparative HPLC (Gemini NX column) and a gradient of methanol : water (with 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (10%). MS (ESI): m/z = 530.130 [M+H]+.
Intermediates a) 1 - r4-(4-Fluoro-2-methoxy-phenyl)-p yridin-3 - ylaminol -butan-2-one
The title compound was prepared in analogy to Example 72, from l-(4-iodo-pyridin-3- ylamino)-butan-2-one and 4-fluoro-2-methoxyphenylboronic acid (CAS RN 179899-07-1) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Yellow oil (43%). MS (ESI): m/z = 289.134 [M+H]+. b) l-(4-Iodo-pyridin-3-ylamino)-butan-2-one
The title compound was prepared in analogy to Example 85, intermediate a, from (4-iodo- pyridin-3-yl)-(2-oxo-butyl)-carbamic acid ieri-butyl ester. The compound was purified by silica gel chromatography on a 50 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (95%). MS (ESI): m/z = 290.999 [M+H]+. c) (4-Iodo-pyridin-3-yl)-(2-oxo-butyl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to Example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid tert-butyl ester (example 85, intermediate d) and l-bromo-butan-2- one (CAS RN 816-40-0) and using a gradient of n-heptane : EtOAc (100 : 0 to 40 : 60) for the chromatographic purification. Light brown solid (85%). MS (ESI): m/z = 391.051 [M+H]+. Example 204
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2-oxo-butyl)-5- trifluoromethvl-benzamide
Figure imgf000242_0001
The title compound was prepared in analogy to Example 90, from l-[4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-ylamino]-butan-2-one (example 203, intermediate a) and 3- methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 24 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100), followed by a second chromatography using preparative HPLC
(Gemini NX column) and a gradient of methanol : water (with 0.05% formic acid) (80 : 20 to 98 2). Light red foam (13%). MS (ESI): m/z = 539.126 [M+H]+.
Example 205
N-r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000242_0002
The title compound was prepared in analogy to Example 90, from [4-(2-fluoro-6-methoxy- phenyl)-pyridin-3-yl]-methyl-amine and 3-methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 18 hours. The residue was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). White solid (58%). MS (ESI): m/z = 483.100 [M+H]+.
Intermediate r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-methyl-amine The title compound was prepared in analogy to Example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 2-fluoro-6-methoxyphenylboronic acid (CAS RN 78495-63-3) and using a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) for the chromatographic purification. Light yellow oil (65%). MS (ESI): m/z = 233.109 [M+H]+.
Example 206 N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-2-methoxy-N-methyl-6-trifluoromethyl- isonicotinamide
Figure imgf000243_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate) and 2-methoxy-6- trifluoromethyl-isonicotinic acid after a reaction time of 64 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of ft-heptane : EtOAc (100 : 0 to 0 : 100), followed by a second chromatography using preparative HPLC (Gemini NX column) and a gradient of methanol : water (containing 0.1% formic acid) (20: 80 to 98 : 2) as eluant. Colorless solid (33%). MS (ESI): m/z = 436.13 [M+H]+. Intermediate
2-Methoxy-6-trifluoromethyl-isonicotinic acid
To a solution of 2-chloro-6-(trifluoromethyl)isonicotinic acid (0.15 g, 665 μιηοΐ, prepared according to F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2004, 18, 3793-3798) in methanol (2 mL) sodium methoxide (79.0 mg, 1.46 mmol) was added and the reaction refluxed for 5 hours. Another 287 mg (5.32 mmol) sodium methoxide was added and the white suspension was stirred at reflux temperature overnight. After 23 hours the suspension was allowed to cool to room temperature and was poured on saturated 1M HC1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered and evaporated to give the desired compound as a colorless solid (0.133 g; 90%). MS (ESI): m/z = 220.02 [M-H]~. Example 207
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-(3-methyl-oxetan-3-ylmethyl)-2,6-fa' - trifluoromethyl-isonicotinamide
Figure imgf000244_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(3-methyl-oxetan-3-ylmethyl)-amine and 2,6-bzs(trifluoromethyl) isonicotinic acid (Key Organics Ltd.) after a reaction time of 16 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) followed by a second chromatography using preparative HPLC (Gemini NX column) and a gradient of methanol : water (containing 0.1 % formic acid) (20 : 80 to 98 : 2) as eluant. Colorless solid (12%). MS (ESI): m/z = 544.15 [M+H]+.
Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(3-methyl-oxetan-3-ylmethyl)-amine
A solution of ie/ -butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((3-methyloxetan-3- yl)methyl)carbamate (0.3 g, 745 μιηοΐ) in 2,2,2-trifluorethanol (3.0 mL) was stirred in a microwave oven at 150 °C for 2 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) to give the desired compound as a light brown oil (0.111 g; 49%). MS (ESI): m/z = 303.1 [M+H]+. b) fe/ -Butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((3-methyloxetan-3-yl)methyl)carbamate
To a solution of (4-iodo-pyridin-3-yl)-(3-methyl-oxetan-3-ylmethyl)-carbamic acid tert- butyl ester (0.878 g, 2.17 mmol) in DME (10 niL) under argon 4-fluoro-2- methoxyphenylboronic acid (424 mg, 2.5 mmol, CAS RN 179899-07-1) and 2M aqueous Na2C03 solution (2.77 mL, 5.54 mmol) were added. After stirring for 30 min. at room
temperature, palladium(II) acetate (24.4 mg, 0.109 mmol, CAS RN 3375-31-3) and
triphenylphosphine polymer bound (73.0 mg, 0.217 mmol, CAS RN 39319-11-4) were added and the reaction was stirred at reflux (90 °C oil bath temperature) for 22 hours. Another 4-fluoro- 2-methoxyphenylboronic acid (111 mg, 0.652 mmol) was added and reaction mixture was refluxed for another 4 hours before another 4-fluoro-2-methoxyphenylboronic acid (111 mg, 0.652 mmol) was added. After stirring at reflux temperature for 18 hours the reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of ft-heptane : EtOAc (100 : 0 to 0 : 100) to give the title compounds as a light brown oil (0.784 g; 89%). MS (ESI): m/z = 403.20 [M+H]+.
(4-Iodo-pyridin-3-yl)-(3-methyl-oxetan-3-ylmethyl)-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid tert-butyl ester (example 85, intermediate d) and 3-chloromethyl-3- methyl-oxetane (CAS RN8 22-48-0). After stirring at room temperature for 18 hours another NaH (75.0 mg, 1.72 mmol) and 3-(chloromethyl)-3-methyloxetane (207 mg, 1.72 mmol) were added and stirring was continued at 60 °C for 64 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with water and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 50 : 50) to furnish the desired compound as an off- white solid (0.888 g; 70%). MS (ESI): m/z = 405.07 [M+H]+. Example 208
N-Methyl-3,5-to-trifluorometh^
benzamide
Figure imgf000246_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 1,3,5- trimethyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrazole (CAS RN 844891-04-9) and using DMF as reaction solvent. Pale yellow sticky liquid (11%). MS (ESI): m/z = 457.6 [M+H]+.
Example 209
N-r4-(2^-Dimethyl-thiazol-5-yl)-pyridin-3-yll-N-methyl-3,5-b¾ -trifluoromethyl-benzamide
Figure imgf000246_0002
A mixture of N-(4-bromo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (200 mg, 0.468 mmol, example 25, intermediate a), 2,4-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-l,3-thiazole (107.4 mg, 0.7 mmol, CAS RN 859833-13-9) and K2C03 (193.75 mg, 1.4 mmol) in DMF (6 mL), taken in a sealed tube, was degassed well for 30 min with argon. To this mixture was added S-PHOS (50.1 mg, 0.25 mmol, CAS RN 657408-07-6) and Pd(PPh3)4 (54 mg, 0.05 mmol), and degassed again for 15 min. The reaction mixture was heated to 80 °C for 30 min irradiated with microwave. After the completion of reaction, it was cooled to room temperature, filtered through a bed of celite and the residue washed with EtOAc (50 mL). Volatilities were removed in vacuo and the resultant residue was diluted with water (30 mL) and extracted with EtOAc (2x50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2S04, filtered, and evaporated. The crude residue was purified by column chromatography over silica gel (30-40% EtOAc in n-hexane) to afford the title compound as a pale yellow solid (15 mg, 7%). MS (ESI): m/z = 460.1 [M+H]+.
Example 210
N-r4-(3,5-Dimethyl-isoxazol-4-yl)-pyridin-3-yll-N-methyl-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000247_0001
The title compound was prepared in analogy to example 25, from N-(4-bromo-pyridin-3- yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (example 25, intermediate a) and 3,5- dimethylisoxazole-4-boronic acid (CAS RN 16114-47-9) and using DMF as reaction solvent. Light brown solid (20%). MS (ESI): m/z = 444.0 [M+H]+.
Example 211
N-Methyl-N-r4-(4-methyl-2H-pyrazol-3-yl)-^^
Figure imgf000247_0002
To a solution of N-[4-(2-benzyloxymethyl-4-methyl-2H-pyrazol-3-yl)-pyridin-3-yl]-N- methyl-3,5-bz5-trifluoromethyl-benzamide (70 mg, 128 μιηοΐ) in TFA (3 mL) was added CH2CI2 (300 μί). The reaction mixture was stirred at 80 °C for 2 hours and then concentrated in vacuum. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL
EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (20 mg, 37%). MS (ESI): m/z = 429.114 [M+H]+. Intermediates a) N-r4-(2-Benzyloxymethyl-4-mem^
trifluoromethyl-benzamide
To a solution of N-(4-iodo-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide (138 mg, 422 μηιοΐ, example 98, intermediate a) in THF (4 mL) was added isopropylmagnesium chloride (2M solution in THF, 211 μί, 422 μιηοΐ) dropwise at -40 °C. The reaction mixture was stirred at -40 °C for 20 minutes. Freshly prepared ZnCl2 (1M solution in THF, 1.69 mL, 1.69 mmol) was added dropwise at -40 °C. The cooling bath was removed and the reaction mixture was stirred at room temperature for 90 minutes. A solution of l-benzyloxymethyl-5-iodo-4- methyl- lH-pyrazole (200 mg, 422 μπιοΐ) in THF (4 mL) and
ieirafe'5(triphenylphosphine)palladium(0) (24.4 mg, 21.1 μιηοΐ) was added. The reaction mixture was stirred at reflux for 18 hours and then was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel
chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light yellow foam (79 mg, 34%). MS (ESI): m/z = 549.170 [M+H]+.
1M ZnCl2 solution in THF was prepared by melting solid ZnCl2 under high vacuum by heating with a heatgun. The flask was allowed to cool down to room temperature and then ventilated with argon. The dry ZnCl2 was then dissolved under argon with the required amount of THF. b) l-Benzyloxymethyl-5-iodo-4-methyl- lH-pyrazole
To a solution of 5-iodo-4-methyl- lH-pyrazole (0.5 g, 2.4 mmol, CAS RN 24086-18-8) in CH2C12 (5 mL) was added N,N-diisopropylethylamine (342 mg, 450 μί, 2.64 mmol) and benzyl chloromethyl ether (460 mg, 407 μΐ,, 2.64 mmol, CAS RN 3587-60-8) at 0 °C. The reaction mixture was stirred at room temperature for 30 minutes and then poured on 30 mL 10% aqueous NaHC03 solution and 30 mL CH2C12. The layers were separated and the aqueous layer was extracted a second time with 30 mL CH2C12. The organic layers were washed with 30 mL brine, dried with MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 70 : 30). Colorless oil (610 mg, 77%). MS (ESI): m/z = 329.014 [M+H]+. Example 212
N-r2-Chloro-4-(4-nuoro-2-methoxy-phen
trifluoromethyl-benzamide
Figure imgf000249_0001
The title compound was prepared in analogy to example 90, from [2-chloro-4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-yl]-methyl-amine and 3-methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 66 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50), followed by a second chromatography using preparative HPLC (Gemini NX column) eluting with a gradient of methanol : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (30%). MS (ESI): m/z = 517.06 [M+H]+.
Intermediates a) r2-Chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (2-chloro-4-iodo-pyridin- 3-yl)-methyl-amine and 4-fluoro-2-methoxyphenylboronic acid (CAS RN 179899-07-1). The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 60 : 40). Light yellow solid (78%). MS (ESI): m/z = 267.07 [M+H]+. b) (2-Chloro-4-iodo-pyridin-3-yl)-methyl-amine
To an ice-cold solution of (2-chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid ieri-butyl ester (0.97 g, 2.63 mmol) in CH2C12 (5 mL) was added TFA (6.00 g, 4.05 mL, 52.6 mmol) and the solution was stirred at room temperature for 1.5 hours before another TFA (6.00 g, 4.05 mL, 52.6 mmol) was added. After stirring at room temperature for 3 hours the clear solution was evaporated. The residue was taken up in saturated aqueous NaHC03 solution (50 mL) and CH2C12 (30 mL) and the layers were separated. The aqueous layer was extracted twice with CH2C12 (30 mL each) and the organic layers were washed with brine, dried over MgS04, filtered and evaporated. Colorless oil (0.61 g; 86%). MS (ESI): m/z = 268.93 [M+H]+. c) (2-Chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid fe/ -butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (2-chloro- 4-iodo-pyridin-3-yl)-carbamic acid ie/ -butyl ester (CAS RN 855784-39-3) and methyl iodide and using a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50) for the chromatographic purification. Colorless solid (88%). MS (ESI): m/z = 368.99 [M+H]+.
Example 213 rr4-(2-Fluoro-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-aminol- acetic acid methyl ester
Figure imgf000250_0001
To a solution of methyl 2-(4-(2-fluorophenyl)pyridin-3-ylamino)acetate (272 mg, 1.05 mmol; example 196, intermediate) in CH2CI2 (3 mL) was added 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (280 mg, 1.05 mmol, example 114, intermediate a) and 2-bromo-l- ethylpyridinium tetrafluoroborate (343 mg, 1.25 mmol) and N,N-diisopropylethylamine (270 mg, 365 μί, 2.09 mmol). The reaction mixture was stirred at room temperature for 22 hours and then concentrated under vacuum. The residue was dissolved in 30 mL 1M aqueous HC1 and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL 1M aqueous HC1 and 30 mL 10% aqueous NaHC03 and 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography on a 20 g column using an MPLC
(Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (323 mg, 61%). MS (ESI): m/z = 511.094 [M+H]+. Example 214
N-r4-(2-Fluoro-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2,2,2-trinuoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000251_0001
To a solution of 4-(2-fluorophenyl)-N-(2,2,2-trifluoroethyl)pyridin-3-amine (79 mg, 292 μιηοΐ, example 151, intermediate) in CH2CI2 (2 mL) was added 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (78.4 mg, 292 μιηοΐ, example 114, intermediate) and 2-bromo- l- ethylpyridinium tetrafluoroborate (96.1 mg, 351 μιηοΐ) and N,N-diisopropylethylamine (75.6 mg, 102 μί, 585 μιηοΐ). The reaction mixture was stirred at room temperature for 23 hours. The reaction mixture was concentrated under vacuum. The residue was dissolved in 30 mL IN aqueous HCl and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL 1M aqueous HCl and 30mL 10% aqueous NaHC03 and 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography on a 10 g column using an MPLC (Flashmaster) system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (37 mg, 24%). MS (ESI): m z = 521.076 [M+H]+.
Example 215Error! Not a valid link.N-(2,2-Difluoro-ethyl)-N-r4-(2-fluoro-phenyl)-pyridin-3- yll-3-methanesulfonyl-5-trifluoromethyl-benzamide
Figure imgf000251_0002
To a solution of N-(2,2-difluoroethyl)-4-(2-fluorophenyl)pyridin-3-amine (112 mg, 444 μιηοΐ) in CH2CI2 (3 mL) was added 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (119 mg, 444 μιηοΐ, example 114, intermediate) and 2-bromo-l-ethylpyridinium tetrafluoroborate (146 mg, 533 μηιοΐ) and N,N-diisopropylethylamine (115 mg, 155 μί, 888 μmol). The reaction mixture was stirred at room temperature for 24 hours and then concentrated under vacuum. The residue was dissolevd in 30 mL 1M aqueous HCl and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL 1M aqueous HCl and 30 mL 10% aqueous NaHC03 solution and 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. Yellow solid (84 mg, 38%). MS (ESI): m/z = 503.085 [M+H]+.
Example 216Error! Not a valid link.N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-(2- hvdroxy-ethylsulfanyl)-N-methyl-5-trifluoromethyl-benzamide
Figure imgf000252_0001
A solution of N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-mercapto-5,N-dimethyl- benzamide (0.15 g, 344 μιηοΐ) in acetonitrile (4 mL) was treated with 2-bromoethanol (51.5 mg, 29.2 μί, 412 μιηοΐ) and DIPEA (88.8 mg, 120 μί, 687 μιηοΐ) and the clear solution was stirred at room temperature for 6 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.14 g; 84%). MS (ESI): m/z = 481.12 [M+H]+. Intermediates a) N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-mercapto-5,N-dimethyl -benzamide
To a solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3- (trifluoromethyl)-5-(2-(trimethylsilyl)ethylthio)benzamide (0.711 g, 1.32 mmol) in THF (12.6 mL) was added tetrabutylammonium fluoride (1M solution in THF, 6.96 mL, 6.96 mmol) and the clear light yellow solution was stirred at room temperature for 90 minutes. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system eluting with a gradient of CH2C12 : MeOH (100 : 0 to 90 : 10). Colorless solid (0.41 g; 63%). MS (ESI): m/z = 437.09 [M+H]+. b) N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3-(trifluoromethyl)-5-(2- (trimethylsilyl)ethylthio)benzamide
A solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (0.135 g, 279 μιηοΐ) and 2-(trimethylsilyl)ethanethiol (37.5 mg, 44.1 μί, 279 μιηοΐ) in dioxane (2 mL) was stirred under argon for 5 minutes in a sealed tube. To the clear light yellow solution were added tris(dibenzylideneacetone)dipalladium(0) (6.4 mg, 6.98 μιηοΐ, CAS RN 52409-22-0) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (8.08 mg, 14.0 μιηοΐ, CAS RN 161265-03-8) and DIPEA (72.2 mg, 97.6 μΐ,, 559 μιηοΐ) and the reaction mixture was stirred at 120 °C. After stirring for 4 hours in a sealed tube, heating was stopped. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueos layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (0.116 g; 77%). MS (ESI): m/z = 537.17 [M+H]+. c) 3-Bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5-(trifluoromethyl)- benzamide
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-bromo-5- (trifluoromethyl)benzoic acid after a reaction time of 22 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Off-white solid (68%). MS (ESI): m/z = 483.03 [M+H]+. Example 217
N-r4-(4-Fluoro-2-methoxy-phenyl)^
trifluoromethyl-benzamide
Figure imgf000254_0001
To an ice-cold solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-(2- methoxyethylthio)-N-rnethyl-5-(trifluoromethyl)benzamide (0.032 g, 64.7 μηιοΐ) in MeOH (4 niL) and water (0.5 niL) was added oxone® (99.5 mg, 162 μιηοΐ) and the reaction mixture was stirred at room temperature for 4.5 hours. The white suspension was poured on saturated aqueous NH4C1 solution and EtOAc. The two layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with aqueous sodium thiosulfate 10% solution and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 5 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (0.027 g; 79%). MS (ESI): m/z = 527.13 [M+H]+. Intermediate a) N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-(2-methoxyethylthio)-N-methyl-5- (trifluoromethyl)benzamide
A solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide (0.065 g, 149 μιηοΐ, example 216, intermediate a) in acetonitrile (2 mL) was treated with l-bromo-2-methoxyethane (24.8 mg, 16.8 μί, 179 μιηοΐ) and DIPEA (38.5 mg, 52.0 μί, 298 μιηοΐ) and stirred at room temperature for 5 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (0.04 g; 54%). MS (ESI): m/z = 495.14 [M+H]+. Example 218
N-r4-(4-Fluoro-2-methoxy-phenyl)-p
trifluoromethvl-benzamide
Figure imgf000255_0001
To an ice-cold solution of N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy- ethylsulfanyl)-N-methyl-5-trifluoromethyl-benzamide (0.1 g, 208 μηιοΐ, example 216) in MeOH (4 mL) and water (0.5 mL) was added oxone® (320 mg, 520 μιηοΐ) and the white suspension was stirred at room temperature for 3.25 hours. The white suspension was poured on saturated aqueous NH4C1 solution and EtOAc. The two layers were separated and the aqueous layer was extracted twice with EtOAc. The organic layers were washed once with aqueous sodium thiosulfate 10% solution and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 5 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.069 g; 64%). MS (ESI): m z = 513.11 [M+H]+.
Example 219
N-Carbamoylmethyl-N-r4-(2-fluoro-phenyl)-pyridin-3-yll-3-methanesulfonyl-5-trifluoromethy benzamide
Figure imgf000255_0002
The title compound was prepared in analogy to example 117, from 2-(N-(4-(2- fluorophenyl)pyridin-3-yl)-3-(methylsulfonyl)-5-(trifluoromethyl)benzamido)acetic acid after reaction time of 4 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc : MeOH (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50). Further purification by preparative HPLC
(Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2) furnished the desired compound a a colorless solid (67.5%). MS (ESI): m/z = 496.095 [M+H]+.
Intermediates a) 2-(N-(4-(2-fluorophenyl)pyridin-3-yl)-3-(methylsulfonyl)-5-(trifluoromethyl)benzamido)- acetic acid
The title compound was prepared in analogy to example 84 from [[4-(2-fluoro-phenyl)- pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid methyl ester. Yellow foam (103%). MS (ESI): m/z = 497.079 [M+H]+. b) rr4-(2-Fluoro-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-aminol- acetic acid methyl ester
The title compound was prepared in analogy to example 90, from [4-(2-fluoro-phenyl)- pyridin-3-ylamino]-acetic acid methyl ester (example 196, intermediate) and 3-methanesulfonyl- 5-trifluoromethyl-benzoic acid (280 mg, 1.05 mmol, example 114, intermediate a) after a reaction time of 22 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (323 mg, 61%). MS (ESI): m/z = 511.094 [M+H]+.
Example 220
N-(6-Ethyl-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bis-trifluoromethyl-benzamide
Figure imgf000256_0001
To a solution of N-(6-chloro-4-o-tolylpyridin-3-yl)-N-methyl-3,5-bis(trifluoromethyl)- benzamide (0.1 g, 212 μιηοΐ, example 12) in THF (1 mL) were added tetrakis(triphenyl- phosphine)palladium(O) (12.2 mg, 10.6 μιηοΐ) and diethylzinc (1M solution in n-hexane, 137 μί, 137 μιηοΐ) and the brown solution was stirred at reflux for 16 hours. The solvent was evaporated and the brown gum was diluted with 1M aqueous HC1 and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70). Light yellow solid (0.051 g; 51%). MS (ESI): m/z = 467.16 [M+H]+.
Example 221 N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-2-methanesulfonyl-N-methyl-6-trifluoro- methyl-isonicotinamide
Figure imgf000257_0001
A suspension of L-proline (15.7 mg, 136 μιηοΐ) in DMSO (2 mL) was treated with sodium hydride (5.46 mg, 136 μιηοΐ, 60% dispersion in mineral oil) and stirred at room temperature for 30 minutes. The suspension was added to a flask containing 2-chloro-N-(4-(4-fluoro-2- methoxyphenyl)pyridin-3-yl)-N-methyl-6-(trifluoromethyl)isonicotinamide (0.075 g, 171 μιηοΐ, example 169). Then sodium methanesulfinate (139 mg, 1.36 mmol) and copper (I) iodide (26.0 mg, 136 μιηοΐ) were added and the mixture was heated to 120 °C. After 1.5 hours the light blue and turbid solution was cooled down to room temperature and poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 25 : 75). Colorless solid (0.045 g; 54%). MS (ESI): m/z = 484.09 [M+H]+. Example 222
N-r4-(2-Amino-phenyl)-pyridin-3-yll-N-methyl-3,5-bis-trifluoromethyl-benzamide
Figure imgf000257_0002
The title compound was prepared in analogy to example 72, from N-(4-iodopyridin-3-yl)- N-methyl-3,5-bis(trifluoromethyl)benzamide (example 98, intermediate a) and 2-amino- phenylboronic acid after a reaction time of 4 hours. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Further purification by preparative HPLC (Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (19%). MS (ESI): m/z = 440.119 [M+H]+.
Example 223
N-r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000258_0001
The title compound was prepared in analogy to example 72, intermediate, from [4-(2- fluoro-6-methoxy-phenyl)-pyridin-3-yl]-(2,2,2-trifluoro-ethyl)-amine and 3-methanesulfonyl-5- trifluoromethyl-benzoyl chloride after a reaction time of 12 hours. The compound was purified by preparative HPLC (ammonium acetate/acetonitrile). Off-white solid (27%). MS (ESI): m/z = 551.1 [M+H]+.
Intermediates a) r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- (2,2,2-trifluoro-ethyl)-amine and 2-fluoro-6-methoxyphenylboronic acid after a reaction time of 18 hours. The compound was purified by silica gel column chromatography eluting with a gradient of n-hexane : EtOAc (20 : 80 to 0 : 100). Yellow liquid (62%). LC-MS (ESI): m/z = 301.6 [M+H]+. b) (4-Iodo-pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from 4-iodo- pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester. Yellow solid (95%). LC-MS (ESI): m/z = 303.0 [M+H]+. c) (4-Iodo-pyridin-3-yl)-(2,2,2-trifluoro-ethyl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid tert-butyl ester (example 85, intermediate d) and 2,2,2-trifluoroethyl trifluoromethanesulfonate after a reaction time of 24 hours. The compound was purified by silica gel column chromatography eluting with a gradient of n-hexane : EtOAc (70 : 30 to 60 : 40). Light yellow oil (67%). LC-MS (ESI): m/z = 403.0 [M+H]+. d) 3-Methanesulfonyl-5-trifluoromethyl-benzoyl chloride
To a solution of 3-methanesulfonyl-5-trifluoromethyl-benzoic acid (70 mg, 0.26 mmol) in toluene (5 mL) were added catalytic amount of DMF and SOCl2 (0.2 mL, 2.61 mmol) and the reaction mixture was heated to reflux for 6 hours. The solvent was evaporated and the resulting 3-methanesulfonyl-5-trifluoromethyl-benzoyl chloride (70 mg, crude) was used in the next step without further purification.
Example 224
3-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- benzenesulfonvD-propionic acid methyl ester
Figure imgf000259_0001
To a suspension of methyl 3-(3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)- carbamoyl)-5-(trifluoromethyl)phenylthio)propanoate (0.2 g, 383 μιηοΐ, Example 225) in MeOH (6 mL) and water (0.5 mL) at 0 °C was added oxone® (588 mg, 957 μιηοΐ) and the colorless mixture was stirred at room temperature for 1.75 hours. The white suspension was poured on saturated aqueous NH4C1 solution and EtOAc. The two layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with 10% aqueous sodium thiosulfate solution and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100).
Colorless foam (0.165 g; 77%). MS (ESI): m/z = 555.12 [M+H]+. Example 225
3-(3- j r4-(4-Fluoro-2-methoxy-phenyl)-p
phenylsulfanvP-propionic acid methyl ester
Figure imgf000260_0001
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide (0.2 g, 458 μιηοΐ, example 216, intermediate a) in acetonitrile (4 mL) were added DIPEA (118 mg, 160 μί, 917 μmol) and methyl 3-bromopropanoate (91.8 mg, 60.0 μί, 550 μιηοΐ) and the clear and colorless solution was stirred at room temperature for 2.25 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (0.178 g; 74%). MS (ESI): m/z = 523.13 [M+H]+.
Example 226 N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-hydroxy-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000260_0002
To a solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (0.1 g, 207 μιηοΐ, example 216, intermediate c) in THF (1 mL) was added triisopropyl borate (75.1 mg, 92.7 μί, 399 μιηοΐ) and a cooling bath was installed. At -75 °C ft-butyllithium in (1.6 M solution in n-hexane, 136 μί, 217 μιηοΐ) was added dropwise and the brown mixture was stirred at -75 °C for 2 hours. To this mixture at 0 °C, a solution of acetic acid (52.7 mg, 50.2 μί, 877 μιηοΐ) in water (0.05 mL) was added, followed by addition of hydrogen peroxide (35% solution in water, 30.2 mg, 27.2 μί, 310 μιηοΐ). The reaction mixture was stirred at 0 °C for 1.25 hours, then poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered and evaporated. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water
(containing 0.1 % formic acid) (20: 80 to 98 : 2). Colorless solid (0.020 g; 23%). MS (ESI): m/z = 421.12 [M+H]+.
Example 227 3-Chloro-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5-trifluoromethoxy- benzamide
Figure imgf000261_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-chloro-5- (trifluoromethoxy)benzoic acid (228 mg, 947 μιηοΐ, CAS RN 433926-46-6) after a reaction time of 19.5 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (47%). MS (ESI): m/z = 455.08 [M+H]+.
Example 228 N-Cyanomethyl-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-5- trifluoromethyl-benzamide
Figure imgf000261_0002
The title compound was prepared in analogy to example 90, from 2-(4-(4-fluoro-2- methoxyphenyl)pyridin-3-ylamino)acetonitrile and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (51%). MS (ESI): m/z = 508.096 [M+H]+.
Intermediate a) 2-(4-(4-Fluoro-2-methoxyphenyl)pyridin-3-ylamino)acetonitrile
The title compound wa prepared in analogy to example 85, intermediate a, from tert-butyl cyanomethyl(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)carbamate (example 161, intermediate c) after a reaction time of 4 hours at room temperature. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (37%). MS (ESI): m/z = 258.105 [M+H]+. Example 229
N-r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2-methoxy-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000262_0001
The title compound was prepared in analogy to example 223, from [4-(2-fluoro-6- methoxy-phenyl)-pyridin-3-yl]-(2-methoxy-ethyl)-amine and 3-methanesulfonyl-5- trifluoromethyl-benzoyl chloride (example 223, intermediate d) and using preparative HPLC (ammonium acetate/acetonitrile) for purification. Yellow solid (17%). MS (ESI): m/z = 527.2 [M+H]+. Intermediates a) r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-(2-methoxy-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from [4-(2- fluoro-6-methoxy-phenyl)-pyridin-3-yl]-(2-methoxy-ethyl)-carbamic acid tert-butyl ester after a reaction time of 2 hours. Colourless sticky liquid (82%). MS (ESI): m/z = 277.0 [M+H]+. b) r4-(2-Fluoro-6-methoxy-phenyl)-pyridin-3-yll-(2-methoxy-ethyl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)-(2- methoxy-ethyl)-carbamic acid tert-butyl ester and 2-fluoro-6-methoxyphenylboronic after a reaction time of 18 hours at 100 °C. The compound was purified by column chromatography eluting with a gradient of n-hexane : EtOAc (50 : 50 to 0 : 100). Yellow liquid (52%). MS (ESI): m/z = 377.0 [M+H]+. c) (4-Iodo-pyridin-3-yl)-(2-methoxy-ethyl)-carbamic acid tert-butyl ester
The title compound was prepared in analogy to example 85, intermediate d from (4-iodo- pyridin-3-yl)-carbamic acid tert-butyl ester (example 85, intermediate d) and l-bromo-2- methoxyethane and using a gradient of n-hexane : EtOAc (70 : 30 to 60 : 40) for the
chromatographic purification. Light yellow oil (63%). MS (ESI): m/z = 379.2 [M+H]+.
Example 230
N-r4-(4-Fluoro-2-methoxy-phenyl)-2-methyl-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000263_0001
To a solution of N-(2-chloro-4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3- (methylsulfonyl)-5-(trifluoromethyl)benzamide (0.1 g, 193 μιηοΐ, Example 212) in THF (3 mL) were added methylzinc(II)chloride (193 μί, 387 μιηοΐ), l,3-dimethyl-2-imidazolidinone (DMI) (0.6 mL) and PEPPSI-IPr (CAS 905459-27-0) (2.7 mg, 3.87 μπιοΐ) and the reaction mixture was heated at 50 °C for 3 hours. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.05% triethylamine) (20: 80 to 60 : 40). Colorless solid (0.035 g; 36%). MS (ESI): m/z = 497.12 [M+H]+
Example 231 N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(5-methyl-isoxazol-3- ylmeth vD- 5 -trifluoromethyl-benzamide
Figure imgf000264_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(5-methyl-isoxazol-3-ylmethyl)-amine and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (53%). MS (ESI): m/z = 564.121 [M+H]+.
Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(5-methyl-isoxazol-3-ylmethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((5-methylisoxazol-3-yl)methyl)carbamate after a reaction time of 2 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (82%). MS (ESI): m/z = 314.130
[M+H]+. b) fe/t-Butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((5-methylisoxazol-3-yl)methyl)- carbamate
The title compound was prepared in analogy to example 72, from tert-butyX 4-iodopyridin- 3-yl((5-methylisoxazol-3-yl)methyl)carbamate and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (88%). MS (ESI): m/z = 414.182 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl((5-methylisoxazol-3-yl)methyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from tert-butyX 4-iodopyridin-3-ylcarbamate (example 85, intermediate d) and 3-(bromomethyl)-5- methylisoxazole (CAS RN 130628-75-0) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 20 : 80). Light yellow solid (66%). MS (EI): m/z = 415 [M]+. Example 232 and Example 233
(+)-N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-r i-(tetrahvdro-furan- 2-yl)methyll-5-trifluoromethyl-benzamide and
(-)-N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-r i-(tetrahvdro-furan- 2-yl)methyll-5-trifluoromethyl-benzamide
Figure imgf000265_0001
The title compounds were prepared in analogy to example 90, from [4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-yl]-[l-(tetrahydro-furan-2-yl)methyl]-amine and 3-(methylsulfonyl)- 5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The enantiomeric mixture was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Chiral chromatography on a Chiralpak AD column with a gradient of 2- propanol : n-heptane (30 : 70) furnished the two enantiomers with the (+)-enantiomer eluting first.
(+)-N- [4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3 -yl] -3 -methanesulfonyl-N- [ 1 -(tetrahydro-furan- 2-yl)methyl]-5-trifluoromethyl-benzamide: Light yellow oil (28 mg, 43%). MS (ESI): m/z = 553.142 [M+H]+ and
(-)-N-[4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)-l-(tetrahydro- furan-2-yl)methyl]-5-trifluoromethyl-benzamide: Light yellow oil (49%). MS (ESI): m/z = 553.142 [M+H]+. Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-ri-(tetrahvdro-furan-2-yl)methyll-amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((tetrahydrofuran-2-yl)methyl)carbamate after a reaction time of 2 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless oil (208 mg, 84.2%). MS (ESI): m/z = 303.150 [M+H]+. b) fe/ -Butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((tetrahvdrofuran-2-yl)methyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from ieri-butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-ylcarbamate and tetrahydrofurfurylchloride after a reaction time of 72 hours at 70 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (38%). MS (ESI): m/z = 403.205 [M+H]+. c) fe/ -Butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-ylcarbamate
The title compound was prepared in analogy to example 72, from ieri-butyl 4-iodopyridin- 3-ylcarbamate (example 85, intermediate d) and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 18 hours at 90 °C. The residue was purified by silica gel chromatography on a 120 g column using an MPLC system (CombiFlash Companion XL, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Colorless solid (67%). MS (ESI): m/z = 319.146 [M+H]+. Example 234
Γ2-(3- j r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-m
phenylsulfanvD-ethyll-carbamic acid tert-butyl ester
Figure imgf000267_0001
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide (0.1 g, 229 μηιοΐ, example 216, intermediate a) in acetonitrile (2 mL) were added tert-butyl 2-bromoethylcarbamate (56.5 mg, 252 μιηοΐ) and DIPEA (59.2 mg, 80.0 μί, 458 μιηοΐ). After the addition of DIPEA the white suspension turned to a yellow solution, which was stirred a troom temperature for 3 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.111 g; 83%). MS (ESI): m z = 580.19 [M+H]+.
Example 235
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3-oxetan-3-yl-5-trifluoromethyl- benzamide
Figure imgf000267_0002
To a suspension of 3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5- (trifluoromethyl)phenylboronic acid (0.1 g, 223 μιηοΐ) in 2-propanol (1 mL) were added 3- iodooxetane (41.0 mg, 223 μιηοΐ), (1 ?,2 ?)-2-aminocyclohexanol hydrochloride (2.03 mg, 13.4 μηιοΐ), nickel(II) iodide (4.18 mg, 13.4 μιηοΐ) and sodium hexamethyldisilazan (40.9 mg, 223 μιηοΐ) and the suspension was heated in a microwave oven at 80 °C for 20 minutes. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). The mixture was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.004 g; 3%). MS (ESI): m/z = 461.15 [M+H]+. Intermediates a) 3-((4-(4-Fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5-(trifluoromethyl)- phenylboronic acid
To a solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (1 g, 2.07 mmol, example 216, intermediate c) in THF (10.0 mL) was added triisopropyl borate (751 mg, 927 μί, 3.99 mmol) and a cooling bath was installed. At -75 °C ft-butyllithium (1.6 M solution in hexane, 1.36 mL, 2.17 mmol) was added dropwise and the brown mixture was stirred at -75 °C for 2 hours. To this mixture at 0 °C, a solution of acetic acid (527 mg, 502 μί, 8.77 mmol) in water (0.50 mL) was added, followed by addition of hydrogen peroxide (35% in water, 302 mg, 272 μί, 3.1 mmol). The reaction mixture was stirred at 0 °C for 2.25 hours, then poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with 10% aqueous sodium thioslufate solution and once with brine, dried over MgS04, filtered and evaporated. The product was purified by preparative SFC (Waters Viridis SFC 2-Ethylpyridine column) using an isocratic mixture of MeOH : carbondioxide (40 : 60). Light brown solid (0.363 g; 31%). MS (ESI): m/z = 493.12 [M+HCOO]".
Example 236
N-r4-(4-Fluoro-2-methoxy-phenyl)-p^
trifluoromethyl-benzamide
Figure imgf000269_0001
To a suspension of N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-hydroxy-N-methyl-
5 -trifluoromethyl-benzamide (0.06 g, 143 μιηοΐ) in acetonitrile (1 mL) were added l-bromo-2- methoxyethane (19.8 mg, 143 μπιοΐ) and DIPEA (22.1 mg, 29.9 μΐ,, 171 μπιοΐ) and the light yellow suspension was stirred at room temperature for 45 minutes. To the reaction mixture was added potassium carbonate (23.7 mg, 171 μιηοΐ) and stirrring was continued for 2.75 hours at room temperature. Then the reaction mixture was stirred at reflux temperature for 16 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Light brown solid (0.048 g; 70%). MS (ESI): m/z = 479.16
[M+H]+.
Intermediates a) N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-hvdroxy-N-methyl-5-trifluoromethyl- benzamide
To a solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (1 g, 2.07 mmol, example 216, intermediate c) in THF (10.0 mL) was added triisopropyl borate (751 mg, 927 μί, 3.99 mmol) and a cooling bath was installed. At -75 °C ft-butyllithium (1.6M solution in hexane, 1.36 mL, 2.17 mmol) was added dropwise and the brown mixture was stirred at -75 °C for 2 hours. To this mixture, at 0°C, a solution of acetic acid (527 mg, 502 μί, 8.77 mmol) in water (0.50 mL) was added, followed by addition of hydrogen peroxide (35% in water, 302 mg, 272 μί, 3.1 mmol). The reaction mixture was stirred at 0 °C for 2.25 hours, then poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with 10 % aqueous sodium thioslufate solution and once with brine, dried over MgS04, filtered and evaporated. The product was purified by preparative SFC (Waters Viridis SFC 2-Ethylpyridine column) using an isocratic mixture of MeOH : carbondioxide (40 60). Light brown solid (0.195 g; 22%). MS (ESI): m/z = 421.12 [M+H]+.
Example 237
3-(2-Amino-ethylsulfanyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000270_0001
The title compound was prepared in analogy to example 85, intermediate a, from tert-butyl 2-(3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5-(trifluoromethyl)- phenylthio)ethylcarbamate after a reaction time of 2 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of CH2CI2 : MeOHe (100 : 0 to 70 : 30). Colorless foam (85%). MS (ESI): m/z = 480.14 [M+H]+.
Intermediates a) fe/ -Butyl 2-(3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5- (trifluoromethyl)phenylthio)ethylcarbamate
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide (0.1 g, 229 μιηοΐ, example 216, intermediate a) in acetonitrile (2 mL) were added tert-butyl 2-bromoethylcarbamate (56.5 mg, 252 μιηοΐ) and DIPEA (59.2 mg, 80.0 μί, 458 μιηοΐ). After the addition of DIPEA the white suspension turned to a yellow solution, which was stirred at room temperature for 3 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.111 g; 83%). MS (ESI): m/z = 580.19 [M+H]+. Example 238
3-Chloro-5-cvclopropyl-N-r4-(4-nuoro^
Figure imgf000271_0001
The title compound was prepared in analogy to example 90, from 3-chloro-5- cyclopropylbenzoic acid and 4-(4-fluoro-2-methoxyphenyl)-N-methylpyridin-3-amine (0.18 g, 775 μιηοΐ, example 129, intermediate) after a reaction time of 41 hours at room temperature. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.012 g; 3%). MS (ESI): m/z = 411.13 [M+H]+.
Intermediates a) 3-Chloro-5-cvclopropylbenzoic acid The title compound was prepared in analogy to example 84, from methyl 3-chloro-5- cyclopropylbenzoate. Silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) gave the desired compound as a 2 : 1 mixture with 3, 5-dicyclopropyl -benzoic acid. Colorless solid (76%). b) Methyl 3-chloro-5-cvclopropylbenzoate To a solution of methyl 3-chloro-5-iodobenzoate (0.5 g, 1.69 mmol) in THF (5 mL) were added cyclopropylzinc(II)bromide (3.71 mL, 1.86 mmol), PEPPSI-IPr (22.9 mg, 33.7 μιηοΐ, CAS RN 905459-27-0) and l,3-dimethyl-2-imidazolidinone (DMI) (1 mL) and the turbid light brown solution was stirred at 50 °C for 2.25 hours. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 50 g column using an MPLC (Flasmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 70 : 30). The obtained fraction (light yellow oil, 315 mg) was dissolved in THF (5 mL), to the clear solution were added cyclopropylzinc(II) bromide (3.71 mL, 1.86 mmol), PEPPSI-IPr (22.9 mg, 33.7 μιηοΐ, CAS RN 905459-27-0) and l,3-dimethyl-2- imidazolidinone (DMI) (1 mL) and the reaction mixture was heated at 50 °C for 2.25 hours. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 40 : 60) to give the title compound as a light brown oil (0.225 g; 63%) containing 3,5-dicyclopropyl-benzoic acid methyl ester.
Example 239
4-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- phenylsulfanvP-butyric acid
Figure imgf000272_0001
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5-
(trifluoromethyl)benzamide (0.05 g, 115 μιτιοΐ, Example 216, intermediate a) in acetonitrile (1 mL) were added 4-bromobutanoic acid (36.4 mg, 218 μιτιοΐ) and DIPEA (29.6 mg, 40.0 μί, 229 μιτιοΐ). After the addition of DIPEA the white suspension turned to a light yellow soution, which was stirred at room temperature for 24 hours before another batch of DIPEA (29.6 mg, 40.0 μί, 229 μιτιοΐ) was added (white suspension turned into light yellow solution). The reaction mixture was stirred at room temperature for another 20 hours and then poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered and evaporated. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.01 g; 16%). MS (ESI): m/z = 523.13 [M+H]+. Example 240
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-(2-hvdroxy-ethoxy)-N-methyl-5- trifluoromethvl-benzamide
Figure imgf000273_0001
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-hydroxy-N-methyl-5-
(trifluoromethyl)benzamide (0.06 g, 143 μηιοΐ, Example 236, intermediate) in acetonitrile (2 mL) were added 2-bromoethanol (21.4 mg, 12.1 μί, 171 μιηοΐ) and potassium carbonate (23.7 mg, 171 μιηοΐ) and the light brown suspension was heated to reflux for 24 hours before another batch of 2-bromoethanol (21.4 mg, 12.1 μί, 171 μιηοΐ) and potassium carbonate (29.6 mg, 214 μιηοΐ) were added. After heating at reflux for another 20 hours the reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered and evaporated. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (0.021 g; 31%). MS (ESI): m/z = 465.14 [M+H]+.
Example 241
3-(2-Amino-ethanesulfonyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000273_0002
To an ice-cold solution of 3-(2-aminoethylthio)-N-(4-(4-fluoro-2-methoxyphenyl)pyridin- 3-yl)-N-methyl-5-(trifluoromethyl)benzamide (0.064 g, 133 μιηοΐ, example 237) in MeOH (2 mL) and water (0.5 mL) was added oxone (205 mg, 334 μιηοΐ) and the white suspension was stirred at room temperature for 4.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (Flasmaster) system eluting with a gradient of CH2C12 (100 : 0 to 85 : 15). Colorless solid (0.016 g; 23%). MS (ESI): m/z = 512.13 [M+H]+.
Example 242
N-r4-(2-Cvclopropoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000274_0001
The title compound was prepared in analogy to example 90, from [4-(2-cyclopropoxy- phenyl)-pyridin-3-yl]-methyl-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC
(Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow foam (65%). MS (ESI): m/z = 491.125 [M+H]+.
Intermediate r4-(2-Cyclopropoxy-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 2-cyclopropoxyphenylboronic acid after stirring at 90 °C for 18 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (94%). MS (ESI): m/z = 241.134 [M+H]+. Example 243
5-(3- j r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-m
phenylsurfanvP-pentanoic acid
Figure imgf000275_0001
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5-
(trifluoromethyl)benzamide (0.115 g, 264 μηιοΐ, Example 216, intermediate a) in acetonitrile (2 mL) were added 5-bromopentanoic acid (59.6 mg, 329 μιηοΐ) and DIPEA (85.1 mg, 115 μί, 659 μιηοΐ). After the addition of DIPEA the white suspension turned to a light yellow solution, which was stirred at room temperature for 18 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (Flashmaster) system eluting with a gradient of CH2CI2 : MeOH (100 : 0 to 0 : 0). The product was further purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.10 g; 70%). MS (ESI): m/z = 537.15 [M+H]+.
Example 244
N-r4-(2-Fluoro-phenyl)-pyridin-3-yll-N-(2-hydroxy-ethyl)-3-methanesulfonyl-5-trifluoromethy benzamide
Figure imgf000275_0002
To a solution of [[4-(2-fluoro-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl- benzoyl)-amino] -acetic acid methyl ester (80 mg, 157 μιηοΐ, example 186) in MeOH (2 mL) was added NaBH4 (11.9 mg, 313 μιηοΐ) at 0 °C. The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (9 mg, 12%). MS (ESI): m/z = 483.100 [M+H]+.
Example 245
3-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- phenvD-azetidine-l-carboxylic acid fe/ -butyl ester
Figure imgf000276_0001
To a suspension of 3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5- (trifluoromethyl)phenylboronic acid (0.1 g, 223 μιηοΐ, example 235, intermediate) in 2-propanol (1.0 mL) were added ieri-butyl 3-iodoazetidine-l-carboxylate (63.2 mg, 223 μιηοΐ), (lR,2R)-2- aminocyclohexanol hydrochloride (2.03 mg, 13.4 μιηοΐ, CAS RN 13374-31-7), nickel(II) iodide (4.18 mg, 13.4 μιηοΐ) and sodium hexamethyldisilazan (40.9 mg, 223 μιηοΐ) and the suspension was heated in a microwave oven at 80 °C for 50 minutes. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product (light brown solid, 0.048g) was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.008 g; 6%). MS (ESI): m/z = 560.22 [M+H]+. Example 246
3-Bromo-N-r4-(4-nuoro-2-methoxy-phenyl^
benzamide
Figure imgf000277_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-bromo-5- (trifluoromethoxy)benzoic acid (CAS RN 453565-90-7) after a reaction time of 16 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (60%). MS (ESI): m/z = 501.03 [M+H]+.
Example 247
4-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- benzenesulfonvD-butyric acid
Figure imgf000277_0002
To an ice-cold suspension of 4-(3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3- yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenylthio)butanoic acid (0.027 g, 51.7 μιηοΐ, example 239) in MeOH (2 mL) and water (0.5 mL) was added oxone® (79.4 mg, 129 μιηοΐ) and the reaction mixture was stirred at room temperature for 4.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, and evaporated. The crude product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (0.012 g; 41%). MS (ESI): m/z = 555.12 [M+H]+.
Example 248
5-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- benzenesulfonvD-pentanoic acid
Figure imgf000278_0001
To an ice-cold suspension of 5-(3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)- carbamoyl)-5-(trifluoromethyl)phenylthio)pentanoic acid (0.086 g, 160 μιηοΐ, example 243) in MeOH (4 mL) and water (0.5 mL) was added oxone® (246 mg, 401 μιηοΐ) and the reaction mixture was stirred at room temperature for 4.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, and evaporated. The crude product (0.11 g) was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (0.05 g; 54%). MS (ESI): m/z = 569.13 [M+H]+.
Example 249
3-(Azetidine-l-sulfonyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000278_0002
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-(azetidine- l- sulfonyl)-5-trifluoromethyl-benzoic acid after a reaction time of 16.5 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with EtOAc (isocratic). Colorless foam (43%). MS (ESI): m/z = 524.13 [M+H]+.
Intermediates a) 3-(Azetidine- l-sulfonyl)-5-trifluoromethyl-benzoic acid
The title compound was prepared in analogy to example 84, from methyl 3-(azetidin- l- ylsulfonyl)-5-(trifluoromethyl)benzoate after a reaction time of 2.25 hours. The clear, light yellow solution was evaporated until dioxane was removed. The residue was adjusted to pH 1 using 1M aqueous HC1. The resulting suspension was filtered and the filter cake was washed with water. Colorless solid (76%). MS (ESI): m/z = 308.02 [M-H]". b) Methyl 3-(azetidin-l-ylsulfonyl)-5-(trifluoromethyl)benzoate
To a solution of methyl 3-(chlorosulfonyl)-5-(trifluoromethyl)benzoate (0.3 g, 991 μιηοΐ; Buttpark Ltd.) in CH2C12 (1 mL) were added DIPEA (192 mg, 260 μί, 1.49 mmol) and azetidine (62.3 mg, 73.5 μί, 1.09 mmol). The clear, light yellow solution was stirred at room temperature for 4 hours and then poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, and evaporated. Light brown solid (0.316 g; 98%). MS (EI): m/z = 323 [M] .
Example 250 N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(l -methyl- lH-imidazol- 2-ylmethyl)-5-trifluoromethyl-benzamide
Figure imgf000279_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(l-methyl- lH-imidazol-2-ylmethyl)-amine and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of CH2CI2 : MeOH (100 : 0 to 80 : 15). Further purification by preparative HPLC (Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Light yellow foam (54%). MS (ESI): m/z = 563.135 [M+H]+.
Intermediate a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(l -methyl- lH-imidazol-2-ylmethyl)-amine
The title compound was prepared in analogy to example 72, from 4-iodo- V-((l -methyl- 1H- imidazol-2-yl)methyl)pyridin-3-amine and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of CH2CI2 : MeOH (100 : 0 to 85 : 15). Light yellow solid (95%). MS (ESI): m/z = 313.145 [M+H]+. b) 4-Iodo- V-(( 1 -methyl- 1 H-imidazol-2-yl)methyl)pyridin-3 -amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-iodopyridin-3-yl((l -methyl- lH-imidazol-2-yl)methyl)carbamate after a reaction time of 2 hours at room temperature. Light yellow solid (83%). MS (ESI): m/z = 315.010 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl((l-methyl-lH-imidazol-2-yl)methyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from ieri-butyl 4-iodopyridin-3-ylcarbamate (example 85, intermediate d) and 2-(chloromethyl)- l-methyl-lH- imidazole hydrochloride after a reaction time of 18 hours at room temperature. The residue was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc : MeOH (100 : 0 : 0 to 0 : 100 : 0 to 0 : 50 : 50). Colorless solid (90%). MS (ESI): m/z = 437.046 [M+H]+.
Example 251
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3-(oxetan-3-ylsulfanyl)-5- trifluoromethvl-benzamide
Figure imgf000281_0001
To a solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide (0.1 g, 229 μηιοΐ, example 129, intermediate) in acetonitrile (2 mL) were added 3-iodooxetane (52.7 mg, 286 μιηοΐ, CAS RN 26272-85-5) and DIPEA (74.0 mg, 100 μί, 573 μιηοΐ) and the yellow solution was stirred at room temperature for 1.5 hours. Then heating was installed and the yellow solution was stirred at reflux for 2.5 hours. The colorless solution was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (0.052 g; 46%). MS (ESI): m z = 493.12 [M+H]+.
Example 252
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethoxv-benzamide
Figure imgf000281_0002
To a solution of L-proline (18.4 mg, 160 μιηοΐ) in DMSO (2 mL) was added sodium hydroxide (6.41 mg, 160 μιηοΐ) and the turbid mixture was stirred at room temperature for 30 minutes. This mixture was added to 3-bromo-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N- methyl-5-trifluoromethoxy-benzamide (0.1 g, 200 μιηοΐ) and the resulting suspension was treated with copper(I)iodide (30.5 mg, 160 μηιοΐ) and sodium methanesulfinate (164 mg, 1.6 mmol). The reaction mixture was heated to 120 °C for 19 hours. After cooling down to room temperature the reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.065 g; 65%). MS (ESI): m/z = 499.09 [M+H]+.
Intermediate a) 3-Bromo-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5-trifluoromethoxy- benzamide
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-bromo-5- (trifluoromethoxy)benzoic acid (CAS RN 453565-90-7) after a reaction time of 16 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (60%). MS (ESI): m/z = 501.03 [M+H]+.
Example 253
N-r6-Chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000282_0001
The title compound was prepared in analogy to example 90, from [6-chloro-4-(5-fluoro-2- methyl-phenyl)-pyridin-3-yl]-methyl-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 64 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). The product was further purified by
preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (5%). MS (ESI): m/z = 501.07 [M+H]+. Intermediates a) r6-Chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from 6-chloro-4-iodo- V- methylpyridin-3-amine (prepared according to WO2006013050) and 5-fluoro-2- methylphenylboronic acid after heating at reflux for 21 hours. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (85%). MS (ESI): m/z = 251.08 [M+H]+.
Example 254
3-(4-Carbamoyl-butane- l-sulfonyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl- 5 -trifluorometh yl-benzamide
Figure imgf000283_0001
The title compound was prepared in analogy to example 117, from 5-(3-((4-(4-fluoro-2- methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenylsulfonyl)pentanoic acid (example 243) after a reaction time of 68 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (Flasmaster) system eluting with a gradient of CH2C12 : MeOH (100 : 0 to 40 : 60). Colorless foam (84%). MS (ESI): m/z = 568.15 [M+H]+.
Example 255
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-/V-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide
Figure imgf000283_0002
To an ice-cold solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3- (oxetan-3-ylthio)-5-(trifluoromethyl)benzamide (0.042 g, 85.3 μηιοΐ, example 251) in MeOH (2 mL) and water (0.5 mL) was added oxone® (131 mg, 213 μιηοΐ) and the reaction mixture was stirred at room temperature for 2.75 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 5 g column using an MPLC (ISCO) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless gum (0.021 g; 46%). MS (ESI): m/z = 525.11 [M+H]+.
Example 256
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3-(morpholine-4-sulfonyl)-5- trifluoromethyl-benzamide
Figure imgf000284_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-(morpholine-4- sulfonyl)-5-trifluoromethyl-benzoic acid after a reaction time of 64 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with EtOAc (isocratic). Light yellow solid (34%). MS (ESI): m/z = 554.14 [M+H]+.
Intermediates a) 3-(Morpholine-4-sulfonyl)-5-trifluoromethyl-benzoic acid
The title compound was prepared in analogy to example 84, from methyl 3- (morpholinosulfonyl)-5-(trifluoromethyl)benzoate after a reaction time of 2.5 hours. Dioxane was evaporated and the residue was diluted with water and the pH was adjusted to 1 using concentrated HC1. The resulting off-white suspension was filtered and washed with water.
Colorless solid (75%). MS (ESI): m/z = 338.03 [M-H]". b) Methyl 3-(morpholinosulfonyl)-5-(trifluoromethyl)benzoate
To a solution of methyl 3-(chlorosulfonyl)-5-(trifluoromethyl)benzoate (0.3 g, 991 μιηοΐ, Buttpark Ltd.) in CH2C12 (1.0 mL) were added DIPEA (192 mg, 260 μΐ,, 1.49 mmol) and morpholine (86.4 mg, 86.4 μί, 991 μιηοΐ). The clear light yellow solution was stirred at room temperature for 1.3 hours and then poured on saturated aqueous NH4C1 solution and CH2C12. The layers were separated and the aqueous layer was extracted twice with CH2C12. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. Light brown solid (0.357 g; 91%). MS (EI): m/z = 353 [M] .
Example 257 3-Chloro-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-5-methanesulfonyl-N-methyl- benzamide
Figure imgf000285_0001
To a solution of L-proline (27.8 mg, 242 μιηοΐ) in DMSO (3 ml) was added sodium hydride (9.66 mg, 242 μιηοΐ, 60% dispersion in mineral oil). The mixture was stirred at room temperature for 30 minutes then copper(I)iodide (46.0 mg, 242 μιηοΐ) and N-[4-(4-fluoro-2- methoxy-phenyl)-pyridin-3-yl]-3-iodo-5-methanesulfonyl-N-methyl-benzamide (150 mg, 302 μιηοΐ) and sodium methanesulfonate (247 mg, 2.42 mmol) were added. The reaction mixture was stirred for 4 hours at 120°C. The reaction mixture was poured on 30 mL 10% aqueous NH4C1 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (121 mg, 89.3%). MS (ESI): m/z = 449.071 [M+H]+. Intermediates a) N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-iodo-5-methanesulfonyl-N-methyl- benzamide
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 239, intermediate a) and 3-chloro-5-iodobenzoic acid after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of CH2C12 : MeOH (100 : 0 to 80 : 15). Light yellow solid (77%). MS (ESI): m/z = 496.991 [M+H]+. b) 3-Chloro-5-iodobenzoic acid
The title compound was prepared in analogy to example 84, from methyl 3-chloro-5- iodobenzoate after a reaction time of 3 hours. Colorless solid (100%). MS (ESI): m/z = 280. [M-H]".
Example 258
N-r4-(2-Benzyloxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000286_0001
The title compound was prepared in analogy to example 90, from 4-(2-(benzyloxy)phenyl)- N-methylpyridin-3-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow foam (83%). MS (ESI): m/z = 541.140 [M+H]+. Intermediate
4-(2- (B enz ylox y)phen yl) -N-meth yi yridin- 3 - amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 2-(benzyloxy)phenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (81%). MS (ESI): m/z = 291.149 [M+H]+.
Example 259
3-(2-Azetidin- l-yl-ethylsulfanyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000287_0001
To an ice-cold solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-(2- hydroxyethylthio)-N-methyl-5-(trifluoromethyl)benzamide (0.16 g, 333 μιηοΐ, example 216) in CH2CI2 (2 mL) were added triethylamine (50.5 mg, 69.6 μί, 500 μιηοΐ) and methanesulfonyl chloride (38.1 mg, 25.8 μί, 333 μιηοΐ) and the clear colorless solution was stirred at 0 °C for
3.75 hours. The reaction mixture was poured on saturated aqueous NaHC03 solution and CH2CI2 and the layers were separated. The aqueous layer was extracted twice with CH2CI2. The organic layers were washed once with brine, dried over MgS04, filtered, and evaporated. The
intermediate mesylate was dissolved in isopropylacetate (2.0 mL), treated with azetidine (41.8 mg, 49.4 μί, 733 μιηοΐ) and heated to reflux (oil bath 95 °C) for 16 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered and evaporated. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1 % formic acid) (20: 80 to 98 : 2). Colorless solid (0.055 g; 31%). MS (ESI): m/z = 520.17 [M+H]+. Example 260
3-Cvclopropyl-N-r4-(4-fluoro-2-methox
benzamide
Figure imgf000288_0001
The title compound was prepared in analogy to example 90, from 3-cyclopropyl-5- methanesulfonyl-benzoic acid (119 mg, 495 μιηοΐ) and 4-(4-fluoro-2-methoxyphenyl)- V- methylpyridin-3-amine (example 129, intermediate) after a reaction time of 19.5 hours. The compound was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Off-white solid (0.082 g; 36%). MS (ESI): m/z = 455.14 [M+H]+.
Intermediates a) 3-Cvclopropyl-5-methanesurfonyl-benzoic acid
To a solution of methyl 3-chloro-5-(methylsulfonyl)benzoate (1.32 g, 5.31 mmol) in THF (15 mL) were added PEPPSI-IPr (72.1 mg, 106 μιηοΐ, CAS RN 905459-27-0),
cyclopropylzinc(II) bromide (0.5 M solution in THF, 25.5 mL, 12.7 mmol) and l,3-dimethyl-2- imidazolidinone (3 mL) and the reaction mixture was heated to reflux for 22 hours before another batch of cyclopropylzinc(II) bromide (0.5 M solution in THF, 12.7 mL, 6.37 mmol) was added. Stirring at reflux was continued for 22 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with saturated aqueous NaHC03 solution. The pH of the aqueous phase was adjusted to 1, saturated with solid sodium chloride and extracted three times with EtOAc. The organic layers were dried over MgS04, filtered and evaporated. The product was purified by preparative SFC (Waters Viridis SFC 2- Ethylpyridine column) using an isocratic mixture of MeOH : carbondioxide (40 : 60). Light brown solid (0.119 g; 9%). MS (ESI): m/z = 239.0 [M+H]+. b) Methyl 3-chloro-5-(methylsulfonyl)benzoate
To a solution of L-proline (77.7 mg, 675 μιηοΐ) in DMSO (4 mL) was added sodium hydride (27.0 mg, 675 μιηοΐ, 60% dispersion in mineral oil) and the mixture was stirred at room temperature for 30 minutes before copper(I)iodide (128 mg, 675 μιηοΐ), methyl 3-chloro-5- iodobenzoate (0.25 g, 843 μιηοΐ) and sodium methanesulfinate (689 mg, 6.75 mmol) were added. The reaction mixture was heated to 120 °C in a sealed tube to give a turbid blue solution. After 2 hours the reaction mixture was allowed to cool down and was poured on saturated aqueous NaHC03 solution and EtOAc and filtered. The filtrate layers were separated and the aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered and evaporated. Light brown solid (0.135 g; 64%). MS (EI): m/z = 248 [M].
Example 261
N-r4-(4-fluoro-2-methoxyphenyl)pyridin-3-yll-N-methyl-3-i r2-(sulfamoylamino)ethyll- sulfanyl I -5-(trifluoromethyl)benzamide
Figure imgf000289_0001
To a solution of 3-(2-aminoethylthio)-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N- methyl-5-(trifluoromethyl)benzamide (0.1 g, 209 μιηοΐ, example 237) in isopropylacetate (2 mL) was added sulfamide (80.2 mg, 834 μιηοΐ) and the mixture was heated at reflux for 23 hours while the solvent was vaporized. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2).
Colorless foam (0.067 g; 57%). MS (ESI): m/z = 559.11 [M+H]+. Example 262
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-(2-methanesulfonylamino-ethylsulfanv methvl-5-trifluoromethvl-benzamide
Figure imgf000290_0001
To an ice-cold solution of 3-(2-aminoethylthio)-N-(4-(4-fluoro-2-methoxyphenyl)pyridin- 3-yl)-N-methyl-5-(trifluoromethyl)benzamide (0.12 g, 250 μηιοΐ, example 237) and DIPEA (64.7 mg, 87.4 μί, 501 μιηοΐ) in CH2CI2 (2 mL) was added methanesulfonyl chloride (35.8 mg, 24.4 μί, 313 μιηοΐ) and the clear colorless solution was stirred at 0 °C for 2.5 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2CI2 and the layers were separated. The aqueous layer was extracted three times with CH2CI2. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 5 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.121 g; 86%). MS (ESI): m/z = 558.11 [M+H]+.
Example 263
3-Methanesulfonyl-N-r4-(2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000290_0002
To a solution of N-[4-(2-hydroxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide (40 mg, 88.8 μιηοΐ) in DMF (1 ml) was added K2C03 (24.5 mg, 178 μιηοΐ) and methyliodide (13.9 mg, 6.09 μΐ, 97.7 μιηοΐ). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography on a 5 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (28 mg, 68%). MS (ESI): m/z = 465.108 [M+H]+.
Intermediate a) N-r4-(2-Hvdroxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide
To a solution of N-[4-(2-benzyloxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide (200 mg, 370 μιηοΐ, example 258) in MeOH (2 mL) and EtOAc (2.00 mL) was added 10% palladium on charcoal (30 mg, 370 μιηοΐ) under argon atmosphere. The reaction was evacuated and purged with hydrogen gas. The reaction was stirred for 5 hours at 1.7 bar under H2 atmosphere. The reaction mixture was filtered over dicalite and the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (150 mg, 90%). MS (ESI): m/z = 451.094 [M+H]+.
Example 264
/V-r4-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000291_0001
To a solution of N-(6-chloro-4-(5-fluoro-2-methylphenyl)pyridin-3-yl)-/V-methyl-3- (methylsulfonyl)-5-(trifluoromethyl)benzamide (0.055 g, 110 μιηοΐ, example 253) in THF (1.5 mL) were added methylzinc(II) chloride (82.4 μί, 165 μιηοΐ), l,3-dimethyl-2-imidazolidinone (DMI) (0.3 mL) and PEPPSI-IPr (1.49 mg, 2.2 μιηοΐ, CAS RN 905459-27-0) and the clear solution was stirred at 50 °C for 2 hours. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 5 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 100 : 100). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.05% triethylamine) (20: 80 to 98 : 2). Colorless foam (0.022 g; 41%). MS (ESI): m/z = 481.12 [M+H]+.
Example 265
3-(2-Azetidin- l-yl-ethanesulfonyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000292_0001
To an ice-cold solution of 3-(2-(azetidin-l-yl)ethylthio)-N-(4-(4-fluoro-2-methoxyphenyl)- pyridin-3-yl)-N-methyl-5-(trifluoromethyl)benzamide (0.05 g, 96.2 μιηοΐ, example 259) in MeOH (2 mL) and water (0.5 mL) was added oxone® (148 mg, 241 μιηοΐ) and the white suspension was stirred at room temperature for 3 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The crude product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.05% triethylamine) (20: 80 to 98 : 2). Colorless solid (0.017 g; 32%). MS (ESI): m/z = 552.16 [M+H]+.
Example 266
3-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- phenyl) -propionic acid ethyl ester
Figure imgf000292_0002
To a solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (0.1 g, 207 μηιοΐ, example 216, intermediate c) in DMF (1 mL) were added 3,3-diethoxyprop- l-ene (80.8 mg, 95.1 μί, 621 μιηοΐ), π-tributylamine (76.7 mg, 98.7 μί, 414 μmol), tetrabutylammonium chloride (57.5 mg, 207 μιηοΐ) and palladium (II) acetate (1.39 mg, 6.21 μιηοΐ) and the light brown solution was stirred at 90 °C for 25 hours. The reaction mixture was poured on aqueous 1M HCl solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.05% triethylamine) (20: 80 to 98 : 2). Colorless gum (0.015 g; 12%). MS (ESI): m/z = [M+H]+
Example 267
N-r4-(2-Benzyloxy-4-fluoro-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000293_0001
The title compound was prepared in analogy to example 90, from 4-(2-(benzyloxy)-4- fluorophenyl)-N-methylpyridin-3-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (637 mg, 69%). MS (ESI): m/z = 559.131 [M+H]+.
Intermediate a) 4-(2-(Benzyloxy)-4-fluorophenyl)-N-methylpyridin-3-amine The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 2-(benzyloxy)-4-fluorophenylboronic acid after a reaction time of 72 hours at 90 °C. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (79%). MS (ESI): m/z = 309.140 [M+H]+.
Example 268
3-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- phenylsulfanyD-azetidine-l-carboxylic acid fe/ -butyl ester
Figure imgf000294_0001
To a suspension of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide (0.35 g, 802 μηιοΐ, example 216, intermediate a) in acetonitrile (4 mL) was added DIPEA (259 mg, 350 μί, 2.00 mmol). The instantly formed yellow solution was treated with ieri-butyl 3-iodoazetidine-l-carboxylate (284 mg, 1.0 mmol) and heated to reflux for 75 minutes. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.405 g; 85%). MS (ESI): m/z = 592.19 [M+H]+.
Example 269
N-r4-(4-fluoro-2-methoxyphenyl)pyridin-3-yll-/V-methyl-3-i r2-(sulfamoylamino)ethyll- sulfonyl I -5-(trifluoromethyl)benzamide
Figure imgf000294_0002
To an ice-cold solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3-(2- (sulfamoylamino)ethylthio)-5-(trifluoromethyl)benzamide (0.058 g, 104 μηιοΐ, example 261) in MeOH (2 mL) and water (0.5 mL) was added oxone (160 mg, 260 μιηοΐ) and the white suspension was stirred at room temperature for 3.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The crude product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.047 g; 76%). MS (ESI): m/z = 591.10 [M+H]+.
Example 270
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-(2-methanesulfonylamino-ethanesulfonyl)-N- methyl-5-trifluoromethyl-benzamide
Figure imgf000295_0001
To an ice-cold solution of N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-3-(2- (methylsulfonamido)ethylthio)-5-(trifluoromethyl)benzamide (0.105 g, 188 μιηοΐ, example 262) in MeOH (3 mL) and water (0.6 mL) was added oxone® (289 mg, 471 μιηοΐ) and the white suspension was stirred at room temperature for 4 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over
MgS04, filtered, treated with silica gel and evaporated. The crude product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (0.094 g; 84%). MS (ESI): m/z = 590.10 [M+H]+. Example 271
3-(2-Hydroxy-ethylamino)-N-mem^
Figure imgf000296_0001
The title compound was prepared in analogy to example 85, intermediate c, from 3-amino- N-methyl-N-(4-o-tolylpyridin-3-yl)-5-(trifluoromethyl)benzamide (example 164) and 2- bromoethanol after a reaction time of 48 hours at 80 °C. Light yellow oil (11%). MS (ESI): m/z = 430.175 [M+H]+.
Example 272
3-Methanesulfonyl-N-methyl-N-{4-r2-(oxetan-3-yloxy)-phenyll-pyridin-3-yl|-5-trifluoromethy benzamide
Figure imgf000296_0002
To a solution N-(4-(2-hydroxyphenyl)pyridin-3-yl)-N-methyl-3-(methylsulfonyl)-5- (trifluoromethyl)benzamide (100 mg, 222 μιηοΐ, example 263, intermediate a) in DMF (2 ml) was added K2CO3 (61.4 mg, 444 μιηοΐ) and 3-iodooxetane (44.9 mg, 244 μιηοΐ). The reaction mixture was stirred for 18 hours at 80 °C. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (52 mg, 46%). MS (ESI): m/z = 507.120 [M+H]+. Example 273
N-r4-(4-Fluoro-2-methoxy-phenyl)-p^
ylmeth vD- 5 -trifluoromethyl-benzamide
Figure imgf000297_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(tetrahydro-furan-3-ylmethyl)-amine and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 72 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The resulting brown oil was further purification by preparative HPLC (Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless foam (11%). MS (ESI): m/z = 553.141 [M+H]+.
Intermediate a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(tetrahvdro-furan-3-ylmethyl)-amine The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl
4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((tetrahydrofuran-3-yl)methyl)carbamate after a reaction time of 2 hours at room temperature. Light yellow foam (99%). MS (ESI): m/z = 303.150 [M+H]+. b) fe/ -Butyl 4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl((tetrahvdrofuran-3-yl)methyl)carbamate
The title compound was prepared in analogy to example 72, from ieri-butyl 4-iodopyridin- 3-yl((tetrahydrofuran-3-yl)methyl)carbamate and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (79%). MS (ESI): m/z = 403.203 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl((tetrahvdrofuran-3-yl)methyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from tert-butyl 4-iodopyridin-3-ylcarbamate (example 85, intermediate d) and 3-(bromomethyl)tetrahydrofuran (567 mg, 3.44 mmol) after a reaction time of 18 hours at 60 °C. The compound was purified by silica gel chromatography on a 50 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (883 mg, 69.9%). MS (ESI): m/z = 405.064 [M+H]+.
Example 274
3-Methanesulfonyl-N-methyl-N-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-5-trifluoromethyl- benzamide
Figure imgf000298_0001
The title compound was prepared in analogy to example 90, from methyl- [4-(2- trifluoromethoxy-phenyl) -pyridin- 3 -yl] - amine and 3 - (methylsulf onyl) -5 - (trifluoromethyl) - benzoic acid (example 1 14, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light red foam (39%). MS (ESI): m/z = 519.081 [M+H]+.
Intermediate
Methyl-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll -amine The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 2-(trifluoromethoxy)phenylboronic acid after a reaction time of 7 hours at 90 °C. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (91%). MS (ESI): m/z = 269.090 [M+H]+. Example 275
3-(Azetidin-3-ylsulfanyl)-N-r4-(4-n
trifluoromethyl-benzamide
Figure imgf000299_0003
Figure imgf000299_0001
The title compound was prepared in analogy to example 85, intermediate a, from ie/ -butyl 3-(3-((4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5-(trifluoromethyl)- phenylthio)azetidine-l-carboxylate (example 268) after a reaction time of 1.25 hours. The compound was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (81 %). MS (ESI): m/z = 492.14 [M+H]+.
Example 276
N-r4-(5-Fluoro-2-methyl-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000299_0002
The title compound was prepared in analogy to example 90, from [4-(5-fluoro-2-methyl- phenyl)-pyridin-3-yl]-methyl-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 20.5 hours. The compound was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (20%). MS (ESI): m/z = 467.10 [M+H]+. Intermediate r4-(5-Fluoro-2-methyl-phenyl)-pyridin-3-yll-methyl-amine
A solution of 6-chloro-4-(5-fluoro-2-methylphenyl)-N-methylpyridin-3-amine (0.2 g, 798 μηιοΐ, example 253, intermediate a) in EtOAc (1 mL) and MeOH (1.0 mL) under argon was treated with palladium on carbon (21.2 mg, 19.9 μιηοΐ) and stirred under an hydrogen
atmosphere (0.5 bar overpressure) for 4 hours. Stirring was continued overnight at room temperature. The reaction mixture was filtered over Dicalite and evaporated. The residue was taken up in CH2CI2 and saturated aqueous NaHC03 solution and the layers were separated. The aqueous layer was extracted three times with CH2CI2. The organic layers were dried over MgS04, filtered and evaporated. Light brown solid (0.16 g; 92%). MS (ESI): m z = 217.11 [M+H]+.
Example 277
N-r4-(2-Cvclobutoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000300_0001
To a solution N-(4-(2-hydroxyphenyl)pyridin-3-yl)-N-methyl-3-(methylsulfonyl)-5-
(trifluoromethyl)benzamide (100 mg, 222 μιηοΐ, example 263, intermediate a) in DMF (2 mL) was added K2C03 (61.4 mg, 444 μιηοΐ) and cyclobutylbromide (33.0 mg, 244 μιηοΐ). The reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was stirred for 18 hours at 80 °C. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of ft-heptane : EtOAc (100 : 0 to 0 : 100). A second purification step using preparative HPLC (Gemini NX column) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2) furnished the desired compound as a colorless foam (39 mg, 35%). MS (ESI): m/z = 505.141 [M+H]+. Example 278 N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-methane
Figure imgf000301_0001
The title compound was prepared in analogy to example 90, from [4-(2-chloro-phenyl)- pyridin-3-yl]-methyl-amine (prepared according to DE10008042) and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane EtOAc (100 : 0 to 0 : 100). Another purification step using preparative HPLC (Gemini NX column) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2) gave the desired compound as acolorless foam (26%). MS (ESI): m/z = 469.060 [M+H]+.
Example 279
3-Methanesulfonyl-N-methyl-N-r2-(2,2,2-trifluoro-ethoxy)-r3,4'lbipyridinyl-3'-yll-5- trifluoromethvl-benzamide
Figure imgf000301_0002
The title compound was prepared in analogy to example 90, from methyl- [2-(2,2,2- trifluoro-ethoxy)-[3,4']bipyridinyl-3'-yl]-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)- benzoic acid (example 114, intermediate a) after a reaction time of 18 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2CI2 and the layers were separated. The aqueous layer was extracted three times with CH2CI2. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with EtOAc (isocratic). Further purification by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (41%). MS (ESI): m/z = 534.09 [M+H]+.
Intermediate
Methyl-r2-(2,2,2-trifluoro-ethoxy)-r3,4'lbipyridinyl-3'-yll-amine The title compound was prepared in analogy to example 72, from 4-iodo-N-methylpyridin-
3-amine (example 98, intermediate b) and 2-(2,2,2-trifluoroethoxy)pyridin-3-ylboronic acid after a reaction time of 5 hours at 90 °C. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless oil (76%). MS (ESI): m/z = 284.10 [M+H]+.
Example 280
3-(Azetidine-3-sulfonyl)-N-r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000302_0002
Figure imgf000302_0001
To an ice-cold solution of 3-(azetidin-3-ylthio)-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3- yl)-N-methyl-5-(trifluoromethyl)benzamide (0.257 g, 523 μιηοΐ, example 275) in MeOH (6 mL) and water was added oxone® (804 mg, 1.31 mmol) and stirring was continued at room
temperature for 3.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was saturated with sodium chloride, extracted eight times with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered and evaporated. The product (43 mg) was purified by preparative HPLC
(Gemini NX column) using a gradient of MeOH : water (containing 0.05% triethylamine) (20: 80 to 98 : 2). Colorless solid (0.135 g; 49%). MS (ESI): m/z = 524.13 [M+H]+. Example 281
3-(2-Carbamoyl-ethyl)-N-r4-(4-fluoro-2-m
trifluoromethvl-benzamide
Figure imgf000303_0001
The title compound was prepared in analogy to example 117, from 3-(3-((4-(4-fluoro-2- methoxyphenyl)pyridin-3-yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenyl)propanoic after a reaction time of 18 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of CH2CI2 : MeOH (100 : 0 to 90 : 10). Colorless foam (38%). MS (ESI): m/z = 476.16 [M+H]+. Intermediate
3-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-methyl-carbamoyl|-5-trifluoromethyl- phenyl) -propionic acid
To a solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (0.4 g, 828 μιηοΐ, example 216, intermediate c) in DMF (4.0 mL) were added 3,3-diethoxyprop- l-ene (323 mg, 380 μί, 2.48 mmol), n-tributylamine (921 mg, 1.18 mL, 4.97 mmol), tetrabutylammonium chloride (230 mg, 828 μιηοΐ) and palladium (II) acetate (13.9 mg, 62.1 μιηοΐ) and the light brown solution was stirred at 90 °C for 72 hours. The reaction mixture was poured on aqueous 1M HC1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). The crude product was dissolved in dioxane (4.0 mL) and water (4.0 mL) and lithium hydroxide monohydrate (34.7 mg, 828 μιηοΐ) was added. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1 % formic acid) (20: 80 to 98 : 2), followed by a second chromatography on a 10 g silica gel column using an MPLC (Flasmaster) system eluting with a gradient of CH2C12 : MeOH (100 : 0 to 90 : 10). Colorless foam (0.139 g; 35%). MS (ESI): m/z = 477.14 [M+H]+. Example 282
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-(l-methanesulfonyl-azetidine-3-sulfonv methvl-5-trifluoromethvl-benzamide
Figure imgf000304_0003
Figure imgf000304_0001
To an ice-cold solution of 3-(azetidin-3-ylsulfonyl)-N-(4-(4-fluoro-2-methoxyphenyl)- pyridin-3-yl)-N-methyl-5-(trifluoromethyl)benzamide (0.05 g, 95.5 μηιοΐ, example 280) and DIPEA (24.7 mg, 33.4 μΐ,, 191 μπιοΐ) in CH2C12 (1 mL) was added methanesulfonyl chloride (16.4 mg, 11.2 μί, 143 μιηοΐ) and stirring was continued in an ice-bath for 1.75 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2C12 and the layers were separated. The aqueous layer was extracted twice with CH2C12. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 5 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (0.044 g; 76%). MS (ESI): m/z = 602.10 [M+H]+.
Example 283
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(5-methyl-oxazol-2- vlmeth vl)- 5 -trifluoromethvl-benzamide
Figure imgf000304_0002
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-((5-methyloxazol-2-yl)methyl)pyridin-3-amine (example 231, intermediate) and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 23 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc : MeOH (100 : 0 : 0 to 0 : 100 : 0 to 0 : 90 : 10). Further purification by preparative HPLC (Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (8%). MS (ESI): m/z = 564.120 [M+H]+.
Example 284
N-r4-(2,4-Difluoro-5-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000305_0001
To a solution of [4-(2,4-difluoro-5-methoxy-phenyl)-pyridin-3-yl]-methyl-amine (70 mg, 0.28 mmol) in 2.5 mL pyridine were added 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) (90 mg, 0.34 mmol) and POCl3 (2.3 mL) dropwise at 25 °C and the reaction mixture was stirred for 12 hours at 25 °C. The solvent was evaporated, the residue was dissolved in EtOAc (15 ml) and washed with 2M aqueous HC1 solution (5 mL) followed by saturated NaHC03 solution (10 mL). The organic layer was dried over anhydrous Na2S04 and evaporated. The crude product was purified by preparative HPLC (ammonium
acetate/acetonitrile) to furnish the title compound as a light yellow solid (40 mg, 29%). MS (ESI): m/z = 501.2 [M+H]+. Intermediate r4-(2,4-Difluoro-5-methoxy-phenyl)-pyridin-3-yll-methyl-amine
To a solution of (4-iodo-pyridin-3-yl)-methyl-amine (100 mg, 0.43 mmol, example 98, intermediate b) in THF (3 mL) and water (1.5 mL) were added 2,4-difluoro-5-methoxyphenyl- boronic acid (231 mg, 0.85 mmol) and potassium fluoride (50 mg, 0.85 mmol) and the reaction mixture was purged with argon for 15 min. Then Pd2(dba)3 (78 mg, 0.09 mmol) and triphenyl phosphine (22 mg, 0.09 mmol) were added to the reaction mixture and the reaction mixture was stirred at 120 °C for 45 min in a microwave oven. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography eluting with a gradient of n- hexane : EtOAc (80 : 20 to 50 : 50) to give the deired compound as a yellow liquid (75 mg, 70%). MS (ESI): m/z =251.4 [M+H]+.
Example 285
N-r4-(2,6-Difluoro-3-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide
Figure imgf000306_0001
The title compound was prepared in analogy to example 284, from [4-(2,6-difluoro-3- methoxy-phenyl)-pyridin-3-yl]-methyl-amine and 3-methanesulfonyl-5-trifluoromethyl-benzoyl chloride (example 223, intermediate d) and using preparative HPLC (ammonium
acetate/acetonitrile) for the purification. Off-white solid (25%). MS (ESI): m/z = 501.2 [M+H]+.
Intermediate r4-(2,6-Difluoro-3-methoxy-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to compound 284, intermediate, from (4-iodo- pyridin-3-yl)-methyl-amine (example 98, intermediate) and 2,6-difluoro-3- methoxyphenylboronic acid and using a gradient of n-hexane : EtOAc (70 : 30 to 60 : 40) for the chromatographic purification. Brown solid (75%). MS (ESI): m/z = 251.2 [M+H]+.
Example 286
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-N-cvanomethyl-3-methanesulfonyl-5-trinuorom
benzamide
Figure imgf000307_0001
The title compound was prepared in analogy to example 90, from [4-(2-chloro-phenyl)- pyridin-3-ylamino]-acetonitrile and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 6 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Another purification step using preparative HPLC (Gemini NX column) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2) yielded the title compound as colorless solid (25%). MS (ESI): m/z = 494.055 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-ylaminol-acetonitrile
The title compound was prepared in analogy to example 85, intermediate a, from tert-butyl 4-(2-chlorophenyl)pyridin-3-yl(cyanomethyl)carbamate after a reaction time of 4 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100) Colorless solid (51%). MS (ESI): m/z = 244.064 [M+H]+. b) tert-butyl 4-(2-chlorophenyl)pyridin-3-yl(cyanomethyl)carbamate
The title compound was prepared in analogy to example 72, from tert-butyl cyanomethyl(4- iodopyridin-3-yl)carbamate (example 161, intermediate c) and 2-chlorophenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (83%). MS (ESI): m/z = 344.116 [M+H]+. Example 287
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethvl-benzamide
Figure imgf000308_0001
The title compound was prepared in analogy to example 90, from 4-(2-chlorophenyl)- V- (2,2,2-trifluoroethyl)pyridin-3-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC
(Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Further purification by preparative HPLC (Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (31%). MS (ESI): m/z = 537.045 [M+H]+
Intermediate r4-(2-Chloro-phenyl)-pyridin-3-yll-(2,2,2-trifluoro-ethyl)-amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-(2-chlorophenyl)pyridin-3-yl(2,2,2-trifluoroethyl)carbamate after a reaction time of 4 hours at room temperature. Light yellow solid (33%). MS (ESI): m/z = 287.057 [M+H]+. fe/ -Butyl 4-(2-chlorophenyl)pyridin-3-yl(2,2,2-trifluoroethyl)carbamate
The title compound was prepared in analogy to example 72, from ieri-butyl 4-iodopyridin-3- yl(2,2,2-trifluoroethyl)carbamate (example 85, intermediate c) and 2-chlorophenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel
chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Yellow oil (90%). MS (ESI): m/z = 387.109 [M+H]+. Example 288
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-5^ trifluoromethyl-benzamide
Figure imgf000309_0001
The title compound was prepared in analogy to example 90, from [4-(2-chloro-phenyl)- pyridin-3-yl]-(2-methanesulfonyl-ethyl)-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)- benzoic acid (example 114, intermediate a) after a reaction time of 18 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). A further purification step using preparative HPLC (Gemini NX) with a gradient of MeOH : water
(containing 0.05% formic acid) (80 : 20 to 98 : 2) gave the desired compound as a colorless oil (13%). MS (ESI): m/z = 561.052 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-(2-methanesulfonyl-ethyl)-amine The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl
4-(2-chlorophenyl)pyridin-3-yl(2-(methylsulfonyl)ethyl)carbamate after a reaction time of 4 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc : MeOH (100 : 0 : 0 to 0 : 100 : 0 to 0 : 75 : 25). Colorless foam (91%). MS (ESI): m/z = 331.062 [M+H]+. b) fe/ -Butyl 4-(2-chlorophenyl)pyridin-3-yl(2-(methylsulfonyl)ethyl)carbamate
The title compound was prepared in analogy to example 72, from ieri-butyl 4-iodopyridin- 3-yl(2-(methylsulfonyl)ethyl)carbamate (example 112, intermediate c) and 2-chlorophenyl- boronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (87%). MS (ESI): m/z = 411.115 [M+H]+.
Example 289 rr4-(2-Chloro-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-aminol- acetic acid methyl ester
Figure imgf000310_0001
The title compound was prepared in analogy to example 90, from [4-(2-chloro-phenyl)- pyridin-3-ylamino]-acetic acid methyl ester and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 6 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC
(Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light red foam (25%). MS (ESI): m/z = 527.066 [M+H]+.
Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-ylaminol-acetic acid methyl ester The title compound was prepared in analogy to example 85, intermediate a, from methyl 2-
(ieri-butoxycarbonyl(4-(2-chlorophenyl)pyridin-3-yl)amino)acetate after a reaction time of 4 hours at room temperature. Colorless solid (99%). MS (ESI): m/z = 277.074 [M+H]+. b) Methyl 2-(fer?-butoxycarbonyl(4-(2-chlorophenyl)pyridin-3-yl)amino)acetate
The title compound was prepared in analogy to example 72, from methyl 2-(tert- butoxycarbonyl(4-iodopyridin-3-yl)amino)acetate (example 165, intermediate c) and 2- chlorophenylboronic acid after a reaction time of 18 hours at 90 °C. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (33%). MS (ESI): m/z = 377.127 [M+H]+. Examples 290 and 291
(-)-N-r4-(4-Fluoro-2-methoxy-phen^
2-yl)methyll-5-trifluoromethyl-benzamide and (+)-N-r4-(4-Fluoro-2-methoxy-phenyl)-p
2-yl)methyll-5-trifluoromethyl-benzamide
Figure imgf000311_0001
The title compounds were prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-[l-(tetrahydro-pyran-2-yl)methyl]-amine and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 68 hours at room temperature. The residue obtained after work-up was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product-containing fractions were pooled, evaporated and the mixture was dissolved in 50 mL 1M aqueous HC1 and 50 mL EtOAc and the layers were separated. The organic layer was separated, dried over Mg2S04, filtered and evaporated. The product was purified by preparative HPLC (Gemini NX column) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Chiral chromatography on a Chiralpak AD column with a gradient of ethanol (containing 0.05% formic acid) : n-heptane (30 : 70) furnished the two enantiomers with the (-)-enantiomer eluting first. (-)-N-[4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[l-(tetrahydro-pyran- 2-yl)methyl]-5-trifluoromethyl-benzamide. Off-white solid (43%). MS (ESI): m/z = 567.156 [M+H]+ and
(+)-N-[4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[l-(tetrahydro-pyran- 2-yl)methyl]-5-trifluoromethyl-benzamide. Light red solid (43%). MS (ESI): m/z = 567.157 [M+H]+. Intermediates a) r4-(4-Fluoro-2-methoxy-phenyl)-pyri
The title compound was prepared in analogy to example 72, from 4-iodo-N-((tetrahydro-2H- pyran-2-yl)methyl)pyridin-3-amine and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 3.5 hours at reflux. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100) followed by EtOAc : MeOH (100 : 0 to 90 : 10). Brown oil (103%). MS (ESI): m/z = 317.167 [M+H]+. b) 4-Iodo-N-((tetrahvdro-2H-pyran-2-yl)methyl)pyridin-3-amine The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl
4-iodopyridin-3-yl((tetrahydro-2H-pyran-2-yl)methyl)carbamate after a reaction time of 2 hours at room temperature. Light brown solid (97%). MS (ESI): m/z = 319.032 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl((tetrahvdro-2H-pyran-2-yl)methyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from tert-butyl 4-iodopyridin-3-ylcarbamate (example 85, intermediate d) and 2-(bromomethyl)tetrahydro-2H- pyran after a reaction time of 22 hours at 60 °C. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light yellow viscous oil (56%) MS (ESI): m/z = 419.084 [M+H]+. Example 292
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3-(l-sulfamoyl-azetidine-3- sulfonyl)-5-trifluoromethyl-benzamide
Figure imgf000312_0001
A suspension of 3-(azetidin-3-ylsulfonyl)-N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)- N-methyl-5-(trifluoromethyl)benzamide (0.05 g, 95.5 μιηοΐ, example 280) and sulfuric diamide (36.7 mg, 382 μιηοΐ) in isopropylacetate (1 mL) was heated at reflux for 19 hours. The reaction mixture was evaporated and the product purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1 % formic acid) (20: 80 to 98 : 2). Light brown solid (0.035 g; 60%). MS (ESI): m/z = 603.10 [M+H]+.
Example 293 N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(4-methyl-oxazol-2- ylmeth vD- 5 -trifluoromethyl-benzamide
Figure imgf000313_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(4-methyl-oxazol-2-ylmethyl)-amine and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 90 hours at room temperature. The product was purified by preparative HPLC (Gemini NX) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (34%). MS (ESI): m/z = 564.121 [M+H]+.
Intermediate a) r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(4-methyl-oxazol-2-ylmethyl)-amine
The title compound was prepared in analogy to example 72, from 4-iodo- V-((4- methyloxazol-2-yl)methyl)pyridin-3 -amine and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 23 hours at reflux. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100), then EtOAc : MeOH (100 : 0 to 90 : 10). Off- white solid (88%). MS (ESI): m/z = 314.130 [M+H]+. b) 4-Iodo-N-((4-methyloxazol-2-yl)methyl)pyridin-3-amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-iodopyridin-3-yl((4-methyloxazol-2-yl)methyl)carbamate after a reaction time of 2 hours at room temperature. Off-white solid (97%). MS (ESI): m/z = 315.995 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl((4-methyloxazol-2-yl)methyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from ieri-butyl 4-iodopyridin-3-ylcarbamate (example 85, intermediate d) and 2-(chloromethyl)-4- methyloxazole after a reaction time of 23 hours. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Yellow oil (48%). MS (ESI): m/z = 416.046 [M+H]+.
Example 294
N-r4-(2-Chloro-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-oxazol-2-ylmethyl-5- trifluoromethyl-benzamide
Figure imgf000314_0001
The title compound was prepared in analogy to example 90, from [4-(2-chloro-phenyl)- pyridin-3-yl]-oxazol-2-ylmethyl-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 21 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product was purified by preparative HPLC (Gemini NX column) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (157 mg, 42%) MS (ESI): m/z = 536.065 [M+H]+. Intermediates a) r4-(2-Chloro-phenyl)-pyridin-3-yll-oxazol-2-ylmethyl-amine
The title compound was prepared in analogy to example 72, from 4-iodo- V-(oxazol-2- ylmethyl)pyridin-3-amine and 2-chlorophenylboronic acid after a reaction time of 5 hours at reflux. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100), then EtOAc : MeOH (100 : 0 to 90 : 10). Light yellow solid (93%). MS (ESI): m/z = 286.074 [M+H]+. b) 4-Iodo-N-(oxazol-2-ylmethyl)pyridin-3-amine
The title compound was prepared in analogy to example 85, intermediate a, from tert-butyl 4-iodopyridin-3-yl(oxazol-2-ylmethyl)carbamate after a reaction time of 2 hours at room temperature. Off-white solid (98%). MS (ESI): m/z = 301.979 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl(oxazol-2-ylmethyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from tert-butyl 4-iodopyridin-3-ylcarbamate (example 85, intermediate d) and 2-(chloromethyl)oxazole after a reaction time of 3 hours at room temperature. The residue was purified by silica gel
chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow oil (92%). MS (ESI): m/z = 402.031 [M+H]+. Example 295
N-r4-(3-Fluoro-2-methyl-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000315_0001
The title compound was prepared in analogy to example 90, from [4-(3-fluoro-2-methyl- phenyl)-pyridin-3-yl]-methyl-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 23 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The Product was purified by preparative HPLC (Gemini NX column) with a gradient of MeOH : water (containing 0.05% formic acid) (80 : 20 to 98 : 2). Colorless solid (42%). MS (ESI): m/z 467.104 [M+H]+.
Intermediate r4-(3-Fluoro-2-methyl-phenyl)-pyridin-3-yll-methyl-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine (example 36, intermediate b) and 3-fluoro-2-methylphenylboronic after a reaction time of 24 hours at reflux. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (96%). MS (ESI): m/z = 217.114
[M+H]+.
Example 296
N-Carbamoylmethyl-N-r4-(2-chloro-phenyl)-pyridin-3-yll-3-methanesulfonyl-5-trifluoromethyl- benzamide
Figure imgf000316_0001
The title compound was prepared in analogy to example 117, from 2-[[4-(2-chloro-phenyl)- pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid after a reaction time of 4 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc : MeOH
(100 : 0 : 0 to 0 : 100 : 0 to 0 : 80 : 20). Colorless solid (66%). MS (ESI): m/z = 512.065 [M+H]+. Intermediates a) rr4-(2-Chloro-phenyl)-pyridin-3-yll-(3-methane
acetic acid
The title compound was prepared in analogy to example 84, from methyl 2-(N-(4-(2- chlorophenyl)pyridin-3-yl)-3-(methylsulfonyl)-5-(trifluoromethyl)benzamido)acetate (example 289) after a reaction time of 2 hours at room temperature. Off-white solid (101%). MS (ESI): m/z = 513.049 [M+H]+.
Example 297 rr4-(5-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- aminol -acetic acid methyl ester
Figure imgf000317_0001
To a solution of N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide (50 mg, 0.11 mmol) in THF (5 mL) were added potassium tert- butoxide (24 mg, 0.21 mmol) and methyl bromoacetate (22 mg, 0.14 mmol) at 0 °C and the reaction mixture was stirred for 12 hours at 25 °C. The reaction mixture was quenched with water (5 mL) and extracted by EtOAc (2x20 mL). The combined EtOAc layers were dried over Na2S04 and evaporated. The crude product was purified by preparative HPLC (ammonium acetate/acetonitrile) to get the desired compound as an off-white solid (8 mg, 14%). MS (ESI): m/z = 541.0 [M+H]+. Intermediates a) N-r4-(5-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-5-trifluoromethyl- benzamide
The title compound was prepared in analogy to example 90, from 4-(5-fluoro-2-methoxy- phenyl)-pyridin-3-ylamine and 3-methanesulfonyl-5-trifluoromethyl-benzoic acid (example 114, intermediate a) after a reaction time of 18 hours. The residue was purified by column
chromatography eluting with a gradient of n-hexane : EtOAc (40 : 60 to 20 : 80. Brown liquid (68%). MS (ESI): m/z = 469.2 [M+H]+. b) 4-(5-Fluoro-2-methoxy-phenyl)-pyridin-3-ylamine
The title compound was prepared in analogy to example 72, from 4-iodo-pyridin-3-ylamine (CAS RN 105752-11-2) and 3-fluoro-6-methoxy-phenylboronic acid (CAS RN 179897-94-0) after a reaction time of 18 hours at reflux. The compound was purified by column
chromatography eluting with a gradient of n-hexane : EtOAc (40 : 60 to 20 : 80). Yellow solid (84%). MS (ESI): m/z = 219.6 [M+H]+.
Example 298
3-Methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-N^
trifluoromethyl-benzamide
Figure imgf000318_0001
The title compound was prepared in analogy to example 72, intermediate, from (2,2,2- trifluoro-ethyl)-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-amine (37) and 3- methanesulfonyl-5-trifluoromethyl-benzoyl chloride (example 223, intermediate d) after a reaction time of 12 hours at 25 °C. The crude product was purified by preparative HPLC
(ammonium acetate/acetonitrile) to give the desired compound as an off-white solid (12 mg, 20%). MS (ESI): m/z = 587.2 [M+H]+.
Intermediates a) (2,2,2-Trifluoro-ethyl)-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-amine
The title compound was prepared in analogy to example 85, intermediate a, from (2,2,2- trifluoro-ethyl)-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-carbamic acid ie/ -butyl ester after a reaction time of 2 hours. Yellow solid (95%). MS (ESI): m/z = 337.6 [M+H]+. b) (2,2,2-Trifluoro-ethyl)-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from [4-(2- trifluoromethoxy-phenyl)-pyridin-3-yl]-carbamic acid tert-butylester and 2,2,2-trifluoroethyl trifluoromethanesulfonate after a reaction time of 12 hours. The resulting crude was purified by column chromatography eluting with a gradient of n-hexane : EtOAc (90 : 10 to 85 : 15). Light brown sticky liquid (66%). MS (ESI): m/z = 437.4 [M+H]+. c) r4-(2-Trifluoromethoxy-phenyl)-pyridin-3-yll-carbamic acid fe/ -butylester
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- carbamic acid ie/ -butyl ester and 2-trifluoromethoxyphenylboronic acid after a reaction time of 16 hours at reflux. The crude product was purified by column chromatography eluting with a gradient of n-hexane : EtOAc (80 : 20 to 70 : 30). Light yellow sticky liquid (80%). MS (ESI): m/z = 355.2 [M+H]+.
Example 299 (+)-N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-ri-(tetrahvdro-pyran-
3-yl)methyll-5-trifluoromethyl-benzamide
Figure imgf000319_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-((tetrahydro-2H-pyran-3-yl)methyl)pyridin-3-amine and 3-(methylsulfonyl)- 5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 90 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Chiral chromatography on a Ciralpak AD column with a gradient of ethanol (containing 0.05% formic acid) : n-heptane (40 : 60) furnished both enantiomers, with the desired enantiomer eluting second. Colorless solid (19%). MS (ESI): m/z = 567.158 [M+H]+.
Intermediates a) 4-(4-Fluoro-2-methoxyphenyl)-N-((tetrahydro-2H-pyran-3-yl)methyl)pyridin-3-amine
The title compound was prepared in analogy to example 72, from 4-iodo-N-((tetrahydro- 2H-pyran-3-yl)methyl)pyridin-3-amine and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 5 hours at reflux. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100) followed by EtOAc : MeOH (100 : 0 to 90 : 10).
Yellow oil (106%). MS (ESI): m/z = 317.166 [M+H]+. b) 4-Iodo-N-((tetrahvdro-2H-pyran-3-yl)methyl)pyridin-3-amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-iodopyridin-3-yl((tetrahydro-2H-pyran-3-yl)methyl)carbamate after a reaction time of 2 hours at room temperature (96%). MS (ESI): m/z = 319.030 [M+H]+. c) fe/ -Butyl 4-iodopyridin-3-yl((tetrahvdro-2H-pyran-3-yl)methyl)carbamate The title compound was prepared in analogy to example 85, intermediate c, from (4-iodo- pyridin-3-yl)-carbamic acid ieri-butyl ester (example 85, intermediate d) and 3- (bromomethyl)tetrahydro-2H-pyran after a reaction time of 24 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70).
Colorless oil (74%). MS (ESI): m/z = 419.083 [M+H]+.
Example 300
N-r4-(2-Chloro-phenyl)-6-methyl-pyridin-3-yll-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide
Figure imgf000320_0001
To a solution of 4-(2-chlorophenyl)-6-methyl-N-(2,2,2-trifluoroethyl)pyridin-3-amine
(0.066 g, 219 μιηοΐ) and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoyl chloride (66.1 mg, 230 μιηοΐ, example 223, intermediate d) in CH2CI2 (1 mL) was added DIPEA (56.7 mg, 76.7 μί, 439 μιηοΐ) and the clear yellow solution was stirred at room temperature for 4 hours. Another bactch of 3-(methylsulfonyl)-5-(trifluoromethyl)benzoyl chloride (66.1 mg, 230 μιηοΐ, example 223, intermediate d) and DIPEA (56.7 mg, 76.7 μί, 439 μιηοΐ) were added and stirring was continued for another 48 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (ISCO) system eluting with EtOAc (isocratic). The product was further purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Light brown solid (5%). MS (ESI): m/z = 551.06 [M+H]+. Intermediates a) 4-(2-chlorophenyl)-6-methyl-N-(2,2,2-trifluoroethyl)pyridin-3-amine
The title compound was prepared in analogy to example 72, from 4-iodo-6-methyl- V- (2,2,2-trifluoroethyl)pyridin-3-amine and 2-chlorophenylboronic acid after a reaction time of 15.5 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (71%). MS (ESI): m/z = 301.07 [M+H]+. b) 4-Iodo-6-methyl-N-(2,2,2-trifluoroethyl)pyridin-3-amine
The title compound was prepared in analogy to example 85, intermediate a, from ieri-butyl 4-iodo-6-methylpyridin-3-yl-(2,2,2-trifluoroethyl)carbamate after a reaction time of 2.5 hours. Colorless solid (58%). MS (ESI): m/z = 316.98 [M+H]+. c) fe/ -Butyl 4-iodo-6-methylpyridin-3-yl-(2,2,2-trifluoroethyl)carbamate
The title compound was prepared in analogy to example 85, intermediate c, from ieri-butyl 4-iodo-6-methylpyridin-3-ylcarbamate and 2,2,2-trifluoroethyl trifluoromethanesulfonate after a reaction time of 4 hours. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless solid (76%). MS (ESI): m/z = 417.03 [M+H]+. d) fe/ -Butyl 4-iodo-6-methylpyridin-3-ylcarbamate
To a solution of ieri-butyl 6-methylpyridin-3-ylcarbamate (9 g, 43.2 mmol) in diethyl ether (150 mL) was added TMEDA (5.27 g, 6.85 mL, 45.4 mmol) and the solution was cooled down to -75 °C. ft-Butyl lithium (1.6 M solution in hexane, 72.1 mL, 115 mmol) was added dropwise over 20 minutes. The orange suspension was stirred for 1.25 hours at temperatures between -14 to -25 °C. After cooling down to -75 °C a solution of iodine (16.8 g, 66.1 mmol) in diethyl ether (150 mL) was added dropwise over 45 minutes below -68 °C. The resulting mixture was stirred at -75 °C for 30 minutes before stirring in an ice bath for 1.75 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution (300 mL) and EtOAc (200 mL) and the layers were separated. The aqueous layer was extracted twice with EtOAc (100 mL). The organic layers were washed with 10% aqueous Na2S203 solution (100 mL) and brine (100 mL), dried over MgS04, filtered, treated with silica gel (30 g) and evaporated. The compound was purified by silica gel chromatography on a 330 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 50 : 50). The impure fractions were combined, purified by silica gel chromatography on a 120 g column using an MPLC (Flasmaster) system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 50 : 50). The product containing fractions were combined and evaporated until a suspension formed, which was filtered and washed with n-heptane. Colorless solid (2.84 g; 19%). MS (ESI): m/z = 335.1 [M+H]+. e) fe/ -Butyl 6-methylpyridin-3-ylcarbamate
To a suspension of 6-methylnicotinic acid (4.5 g, 32.8 mmol) in toluene (45.0 mL) were added DIPEA (4.67 g, 6.3 mL, 36.1 mmol) and diphenyl phosphorazidate (9.93 g, 7.78 mL, 36.1 mmol) and the suspension was stirred at room temperature for 15 minutes before ie/t-butanol (24.3 g, 30.8 mL, 328 mmol) was added and the reaction mixture was heated to 80 °C overnight. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted six times with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 120 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (5.05 g; 73%). MS (ESI): m/z = 209.1 [M+H]+.
Example 301
3-Chloro-N-r4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-5-methanesulfonyl-N- methyl-benzamide
Figure imgf000322_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N,6-dimethylpyridin-3-amine and 3-chloro-5-(methylsulfonyl)benzoic acid (example 114, intermediate a) after a reaction time of 15.5 hours. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless oil (41%). MS (ESI): m/z = 463.09 [M+H]+. Intermediates a) 4-(4-nuoro-2-methoxyphenyl)-N,6-dimethylpyridin-3-amine
The title compound was prepared in analogy to example 72, from (4-iodo-6-methyl- pyridin-3-yl)-methyl-amine and 4-fluoro-2-methoxyphenylboronic acid after a reaction time of 14.5 hours at reflux. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Light brown solid (84%). MS (ESI): m/z = 247.12 [M+H]+. b) (4-Iodo-6-methyl-pyridin-3-yl)-methyl-amine
The title compound was prepared in analogy to example 85, intermediate a, from (4-iodo- 6-methyl-pyridin-3-yl)-methyl-carbamic acid ieri-butyl ester after a reaction time of 1.25 hours. Colorless solid (99%). MS (ESI): m/z = 248.99 [M+H]+. c) (4-Iodo-6-methyl-pyridin-3-yl)-methyl-carbamic acid fe/t-butyl ester
The title compound was prepared in analogy to example 85, intermediate c, from ieri-butyl 4-iodo-6-methylpyridin-3-ylcarbamate (example 300, intermediate d) and iodomethane after a reaction time of 4 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Light brown solid (0.846 g; 81%). MS (ESI): m/z = 369.04 [M+H]+.
Example 302
N-r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-N-methyl-3-(morpholine-4-sulfonyl)-
5 -trifluorometh yl-benzamide
Figure imgf000323_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N,6-dimethylpyridin-3-amine (example 301, intermediate a) and 3- (morpholinosulfonyl)-5-(trifluoromethyl)benzoic acid (example 256, intermediate) after a reaction time of 15.5 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system eluting with EtOAc (isocratic). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1 % formic acid) (20: 80 to 98 : 2). Colorless oil (67%). MS (ESI): m/z = 568.15 [M+H]+.
Example 303
3-Bromo-N-r4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-N-methyl-5-trifluoromethyl- benzamide
Figure imgf000324_0001
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N,6-dimethylpyridin-3-amine (example 301, intermediate a) and 3-bromo-5- (trifluoromethyl)benzoic acid after a reaction time of 20 hours. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (88%). MS (ESI): m/z = 497.05 [M+H]+.
Example 304 3 -( 1, 1 -Dioxo-thiomorpholine-4- sulfonyl)- V- r4-(4-fluoro-2-methoxy-phenyl)-pyridin-3 -yll -N- methyl-5-trifluoromethyl-benzamide
Figure imgf000324_0002
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N-methylpyridin-3-amine (example 129, intermediate) and 3-(l,l-dioxo- thiomorpholine-4-sulfonyl)-5-trifluoromethyl-benzoic after a reaction time of 46 hours.The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). The product-containing fractions were pooled, evaporated and dissolved in EtOAc. The organic layer was extracted three times with aqueous 1M NaOH solution and once with brine, dried over MgS04, filtered and evaporated. Light brown solid (3%). MS (ESI): m/z = 602.10 [M+H]+.
Intermediates a) 3-(lJ-Dioxo-thiomorpholine-4-sulfonyl)-5-trifluoromethyl-benzoic acid
The title compound was prepared in analogy to example 84, from 3-(l,l-dioxo- thiomorpholine-4-sulfonyl)-5-trifluoromethyl-benzoic acid methyl after a reaction time of 3 hours. Colorless solid (95%). MS (ESI): m/z = 386.00 [M-H]". b) 3-(lJ-Dioxo-thiomorpholine-4-sulfonyl)-5-trifluoromethyl-benzoic acid methyl ester
To a solution of methyl 3-(chlorosulfonyl)-5-(trifluoromethyl)benzoate (1 g, 3.3 mmol, Buttpark Ltd.) and DIPEA (641 mg, 866 μί, 4.96 mmol) in CH2C12 (4 mL) was added dropwise a solution of thiomorpholine 1,1-dioxide (447 mg, 3.3 mmol, CAS RN 39093-93-1) in CH2C12 (4.00 mL). After 90 min tes the suspension was poured on saturated aqueous NH4C1 solution and CH2C12 and the layers were separated. The aqueous layer was extracted twice with CH2C12. The organic layers were dried over MgS04, filtered and evaporated. The compound was purified by silica gel chromatography on a 50 g column using an MPLC (Flasmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 80 : 20). Light brown solid (0.99 g; 74%). MS (ESI): m/z = 419.05 [M+NH4]+.
Example 305
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-N-methyl-3-(2-oxa-6-aza-spiror3.31heptane-6- sulfonyl)-5-trifluoromethyl-benzamide
Figure imgf000325_0001
The title compound was prepared in analogy to example 90, from [4-(4-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-methyl-amine (example 129, intermediate) and 3-(2-oxa-6- azaspiro[3.3]heptan-6-ylsulfonyl)-5-(trifluoromethyl)benzoic acid after a reaction time of 90 hours at room temperature. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (61%). MS (ESI): m/z = 566.136 [M+H]+.
Intermediates a) 3-(2-Qxa-6-azaspiror3.31heptan-6-ylsulfonyl)-5-(trifluoromethyl)benzoic acid
The title compound was prepared in analogy to example 84, from methyl 3-(2-oxa-6- azaspiro[3.3]heptan-6-ylsulfonyl)-5-(trifluoromethyl)benzoate after a reaction time of 3 hours. Colorless solid (99%). MS (ESI): m/z = 350.033 [M-H]~. b) Methyl 3-(2-oxa-6-azaspiror3.31heptan-6-ylsulfonyl)-5-(trifluoromethyl)benzoate
To an ice-cooled solution of methyl 3-(chlorosulfonyl)-5-(trifluoromethyl)benzoate (1 g, 1.33 mmol, Buttpark Ltd.) in CH2CI2 (10 mL) was added N,N-ethyldiisopropylamine (1.28 g, 1.73 mL, 9.91 mmol, Eq: 3) and 2-oxa-6-aza-spiro[3.3]heptane oxalate (524 mg, 1.82 mmol). The reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL CH2CI2 and the layers were separated. The aqueous layer was extracted a second time with 30 mL CH2CI2. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 30 : 70). Colorless solid (460 mg, 38.1%). MS (ESI): m/z = 365 [M+H]+.
Example 306
N-r4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfonyl-N-(2-methanesulfonyl- ethyl)-5-trifluoromethyl-benzamide
Figure imgf000326_0001
To a solution of 4-(4-fluoro-2-methoxyphenyl)-N-(2-(methylsulfonyl)ethyl)pyridin-3- amine (0.08 g, 247 μηιοΐ, examplel92, intermediate a) and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoyl chloride (177 mg, 617 μιηοΐ, example 223, intermediate d) in CH2CI2 (2 mL) was added DIPEA (128 mg, 172 μί, 987 μιηοΐ) and the clear solution was stirred at room temperature for 19 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2CI2 and the layers were separated. The aqueous layer was extracted twice with CH2CI2. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (0.075 g; 52%). MS (ESI): m/z = 575.09 [M+H]+.
Example 307
N-r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-3-methanesulfonyl-N-(2,2,2- trifluoro-ethyl)-5-trifluoromethyl-benzamide
Figure imgf000327_0001
The title compound was prepared in analogy to example 72, intermediate, from 4-(4- fluoro-2-methoxyphenyl)-6-methyl-N-(2,2,2-trifluoroethyl)pyridin-3-amine and 3- (methylsulfonyl)-5-(trifluoromethyl)benzoyl chloride (example 223, intermediate d) after a reaction time of 42 hours. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1 % formic acid) (20: 80 to 98 : 2). Colorless solid (32%). MS (ESI): m/z = 565.10 [M+H]+.
Intermediates a) 4-(4-Fluoro-2-methoxyphenyl)-6-methyl-N-(2,2,2-trifluoroethyl)pyridin-3-amine
The title compound was prepared in analogy to example 72, from 4-iodo-6-methyl- V- (2,2,2-trifluoroethyl)pyridin-3-amine (example 300, intermediate b) and 4-fluoro-2- methoxyphenylboronic acid after a reaction time of 16.5 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (83%). MS (ESI): m/z = 315.11 [M+H]+.
Example 308
3-Methanesulfonyl-N-(2-methanesulfonyl-ethyl)-N-r4-(2-trifluoromethoxy-phenyl)-pyridin-3- yll -5-trifluoromethyl-benzamide
Figure imgf000328_0001
The title compound was prepared in analogy to example 72, intermediate, from (2- methanesulfonyl-ethyl)-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-amine, DIPEA and 3- methanesulfonyl-5-trifluoromethyl-benzoyl chloride (example 223, intermediate d) in CH2CI2 after a reaction time of 12 hours at 25 °C. The crude thus obtained was purified by preparative HPLC (ammonium acetate/acetonitrile) to furnish the title compound as an off-white solid (15 mg, 13%). MS (ESI): m/z = 611.2 [M+H]+.
Intermediates a) (2-Methanesulfonyl-ethyl)-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-amine (41) The title compound was prepared in analogy to example 298, intermediate a, from (2- methanesulfonyl-ethyl)-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-carbamic acid tert-buty\ ester. Brown solid (97%). MS (ESI): m/z = 361.0 [M+H]+. b) (2-Methanesulfonyl-ethyl)-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-carbamic acid tert- butyl ester The title compound was prepared in analogy to example 298, intermediate b, from [4-(2- trifluoromethoxy-phenyl)-pyridin-3-yl]-carbamic acid ie/ -butyl ester and l-chloro-2- (methylsulfonyl)ethane and using a gradient of n-hexane : EtOAc (50 : 50 to 40 : 60) for the chromatographic purification. Colourless sticky solid (96%). MS (ESI): m/z = 461.4 [M+H]+. Example 309
N-Carbamoylmethyl-N-r4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yll-3-methanesulfo
trifluoromethvl-benzamide
Figure imgf000329_0001
The title compound was prepared in analogy to example 117, from [[4-(5-fluoro-2- methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid after a reaction time of 4 hours. The crude product was purified by preparative HPLC (ammonium acetate/acetonitrile) to get the desired product as a colourless sticky solid (35%). MS (ESI): m/z = 526.4 [M+H]+.
Intermediate rr4-(5-Fluoro-2-methoxy-phenyl)-pyridin-3-yll-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- aminol -acetic acid
The title compound was prepared in analogy to example 84, from [[4-(5-fluoro-2-methoxy- phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]-acetic acid methyl ester (example 297) after a reaction time of 3 hours at 25 °C. The product was purified by preparative HPLC (ammonium acetate/acetonitrile) to yield the title compound as an off-white solid (40%). MS (ESI): m/z = 527.2 [M+H]+.
Example 310
N-r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-N-methyl-3-(oxetan-3-ylsulfanyl)-5- trifluoromethyl-benzamide
Figure imgf000329_0003
Figure imgf000329_0002
To a solution of N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-3-mercapto-N- methyl-5-(trifluoromethyl)benzamide (0.093 g, 206 μηιοΐ) in acetonitrile (2 niL) were added 3- iodooxetane (57.0 mg, 310 μηιοΐ) and DIPEA (66.7 mg, 90.1 μί, 516 μηιοΐ) and the clear, light yellow solution was heated under reflux for 2.5 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless foam (0.05 g; 47%). MS (ESI): m/z = 507.14 [M+H]+. Intermediates a) N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-3-mercapto-N-methyl-5- (trifluoromethyl)benzamide
To a solution of N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-N-methyl-3- (trifluoromethyl)-5-(2-(trimethylsilyl)ethylthio)benzamide (0.477 g, 866 μιηοΐ) in THF (10 mL) was added tetrabutylammonium fluoride (1M solution in THF, 4.55 mL, 4.55 mmol) and the the clear, light yellow solution was stirred at room temperature for 75 minutes. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of CH2C12 : MeOH (100 : 0 to 90 : 10). Light brown solid (93%). MS (ESI): m/z = 449.10 [M+H]+. b) N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-N-methyl-3-(trifluoromethyl)-5-(2- (trimethylsilyl)ethylthio)benzamide
A solution of 3-bromo-N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-N-methyl-5- (trifluoromethyl)benzamide (0.59 g, 1.19 mmol) and 2-(trimethylsilyl)ethanethiol (159 mg, 187 μί, 1.19 mmol) in dioxane (5.9 mL) was stirred under argon for 5 minutes in a sealed tube. To the clear, light yellow solution were added tris(dibenzylideneacetone)dipalladium (0) (27.2 mg, 29.7 μιηοΐ, CAS RN 52409-22-0), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (34.3 mg, 59.3 μιηοΐ, CAS RN 161265-03-8 ) and DIPEA (307 mg, 414 μΐ,, 2.37 mmol) and the reaction mixture was stirred at 120 °C for 5.5 hours, followed by stirring at room temperature overnight. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueos layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified twice by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Off-white solid (0.483 g; 73%). MS (ESI): m/z = 551.18 [M+H]+. c) 3-Bromo-N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-N-methyl-5-
(trifluoromethyl)benzamide
The title compound was prepared in analogy to example 90, from 4-(4-fluoro-2- methoxyphenyl)-N,6-dimethylpyridin-3-amine and 3-bromo-5-(trifluoromethyl)benzoic acid after a reaction time of 20 hours. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (88%). MS (ESI): m/z = 497.05 [M+H]+.
Example 311
N-Cvanomethyl-3-methanesulfonyl-N-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-5- trifluoromethyl-benzamide
Figure imgf000331_0001
To a solution of 2-(4-(2-(trifluoromethoxy)phenyl)pyridin-3-ylamino)acetonitrile (0.07 g, 239 μιτιοΐ) in CH2CI2 (2 mL) were added 3-(methylsulfonyl)-5-(trifluoromethyl)benzoyl chloride (137 mg, 477 μιτιοΐ, example 223, intermediate d) and DIPEA (123 mg, 167 μί, 955 μιτιοΐ) and the clear, yellow solution was stirred at room temperature for 18 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2CI2 and the layers were separated. The aqueous layer was extracted three times with CH2CI2. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1 % formic acid) (20: 80 to 98 : 2). Colorless solid (0.085 g; 65%). MS (ESI): m/z = 544.08 [M+H]+. Intermediates a) 2-(4-(2-(Trifluoromethoxy)phenyl)pyridin-3-ylamino)acetonitrile
To a solution of cyanomethyl-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-carbamic acid ie/ -butyl ester (185 mg, 0.47 mmol) in CH2CI2 (5 mL) was added trifluoroacetic acid (1 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours and then concentrated under vacuum. The residue was dissolved in 10 mL aqueous sodium bicarbonate solution and 20 mL CH2CI2 and the layers were separated. The aqueous layer was extracted again with 10 mL CH2CI2. The combined organic layer was washed with 20 mL brine, dried over Na2S04, filtered and concentrated under vacuum. The resulting light yellow solid was pure enough to be used in the next step without further opurification (115 mg, 83%). LC-MS (ESI): m/z = 294.0 (M+H). b) Cvanomethyl-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-carbamic acid fe/ -butyl ester
To a solution of [4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-carbamic acid ie/ -butyl ester (190 mg, 0.54 mmol) in DMF (5 mL) was added sodium hydride (24 mg, 0.59 mmol, 60% dispersion in mineral oil) at 0 °C. The reaction mixture was stirred at 25 °C for 30 minutes. Then bromoacetonitrile (71 mg, 0.59 mmol) was added to the reaction mixture and it was stirred at 25 °C for 24 hours. The reaction mixture was quenched with 10 mL saturated NH4C1 solution and extracted with EtOAc (2x40 mL). The combined EtOAc part was dried over Na2S04 and evaporated. The residue crude was purified by silica gel column chromatography eluting with a gradient of n-hexane : EtOAc (85 : 15 to 70 : 30) to get the desired compound as a light yellow sticky liquid (185 mg, 88 %). LC-MS (ESI): m/z = 394.4 [M+H]+. c) r4-(2-Trifluoromethoxy-phenyl)-pyridin-3-yll-carbamic acid tert-butylester
To a solution of (4-iodo-pyridin-3-yl)-carbamic acid tert-butyl ester (500 mg, 1.56 mmol, example 85, intermediate d) in 6 mL DME were added 2-trifluoromethoxyphenylboronic acid (643 mg, 3.12 mmol) and 2M aqueous Na2C03 solution (2.0 mL) and the reaction mixture was purged with nitrogen for 15 min. Then Pd(OAc)2 (36 mg, 0.16 mmol) and triphenylphosphine (82 mg, 0.31 mmol) were added and the reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted with 30 mL EtOAc. The combined organic layer was washed with 30 mL brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography eluting with a gradient of n-hexane : EtOAc (80 : 20 to 70 : 30) to yield the desried compound as a light yellow sticky liquid (440 mg, 80%). LC-MS: m/z = 355.0 [M+H]+. Example 312
5-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-methyl-carbamoyl|-5- trifluoromethyl-phenylsulfanvD-pentanoic acid
Figure imgf000333_0001
To a solution of N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-3-mercapto-N- methyl-5-(trifluoromethyl)benzamide (0.263 g, 584 μηιοΐ, example 310, intermediate a) in acetonitrile (4 mL) were added 5-bromopentanoic acid (132 mg, 730 μιηοΐ) and DIPEA (189 mg, 255 μί, 1.46 mmol) and the clear, light yellow solution was stirred at room temperature for 2.25 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system eluting with a gradient of CH2C12 : MeOH (100 : 0 to 50 : 50). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.119 g, 74%). MS (ESI): m/z = 551.16 [M+H]+.
Example 313
N-(2-Chloro-r3,41bipyridinyl-3'-yl)-3-methanesulfonyl-N-methyl-5-trifluoromethyl-benzamide
Figure imgf000333_0002
The title compound was prepared in analogy to example 90, from 2-chloro-N-methyl-3,4'- bipyridin-3'-amine and 3-(methylsulfonyl)-5-(trifluoromethyl)benzoic acid (example 114, intermediate a) after a reaction time of 18 hours. The compound was purified by silica gel chromatography on a 20 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (12%). MS (ESI): m/z = 470.055 [M+H]+.
Intermediate
2-Chloro-N-methyl-3,4'-bipyridin-3'-amine
The title compound was prepared in analogy to example 72, from (4-iodo-pyridin-3-yl)- methyl-amine and 2-chloropyridin-3-ylboronic acid after a reaction time of 5 hours at 90 °C. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Light yellow solid (82%). MS (EI): m/z = 219 [M]+.
Example 314
N-r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide
Figure imgf000334_0002
Figure imgf000334_0001
To an ice-cold solution of N-(4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)-N- methyl-3-(oxetan-3-ylthio)-5-(trifluoromethyl)benzamide (0.045 g, 88.8 μιηοΐ, example 310) in MeOH (2 mL) and water (0.5 mL) was added oxone® (137 mg, 222 μιηοΐ) and stirring was continued at room temperature for 2.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was saturated with sodium chloride, extracted three times with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered and evaporated. The compound was purified by silica gel chromatography on a 10 g column using an MPLC (ISCO) system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Light brown foam (0.038 g; 79%). MS (ESI): m/z = 539.13 [M+H]+. Example 315 r5-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-methyl-carbamoyl|-5- trifluoromethyl-phenylsulfanvD-pentanoylaminol -acetic acid
Figure imgf000335_0001
The title compound was prepared in analogy to example 84, from methyl 2-(5-(3-((4-(4- fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenyl- thio)pentanamido)acetate after a reaction time of 1.5 hours. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless foam (65%). MS (ESI): m/z = 608.18 [M+H]+. Intermediates a) Methyl 2-(5-(3-((4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3-yl)(methyl)carbamoyl)-5- (trifluoromethyl)phenylthio)pentanamido)acetate
To a solution of 5-(3-((4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3- yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenylthio)pentanoic acid (0.15 g, 272 μιηοΐ, example 312) in DMF (1 mL) was added Ι,Γ-carbonyldiimidazole (66.3 mg, 409 μιηοΐ) and the clear solution was stirred at room temperature for 45 minutes before glycin methyl ester hydrochloride (37.6 mg, 300 μιηοΐ) was added. Reaction mixture was stirred at room temperature for 20.5 hours before DIPEA (35.2 mg, 47.6 μί, 272 μιηοΐ) and glycin methyl ester hydrochloride (37.6 mg, 300 μιηοΐ) was added. After 23 hours the reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with water and once with brine, dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 20 g column using a MPLC system eluting with a gradient of CH2CI2 : MeOHe (100 : 0 to 90 : 10). Colorless foam (0.142 g; 79%). MS (ESI): m/z = 622.20 [M+H]+. Example 316
5-(3-i r4-(5-Chloro-4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-methyl-carba
trifluoromethyl-benzenesulfonvD-pentanoic acid
Figure imgf000336_0001
To an ice-cold, turbid solution of 5-(3-((4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3- yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenylthio)pentanoic acid (0.115 g, 209 μηιοΐ, example 312) in MeOH (7 mL) and water (0.5 mL) was added oxone® (321 mg, 522 μιηοΐ) and the reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was poured on 10% aqueous citric acid solution and EtOAc and the layers were separated. The aqueous layer was saturated with sodium chloride, extracted three times with EtOAc. The organic layers were washed once with 10% aqueous Na2S203 solution and once with brine, dried over MgS04, filtered and evaporated. The compound was purified by silica gel chromatography on a 20 g column using an MPLC (Flashmaster) system eluting with a gradient of CH2C12 :
MeOH (100 : 0 to 90 : 10). The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.065 g; 50%). MS (ESI): m/z = 617.11 [M+H]+.
Example 317 r5-(3-i r4-(4-Fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yll-methyl-carbamoyl|-5- trifluoromethyl-benzenesulfonyD-pentanoylaminol -acetic acid
Figure imgf000336_0002
To an ice-cold solution of 2-(5-(3-((4-(4-fluoro-2-methoxyphenyl)-6-methylpyridin-3- yl)(methyl)carbamoyl)-5-(trifluoromethyl)phenylthio)pentanamido)acetic acid (0.08 g, 132 μιηοΐ, example 315) in MeOH (2 mL) and water (0.5 ml) was added oxone® (202 mg, 329 μιηοΐ) and the white suspension was stirred at room temperature for 3.5 hours. The reaction mixture was poured on 10% aqueous Na2S203 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed once with brine, dried over MgS04, filtered, and evaporated. The crude product (0.11 g) was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless solid (0.068 g; 80%). MS (ESI): m/z = 640.17 [M+H]+.
Example 318
3-Methanesulfonyl-N-methyl-N-{ 6-methyl-4-r2-(oxetan-3-yloxy)-phenyll-pyridin-3-yl|-5- trifluoromethyl-benzamide
Figure imgf000337_0001
To a solution of N-(4-(2-hydroxyphenyl)-6-methylpyridin-3-yl)-N-methyl-3- (methylsulfonyl)-5-(trifluoromethyl)benzamide (100 mg, 215 μιηοΐ) in DMF (2 mL) was added K2C03 (59.5 mg, 431 μιηοΐ) and 3-iodooxetane (43.6 mg, 237 μιηοΐ). The reaction mixture was stirred for 2 hours at room temperature followed by stirring for 18 hours at 80 °C. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel chromatography on a 10 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n -heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (30 mg, 27%). MS (ESI): m/z = 521.134 [M+H]+.
Intermediates a) N-(4-(2-hvdroxyphenyl)-6-methylpyridin-3-yl)-/V-methyl-3-(methylsulfonyl)-5- (trifluoromethyl)benzamide To a solution of N-(4-(2-(benzyloxy)phenyl)-6-methylpyridin-3-yl)-/V-methyl-3-
(methylsulfonyl)-5-(trifluoromethyl)benzamide (1.63 g, 2.94 mmol) in MeOH (16 mL) and EtOAc (16 mL) was added Pd on carbon (10%, 200 mg, 2.94 mmol) under argon atmosphere. The reaction was evacuated and purged with hydrogen. The reaction was stirred for 5 hours at 1.7 bar under hydrogen atmosphere. The reaction mixture was filtered over dicalite. The filtrate was concentrated under vacuum and the compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (1.367 g, 100%). MS (ESI): m/z = 465.109 [M+H]+. b) N-(4-(2-(benzyloxy)phenyl)-6-methylpyridin-3-yl)-N-methyl-3-(methylsulfonyl)-5- (trifluoromethyl)benzamide
The title compound was prepared in analogy to example 90, from 4-(2- (benzyloxy)phenyl)-N,6-dimethylpyridin-3-amine and 3-(methylsulfonyl)-5- (trifluoromethyl)benzoic acid (1.49 g, 5.55 mmol, example 114, intermediate a) after a reaction time of 3.5 days at room temperature. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 10 : 90). Off-white solid (53%). MS (ESI): m/z = 555.156 [M+H]+. c) 4-(2-(Benzyloxy)phenyl)-N,6-dimethylpyridin-3-amine The title compound was prepared in analogy to example 72, intermediate a, from (4-iodo-6- methyl-pyridin-3-yl)-methyl-amine (example 301, intermediate b) and 2- (benzyloxy)phenylboronic acid after a reaction time of 5 hours at 90 °C. The compound was purified by silica gel chromatography on a 50 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 20 : 80). Yellow solid (93%). MS (ESI): m/z = 305.165 [M+H]+.
Example 319
N-Carbamoylmethyl-3-methanesulfonyl-N-r4-(2-trifluoromethoxy-phenyl)-pyridin-3-yll-5- trifluoromethyl-benzamide
Figure imgf000338_0001
To a solution of { (3-methanesulfonyl-5-trifluoromethyl-benzoyl)-[4-(2-trifluoromethoxy- phenyl)-pyridin-3-yl]-amino}-acetic acid (190 mg, crude, 0.34 mmol) in DMF (2 mL) were added EDC (130 mg, 0.68 mmol), HOBt-NH3 complex (103 mg, 0.68 mmol) and N,N diisopropyl ethylamine (0.57 mL, 3.37 mmol) and the reaction mixture was stirred at room temperature for 4 hours. The solvent was evaporated and the resulting residue was dissolved in EtOAc (15 niL) and washed with water (2x10 niL) and brine (10 niL). The organic layer was dried (Na2S04) and evaporated under reduced pressure. The residue was purified by preparative HPLC (ammonium acetate/acetonitrile) to yield the desired compound as a brown solid (23 mg, 4% from intermediate c). MS (ESI): m/z = 562.0 [M+H]+.
Intermediates a) {(3-Methanesulfonyl-5-trifluoromethyl-benzoyl)-r4-(2-trifluoromethoxy-phenyl)-pyridin-3- yll -amino I -acetic acid
The title compound was prepared in analogy to example 84, from [{(3-methanesulfonyl-5- trifluoromethyl-benzoyl)-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester and was used in the next step without further purification. Brown solid. MS (ESI): m/z = 563.2 [M+H]+. b) {(3-Methanesulfonyl-5-trifluoromethyl-benzoyl)-r4-(2-trifluoromethoxy-phenyl)-pyridin-3- yll -amino I -acetic acid methyl ester The title compound was prepared in analogy to example 284, from [4-(2-trifluoromethoxy- phenyl)-pyridin-3-ylamino]-acetic acid methyl ester and 3-methanesulfonyl-5-trifluoromethyl- benzoyl chloride (example 223, intermediate d). The crude product was used in the next step without further purification. Brown sticky liquid. MS (ESI): m/z = 577.2 [M+H]+. c) r4-(2-Trifluoromethoxy-phenyl)-pyridin-3-ylaminol-acetic acid methyl ester The title compound was prepared in analogy to example 298, intermediate c, from (4-iodo- pyridin-3-ylamino)-acetic acid methyl ester (example 176, intermediate b) and 2- trifluoromethoxyphenyl boronic acid (CAS RN 175676-65-0). Yellow liquid (87%). MS (ESI): m/z = 328.4 [M+H]+.
Example 320
3-j 3'-r(3-Methanesulfonyl-5-trifluoromethyl-benzoyl)-me
yloxyj-azetidine-l-carboxylic acid fe/t-butyl ester
Figure imgf000340_0001
To a solution of ie/ -butyl 3-(3'-(methylamino)-3,4'-bipyridin-2-yloxy)azetidine-l- carboxylate (0.149 g, 418 μηιοΐ) in CH2C12 (4 niL) were added 3-(methylsulfonyl)-5- (trifluoromethyl)benzoyl chloride (240 mg, 836 μηιοΐ, example 223, intermediate d) and DIPEA (216 mg, 292 μί, 1.67 mmol) and the light yellow solution was stirred a troom temperature for 24 hours. Another batch of 3-(methylsulfonyl)-5-(trifluoromethyl)benzoyl chloride (164 mg, 573 μιηοΐ) and DIPEA (162 mg, 219 μί, 1.25 mmol) was added and stirring was continued at room temperature for 24 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2C12 and the layers were separated. The aqueous layer was extracted three times with CH2C12. The organic layers were dried over MgS04, filtered, treated with silica gel and evaporated. The compound was twice purified by silica gel chromatography on a 20 g column using an MPLC system eluting with EtOAc. Light yellow gum (0.105 g; 41 %). MS (ESI): m/z = 607.18 [M+H]+.
Intermediates a) fe/ -Butyl 3-(3'-(methylamino)-3,4'-bipyridin-2-yloxy)azetidine- l-carboxylate
To a solution of ieri-butyl 3-hydroxyazetidine-l-carboxylate (81.1 mg, 468 μιηοΐ, Fluorochem) in DMF (1 mL) was added sodium hydride (approx. 55% in mineral oil) (18.6 mg, 426 μιηοΐ) and the resulting suspension was stirred at room temperature for 30 minutes until gas evolution ceased. To the turbid solution was added N-(2-chloro-3,4'-bipyridin-3'-yl)-N-methyl-3- (methylsulfonyl)-5-(trifluoromethyl)benzamide (0.1 g, 213 μιηοΐ) in one portion. The light brown reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and EtOAc and the layers were separated. The aqueous layer was extracted twice with EtOAc. The organic layers were washed twice with water and once with brine, dried over MgS04, filtered and evaporated. The product was purified by preparative HPLC (Gemini NX column) using a gradient of MeOH : water (containing 0.1% formic acid) (20: 80 to 98 : 2). Colorless oil (0.027 g; 35%). MS (ESI): m/z = 357.19 [M+H]+. b) N-(2-chloro-3^'-bipyridin-3'-yl)-N-methyl-3-(methylsulfonyl)-5-(trifluoromethyl)benzamide
To a solution of 2-chloro-N-methyl-3,4'-bipyridin-3'-amine (0.2 g, 910 μιηοΐ, example 313, intermediate a) in CH2CI2 (5 mL) were added 3-(methylsulfonyl)-5-(trifluoromethyl)benzoyl chloride (522 mg, 1.82 mmol, example 223, intermediate d) and DIPEA (471 mg, 636 μί, 3.64 mmol) and the light yellow solution was stirred at room temperature for 16 hours. The reaction mixture was poured on saturated aqueous NH4C1 solution and CH2CI2 and the layers were separated. The aqueous layer was extracted four times with CH2CI2. The organic layers dried over MgS04, filtered, treated with silica gel and evaporated. The compound was purified by silica gel chromatography on a 10 g column using a MPLC system eluting with a gradient of n- heptane : EtOAc (100 : 0 to 0 : 100). Light brown foam (0.393 g; 91%). MS (ESI): m/z = 470.06 [M+H]+.
Example 321 3-Methanesulfonyl-N-methyl-N-{ 6-methyl-4-r2-(oxetan-3-ylmethoxy)-phenyll-pyridin-3-yl|-5- trifluoromethyl-benzamide
Figure imgf000341_0001
To a solution N-(4-(2-hydroxyphenyl)-6-methylpyridin-3-yl)-N-methyl-3-(methylsulfonyl)- 5-(trifluoromethyl)benzamide (100 mg, 215 μιηοΐ, example 318, intermediate a) in DMF (2 ml) was added K2CO3 (59.5 mg, 431 μιηοΐ) and oxetan-3-ylmethyl 4-methylbenzenesulfonate (57.4 mg, 237 μιηοΐ). The reaction mixture was stirred for 2 hours at room temperature and for 18 hours at 80 °C. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted a second time with 30 mL EtOAc. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel
chromatography on a 10 g column using an MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 0 : 100). Colorless solid (87 mg, 76%). MS (ESI): m/z = 535.150 [M+H]+. Intermediate
Qxetan-3 - ylmethyl 4-methylbenzenesulfonate
To a solution of oxetan-3-yl-methanol (300 mg, 3.41 mmol, CAS RN 6246-06-6) in
CH2C12 (3 mL) was added triethylamine (517 mg, 712 μΐ, 5.11 mmol), DMAP (41.6 mg, 341 μιηοΐ) and /?-toluenesulfonyl chloride (779 mg, 4.09 mmol) at 0 °C. The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was poured on 30 mL 1M aqueous HCl and 30 mL CH2C12 and the layers were separated. The aqueous layer was extracted a second time with 30 mL CH2C12. The organic layers were washed with 30 mL brine, dried over MgS04, filtered and concentrated under vacuum. The compound was purified by silica gel
chromatography on a 20 g column using a MPLC system (CombiFlash Companion, Isco Inc.) eluting with a gradient of n-heptane : EtOAc (100 : 0 to 50 : 50). Colorless liquid (595 mg, 72%).
Example 322
N-Methyl-N-(4-phenyl-pyridin-3-yl)-3,5-b¾' -trifluoromethyl-benzamide
Figure imgf000342_0001
To a solution of methyl-(4-phenyl-pyridin-3-yl)-amine (160 mg, 0.87 mmol) in THF (4 mL) under nitrogen was added LiHMDS (1.3 mL, 1.3 mmol, 1M solution in THF) at -78 °C and the resulting reaction mixture was stirred for 30 min. at -78 °C. Then 3,5-bis(trifluoromethyl)- benzoyl chloride (480 mg, 1.74 mmol, CAS RN 1271-19-8) in THF (1 mL) was added to the reaction mixture at -78 °C and the reaction mixture was stirred for another 12 hours at 25 °C. The reaction mixture was quenched with 10 mL saturated NH4C1 solution and extracted with EtOAc (2x20 mL). The combined organic layers were dried and evaporated. The crude product was purified by preparative HPLC (ammonium acetate/acetonitrile) to furnish the desired compound as off-white solid (125 mg, 34%). MS (ESI): m/z = 425.2 [M+H]+.
Intermediate Methyl-(4-phenyl-pyridin-3-yl)-amine
To a solution of (4-iodo-pyridin-3-yl)-methyl-amine (225 mg, 0.96 mmol, example 36, intermediate b) in DME (5 mL) were added phenyl boronic acid (234 mg, 1.92 mmol) and 2M aqueous Na2C03 solution (2 mL) and the reaction mixture was purged with nitrogen for 15 min. Then Pd(OAc)2 (22 mg, 0.1 mmol) and triphenylphosphine (50 mg, 0.19 mmol) were added and the reaction mixture was stirred at 100 °C for 5 hours. The reaction mixture was poured on 30 mL 10% aqueous NaHC03 solution and 30 mL EtOAc and the layers were separated. The aqueous layer was extracted with 30 mL EtOAc. The combined organic layer was washed with brine (30 mL), dried over Na2S04 and evaporated. The residue was purified by column chromatography eluting with a gradient of n-hexane : EtOAc (80 : 20 to 70 : 30) to yield the desired compound as a yellow solid (160 mg, 90 %) MS (ESI): m/z = 185.0 [M+H]+.
Example 323 3-Methanesulfonyl-N-methyl-N-(4-phenyl-pyridin-3-yl)-5-trifluoromethyl-benzamide
Figure imgf000343_0001
The title compound was prepared in analogy to example 284, from methyl-(4-phenyl- pyridin-3-yl)-amine (example 322, intermediate) and 3-methanesulfonyl-5-trifluoromethyl- benzoic acid (example 114, intermediate a). Off-white solid (34%). MS (ESI): m/z = 435.2 [M+H]+.
Example A
Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per tablet
Kernel:
Compound of formula I 10.0 mg 200.0 mg
Microcrystalline cellulose 23.5 mg 43.5 mg
Lactose hydrous 60.0 mg 70.0 mg
Polyvinylpyrrolidone K30 12.5 mg 15.0 mg
Sodium starch glycolate 12.5 mg 17.0 mg
Magnesium stearate 1.5 mg 4.5 mg
(Kernel Weight) 120.0 mg 350.0 mg Film Coat:
Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg
Polyethylene glycol 6000 0.8 mg 1.6 mg
Talc 1.3 mg 2.6 mg
Iron oxyde (yellow) 0.8 mg 1.6 mg
Titan dioxide 0.8 mg 1.6 mg
The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 120 or 350 mg, respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat. Example B
Capsules containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per capsule
Compound of formula I 25.0 mg
Lactose 150.0 mg
Maize starch 20.0 mg
Talc 5.0 mg
The components are sieved and mixed and filled into capsules of size 2.
Example C
Injection solutions can have the following composition:
Compound of formula I 3.0 mg
Polyethylene Glycol 400 150.0 mg
Acetic acid q.s. ad pH 5.0
Water for injection solutions ad 1.0 ml
The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by Acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized. Example D
Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
Capsule contents
Compound of formula I 5.0 mg
Yellow wax 8.0 mg
Hydrogenated Soya bean oil 8.0 mg
Partially hydrogenated plant oils 34.0 mg
Soya bean oil 110.0 mg
Weight of capsule contents 165.0 mg Gelatin capsule
Gelatin 75.0 mg
Glycerol 85 % 32.0 mg
Karion 83 8.0 mg (dry matter)
Titan dioxide 0.4 mg
Iron oxide yellow 1.1 mg
The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules treated according to the usual procedures. Example E
Sachets containing the following ingredients can be manufactured in a conventional manner:
Compound of formula I 50.0 mg
Lactose, fine powder 1015.0 mg
Microcrystalline cellulose (AVICEL PH 102) 1400.0 mg
Sodium carboxymethyl cellulose 14.0 mg
Polyvinylpyrrolidone K 30 10.0 mg
Magnesium stearate 10.0 mg
Flavoring additives 1.0 mg
The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Claims

Claims
1. Compounds of the formula
Figure imgf000348_0001
wherein
B1 is CR7 or N; B2 is CR8 or N;
R1 is selected from the group consisting of phenyl, said phenyl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7- alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl, hydroxy- Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7-alkoxy, C1-7- alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, phenyl-Ci_7- alkoxy,
heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl, heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, C1-7- alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl,
3,6-dihydro-2H-pyran-4-yl, and piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups; is selected from the group consisting of hydrogen, Ci_7-alkyl,
halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cyano,
Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino,
aminocarbonyl, Ci_7-alkylaminocarbonyl, di-Ci_7-alkylaminocarbonyl,
hydroxy-Ci_7-alkyl-(Ci_7-alkyl)amino, Ci_7-alkoxy-Ci_7-alkyl-(Ci_7-alkyl)amino, and heteroaryl; is selected from the group consisting of hydrogen, methyl and halogen; is selected from the group consisting of Ci_7-alkyl,
halogen-Ci_7-alkyl, hydroxy-Ci_7-alkyl, Ci_7-alkoxy-Ci_7-alkyl, Ci_7-alkylcarbonyl-Ci_7- alkyl, carboxyl-Ci_7-alkyl, Ci_7-alkoxycarbonyl-Ci_7-alkyl, cyano-Ci_7-alkyl,
aminocarbonyl-Ci_7-alkyl, Ci_7-alkylaminocarbonyl-Ci_7-alkyl,
di-Ci_7-alkylaminocarbonyl-Ci_7-alkyl, Ci_7-alkylsulfonyl-Ci_7-alkyl,
C3_7-cycloalkyl, C3_7-cycloalkyl-Ci_7-alkyl,
unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, hydroxy and Ci_7-alkyl,
heterocyclyl-Ci_7-alkyl, wherein heterocyclyl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl,
heteroaryl-Ci_7-alkyl, wherein heteroaryl is unsubstituted or substituted with one or two groups selected from halogen, oxo and Ci_7-alkyl and
phenyl-Ci_7-alkoxycarbonylamino-Ci_7-alkyl; is selected from the group consisting of hydrogen, halogen, Ci_7-alkyl and Ci_7-alkoxy; and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, Ci_7-cycloalkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, carboxyl, Ci_7-alkoxycarbonyl,
Ci_7-alkoxycarbonyl-Ci_7-alkyl,
hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkoxy,
Ci_7-alkylsulfanyl, hydroxy-Ci_7-alkylsulfanyl, Ci_7-alkoxy-Ci_7-alkylsulfanyl,
Ci_7-alkylsulfonyl, hydroxy-Ci_7-alkylsulfonyl, Ci_7-alkoxy-Ci_7-alkylsulfonyl,
carboxyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkylsulfonyl,
Ci_7-alkoxycarbonyl-Ci_7-alkylsulfanyl, Ci_7-alkoxycarbonyl-Ci_7-alkylsulfonyl,
Ci_7-alkoxycarbonylamino-Ci_7-alkylsulfanyl,
carboxyl-Ci_7-alkyl-aminocarbonyl-Ci_7-alkylsulfanyl, carboxyl-Ci_7-alkyl-aminocarbonyl- Ci_7-alkylsulfonyl,
heterocyclylsulfanyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl, heterocyclylsulfonyl, wherein heterocyclyl is unsubstituted or substituted by C1-7- alkoxycarbonyl, oxo, Ci_7-alkylsulfonyl or aminosulfonyl,
heterocyclyl-Ci_7-alkylsulfanyl, heterocyclyl-Ci_7-alkylsulfonyl,
aminosulfonyl, Ci_7-alkylaminosulfonyl, di-(Ci_7-alkyl)-aminosulfonyl,
Ci_7-alkylsulfonylamino-Ci_7-alkylsulfanyl, Ci_7-alkylsulfonylamino-Ci_7-alkylsulfonyl, aminosulfonylamino-Ci_7-alkylsulfanyl, aminosulfonylamino-Ci_7-alkylsulfonyl, amino-Ci_7-alkylsulfanyl, amino-Ci_7-alkylsulfonyl,
aminocarbonyl-Ci_7-alkyl, aminocarbonyl-Ci_7-alkylsulfonyl
amino, Ci_7-alkylamino, di-(Ci_7-alkyl)-amino, hydroxy-Ci_7-alkylamino, nitro,
unsubstituted heterocyclyl or heterocyclyl substituted with one or two groups selected from halogen, oxo, Ci_7-alkyl and Ci_7-alkoxycarbonyl;
R is hydrogen or halogen; and
R is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen,
halogen-Ci_7-alkyl and Ci_7-alkoxy; or pharmaceutically acceptable salts thereof.
2. Compounds of formula I according to claim 1, wherein R1 is phenyl, said phenyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, C1-7- cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl- oxy, cycloalkyl-Ci_7-alkoxy, cyano, cyano-Ci_7-alkoxy, carboxyl, carboxyl-Ci_7-alkyl, C1-7- alkoxycarbonyl, hydroxy-Ci_7-alkyl, hydroxy-Ci_7-alkoxy, Ci_7-alkoxy-Ci_7-alkyl, carboxyl-Ci_7- alkoxy, Ci_7-alkoxycarbonyl-Ci_7-alkoxy, amino, Ci_7-alkylamino, di-Ci_7-alkylamino, phenyl-Ci_ 7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl.
3. Compounds of formula I according to claims 1 or 2, wherein R1 is phenyl, said phenyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, halogen and Ci_7-alkoxy.
4. Compounds of formula I according to claim 1, wherein R1 is selected from the group consisting of heteroaryl, said heteroaryl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen- Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl,
3,6-dihydro-2H-pyran-4-yl, and piperidinyl, said piperidinyl being substituted with one to four Ci_7-alkyl groups.
5. Compounds of formula I according to claims 1 or 4, wherein R1 is pyridyl, said pyridyl being substituted with one, two or three groups selected from the group consisting of Ci_7-alkyl, Ci_7-cycloalkyl, halogen, hydroxy, Ci_7-alkoxy, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, cycloalkyl-oxy, cycloalkyl-Ci_7-alkoxy, heterocyclyl-oxy and heterocyclyl-Ci_7-alkoxy, wherein heterocyclyl is unsubstituted or substituted by Ci_7-alkoxycarbonyl.
2
6. Compounds of formula I according to any one of claims 1 to 5, wherein R is hydi halogen.
7. Compounds of formula I according to any one of claims 1 to 6, wherein R2a is hydrogen.
8. Compounds of formula I according to any one of claims 1 to 7, wherein R is selected from the group consisting of Ci_7-alkyl, halogen-Ci_7-alkyl, aminocarbonyl-Ci_7-alkyl and C1-7- alkylsulfonyl-Ci_7-alkyl.
9. Compounds of formula I according to any one of claims 1 to 8, wherein R4 is hydrogen or halogen.
10. Compounds of formula I according to any one of claims 1 to 9, wherein R5 and R6 are independently from each other selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl, halogen-Ci_7-alkoxy, hydroxy, hydroxy-Ci_7-alkyl, Ci_7-alkoxy, cyano, Ci_7-alkoxycarbonyl, Ci_7-alkylsulfonyl, di-(Ci_7-alkyl)-aminosulfonyl, amino, nitro, heterocyclyl selected from morpholinyl or 2-oxo-pyrrolidinyl, and heterocyclylsulfonyl, wherein heterocyclyl is oxetanyl or morpholinyl.
11. Compounds of formula I according to any one of claims 1 to 10, wherein R5 and R6 are independently from each other selected from the group consisting of halogen, halogen-Ci_7-alkyl,
Ci_7-alkyl and Ci_7-alkylsulfonyl.
12. Compounds of formula I according to any one of claims 1 to 11, wherein B 1 is CR 7 and
B 2 is CR 8 and wherein R 7 is hydrogen or halogen and R 8 is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen-Ci_7-alkyl and Ci_7-alkoxy.
13. Compounds of formula I according to claim 12, wherein R 7 and R 8 are hydrogen.
14. Compounds of formula I according to any one of claims 1 to 11, wherein B1 is N and
B 2 is CR 8 and R 8 is selected from the group consisting of hydrogen, Ci_7-alkyl, halogen, halogen- Ci_7-alkyl and Ci_7-alkoxy.
15. Compounds of formula I according to any one of claims 1 to 11, wherein B 1 is CR 7 and
B 2 is N and wherein R 7 is hydrogen or halogen.
16. Compounds of formula I according to claim 1, selected from the group consisting of
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
2- fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
4-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3- fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
2- fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3,5-dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3,5-difluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3,4-dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3- chloro-4-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
3,5-dichloro-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-benzamide,
N-(6-methoxy-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(6-methylamino-4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide, N-(6-amino-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[6-(4-methanesulfonyl-piperazin-l-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-3,5-bz5- trifluoromethyl-benzamide,
N-{6-[(2-methoxy-ethyl)-methyl-amino]-4-o-tolyl-pyridin-3-yl}-N-methyl-3,5-bz5- trifluoromethyl-benzamide,
N-(6-cyano-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-methyl-N-(2-methyl-3,4,5,6-tetrahydro-2H-[l,4'^
benzamide,
3,5-dichloro-N-methyl-N-(2-methyl-3,4,5,6-tetra ydro-2H-[l,4']bipyridinyl-3'-yl)-benzam hydrochloride salt,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-oxazol-2-ylmethyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-meth^
3,5-dichloro-N-[4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-benzamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2,4-dimethyl-phenyl)-pyridin-3-yl]-N-m
N-[4-(4-methoxy-2-methyl-phenyl)-pyridin-3-yl]-N-m
N-methyl-3,5-bz5-trifluoromethyl-N-[4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-benzam
N-[4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
N-[4-(4-chloro-2-methyl-phenyl)-pyridin^
N-methyl-N- [4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl] -3 ,5-bzs-trifluoromethyl-benzamide, N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
N-methyl-N-(2-methyl-[3,4']bipyridinyl-3'-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-(3'-methyl-[4,4']bipyridinyl-3-yl)-3,5-bz5-trifluoromethyl -benzamide,
N-[4-(2-isopropoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-cyano-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2,4-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl- benzamide,
N-[4-(2,3-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(3-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-fluoro-5-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-benzyloxy-4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-(5-fluoro-2-methoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-(5-chloro-2-methoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-(2-isopropoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(2-methoxy-6-methyl-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(4-fluoro-2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, (2-{3-[(3,5-bz5-trifluoromethyl-benzoyl)-methyl-amino]-pyridin-4-yl}-5-fluoro-phenoxy)-acetic acid methyl ester,
N-(3'-chloro-2'-methoxy-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-cyanomethoxy-4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl- benzamide, N-{4- [4-fluoro-2-(2-hydroxy-ethoxy)-phenyl] -pyridin-3 -yl } -N-methyl-3 ,5-bz5-trifluoromethyl- benz amide,
N- { 4- [2-(cyano-methyl-methoxy)-4-fluoro-phenyl] -pyridin-3 -yl } -N-methyl-3 ,5-bis- trifluoromethyl-benzamide,
N-[4-(3,6-dimethoxy-pyridazin-4-yl)-pyridin-3^
N-(2-chloro-5-fluoro-[3,4']bipyridinyl-3'-yl)-N^
N-(2'-chloro-3'-fluoro-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzam
N-methyl-N-(3-methyl-[2,4']bipyridinyl-3'-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzam N-[4-(3,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluorometh
benzamide,
N- [4-(3 ,4-difluoro-2-methoxy-phenyl)-pyridin-3 -yl] -N-methyl-3 ,5 -bz's-trifluoromethyl- benzamide,
N-[4-(2,5-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-fluoro-3-methoxy-phenyl)-pyridin-3-yl]-N^
N-[4-(2-fluoro-5-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzam
N-[4-(2,6-difluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-chloro-3-fluoro-phenyl)-pyridin-3-yl]-N-me
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzam N-[4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-N-mem^
N-(3-fluoro-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(3'-methoxy-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamid
N-(3'-fluoro-[4,4']bipyridinyl-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(6-chloro-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-^^
benzamide,
N-(3,6'-dichloro-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
3- bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl-isophthalamic acid methyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-hydroxymethyl-N-methyl-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-(l-hydroxy-l-methyl-ethyl)-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl -benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-hydroxy-N-methyl-5-trifluoromethyl-benzamide,
4- bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methoxy-N-methyl-5-trifluoromethyl-benzamide, N-[4-(5-chloro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, 3 - { 3 - [(3 ,5-bz5-trifluoromethyl-benzoyl)-methyl-amino] -pyridin-4-yl } -4-methyl-benzoic acid methyl ester,
3- {3-[(3,5-bzs-trifluoromethyl-benzoyl)-mem^ acid, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2,2,2-tri^
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-cyclopro^
N-(6,5'-dichloro-2'-fluoro-[4,4']bipyridinyl-3-y^^
{(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-methoxy-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide,
4,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
4- methoxy-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
N-{4-[2-(2-hydroxy-ethyl)-phenyl]-pyridin-3-yl}-N-methyl-3,5-bz5-trifluoromethyl-benzamide, 3-f uoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide,
4-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3-trifluoromethyl-benzamide,
3,5,N-trimethyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-4-trifluoromethyl-benzamide,
N-(6-methoxy-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(6-methoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethoxy-benzamide,
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-3,4-bz5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methylcarbamoylmethyl-3,5-bz5-trifluoromethyl- benzamide,
3-chloro-5-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
3,4,5-trifluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide,
N-[4-(2,3-dimethyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-methyl-N-[2-(2,2,2-trifluoro-ethoxy)-[3,4']bipyridinyl-3'-yl]-3,5-bz5-trifluoromethyl- benzamide,
N-(2-cyclopropylmethoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide, 3,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
3-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-fluoro-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(3-chloro-2-fluoro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5-trifluoromethyl- benzamide,
N-methyl-N-[6-(lH-pyrrol-2-yl)-4-o-tolyl-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide,
3-methanesulfonyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-hydroxy-ethyl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2,2-difluoro-ethyl)-3,5-bz5-trifluoromethyl-benza
N-carbamoylmethyl-N-[4-(2-chloro-phenyl)-py
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-dim
benzamide,
2-chloro-6,N-dimethyl-N-(4-o-tolyl-pyridin-3-yl)-isonicotinamide,
2,6-dichloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-isonicotinamide,
4,6-dimethyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide,
4- chloro-6-methyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide,
4,6-dichloro-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-cyclopropyl-3,5-bz5-trifluoromethyl-benzamide, (2-{(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-ethyl)- carbamic acid benzyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-isopropyl-3,5-bz5-trifluoromethyl -benzamide,
N-methyl-N-(6-methyl-4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
3-dimethylsulfamoyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamid
3-fluoro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-fluoro-N-methyl-5-trifluoromethyl- benzamide,
N-methyl-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-fluoro-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-dimethylsulfamoyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyi
5- trifluoromethyl-benzamide,
3-fluoro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-3,5-bz'5-trifluorometh
benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-dimethylsulfamoyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide, 3-fluoro-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5-trifluoromethyl- benzamide,
3-methanesulfonyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-dimethylsulfamoyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-y^
isonicotinamide,
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-2,6-bz'5-trifluoromethyl- isonicotinamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-2,6-bz5-trifluoromethyl- isonicotinamide,
3-cyano-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-(4-o-tolyl-pyridin-3-yl)-N-(2,2,2-trifluoro-em^
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-methyl-3-morpholin-4-yl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-(2,2-difluoro-ethyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5- trifluoromethyl-isonicotinamide,
N-(2,2-difluoro-ethyl)-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide^ N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2-methanesulfonyl-ethyl)-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-cyanomethyl-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide, N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-(2-methanesulfonyl-ethyl)-N-(4-o-tolyl-pyridm^
3-amino-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide,
N-(2-cyano-ethyl)-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(3,6-dihydro-2H-pyran-4-yl)-pyridin-3-yl]-N-m
N-[4-(2,3-dimethoxy-phenyl)-pyridin-3-yl]-N-mem^
N-[4-(2-ethyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
2- chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-6-trifluoromethyl- isonicotinamide,
3- dimethylsulfamoyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
2-chloro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-6-trifluoromethyl-isonicotinamide,
[[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl- benzoyl)-amino] -acetic acid methyl ester,
{ (2,6-bz5-trifluoromethyl-pyridine-4-carbonyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3- yl]- amino} -acetic acid methyl ester,
N-(2-amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- bzs(trifluoromethyl)isonicotinamide,
N-[4-(2-cyanomethyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, methyl 2-(N-(4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- bz5(trifluoromethyl)isonicotinamido)acetate,
N-carbamoylmethyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2,6-bis-trifluoromethyl- isonicotinamide,
methyl 2-(3-(N,N-dimethylsulfamoyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-5- (trifluoromethyl)benzamido)acetate,
N-carbamoylmethyl-3-dimethylsulfamoyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-5- trifluoromethyl-benzamide,
[(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-(2-methoxy-[3,4']bipyridinyl-3'-yl)-amino]- acetic acid methyl ester,
N-carbamoylmethyl-3-methanesulfonyl-N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-5-trifluoromethyl- benzamide,
methyl 2-(N-(2-methoxy-3,4'-bipyridin-3'-yl)-2,6-bz5(trifluoromethyl)isonicotinamido)acetate, N-(2-amino-2-oxoethyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-2,6- bz's(trifluoromethyl)isonicotinamide,
N-methyl-3-nitro-N-(4-o-tolylpyridin-3-yl)-5-(trifluoromethyl)benzamide,
N-methyl-3-(2-oxo-pyrrolidin-l-yl)-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzamide, [[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- amino] -acetic acid methyl ester,
N-carbamoylmethyl-N-[4-(4-fluoro-2-meth^
trifluoromethyl-benzamide,
{(3,5-bz5-trifluoromethyl-benzoyl)-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-am acetic acid methyl ester,
N-carbamoylmethyl-N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3,5-bz5- trifluoromethyl-benzamide,
4,6-bz5-trifluoromethyl-pyridine-2-carboxylic acid methyl-(4-o-tolyl-pyridin-3-yl)-amide, N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5-trifluoromethyl- benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5- trifluoromethyl-benzamide,
N-(2-amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-3-(methylsulfonyl)- 5-(trifluoromethyl)benzamide,
2-methanesulfonyl-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-6-trifluoromethyl-isonicotinamide, methyl 2-(N-(4-(2-fluoro-6-methoxyphenyl)pyridin-3-yl)-2,6- bz5(trifluoromethyl)isonicotinamido)acetate,
methyl 2-(N-(4-(2-fluorophenyl)pyridin-3-yl)-2,6-bz5(trifluoromethyl)isonicotinamido)acetate, N-carbamoylmethyl-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
2-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-6-methoxy-N-methyl-isonicotinamide,
N-carbamoylmethyl-N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-oxetan-3-yl-N-(4-o-tolyl-pyridin-3-yl)-3,5-bz5-trifluoromethyl-benzamide,
N-[6-chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(2-oxo-butyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-oxo-butyl)-5- trifluoromethyl-benzamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2-methoxy-N-methyl-6-trifluoromethyl- isonicotinamide, N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-(3-methyl-oxetan-3-ylmethyl)-2,6-bz5- trifluoromethyl-isonicotinamide,
N-methyl-3,5-bz5-trifluoromethyl-N-[4-(l,3,5-trimethyl-lH-pyrazol-4-yl)-pyridin-3-yl^ benzamide,
N-[4-(2,4-dimethyl-thiazol-5-yl)-pyridin-3-yl]-N-^
N-[4-(3,5-dimethyl-isoxazol-4-yl)-pyridin-3-yl]-N-^
N-methyl-N-[4-(4-methyl-2H-pyrazol-3-yl)-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide, N-[2-chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
[[4-(2-fluoro-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]- acetic acid methyl ester,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-(2,2-difluoro-ethyl)-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy-ethylsulfanyl)-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methoxy-ethanesulfonyl)-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy-ethanesulfonyl)-N-methyl-5- trifluoromethyl-benzamide,
N-carbamoylmethyl-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5-trifluoromethyl- benzamide,
N-(6-ethyl-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bis-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2-methanesulfonyl-N-methyl-6-trifluoromethyl- isonicotinamide,
N-[4-(2-amino-phenyl)-pyridin-3-yl]-N-methyl-3,5-bis-trifluoromethyl -benzamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-propionic acid methyl ester,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-propionic acid methyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-hydroxy-N-methyl-5-trifluoromethyl- benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethoxy- benzamide, N-cyanomethyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-methoxy-ethyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-2-methyl-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(5-methyl-isoxazol-3- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(R)- l-(tetrahydro-furan- 2-yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)- l-(tetrahydro-furan-
2- yl)methyl]-5-trifluoromethyl-benzamide,
[2-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-ethyl]-carbamic acid tert-butyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-oxetan-3-yl-5-trifluoromethyl- benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methoxy-ethoxy)-N-methyl-5- trifluoromethyl-benzamide,
3- (2-amino-ethylsulfanyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3- chloro-5-cyclopropyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-benzamide,
4- (3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-butyric acid,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-hydroxy-ethoxy)-N-methyl-5- trifluoromethyl-benzamide,
3-(2-amino-ethanesulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(2-cyclopropoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-pentanoic acid,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-hydroxy-ethyl)-3-methanesulfonyl-5-trifluoromethyl- benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenyl)-azetidine-l-carboxylic acid tert-butyl ester,
3-bromo-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethoxy- benzamide, 4- (3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-butyric acid,
5- (3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-pentanoic acid,
3-(azetidine-l-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(l-methyl-lH-imidazol-
2- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(oxetan-3-ylsulfanyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethoxy-benzamide,
N-[6-chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3-(4-carbamoyl-butane-l-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(morpholine-4-sulfonyl)-5- trifluoromethyl-benzamide,
3- chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-5-methanesulfonyl-N-methyl- benzamide,
N-[4-(2-benzyloxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
3-(2-azetidin- l-yl-ethylsulfanyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3-cyclopropyl-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-5-methanesulfonyl-N-methyl- benzamide,
N-[4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl]-N-methyl-3-{ [2- (sulfamoylamino)ethyl]sulfanyl}-5-(trifluoromethyl)benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methanesulfonylamino-ethylsulfanyl)-N- methyl-5-trifluoromethyl-benzamide,
3-methanesulfonyl-N-[4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3-(2-azetidin- l-yl-ethanesulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide, 3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenyl) -propionic acid ethyl ester,
N-[4-(2-benzyloxy-4-fluoro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- phenylsulfanyl)-azetidine- l-carboxylic acid tert-butyl ester,
N-[4-(4-fluoro-2-methoxyphenyl)pyridin-3-yl]-N-methyl-3-{ [2- (sulfamoylamino)ethyl]sulfonyl}-5-(trifluoromethyl)benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(2-methanesulfonylamino-ethanesulfonyl)-N- methyl-5-trifluoromethyl -benzamide,
3-(2-hydroxy-ethylamino)-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-5-trifluoromethyl-benzam 3-methanesulfonyl-N-methyl-N-{4-[2-(oxetan-3-yloxy)-phenyl]-pyridin-3-yl}-5-trifluoromethyl- benz amide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(tetrahydro-furan-3- ylmethyl)-5-trifluoromethyl-benzamide,
3-methanesulfonyl-N-methyl-N-[4-(2-trifluoro
benzamide,
3-(azetidin-3-ylsulfanyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(2-cyclobutoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl-benzamide, 3-methanesulfonyl-N-methyl-N-[2-(2,2,2-trifluoro-ethoxy)-[3,4']bipyridinyl-3'-yl]-5- trifluoromethyl-benzamide,
3-(azetidine-3-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
3-(2-carbamoyl-ethyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-(l-methanesulfonyl-azetidine-3-sulfonyl)-N- methyl-5-trifluoromethyl -benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(5-methyl-oxazol-2- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(2,4-difluoro-5-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
N-[4-(2,6-difluoro-3-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide, N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-cyanomethyl-3-methanesulfonyl-5-trifluoromethyl- benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-5- trifluoromethyl-benzamide,
[[4-(2-chloro-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-amino]- acetic acid methyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(R)- l-(tetrahydro-pyran- 2-yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)- l-(tetrahydro-pyran-
2- yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-mem^
5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(4-methyl-oxazol-2- ylmethyl)-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-oxazol-2-ylmethyl-5-trifluorom benzamide,
N-[4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluorom benzamide,
N-carbamoylmethyl-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-[(S)- l-(tetrahydro-pyran-
3- yl)methyl]-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro-ethyl)-5- trifluoromethyl-benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-5-methanesulfonyl-N- methyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-3-(morpholine-4-sulfonyl)- 5-trifluoromethyl-benzamide,
3-bromo-N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-5-trifluoromethyl- benzamide,
3-(l, l-dioxo-thiomorpholine-4-sulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N- methyl-5-trifluoromethyl -benzamide, N-[4-(4-Fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(2-oxa-6-aza-spiro[3.3]heptane-6- sulfonyl)-5-trifluoromethyl-benzamide
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2-methanesulfonyl- ethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro^ ethyl)-5-trifluoromethyl-benzamide,
3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3- yl]-5-trifluoromethyl-benzamide,
[[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-(3-methanesulfonyl-5-trifluoromethyl-benzoyl)- amino] -acetic acid methyl ester,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-3-(oxetan-3-ylsulfanyl)-5- trifluoromethyl-benzamide,
N-cyanomethyl-3-methanesulfonyl-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-5- trifluoromethyl-benzamide,
5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-phenylsulfanyl)-pentanoic acid,
N-(2-chloro-[3,4']bipyridinyl-3'-yl)-3-methanesulfonyl-N-methyl-5-trifluoromethyl-benzamide, N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide,
[5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-phenylsulfanyl)-pentanoylamino] -acetic acid,
5-(3-{ [4-(5-chloro-4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-benzenesulfonyl)-pentanoic acid,
[5-(3-{ [4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-methyl-carbamoyl}-5- trifluoromethyl-benzenesulfonyl)-pentanoylamino] -acetic acid,
3-methanesulfonyl-N-methyl-N-{ 6-methyl-4-[2-(oxetan-3-yloxy)-phenyl]-pyridin-3-yl}-5- trifluoromethyl-benzamide,
N-carbamoylmethyl-3-methanesulfonyl-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3-yl]-5- trifluoromethyl-benzamide,
3-{ 3'-[(3-methanesulfonyl-5-trifluoromethyl-benzoyl)-methyl-amino]-[3,4']bipyridinyl-2- yloxy}-azetidine-l-carboxylic acid tert-butyl ester,
3-methanesulfonyl-N-methyl-N-{ 6-methyl-4-[2-(oxetan-3-ylmethoxy)-phenyl]-pyridin-3-yl}-5- trifluoromethyl-benzamide,
N-methyl-N-(4-phenyl-pyridin-3-yl)-3,5-bis-trifluoromethyl-benzamide, and
3-methanesulfonyl-N-methyl-N-(4-phenyl-pyridin-3-yl)-5-trifluoromethyl-benzamide, or pharmaceutically acceptable salts thereof.
17. Compounds of formula I according to claim 1, selected from the group consisting of
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-(2-methoxy-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl- benzamide,
N-[4-(3-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
3- bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
4- bromo-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-3-trifluoromethyl-benzamide,
N-[4-(5-chloro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-3,5-bz5-trifluoromethyl-benzamide, 3 - { 3 - [(3 ,5-bz5-trifluoromethyl-benzoyl)-methyl-amino] -pyridin-4-yl } -4-methyl-benzoic acid methyl ester,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-3,5-bis-trifluoromethyl-benzamide, {(3,5-bz5-trifluoromethyl-benzoyl)-[4-(2-chloro-phenyl)-pyridin-3-yl]-amino}-acetic acid methyl ester,
N-(6-methoxy-[2,4']bipyridinyl-3'-yl)-N-methyl-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-fluoro-ethyl)-3,5-bz5-trifluoromethyl-benzamide,
N-[4-(2-chloro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-3,5-bz5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(2-chloro-phenyl)-pyridin-3-yl]-3,5-bz5-trifluoromethyl-benzamide, N-methyl-N-(4-o-tolyl-pyridin-3-yl)-2,6-bz5-trifluoromethyl-isonicotinamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide,
N-[4-(4,5-difluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-2,6-bz5-trifluoromethyl- isonicotinamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2,2,2-trifluoro-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide,
N-(2,2-difluoro-ethyl)-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-N-(2-methanesulfonyl-ethyl)-2,6-bz5-trifluoromethyl- isonicotinamide, N-(2-amino-2-oxoethyl)-N-(4-(4,5-difluoro-2-methoxyphenyl)pyridin-3-yl)-2,6- bzs(trifluoromethyl)isonicotinamide,
N-carbamoylmethyl-N-[4-(4-fluoro-2-methoxy-pheny^
isonicotinamide,
N-(2-amino-2-oxoethyl)-N-(2-methoxy-3,4'-bipyridin-3'-yl)-2,6- bzs(trifluoromethyl)isonicotinamide,
N-carbamoylmethyl-N-[4-(2-fluoro-phenyl)-pyridin-3-yl]-2,6-bz5-trifluoromethyl- isonicotinamide,
N-carbamoylmethyl-N-[4-(2-fluoro-6-methoxy-phenyl ^
isonicotinamide,
N-[4-(2-fluoro-6-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5-trifluoromethyl- benzamide, and
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-2-methoxy-N-methyl-6-trifluoromethyl- isonicotinamide,
N-[2-chloro-4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-N-methyl-5- trifluoromethyl-benzamide,
3- (2-amino-ethanesulfonyl)-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-5- trifluoromethyl-benzamide,
4- (3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-butyric acid,
5- (3-{ [4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-methyl-carbamoyl}-5-trifluoromethyl- benzenesulfonyl)-pentanoic acid,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(oxetane-3-sulfonyl)-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-3-(morpholine-4-sulfonyl)-5- trifluoromethyl-benzamide,
3-chloro-N-[4-(4-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-5-methanesulfonyl-N-methyl- benzamide,
3-methanesulfonyl-N-methyl-N-{4-[2-(oxetan-3-yloxy)-phenyl]-pyridin-3-yl}-5-trifluoromethyl- benzamide,
N-carbamoylmethyl-N-[4-(5-fluoro-2-methoxy-phenyl)-pyridin-3-yl]-3-methanesulfonyl-5- trifluoromethyl-benzamide,
N-[4-(4-fluoro-2-methoxy-phenyl)-6-methyl-pyridin-3-yl]-3-methanesulfonyl-N-(2,2,2-trifluoro- ethyl)-5-trifluoromethyl-benzamide, and
3-methanesulfonyl-N-(2-methanesulfonyl-ethyl)-N-[4-(2-trifluoromethoxy-phenyl)-pyridin-3- yl] -5-trifluoromethyl-benzamide,
or pharmaceutically acceptable salts thereof.
18. A process for the manufacture of compounds of formula I as defined in claim 1, which process comprises a) reacting a compound of the formula II
Figure imgf000368_0001
wherein G is -OH or -CI, B1, B2 and R4 to R6 are as defined in claim 1, with an amine of the formula III
Figure imgf000368_0002
wherein R 1 to R 3 are as defined in claim 1, in the presence of a coupling reagent under basic conditions to obtain a compound of the formula I
Figure imgf000368_0003
wherein B1, B2 and R1 to R6 are as defined in claim 1, and, if desired,
converting the compound obtained into a pharmaceutically acceptable salt, or, alternatively, b) reacting a compound of the formula IV
Figure imgf000369_0001
wherein B1, B2 and R2 to R6 are as defined in claim 1 and X means a halogen atom, with a boronic acid or ester of the formula V
R^BCOR'^ V, wherein R is as defined in claim 1 and R' is hydrogen or a pinacol or trimethylene glycol ester, in the presence of a palladium catalyst and a base to obtain a compound of the formula I
Figure imgf000369_0002
wherein B 1, B2 and R1 to R6 are as defined in claim 1, and, if desired,
converting the compound obtained into a pharmaceutically acceptable salt, c) reacting a compound of the formula VI
Figure imgf000369_0003
wherein B1, B2, R1 and R3 to R6 are as defined in claim 1 and X' means a halogen atom, with a boronic acid or ester of the formula V
R2'-B(OR')2 V, wherein R is selected from the group consisting of Ci_7-alkyl, C3_7-cycloalkyl, halogen- Ci_7-alkyl and heteroaryl and R' is hydrogen or a pinacol or trimethylene glycol ester, in the presence of a palladiu d of the formula I*
Figure imgf000370_0001
wherein B1, B2, R1 and R3 to R6 are as defined in claim 1 and R2 is selected from the group consisting of Ci-7-alkyl, C3_7-cycloalkyl, halogen-Ci-7-alkyl and heteroaryl, and, if desired, converting the compound obtained into a pharmaceutically acceptable salt.
19. Pharmaceutical compositions comprising a compound of formula I according to any one of claims 1 to 17 and a pharmaceutically acceptable carrier and/or adjuvant.
20. Compounds of formula I according to any one of claims 1 to 17 for use as therapeutic active substances.
21. Compounds of formula I according to any one of claims 1 to 17 for use as therapeutic active substances for the treatment of diseases which are associated with the modulation of GPBAR1 activity.
22. Compounds of formula I according to any one of claims 1 to 17 for use as therapeutic active substances for the treatment of diabetes, particularly type II diabetes or gestational diabetes.
23. A method for the treatment of diseases which are associated with the modulation of GPBAR1 activity, particularly for the treatment of diabetes, particularly type 2 diabetes or gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ischemia, myocardial infarction, retinopathy, vascular restenosis, hypercholesterolemia, hypertriglyceridemia, dyslipidemia or hyperlipidemia, lipid disorders such as low HDL cholesterol or high LDL cholesterol, high blood pressure, angina pectoris, coronary artery disease, atherosclerosis, cardiac hypertrophy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), psoriasis, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during small bowl syndrome, irritable bowl syndrome (IBS), allergy diseases, particularly disorders associated with the liver and the kidneys, e.g. including renal disorders, kidney disorders, e.g. diabetic nephropathy, acute kidney injury, acute renal disease, kidney fibrosis, liver disorders, e.g.
hepatitis, liver failure, acute/chronic hepatitis, acute/chronic interstitial/glomerulonephritis, granulomatous diseases, fatty liver (e.g. non-alcoholic fatty liver disease, NAFLD), liver fibrosis (e.g. non-alcoholic steatohepatitis, NASH), primary sclerosing cholangitis (PSC), liver cirrhosis, primary biliary cirrhosis (PBC), liver colestasis, kidney fibrosis, anorexia nervosa, bulimia nervosa and neurological disorders such as Alzheimer's disease, multiple sclerosis,
schizophrenia and impaired cognition, which method comprises administering a therapeutically active amount of a compound of formula I according to any one of claims 1 to 17 to a human being or animal.
24. The use of compounds of formula I according to any one of claims 1 to 17 for the preparation of medicaments for the treatment of diseases which are associated with the modulation of GPBAR1 activity.
25. The invention as herein before defined.
PCT/EP2012/053386 2011-03-03 2012-02-29 3-amino-pyridines as gpbar1 agonists WO2012117000A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP12706049.9A EP2681194B1 (en) 2011-03-03 2012-02-29 3-amino-pyridines as gpbar1 agonists
CN201280010939.5A CN103415507B (en) 2011-03-03 2012-02-29 As the 3-amino-pyridine class of GPBAR1 agonist
MX2013009356A MX341565B (en) 2011-03-03 2012-02-29 3-amino-pyridines as gpbar1 agonists.
ES12706049.9T ES2538655T3 (en) 2011-03-03 2012-02-29 3-Amino-pyridines as GPBAR1 agonists
KR1020137026117A KR101573997B1 (en) 2011-03-03 2012-02-29 3-amino-pyridines as gpbar1 agonists
RU2013142011/04A RU2594886C2 (en) 2011-03-03 2012-02-29 3-aminopyridines as gpbar1 agonists
JP2013555853A JP5702001B2 (en) 2011-03-03 2012-02-29 3-Amino-pyridine as a GPBAR1 agonist
BR112013022110-0A BR112013022110B1 (en) 2011-03-03 2012-02-29 3-AMINO PYRIDINES AS GPBARI AGONISTS
CA2827718A CA2827718C (en) 2011-03-03 2012-02-29 3-amino-pyridines as gpbar1 agonists
HK14103757.1A HK1190707A1 (en) 2011-03-03 2014-04-18 3-amino-pyridines as gpbar1 agonists gpbar1 3--

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11156711.1 2011-03-03
EP11156711 2011-03-03

Publications (2)

Publication Number Publication Date
WO2012117000A1 true WO2012117000A1 (en) 2012-09-07
WO2012117000A8 WO2012117000A8 (en) 2013-03-07

Family

ID=45768226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/053386 WO2012117000A1 (en) 2011-03-03 2012-02-29 3-amino-pyridines as gpbar1 agonists

Country Status (12)

Country Link
US (2) US8987307B2 (en)
EP (1) EP2681194B1 (en)
JP (1) JP5702001B2 (en)
KR (1) KR101573997B1 (en)
CN (1) CN103415507B (en)
BR (1) BR112013022110B1 (en)
CA (1) CA2827718C (en)
ES (1) ES2538655T3 (en)
HK (1) HK1190707A1 (en)
MX (1) MX341565B (en)
RU (1) RU2594886C2 (en)
WO (1) WO2012117000A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102929A1 (en) 2011-12-26 2013-07-11 Cadila Healthcare Limited Novel compounds for treatment of diabetes, obesity or related disorders
CN103333112A (en) * 2013-06-14 2013-10-02 南开大学 Preparation and application of bixafen type derivatives
CN103333113A (en) * 2013-06-14 2013-10-02 南开大学 Preparation and application research of fluxapyroxad analogue derivative
WO2013149977A1 (en) * 2012-04-04 2013-10-10 F. Hoffmann-La Roche Ag 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
WO2014128591A1 (en) 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
JP2016509591A (en) * 2012-12-27 2016-03-31 ドレクセル ユニバーシティ Novel antiviral agent against HBV infection
WO2017072039A1 (en) 2015-10-26 2017-05-04 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
EP3696175A1 (en) 2019-02-18 2020-08-19 Syngenta Crop Protection AG Pesticidally active azole-amide compounds
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020208036A1 (en) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2021094974A1 (en) * 2019-11-13 2021-05-20 Libra Therapeutics, Inc. Heterocyclic trpml1 agonists
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013060653A1 (en) * 2011-10-26 2013-05-02 F. Hoffmann-La Roche Ag 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
KR101698124B1 (en) * 2015-05-29 2017-01-19 한국외국어대학교 연구산학협력단 Process for preparing 3-(methylamino)-3-((R)-pyrrolidin-3-yl)propanenitrile or its salt
CN109384712B (en) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 NK1 receptor targeting antagonist and application thereof in treatment of nausea and vomiting caused by chemotherapy

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024404A1 (en) 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
DE10008042A1 (en) 1999-02-24 2000-08-31 Hoffmann La Roche Neurokinin-1 receptor antagonist
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2005115977A1 (en) 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Pyrrolidine derivatives as cb1-receptor antagonists
WO2006013050A1 (en) 2004-08-06 2006-02-09 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists against schizophrenia
WO2006018725A1 (en) 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2007072017A2 (en) 2005-12-22 2007-06-28 The Institute Of Cancer Research Enzyme inhibitors
WO2007110237A2 (en) * 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
WO2008025539A1 (en) 2006-08-29 2008-03-06 Phenex Pharmaceuticals Ag Heterocyclic fxr binding compounds
WO2008055847A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Arylsulfonyl pyrrolidines as 5-ht6 inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2008127399A2 (en) 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
WO2008154271A1 (en) 2007-06-06 2008-12-18 Smithkline Beecham Corporation Chemical compounds
WO2009014637A2 (en) * 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
WO2009119700A1 (en) 2008-03-26 2009-10-01 住友化学株式会社 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor
WO2009158431A2 (en) 2008-06-25 2009-12-30 Irm Llc Compounds and compositions as kinase inhibitors
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1169312T3 (en) 1999-03-29 2005-01-31 Hoffmann La Roche glucokinase activators
GB0606202D0 (en) * 2006-03-28 2006-05-10 Novartis Ag Organic compounds
RU2359975C2 (en) 2007-04-04 2009-06-27 Институт нефтехимии и катализа РАН Method for production of modified arabinogalactan
AU2008237944A1 (en) * 2007-04-13 2008-10-23 Novartis Ag Pyridazine-, pyridine- and pyrane-derivatives as GPBAR1 agonisis
US8309734B2 (en) * 2008-10-29 2012-11-13 Hoffmann-La Roche Inc. Substituted pyridines as GPBAR1 agonists

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024404A1 (en) 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
DE10008042A1 (en) 1999-02-24 2000-08-31 Hoffmann La Roche Neurokinin-1 receptor antagonist
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2005115977A1 (en) 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Pyrrolidine derivatives as cb1-receptor antagonists
WO2006013050A1 (en) 2004-08-06 2006-02-09 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists against schizophrenia
WO2006018725A1 (en) 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2007072017A2 (en) 2005-12-22 2007-06-28 The Institute Of Cancer Research Enzyme inhibitors
WO2007110237A2 (en) * 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
WO2008025539A1 (en) 2006-08-29 2008-03-06 Phenex Pharmaceuticals Ag Heterocyclic fxr binding compounds
WO2008127399A2 (en) 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
WO2008055847A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Arylsulfonyl pyrrolidines as 5-ht6 inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2008154271A1 (en) 2007-06-06 2008-12-18 Smithkline Beecham Corporation Chemical compounds
WO2009014637A2 (en) * 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
WO2009119700A1 (en) 2008-03-26 2009-10-01 住友化学株式会社 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor
WO2009158431A2 (en) 2008-06-25 2009-12-30 Irm Llc Compounds and compositions as kinase inhibitors
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

Non-Patent Citations (79)

* Cited by examiner, † Cited by third party
Title
"Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine", 2005, JOHN WILEY & SONS
"Boronic Acids - Preparation and Applications in Organic Synthesis and Medicine", JOHN WILEY & SONS
"Current Protocols in Molecular Biology", WILEY PRESS
"Metal-Catalyzed Cross-Coupling Reactions", 1998, WILEY-VCH, pages: 1 - 47
"Name Reactions for Homologations-Part I: Negishi cross-coupling reaction", 2009, WILEY & SON, pages: 70 - 99
"Name Reactions for Homologations-Part I: Negishi cross-coupling reaction", 2009, WILEY & SONS, pages: 70 - 99
A. C. BISSEMBER; M. G. BANWELL, J. ORG. CHEM., vol. 74, 2009, pages 4893 - 4895
A. CAPPELLI ET AL., CHEMMEDCHEM, vol. 5, 2010, pages 739 - 748
A. SUZUKI, J. ORGANOMET. CHEM., vol. 576, 1999, pages 147 - 168
A. SUZUKI, ORGANOMET. CHEM., vol. 576, 1999, pages 147 - 168
A. SUZUKI, PURE APPL. CHEM., vol. 63, 1991, pages 419 - 422
A. SUZUKI; N. MIYAURA, CHEM. REV., vol. 95, 1979, pages 2457
A. SUZUKI; N. MIYAURA, CHEM. REV., vol. 95, 1979, pages 2457 - 2483
A. SUZUKI; N. MIYAURA, CHEM. REV., vol. 95, 1995, pages 2457 - 2483
ADRIAN ET AL., GUT, vol. 34, 1993, pages 1219 - 1224
BLOOM, NATURE, vol. 418, 2002, pages 650 - 654
BOJANOWSKA ET AL., MED. SCI. MONIT., vol. 8, 2005, pages RA271 - 8
C. TEMPLE, JR. ET AL., J. MED. CHEM., vol. 26, 1983, pages 91 - 95
CHEM. REV., vol. 95, 1995, pages 2457 - 2483
E. ERDIK, TETRAHEDRON, vol. 48, 1992, pages 9577 - 9648
E. K. YUM, BULL. KOREAN CHEM. SOC., vol. 23, 2002, pages 535 - 536
EBERLEIN ET AL., PEPTIDES, vol. 10, 1989, pages 797 - 803
F. EGGERS; U. LUENING, EUR. J. ORG. CHEM., vol. 14, 2009, pages 2328 - 2341
F. LAMATY ET AL., SYNTHETIC COMMUN., vol. 39, 2009, pages 1583 - 1591
G. ORGAN, EUR. J. ORG. CHEM., 2010, pages 4343
G. ORGAN, EUR. J. ORG. CHEM., 2010, pages 4343 - 4354
G. ORGAN, EUR. J. ORG. CHEM., vol. 23, 2010, pages 4343 - 4354
GRANDT ET AL., REGUL. PEPT., vol. 51, 1994, pages 151 - 159
J. A. SODERQUIST ET AL., TETRAHEDRON LETT., vol. 41, 2000, pages 4251 - 4255
J. CLAYDEN ET AL., J. AM. CHEM. SOC., vol. 131, 2009, pages 5331 - 5343
J. F. HARTWIG ET AL., J. AM. CHEM. SOC., vol. 116, 1994, pages 5969 - 5970
J. K. STILLE, ANGEW. CHEM. INT. ED. ENGL., vol. 25, 1986, pages 508 - 524
J. K. STILLE, ANGEW. CHEM. INT., vol. 25, 1986, pages 508 - 524
J. K. STILLE, ANGEW. CHEM., vol. 25, 1986, pages 508 - 524
J. W. STREEF ET AL., J. HETEROCYCL. CHEM., vol. 22, 1985, pages 985 - 991
J.-U. PETERS ET AL., BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 3405 - 3408
KATSUMA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 329, 2005, pages 386 - 390
KAWAMATA ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9435 - 9440
KEITEL ET AL., HEPATOLOGY, vol. 50, 2009, pages 861 - 870
KEITEL, BIOCHEM. BIOPHYS. RES. COMMUN., vol. 372, 2008, pages 78 - 84
KEITEL, HEPATOLOGY, vol. 45, 2007, pages 695 - 704
KREYMANN ET AL., LANCET, vol. 2, 1987, pages 1300 - 1304
M. J. BAMFORD ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 3407 - 3411
M. SCHLOSSER ET AL., EUR. J. ORG. CHEM., vol. 18, 2004, pages 3793 - 3798
M. SCHLOSSER ET AL., EUR. J. ORG. CHEM., vol. 8, 2003, pages 1559 - 1568
M. V. PATEL ET AL., J. MED. CHEM., vol. 49, 2006, pages 7450 - 7465
M.G. BANWELL; A. C. BISSEMBER, J. ORG. CHEM., vol. 74, 2009, pages 4893 - 4895
MARUYAMA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 298, 2002, pages 714 - 719
MD. K. NAZEERUDDIN ET AL., INORG. CHEM., vol. 45, 2006, pages 4642 - 4653
MD. K. NAZEERUDDIN; S. FANTACCI; M. GRAETZEL ET AL., INORG. CHEM., vol. 45, 2006, pages 4642 - 4653
MEIER ET AL., DIABETES METAB. RES. REV., vol. 2, 2005, pages 91 - 117
ORG. SYNTH., COLL., vol. 10, 2004, pages 423
PELLICCIARI ET AL., J. MED. CHEM., vol. 52, 2009, pages 7958 - 7961
PERRY ET AL., CURRENT ALZHEIMER RES., vol. 3, 2005, pages 377 - 385
PLAISANCIE ET AL., J. ENDOCRIN., vol. 145, 1995, pages 521 - 526
R. C. LEMOINE ET AL., BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 704 - 708
R. D. CHAMBERS ET AL., J. CHEM. SOC., PERKIN TRANS. 7, vol. 4, 1988, pages 921 - 926
R. H. PAGER ET AL., AUST. J. CHEM., vol. 56, 2003, pages 913 - 916
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparation", 1999, JOHN WILEY & SONS
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS , NEW YORK
SAVAGE ET AL., GUT, vol. 28, 1987, pages 166 - 170
T. N. MITCHELL, SYNTHESIS, vol. 9, 1992, pages 803 - 815
T. ROSS-KELLY, J. AM. CHEM. SOC., vol. 110, 1988, pages 6471 - 6480
T.W. GREENE; P.G.M. WUT: "Protective Groups in Organic Chemistry", 2006, WILEY
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Chemistry", 2006, WILEY
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Chemistry", 2006, WILEY N.Y
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Chemistry", 2006, WILEY N.Y.
THOMAS ET AL., CELL METABOLISM, vol. 10, 2009, pages 167 - 177
U. LUENING ET AL., EUR. J. ORG. CHEM., vol. 14, 2009, pages 2328 - 2341
V. FARINA ET AL., J. ORG. REACT., vol. 50, 1998, pages 1 - 652
V. FARINA, J. ORG. REACT., vol. 50, 1998, pages 1 - 652
V. POLSHETTIWAR ET AL., CHEM. SUS. CHEM., vol. 3, 2010, pages 502 - 522
V. POLSHETTIWAR, CHEM. SUS. CHEM., vol. 3, 2010, pages 502
V. POLSHETTIWAR, CHEM. SUS. CHEM., vol. 3, 2010, pages 502 - 522
W. ZHU; D. MA, J. ORG. CHEM., vol. 70, no. 7, 2005, pages 2696 - 2700
WATANABE ET AL., NATURE, vol. 439, 2006, pages 484 - 489
Y. NISHIKAWA ET AL., J. MED. CHEM., vol. 32, 1989, pages 583 - 593
YOSHINAGA ET AL., AM. J. PHYSIOL., vol. 263, 1992, pages G695 - 701

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102929A1 (en) 2011-12-26 2013-07-11 Cadila Healthcare Limited Novel compounds for treatment of diabetes, obesity or related disorders
WO2013149977A1 (en) * 2012-04-04 2013-10-10 F. Hoffmann-La Roche Ag 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
US8748434B2 (en) 2012-04-04 2014-06-10 Roche Palo Alto Llc 1,2-pyridazines, 1,6-pyridazines and pyrimidines
CN104203935A (en) * 2012-04-04 2014-12-10 霍夫曼-拉罗奇有限公司 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as GPBAR1 modulators
JP2016509591A (en) * 2012-12-27 2016-03-31 ドレクセル ユニバーシティ Novel antiviral agent against HBV infection
US9938236B2 (en) 2012-12-27 2018-04-10 Drexel University Antiviral agents against HBV infection
EP2938338A4 (en) * 2012-12-27 2016-11-23 Univ Drexel Novel antiviral agents against hbv infection
US9549929B2 (en) 2013-02-22 2017-01-24 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine derivatives
EP3290421A1 (en) 2013-02-22 2018-03-07 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
US9035074B2 (en) 2013-02-22 2015-05-19 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine derivatives
WO2014128591A1 (en) 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
US9545405B2 (en) 2013-02-22 2017-01-17 Pfizer Inc. Pyrrolo[2,3-D]pyrimidine derivatives
CN103333113A (en) * 2013-06-14 2013-10-02 南开大学 Preparation and application research of fluxapyroxad analogue derivative
CN103333112A (en) * 2013-06-14 2013-10-02 南开大学 Preparation and application of bixafen type derivatives
US10966980B2 (en) 2014-08-12 2021-04-06 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
WO2017072039A1 (en) 2015-10-26 2017-05-04 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
EP3696175A1 (en) 2019-02-18 2020-08-19 Syngenta Crop Protection AG Pesticidally active azole-amide compounds
WO2020169445A1 (en) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020208036A1 (en) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
WO2021094974A1 (en) * 2019-11-13 2021-05-20 Libra Therapeutics, Inc. Heterocyclic trpml1 agonists
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Also Published As

Publication number Publication date
HK1190707A1 (en) 2014-07-11
KR101573997B1 (en) 2015-12-02
CA2827718A1 (en) 2012-09-07
RU2594886C2 (en) 2016-08-20
CA2827718C (en) 2018-10-30
US8987307B2 (en) 2015-03-24
MX2013009356A (en) 2013-09-26
US20150152058A1 (en) 2015-06-04
ES2538655T3 (en) 2015-06-23
KR20130133027A (en) 2013-12-05
BR112013022110A8 (en) 2020-09-15
WO2012117000A8 (en) 2013-03-07
US20120232051A1 (en) 2012-09-13
BR112013022110B1 (en) 2021-10-26
BR112013022110A2 (en) 2020-08-25
EP2681194B1 (en) 2015-04-15
EP2681194A1 (en) 2014-01-08
CN103415507A (en) 2013-11-27
JP5702001B2 (en) 2015-04-15
US10385022B2 (en) 2019-08-20
CN103415507B (en) 2016-03-02
JP2014510723A (en) 2014-05-01
RU2013142011A (en) 2015-04-10
MX341565B (en) 2016-08-25

Similar Documents

Publication Publication Date Title
US10385022B2 (en) 3-amino-pyridines as GPBAR1 agonists
KR101368097B1 (en) Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists
EP2526096B1 (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
JP2010501629A (en) Pyridine compounds for treating GPR119 related disorders
EP2593426A1 (en) 1-hydroxyimino-3-phenyl-propanes
EP2834226B1 (en) 1,2-pyridazine, 1,6-pyridazine or pyrimidine-benzamide derivatives as gpbar1 modulators
US20150025110A1 (en) 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12706049

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/009356

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2827718

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013555853

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137026117

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013142011

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013022110

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013022110

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130829